

Grants and Contracts Office

Funding Opportunities Monthly Edition May 2021 Due Dates

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in May 2021. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
085437	RFA-CA-19-049 Revision Applica Resistance (R01 Clinical Trial Not A	ations for Mechanisms of Cancer Drug Allowed)	National Cancer Institute/NIH/DHHS	RFA- CA-19- 049	23-May-2021 [Optional][LOI/Pre- App]	750,000 USD
	Contact Name	Laurence (Austin) Doyle, MD				
	Contact Telephone	240-276-6112				
	Contact Email	Doylela@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 2	23-Jun-2021			
	Synopsis	intended to accelerate cancer research. ongoing NCI-funded R01 Research Proje development of single or combination t microenvironment at the clinical level.	The purpose of this FOA is to support ect grants on underlying mechanisms o herapies to effectively target resistant,	the addition f resistance /refractory	n of new aims and dir , preclinical design ar tumors and/or their	ections to d foster
089582	Toward Translation of Nanotechno Trial Not Allowed)	ology Cancer Interventions (TTNCI) (R01	Clinical National Cancer Institute/NIH/DHHS	PAR- 20-116	20-May-2021	1,900,000 USD
	Contact Name	Piotr Grodzinski, Ph.D.				
	Contact Telephone	240-781-3305				
	Contact Email	grodzinp@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-May-2021 , 18-Nov-2021				
	Synopsis	This Funding Opportunity Announcemer (TTNCI)" is to enable the translation of r formulations and/or nano-devices. The translation of nanotechnology-based ca Cancer Interventions" (TTNCI) awards an nanonarticles and nano-devices which c	nt (FOA), entitled "Toward Translation nanotechnology-based cancer interven TTNCI initiative encourages applicatior ncer diagnostics and therapeutics. The re designed to mature experimental na	of Cancer N tions relyin; is for advan "Toward T anomedicine (a treatment	lanotechnology Inter g on next-generation ced pre-clinical resea ranslation of Nanotec es relying on "next-ge	ventions nanoparticle rch, supporting hnology meration"

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		to enable on a deve	further development of propos lopmental path towards the NC	sed nano CI Experi	otechnology-based intervention mental Therapeutics (NExT) and	s to the st I other NC	age in which they cou I translational progra	uld continue ams.
100992	RFA-CA-21-013 Development of Algorithms for Cancer Research a	f Innovativ nd Manage	e Informatics Methods and ement (R21 Clinical Trial Optiona	<u>al)</u>	National Cancer Institute/NIH/DHHS	RFA- CA-21- 013	09-May-2021 [Optional][LOI/Pre- App]	275,000 USD
	Contact Name	Juli Klemr	n, Ph.D.					
	Contact Telephone	301-480-5	5778					
	Contact Email	juli.klemn	n@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	09-May-2	021 [Optional][LOI/Pre-App], 08	8-Jun-20	021 , 18-Oct-2021 [Optional][LO	l/Pre-App]	, 17-Nov-2021	
	Synopsis	The purpo applicatio science ac diagnosis disparitie applicatio can consid central m priority no method o downstre FOAs liste	ose of this Funding Opportunity ons (R21) for the development of ddressing priority needs across t , early cancer detection, risk ass s. As a component of the NCI's li- ons focused on the development derably improve acquisition, ma ission of ITCR is to promote rese eeds in cancer research. In orde r algorithm is novel and how it v am technology development, fro ed above.	Annour of innova the can sessmen Informa t of nov anagem earch-di er to be will ben rom pro	ncement (FOA) is to invite explo- ative methods and algorithms in cer research continuum includin at and prevention, cancer contro- tics Technology for Cancer Rese- el computational, mathematical ent, analysis, and dissemination riven informatics technology acr successful, there must be a clear efit the cancer research field. Po- totyping to hardening and adapt	ratory/dev biomedic g cancer b l and epid arch (ITCR , and stati of relevar coss the de r rationale otential ap tation, sho	velopmental research al computing, inform iology, cancer treatm emiology, and/or car) Program, this FOA e stical algorithms and at data and/or knowle evelopment lifecycle for how the propose plicants who are inte- puld consult the othe	r grant atics, and data nent and neer health encourages methods that edge. The to address ed informatics erested in r companion
100999	RFA-CA-21-017 Revision Applica Technology for Cancer Research (ations to Su R01 Clinica	upport the Application of Inform Il Trials Optional)	<u>natics</u>	National Cancer Institute/NIH/DHHS	RFA- CA-21- 017	09-May-2021 [Optional][LOI/Pre- App]	200,000 USD
	Contact Name Contact Telephone Contact Email	Juli Klemr 301-480-5 juli.klemn	n, Ph.D. 5778 n@nih.gov					



SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount			
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	09-May-2	9-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021								
	Synopsis	Synopsis Synopsis The purpose of this running opportunity Announcement (FOA) is to checourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support free expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards fro this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, the FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.									
100995 <mark>R</mark>	FA-CA-21-016 Sustained Suppo esearch and Management (U24 (ort for Info Clinical Tri	ormatics Technologies for Cance al Optional)	<u>r</u>	National Cancer Institute/NIH/DHHS	RFA- CA-21- 016	09-May-2021 [Optional][LOI/Pre- App]	Not Specified			
	Contact Name	Juli Klemr	n, Ph.D.								
	Contact Telephone	301-480-	5778								
	Contact Email	juli.klemr	n@nih.gov								
	Sponsor Website										
	Program URL	<u>Link to pr</u>	ogram URL								
	Deadline Dates (ALL)	09-May-2	2021 [Optional][LOI/Pre-App], 08	8-Jun-2	2021 , 18-Oct-2021 [Optional][LO	I/Pre-App]	, 17-Nov-2021				
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applicatio continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including c biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Res (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of exi widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development effort generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to p research-driven informatics technology across the development lifecycle to address priority needs in cancer research order to be successful, the proposed sustainment plan must provide clear justification for why the research resource								ations for the on, ng cancer I and Research f existing, fforts to to promote search. In ource should			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		be mainta assessing between	ained and how it has benefitted and maximizing the value of the the resource and the targeted re	and will continue to benefit the car e resource to researchers and suppo esearch community should be desci	cer research orting collabo ibed.	field. In addition, mea pration and deep enga	chanisms for gement
100993	RFA-CA-21-014 Early-Stage Deve Cancer Research and Managemer	elopment nt (U01 Clin	of Informatics Technologies for nical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA- CA-21- 014	09-May-2021 [Optional][LOI/Pre- App]	900,000 USD
	Contact Name	Juli Klemr	n, Ph.D.				
	Contact Telephone	301-480-	5778				
	Contact Email	juli.klemr	<u>n@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL			1 47 No. 2024	
	Synopsis	The purpe developm data and cancer de compone developm as initial t to promo research. technolog and collal	ose of this Funding Opportunity nent of enabling informatics tech knowledge across the cancer res- etection, risk assessment and pre- nt of the NCI's Informatics Tech nent from prototyping to harden cool development or the significa- te research-driven informatics to In order to be successful, propo- gy is needed and how it will benc porators throughout the develop	Announcement (FOA) is to invite Co nologies to improve the acquisition search continuum including cancer evention, cancer control and epider nology for Cancer Research (ITCR) P ing and adaptation. Early-stage dev ant modification of existing tools for echnology across the development sed development plans must have a efit the cancer research field. In ado pment process must be included.	opperative A n, manageme biology, cano niology, and, rogram, this relopment is r new applica lifecycle to a a clear ratior lition, mecha	greement (U01) applic ent, analysis, and disse cer treatment and diag for cancer health dispa FOA focuses on early- defined for the purpo ations. The central mis ddress priority needs hale on why the propo	eations for the emination of gnosis, early arities. As a stage se of this FOA sion of ITCR is in cancer sed ack from users
100994	RFA-CA-21-015 Advanced Devel Research and Management (U24)	lopment o Clinical Tri	f Informatics Technologies for Ca al Optional)	ancer National Cancer Institute/NIH/DHHS	RFA- CA-21- 015	09-May-2021 [Optional][LOI/Pre- App]	3,000,000 USD
	Contact Name	Juli Klemr	n, Ph.D.				
	Contact Telephone	301-480-	5778				
	Contact Email	<u>juli.klemr</u>	n@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 08	3-Jun-2021 , 18-Oct-2021 [Optional][LO	I/Pre-App],	, 17-Nov-2021				
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications in development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, e cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of th as initial tool development or the significant modification of existing tools for new applications. The central mission of to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback fror and collaborators throughout the development process must be included.									
101003	RFA-CA-21-018 Revision Applica Technology for Cancer Research (I	itions to Support the Application of Inform U01 Clinical Trials Optional)	natics National Cancer Institute/NIH/DHHS	RFA- (CA-21- 018 /	09-May-2021 [Optional][LOI/Pre- App]	200,000 USD			
	Contact Name	Juli Klemm, Ph.D.							
	Contact Telephone	301-480-5778							
	Contact Email	juli.klemm@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 08	3-Jun-2021 , 18-Oct-2021 [Optional][LO	I/Pre-App],	, 17-Nov-2021				
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early Synopsis cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this F as initial tool development or the significant modification of existing tools for new applications. The central mission of ITC									

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		to promo research. technolog and collal	te research-driven informatics t In order to be successful, propo gy is needed and how it will ben porators throughout the develo	echno osed de efit the pment	logy across the development lifed evelopment plans must have a cle e cancer research field. In additio process must be included.	cycle to ac ear ration n, mecha	ddress priority needs ale on why the propo nisms to solicit feedba	n cancer sed ack from users
101004	RFA-CA-21-019 Revision Applica Technology for Cancer Research (ations to Su U24 Clinica	upport the Application of Inform al Trial Optional)	<u>natics</u>	National Cancer Institute/NIH/DHHS	RFA- CA-21- 019	10-May-2021 [Optional][LOI/Pre- App]	200,000 USD
	Contact Name	Juli Klemr	n, Ph.D.					
	Contact Telephone	301-480-5	5778					
	Contact Email	juli.klemn	<u>n@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-May-2	021 [Optional][LOI/Pre-App], 09)-Jun-2	2021 , 19-Oct-2021 [Optional][LO	l/Pre-App], 18-Nov-2021	
	Synopsis	The purpe "competi- expansion through c this FOA a informati- FOA aims tools, and	ose of this Funding Opportunity ng revisions") from currently fur n of the original scope of the par urrent or previous support from are meant to spur novel collabor cs technologies in support of the to promote interdisciplinary co I resources that enable cancer r	Announded N rent st rations e approved llabora	Incement (FOA) is to encourage r ICI U24 research projects. These udy by incorporating informatics ICI Informatics Technology for Ca s and to incentivize the adoption, opriate research communities. As ation in the adoption and enhanc h and accelerate scientific discov	evision a revision a methods ncer Rese adaptations a compo ement of ery.	pplications (formerly opplications can reque pplications can reque tools or resources de earch (ITCR) Program. on, and integration of onent of the NCI ITCR innovative informatic	called st support for eveloped Awards from these program, this s methods,
098155	ntervention Research to Improve Optional)	Native An	nerican Health (R01 Clinical Tria	l	National Cancer Institute/NIH/DHHS	PAR- 20-238	17-Apr-2021 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Shobha S	rinivasan, Ph.D.					
	Contact Telephone	240-276-6	5938					
	Contact Email	<u>ss688k@r</u>	nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadli	ne Dates (ALL) Sep-2022 The purp Native An directly ir Synopsis effectiver or recove dissemina scale-un	D21 [Optional][LOI/Pre-App], 17- , 17-Apr-2023 [Optional][LOI/Pr ose of this funding opportunity nerican (NA) populations. This ir nform intervention development ness of health promotion and dis ry interventions and 4) where a pation and implementation that c and sustainability of effective in	-May-2021, 07-Sep-2021, 17-Apr-2022 re-App], 17-May-2023, 07-Sep-2023 announcement (FOA) is to support rest includes 1) etiologic research, where the t or adaptations, 2) research that devel sease prevention interventions, 3) rese sufficient body of knowledge on interv levelops and tests strategies to overcon-	2 [Optional] earch on intere is a signi- lops, adapts, arch that tere vention effica me barriers	LOI/Pre-App], 17-W erventions to impro ficant gap in knowle or tests the efficac sts culturally inform acy exists, research to the adoption, inte	lay-2022 , 07- ve health in edge, that will y or ed treatment on egration,
098054	Innovative Research Allowed)	n in Cancer Nanotechnol	ogy (IRCN) (R01 Clinical Trial No	t National Cancer Institute/NIH/DHHS	PAR- 20-284 0	6-May-2021	2,250,000 USD
		Contact Name Piotr Groo	dzinski, Ph.D.				
	Cont	act Telephone 240-781-3	3305				
		Contact Email grodzinp(@mail.nih.gov				
	Spo	onsor Website					
		Program URL Link to pr	ogram URL				
	Deadli	ne Dates (ALL) 06-May-2	021 , 04-Nov-2021 , 05-May-202	22 , 03-Nov-2022 , 04-May-2023			
		This Fund applicatio Proposed on mecha biological and inten awards ar based car	ing Opportunity Announcement ons promoting transformative di projects should address major anistic studies to expand the fun systems. These studies are exp ded cancer targets in vivo and/o re expected to produce fundame ocer interventions.	t (FOA) entitled "Innovative Research in scoveries in cancer biology and/or onco barriers in cancer biology and/or oncol damental understanding of nanomater ected to be relevant to the delivery of or characterization of detection and dia ental knowledge to aid future and more	n Cancer Nar ology throug ogy using na rial and/or n nanoparticle agnostic devi e informed c	notechnology (IRCN the use of nanote notechnology and s ano-device interact s and/or nano-devi ces and sensors in v levelopment of nan)" encourages echnology. hould focus ions with ces to desired <i>i</i> tro. IRCN otechnology-
085444	RFA-CA-19-052 R Resistance (P01 Clir	evision Applications for N nical Trial Not Allowed)	Mechanisms of Cancer Drug	National Cancer Institute/NIH/DHHS	RFA- 2 CA-19- [(052 A	3-May-2021 Optional][LOI/Pre- pp]	750,000 USD

Contact Name Laurence (Austin) Doyle, MD



SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
	Contact Telephone	240-276-6	5112					
	Contact Email	Doylela@	mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	23-May-2	021 [Optional][LOI/Pre-App], 23	3-Jun-	2021			
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and direct ongoing NCI-funded P01 Research Project grants on underlying mechanisms of resistance, preclinical design and development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.								ve that is ections to d foster
101323	Notice of Special Interest (NOSI): A Support Global Cancer Stigma Res	Administra search	ntive Supplement Opportunity to	<u>2</u>	National Cancer Institute/NIH/DHHS	NOT- CA-21- 026	15-May-2021	Not Specified
	Contact Name	Vidya Vec	lham, Ph.D.					
	Contact Telephone	240-276-7	7272					
	Contact Email	vidya.ved	ham@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	15-May-2	021					
	Synopsis	This Notic for supple defined b cancer ou global car cancer sti pathways interventi	e of Special Interest informs cu emental funding to support expl elow), assess its impact on cance atcomes in low- and middle-inco neer stigma research are to: 1) e gma on physical and mental we by which stigma is a barrier to e ions to reduce cancer stigma an	rrent a lorato cer cor me co lucida ll-beir cance d imp	awardees that the National Cance ry research studies to expand the ntrol and prevention, and develop puntries (LMICs). The goals of thes ate the etiology and perpetuation ng and associated health behavior r prevention, treatment, palliation rove cancer outcomes.	er Institute current ur stigma-re se administ of cancer s s of patien n, and surv	(NCI) is providing an aderstanding of canc duction interventior trative supplements stigma; 2) measure t ts; 3) identify mecha ivorship; and 4) deve	a opportunity ser stigma (as as to improve focused on he impact of anisms and elop
085268	Neural Regulation of Cancer (R21	Clinical Tri	al Not Allowed)		National Cancer Institute/NIH/DHHS	PAR- 19-354	27-May-2021	275,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		I				
	Contact Name	Chamelli Jhappan, Ph.D.				
	Contact Telephone	240-276-6200				
	Contact Email	jhappanc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-May-2021 , 21-Oct-2021 , 27-May	-2022			
	Synopsis	This Funding Opportunity Announcer and cancer research elements, which to cancer. Leveraging the knowledge, mechanisms used by the nervous sys areas of cancer research including the	nent (FOA) encourages collaborative, to together will advance our current und , tools, experimental models and reage tem to promote tumor initiation, prog e prevention and treatment of non-ce	transdisciplinary re derstanding of the ents in neuroscien ression and metas ntral nervous syste	esearch with both nervous system's ce research to und stasis can ultimate em tumors.	neuroscience contribution cover novel ly inform key
085265 <u>N</u>	leural Regulation of Cancer (R01	Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR- 27 19-353	-May-2021	Not Specified
	Contact Name	Chamelli Jhappan, Ph.D.				
	Contact Telephone	240-276-6200				
	Contact Email	jhappanc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-May-2021 , 21-Oct-2021 , 27-May	-2022			
	Synopsis	This Funding Opportunity Announcer and cancer research elements, which to cancer. Leveraging the knowledge mechanisms used by the nervous sys areas of cancer research including the	nent (FOA) encourages collaborative, to together will advance our current und , tools, experimental models and reage tem to promote tumor initiation, prog e prevention and treatment of non-ce	transdisciplinary re derstanding of the ents in neuroscien ression and metas ntral nervous syste	esearch with both nervous system's ce research to und stasis can ultimate em tumors.	neuroscience contribution cover novel ly inform key
			National Cancer	PAR- 17	-Apr-2021	275,000

 098154
 Research to Improve Native American Health (R21 Clinical Trials Optional)
 National Cancer
 PAR

 Institute/NIH/DHHS
 20-214
 [Optional][LOI/Pre

Contact Name Shobha Srinivasan, Ph.D.



USD

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount		
	Contact Telephone	240-276-6	9938 							
	Contact Eman	<u>55688K@r</u>	<u>lin.gov</u>							
	Sponsor website	Link to pr	ogram LIDI							
	Program ORL	17 Apr 20	<u>Ografii UKL</u>)21 [Ontional][Ol/Dra Ann] 17	Max	2021 07 500 2021 17 405 2022	Ontional	1[1 O O C A = 0] 17 A	401/2022 07		
	Deadline Dates (ALL)	Sep-2022	/-Apr-2021 [Optional][LOI/Pre-App], 1/-May-2021 , 0/-Sep-2021 , 17-Apr-2022 [Optional][LOI/Pre-App], 17-May-2022 , 07- ep-2022 , 17-Apr-2023 [Optional][LOI/Pre-App], 17-May-2023 , 07-Sep-2023							
preparation for health promotion, disease prevention, treatment, or treatment services research to improve heal American (NA) populations. Applications may include 1) etiologic research, where there is a significant gap in kno Synopsis that will directly inform intervention development or adaptations, 2) research to develop and pilot test new or ac interventions for feasibility, acceptability, and scalability, 3) research to test the short-term efficacy of intervention a sufficient body of knowledge on intervention efficacy exists, research on strategies to overcome barriers to the integration, scale-up, and sustainability of effective interventions.								alth in Native nowledge, adapted tions, 4) where adoption,		
086863	<u>Cancer Center Support Grants (CC</u> Clinical Trial Optional)	<u>SGs) for N</u>	CI-designated Cancer Centers (F	<u>230</u>	National Cancer Institute/NIH/DHHS	PAR- 20-043	25-May-2021	Not Specified		
	Contact Name									
	Contact Telephone	240-276-5	5600							
	Contact Email	ncicenter	s-r@mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	25-May-2	021 , 25-Sep-2021 , 25-Jan-2022	2,25-	May-2022 , 25-Sep-2022					
	Synopsis	This Fund NCI-desig demonstr preventio scientific cancer co on basic la cancer res institutior	ing Opportunity Announcement nated Cancer Centers. CCSGs su rate reasonable depth and bread n, control and population-based areas; and 2) Clinical Cancer Cent ntrol, and population-based rest aboratory research. The purpost search capabilities, integrating r nal boundaries. Cancer Centers	t (FOA upport dth of d rese nters, search e of al merito suppo	a) invites applications for P30 Cand three types of Cancer Centers: 1) research activities in each of three arch, and which have substantial which are primarily focused on ba ; or some combination of these and Il types of NCI-designated Cancer prious research into a single transformed through this FOA are expected	cer Center Comprehe e major ar transdiscip asic labora reas, and 3 Centers is disciplinary ed to serve	Support Grants (CCS ensive Cancer Cente eas: basic laboratory linary research that tory; clinical; and pre) Basic Cancer Cente to capitalize on all in v research enterprise as major sources of	Gs) to support rs, which r; clinical; and bridges these evention, rs, which focus stitutional across all discovery of		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the natur significan efforts wi communi	e of cancer and of development tly to the development of Share th other NCI-funded programs a ty.	of more effective approaches to p d Resources that support research nd investigators; and to dissemina	prevention, diagno n; to collaborate an ate research findir	osis, and therapy; nd coordinate the ngs for the benefit	to contribute ir research of the
100809 <mark>(</mark>	Cancer Research Education Grant Trial Not Allowed)	s Program	- Research Experiences (R25 Clir	nical National Cancer Institute/NIH/DHHS	PAR- 21-067 07	-May-2021	1,500,000 USD
	Contact Name	Jeannette	e F. Korczak, Ph.D.				
	Contact Telephone	240-276-5	5630				
	Contact Email	<u>korczakj@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	1 , 25-Sep-2021 , 07-Jan-2022 , 25 -2023 , 07-May-2023 , 25-May-20	-Jan-2022 , 05-Ma 23 , 07-Sep-2023 ,	ay-2022 , 25-May- 25-Sep-2023 , 07	2022 <i>,</i> 07-Sep- -Jan-2024		
	Synopsis	The NIH F overarchi a workfor goal, this encourag cancer, re advance t	Research Education Program (R2 ng goal of this NCI R25 program ree to meet the nation's biomedi FOA will support creative educa ed that propose innovative, stat shabilitation from cancer, or the the NCI mission.	5) supports research education ac is to support educational activitie ical, behavioral and clinical researc tional activities with a primary foc e-of-the-art programs that addres continuing care of cancer patients	tivities in the miss s that complemen ch needs. To accor cus on Research E s the cause, diagn s and the families	tion areas of the N t and/or enhance mplish the stated xperiences. Applic osis, prevention, of of cancer patients	IH. The the training of over-arching ations are or treatment of s, in order to
100808	Cancer Research Education Grant Clinical Trial Not Allowed)	s Program	- Courses for Skills Developmen	t (R25 National Cancer Institute/NIH/DHHS	PAR- 21-066 07	-May-2021	1,500,000 USD
	Contact Name	Jeannette	e F. Korczak, Ph.D.				
	Contact Telephone	240-276-5	5630				
	Contact Email	<u>korczakj@</u>	email.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 25	021 , 25-May-2021 , 07-Sep-202 -Sep-2022 , 07-Jan-2023 , 25-Jan	1 , 25-Sep-2021 , 07-Jan-2022 , 25 -2023 , 07-May-2023 , 25-May-20	-Jan-2022 , 05-Ma 23 , 07-Sep-2023 ,	ay-2022 , 25-May- 25-Sep-2023 , 07	2022 , 07-Sep- -Jan-2024

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Synopsis	The NIH F overarchi a workfor goal, this Applicatic preventio cancer pa	Research Education Program (R2 ng goal of this NCI R25 program ree to meet the nation's biomed FOA will support creative educa ons are encouraged that propose on, or treatment of cancer, rehat itients, in order to advance the N	5) supports research education act is to support educational activities ical, behavioral and clinical researc tional activities with a primary focu e innovative, state-of-the-art progr pilitation from cancer, or the contir NCI mission.	tivities in the miss that complement th needs. To acco us on Courses for ams that address nuing care of cano	sion areas of the N at and/or enhance mplish the stated or Skills Developme the cause, diagno cer patients and th	IIH. The the training of over-arching ent. osis, he families of		
100806 <u>(</u>	Cancer Research Education Grant Development (R25 Clinical Trial N	s Program ot Allowed	<u>- Curriculum or Methods</u> I <u>)</u>	National Cancer Institute/NIH/DHHS	PAR- 21-065	′-May-2021	300,000 USD		
	Contact Name	Jeannette	e F. Korczak, Ph.D.						
	Contact Telephone	240-276-5	5630						
	Contact Email	<u>korczakj@</u>	mail.nih.gov						
	Sponsor Website	2							
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep- 2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024							
	Synopsis	The NIH F overarchi a workfor goal, this Applicatic preventio cancer pa	Research Education Program (R2 ng goal of this NCI R25 program ree to meet the nation's biomed FOA will support creative educa ons are encouraged that propose on, or treatment of cancer, rehab itients, in order to advance the N	5) supports research education act is to support educational activities ical, behavioral and clinical researc tional activities with a primary focu e innovative, state-of-the-art progr pilitation from cancer, or the contin NCI mission.	tivities in the miss that complement th needs. To acco us on Curriculum tams that address thuing care of cano	sion areas of the N at and/or enhance mplish the stated or Methods Deve the cause, diagno cer patients and th	IIH. The the training of over-arching lopment. osis, ne families of		
088519	National Cancer Institute Program Optional)	n Project A	pplications (P01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR- 20-077 07	'-May-2021	Not Specified		
	Contact Name	Referral C	Officer						
	Contact Telephone	240-276-6	5390						
	Contact Email	ncirefof@	dea.nci.nih.gov						
	Sponsor Website								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-202 2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jar	21 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan 1-2023 , 07-May-2023	-2022 <i>,</i> 07-Ma	ay-2022 , 25-May-2	2022 , 07-Sep-		
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investig initiated Program Project (PO1) applications. The proposed Program may address any of the broad areas of cancer resea including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each applica submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The proje must share a common central theme, focus, and/or overall objective.								
067401	Developing Interventions for Heal	th-Enhancing Physical Activity (R21/R33 -	National Cancer	PAR- 07	-May-2021	1,025,000		
	<u>Clinical Trial Optional)</u>		Institute/NIH/DHHS	18-307	•	USD		
	Contact Name	Frank Perna, Ed.D., Ph.D.						
	Contact Telephone	240-276-6782						
	Contact Email	pernafm@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021						
	Synopsis	National Institutes of Health (NIH) and its promising research aimed at developing socioecological model and designed to in from such activity; and 2) that could be n support for up to two years (R21 phase) f transition to expanded research support studies. Transition to the R33 depends or the availability of funds. This program wi	s participating Institutes and Centers in multi-level physical activity intervention crease health-enhancing physical activi nade scalable and sustainable for broad for research planning activities and feas (R33 phase) for optimizing the interver in the completion of applicant-defined r II use the NIH R21/R33 Phased Innovati	vite application n programs and ity: 1) in person l use across the sibility studies notion and com- nilestones, as on Award aw	ons for highly inno cting on at least tw ons or groups that ne nation. This FO, s, followed by a po ducting larger-scal well as program p ard mechanism.	vative and vo levels of the can benefit A provides ssible e feasibility priorities and		
100910	RFA-CA-21-009 Revision Applica Technology to Accelerate Cancer	ntions for Incorporation of Novel NCI-Supp Research (U54 Clinical Trials Optional	oorted National Cancer Institute/NIH/DHHS	RFA- 27 CA-21- [O 009 Ap	-Apr-2021 ptional][LOI/Pre- p]	150,000 USD		

Contact Name Tony Dickherber, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone	301-547-9	9980						
	Contact Email	dickherbe	erai@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	27-Apr-20		-May-2021 , 30-Aug-2021 [Optional][LO	l/Pre-App], 2	29-Sep-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly ca "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporatin technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Techn (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suita emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FC promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer accelerate scientific discovery.							
100916 <mark>R</mark> 1	FA-CA-21-012 Revision Applica echnology to Accelerate Cancer I	i <u>tions for l</u> Research (ncorporation of Novel NCI-Supp P50 Clinical Trial Optional)	oorted National Cancer Institute/NIH/DHHS	RFA- 27 CA-21- [O 012 Ap	7-Apr-2021 ptional][LOI/Pre- pp]	150,000 USD		
	Contact Name	Tony Dick	herber, Ph.D.						
	Contact Telephone	301-547-9	9980						
	Contact Email	<u>dickherbe</u>	eraj@mail.nih.gov						
	Sponsor Website								
	Program URL	<u>Link to pr</u>	ogram URL						
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2021 , 30-Aug-2021 [Optional][LO	I/Pre-App], 2	29-Sep-2021			
	Synopsis	evision appli sing to expar t study by in lecular Analy and accelera of the NCI IM nd methods	ications (formerly nd upon original re icorporating a new ysis Technologies (ate the suitability of IAT program, this F that enable cance	called search technical IMAT) of these OA aims to r research and					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
101460	Notice of Special Interest (NOSI): Study its Dynamics in Brain Aging	New Approaches to Identify Neurogenesis and AD/ADRD (R01 Clinical Trial Not Allow	and National Cancer (ed) Institute/NIH/DHHS	NOT- CA-21- 2 025	27-May-2021	Not Specified			
	Contact Name	Paul C. Pearlman, Ph.D.							
	Contact Telephone	240-276-6429							
	Contact Email	paul.pearlman@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	27-May-2021 , 29-Sep-2021							
	This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) p stimulate exploratory research on technology platforms relevant for global oncology and appropr settings globally. NCI CGH is prepared to support highly meritorious R21 applications submitted to 003 or RFA-CA-21-005, with the goal of helping drive innovation in this field and enrich the pool c in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program.								
100914	RFA-CA-21-011 Revision Applica Technology to Accelerate Cancer	ations for Incorporation of Novel NCI-Supp Research (P01 Clinical Trial Optional)	orted National Cancer Institute/NIH/DHHS	RFA- 2 CA-21- [011 A	27-Apr-2021 Optional][LOI/Pre- App]	150,000 USD			
	Contact Name	Tony Dickherber, Ph.D.							
	Contact Telephone	301-547-9980							
	Contact Email	dickherberaj@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-	-May-2021 , 30-Aug-2021 [Optional][L	OI/Pre-App]	, 29-Sep-2021				
	Synopsis	The purpose of this Funding Opportunity "competing revisions") from currently fur question(s) from specific projects or othe approach or instrument developed throu program. Awards from this FOA are mean	Announcement (FOA) is to encourage nded NCI P01 program projects propos erwise accelerate progress for the pare gh support from the NCI Innovative M nt to incentivize independent validatio	revision app sing to expar nt study by i olecular Ana n and accele	blications (formerly nd upon original res incorporating a new alysis Technologies (erate the suitability o	called earch technical IMAT) of these			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		emerging promote accelerate	technologies for appropriate re interdisciplinary collaboration ir e scientific discovery.	esearch communities. As a component of innovative to	ent of the NC ols and meth	IMAT program, this F ods that enable cance	OA aims to r research and
100903	RFA-CA-21-007 Revision Applica Technology to Accelerate Cancer	a <u>tions for I</u> Research (ncorporation of Novel NCI-Supp R01 Clinical Trial Optional)	orted National Cancer Institute/NIH/DHHS	RFA- CA-21- 007	27-Apr-2021 [Optional][LOI/Pre- App]	150,000 USD
	Contact Name	Tony Dick	herber, Ph.D.				
	Contact Telephone	301-547-9	9980				
	Contact Email	dickherbe	eraj@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2021 , 30-Aug-2021 [Optiona	l][LOI/Pre-Ap	p], 29-Sep-2021	
	Synopsis	The purpe "competi original re or instrun from this by approp collabora discovery	ose of this Funding Opportunity ng revisions") from currently fur esearch question(s) or otherwise nent developed through suppor FOA are meant to incentivize in priate research communities. As tion in the development of inno	Announcement (FOA) is to encouranded NCI R01 research projects. The accelerate progress for the parent t from the NCI Innovative Molecula dependent validation and accelerate a component of the NCI IMAT progrative tools and methods that enable	age revision a e applicants s t study by inc ir Analysis Teo te the adoptio gram, this FO ole cancer res	pplications (formerly hould propose to exp orporating a new tech chnologies (IMAT) pro on of these emerging A aims to promote int earch and accelerate	called and upon the mical approach gram. Awards technologies erdisciplinary scientific
100905	RFA-CA-21-008 Revision Applica Technology to Accelerate Cancer	ations for I Research (ncorporation of Novel NCI- Supp U01 Clinical Trial Optional)	ported National Cancer Institute/NIH/DHHS	RFA- CA-21- 008	27-Apr-2021 [Optional][LOI/Pre- App]	150,000 USD
	Contact Name	Tony Dick	herber, Ph.D.				
	Contact Telephone	301-547-9	9980				
	Contact Email	dickherbe	eraj@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2021 , 30-Aug-2021 [Optiona	l][LOI/Pre-Ap	p], 29-Sep-2021	

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
	Synopsis	The purper "competite original re- or instruct from this for appro collabora discovery	ose of this Funding Opportunity ng revisions") from currently fur esearch question(s) or otherwise nent developed through suppor FOA are meant to incentivize in priate research communities. As tion in the development of inno	Announded Ne accel t from depen s a con vative	uncement (FOA) is to encourage ICI U01 research projects. The a erate progress for the parent st the NCI Innovative Molecular A dent validation and accelerate t nponent of the NCI IMAT progra tools and methods that enable	revision appl pplicants sho udy by incorp nalysis Techn he suitability ım, this FOA a cancer resear	ications (formerly uld propose to exp orating a new tech ologies (IMAT) pro of these emerging ims to promote in ch and accelerate	called and upon the inical approach gram. Awards technologies terdisciplinary scientific
079335 <mark>E</mark>	xploratory/Developmental Bioer rial Not Allowed)	ngineering	Research Grants(EBRG) (R21 Cli	<u>nical</u>	National Cancer Institute/NIH/DHHS	PAR- 19-149	7-May-2021	275,000 USD
	Contact Name	Miguel R.	Ossandon, Ph.D.					
	Contact Telephone	240-276-	5714					
	Contact Email	ossandon	n@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	2021 , 16-Jun-2021 , 07-Sep-202	1,16-0	Oct-2021 , 07-Jan-2022			
	Synopsis	The purpe explorate utility of problems	ose of this engineering-oriented ry/developmental Bioengineeri new capabilities or improvemen in basic biomedical, pre-clinical	fundir ng Res ts in q , or cli	ng opportunity announcement (earch Grant (EBRG) applications uality, speed, efficacy, operabili nical research, clinical care deliv	FOA) is to end s to demonstr ty, costs, and, very, or access	courage submission ate feasibility and or accessibility of sibility.	ns of potential solutions to
082214	Dissemination and Implementatic Optional)	on Researc	<u>h in Health (R01 Clinical Trial</u>		National Cancer Institute/NIH/DHHS	PAR- 19-274 07	7-May-2021	Not Specified
	Contact Name	Gila Neta	, Ph.D.					
	Contact Telephone	240-276-	6785					
	Contact Email	gila.neta(@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-202	1,05-0	Oct-2021 , 07-Jan-2022 , 05-Feb	-2022 , 07-Ma	iy-2022	

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
	Synopsis	The purp understar sustainab circumsta low-value are encou	ose of this Funding Opportunity nding, and developing strategies ility of evidence-based interven nces that create a need to stop , or harmful. In addition, studie maged. All applications must be	Annou for ov tions, t or red s to ad within	uncement (FOA) is to support inn ercoming barriers to the adoptic cools, policies, and guidelines. Co uce ("de-implement") the use of vance dissemination and implem the scope of the mission of one	ovative app n, adaptati nversely, th interventio entation re of the Instit	proaches to identify on, integration, sca here is a benefit in u ons that are ineffect esearch methods an tutes/Centers listed	ing, le-up and inderstanding ive, unproven, d measures above.
085445 <mark>F</mark>	RFA-CA-19-053 Revision Applica Resistance (P50 Clinical Trial Not A	tions for N Allowed)	Aechanisms of Cancer Drug		National Cancer Institute/NIH/DHHS	RFA- 2 CA-19- [053 A	!3-May-2021 Optional][LOI/Pre- \pp]	750,000 USD
	Contact Name	Laurence	(Austin) Doyle, MD					
	Contact Telephone	240-276-6	5112					
	Contact Email	<u>Doylela@</u>	<u>mail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	23-May-2	021 [Optional][LOI/Pre-App], 23	3-Jun-2	021			
	Synopsis	This Fund intended ongoing N developm microenv	ing Opportunity Announcement to accelerate cancer research. T ICI-funded P50 Research Project tent of single or combination th ironment at the clinical level.	t (FOA) The pur t grant erapies	is associated with the Beau Bide pose of this FOA is to support th s on underlying mechanisms of re to effectively target resistant/re	n Cancer N e addition o esistance, p efractory tu	loonshotSM Initiation of new aims and dire preclinical design an mors and/or their	ve that is ections to d foster
100856 <u>F</u>	RFA-CA-21-005 Innovative Biosp Clinical Cancer Research (R21 Clini	ecimen So ical Trial N	ience Technologies for Basic an ot Allowed)	<u>d</u>	National Cancer Institute/NIH/DHHS	RFA- 2 CA-21- [005 A	?7-Apr-2021 Optional][LOI/Pre- App]	400,000 USD
	Contact Name	Tony Dick	herber, Ph.D., Program Director	-				
	Contact Telephone	301-547-9	9980					
	Contact Email	<u>dickherbe</u>	raj@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2	021 , 30-Aug-2021 [Optional][LC	l/Pre-App],	, 29-Sep-2021	

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
	Synopsis	This Fund the early- research analytes of support t utility of k instrumen assessme enhance n issues ass Projects p being pur NCI-spons	ing Opportunity Announcement stage development of highly inr or clinical care. This includes ner during the collection, processing he development of highly innov biological samples used for dow ntation, and associated methods nt/quality control and handling research in cancer biology, early ociated with cancer health disp proposing application of existing sued are not responsive to this sored Innovative Molecular Ana	solicits grant applications propo ve technologies that improve the abilities to address issues related lling, and/or storage of cancer-re echnologies capable of maximizin m analyses. This FOA will support eserve or protect sample integrit diverse conditions. These techno tion, and screening, clinical diagr by reducing pre-analytical variat ologies where the novelty reside ation and will not be reviewed. The echnologies (IMAT) Program.	sing explo quality of to pre-ana levant bios ng or other t the devel y, or estab blogies are nosis, treat cions that a s in the bio his funding	ratory research proje the samples used for lytical degradation of specimens. The overa wise interrogating the opment of tools, dev lish verification criter expected to accelerate ment, epidemiology, affect biospecimen satisfies opportunity is part of	cts focused on cancer f targeted III goal is to ie quality and ices, ria for quality ite and/or or address imple quality. get/question of a broader	
100859	RFA-CA-21-006 Advanced Devel Biospecimen Science Technologies Clinical Trial Not Allowed)	opment and s for Basic	nd Validation of Emerging and Clinical Cancer Research (R	33	National Cancer Institute/NIH/DHHS	RFA- CA-21- 006	27-Apr-2021 [Optional][LOI/Pre- App]	900,000 USD
	Contact Name	Tony Dick	herber, Ph.D., Program Director	r				
	Contact Telephone	301-547-9	9980					
	Contact Email	<u>dickherbe</u>	eraj@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2	2021 , 30-Aug-2021 [Optional][LC	I/Pre-App], 29-Sep-2021	
	Synopsis	This Fund further de research analytes d applicatic supportiv research or otherw the devel	ing Opportunity Announcement evelopment and validation of er or clinical care. This includes new during the collection, processing ons where major feasibility gaps e preliminary data, but still require community. The overall goal is t vise interrogating the quality and opment of tools, devices, instru	t (FOA) mergin w capa g, hand for the uire fui to supp d utilit menta	solicits grant applications propo g technologies that improve the ibilities to address issues related ling, and/or storage of cancer-re e technology or methodology have ther development and rigorous w port the development of highly in y of biological samples used for d tion, and associated methods to	sing explo quality of t to pre-ana levant bios ve been ov validation t novative to lownstrear preserve o	ratory research proje the samples used for alytical degradation of specimens. This FOA ercome, as demonstration to encourage adoptic echnologies capable m analyses. This FOA or protect sample inter	cts focused on cancer f targeted solicits R33 rated with on by the of maximizing will support egrity, or

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		establish technolog diagnosis variations in the app being dev sponsore	verification criteria for quality as gies are expected to accelerate a , treatment, epidemiology, or ac s that affect biospecimen sample plication of the technology or the reloped, are not appropriate for d Innovative Molecular Analysis	ssessn and/or ddress e quali e biolo this Fi Techr	nent/quality control and handling r enhance research in cancer biolo issues associated with cancer he ity. Projects proposing to use exis ogical or clinical question being pu OA and will not be reviewed. This pologies (IMAT) Program.	gunder div ogy, early o alth dispar ting techn ursued, and funding o	rerse conditions. The detection and screen rities, by reducing pre ologies where the no d not the technical ca pportunity is part of	se Ing, clinical I-analytical Ivelty resides Apabilities a broader NCI
100854	RFA-CA-21-003 Innovative Mole Basic and Clinical Cancer Research	ecular and 1 (R21 Clin	Cellular Analysis Technologies fo ical Trial Not Allowed)	<u>or</u>	National Cancer Institute/NIH/DHHS	RFA- CA-21- 003	27-Apr-2021 [Optional][LOI/Pre- App]	400,000 USD
	Contact Name	Tony Dick	herber, Ph.D., Program Director	r				
	Contact Telephone	301-547-9	9980					
	Contact Email	<u>dickherbe</u>	eraj@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27-	-May-	2021 , 30-Aug-2021 [Optional][LC	I/Pre-App], 29-Sep-2021	
	Synopsis	This Fund the early- basic or c high degr Well-suite detection health dis focused c existing to to this sol Analysis T	ing Opportunity Announcement stage development of highly inr linical cancer research. The emp ee of technical innovation for ta ed applications must offer the pe and screening, clinical diagnosis sparities. Technologies proposed on improving molecular and/or c echnologies where the novelty r licitation and will not be reviewe Technologies (IMAT) Program.	t (FOA hovativ bhasis orgetin otenti s, trea d for d cellular cesides ed. Thi) solicits grant applications propo ve technologies offering novel mo of this FOA is on supporting the d ag, probing, or assessing molecula al to accelerate and/or enhance r tment, control, epidemiology, an evelopment may be intended to h r characterizations of cancer biolo is in the biological or clinical target is funding opportunity is part of a	sing explo plecular or evelopme r and cellu esearch in d/or addre nave wides ogy. Projec c/question broader N	ratory research proje cellular analysis capa nt of novel capabilition lar features of cance the areas of cancer l ess issues associated spread applicability b ts proposing the app being pursued are no ICI-sponsored Innova	cts focused o ibilities for es involving a r biology, early with cancer ut must be lication of ot responsive
100855	RFA-CA-21-004 Advanced Devel and Cellular Analysis Technologies Clinical Trial Not Allowed)	opment a s for Basic	nd Validation of Emerging Molec and Clinical Cancer Research (RS	<u>cular</u> 33	National Cancer Institute/NIH/DHHS	RFA- CA-21- 004	27-Apr-2021 [Optional][LOI/Pre- App]	900,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Tony Dick 301-547-9 dickherbe Link to pr 27-Apr-20 This Fund further de molecular major fea data, but suited ap	herber, Ph.D., Program Directo 9980 araj@mail.nih.gov ogram URL 21 [Optional][LOI/Pre-App], 27 ing Opportunity Announcemen evelopment and validation of er and cellular features of cancer sibility gaps for the technology still requires further development oblications must offer the potent	r -May-2021 , 30-Aug-2021 [Optional][L t (FOA) invites grant applications prop merging technologies offering novel ca biology for basic or clinical cancer res or methodology have been overcome, ent and rigorous validation to encourag ial to accelerate and/or enhance rese	OI/Pre-App], 2 osing explorat pabilities for t earch. This FO as demonstra ge adoption by arch in the are	29-Sep-2021 ory research proje argeting, probing, A solicits R33 appl ated with supportiv y the research com as of cancer biolog	ects focused on or assessing ications where ve preliminary munity. Well- gy, early
	Synopsis	detection health dis focused o technolog this solicit Analysis T	and screening, clinical diagnosi parities. Technologies proposed n improving molecular and/or o jes where the novelty resides in ration and will not be reviewed. echnologies (IMAT) Program.	is, treatment, control, epidemiology, a d for development may be intended to cellular characterizations of cancer. Pro n the biological or clinical target/quest This funding opportunity is part of a b	nd/or address have widespr pjects propositi ion being purs proader NCI-sp	issues associated read applicability b ng application of e sued are not respo ponsored Innovativ	with cancer out must be xisting nsive to re Molecular
100913 <mark>F</mark>	RFA-CA-21-010 Revision Applica Technology to Accelerate Cancer F	itions for I Research (ncorporation of Novel NCI-Supp U2C Clinical Trial Optional)	oorted National Cancer Institute/NIH/DHHS	RFA- 27 CA-21- [O 010 Ap	-Apr-2021 ptional][LOI/Pre- p]	150,000 USD
	Contact Name	Tony Dick	herber, Ph.D.				
	Contact Telephone	301-547-9	9980				
	Contact Email	<u>dickherbe</u>	<u>raj@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	27-Apr-20	21 [Optional][LOI/Pre-App], 27	-May-2021 , 30-Aug-2021 [Optional][L	OI/Pre-App], 2	29-Sep-2021	
	Synopsis	The purpo "competi	ose of this Funding Opportunity ng revisions") from currently fu	Announcement (FOA) is to encourage nded NCI U2C Resource-Related Multi-	revision appli Component P	cations (formerly or rojects and Center	called rs proposing to

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		expand u incorpora Analysis T the suitat program, enable ca	pon original research question(s ting a new technical approach o Technologies (IMAT) program. A pility of these emerging technolo this FOA aims to promote intero ncer research and accelerate sc) from or insti wards ogies f discipl ientifi	n specific projects or otherwise ac rument developed through suppo from this FOA are meant to incer or appropriate research commun inary collaboration in the develop c discovery.	ccelerate p ort from th ntivize ind ities. As a oment of i	progress for the pare ne NCI Innovative Mo ependent validation component of the N nnovative tools and	nt study by lecular and accelerate CI IMAT methods that
086964 <mark>(</mark>	ICI Small Grants Program for Can NCI Omnibus R03 Clinical Trial Op	<u>cer Resear</u> otional)	<u>ch for Years 2020, 2021, and 20</u>	<u>22</u>	National Cancer Institute/NIH/DHHS	PAR- 20-052	07-May-2021	100,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 20 [.]	021 , 24-Jun-2021 , 07-Sep-2021 -Oct-2022 , 07-Jan-2023	L,20-	Oct-2021 , 07-Jan-2022 , 24-Feb-2	2022 , 07-1	May-2022 , 24-Jun-20)22 , 07-Sep-
	Synopsis	This fundi period of feasibility methodol	ing opportunity announcement time with limited resources. The studies; secondary analysis of e logy; and development of new r	(FOA) e RO3 existin esearc	supports small research projects grant mechanism supports different g data; small, self-contained rese ch technology.	on cancer ent types arch proje	r that can be carried of projects including cts; development of	out in a short pilot and research
067494 <mark>T</mark>	esting Interventions for Health-E	nhancing I	Physical Activity (R01 - Clinical T	r <u>ial</u>	National Cancer Institute/NIH/DHHS	PAR- 18-324	07-May-2021	Not Specified
	Contact Name	Frank Per	na, Ed.D., Ph.D.					
	Contact Telephone	240-276-6	5782					
	Contact Email	pernafm@	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	National I	nstitutes of Health (NIH) and its	parti	cipating Institutes and Centers inv	/ite applic	ations for highly inno	vative and

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
		promising ecological such activ NIH R01 R	g research that tests multi-level I model and designed to increas rity; and 2) that could be made s Research Project Grant award m	physic e heal scalabl echan	al activity intervention programs th-enhancing physical activity: 1) e and sustainable for broad use a ism.	acting on at in persons of cross the nat	least two levels of r groups that can ion. This program	the socio- benefit from will use the
070540	Academic-Industrial Partnerships and Treatment (R01 - Clinical Tria	for Transla Optional)	tion of Technologies for Diagno	<u>sis</u>	National Cancer Institute/NIH/DHHS	PAR- 18-530	-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Miguel Os 240-276-5 <u>ossandor</u>	ssandon MS 5714 n <u>@mail.nih.gov</u>					
	Program URL Deadline Dates (ALL)	Link to pro	ogram URL 021					
	Synopsis	National I translate to unders rationale of researc diseases w bridge gap partners of alliance to plan, desi academic and/or sys enhance, assessme new capa setting. Th translatio	nstitutes of Health (NIH) and its scientific discoveries and engine tand disease, or in applied resea is to deliver new capabilities to th and delivery of care in pre-clin within the missions of participat os in knowledge and experience on each application should estat o implement a coherent strategy gn, and validate that the solution and one industrial organization stem from a demonstration of p adapt, optimize, validate, and o nt, diagnosis, treatment, and/or bility to end users. This FOA will his FOA is not intended to suppor n as the primary motivation. Th	partic eering arch to meet o nical, o by en olish a / to de n will . Each ossibi therw moni suppo ort cor is FOA	cipating Institutes and Centers inv developments into methods or to assess risk, detect, prevent, diag evolving requirements for techno clinical and non-clinical settings, o stitutes. This FOA specifies a partr gaging the strengths of academic n inter-disciplinary, multi-institution evelop and translate a solution to be suitable for end users. Each par partnership should plan to transi lity to a status useful in the chose ise translate technologies that ad toring of disease status. This FOA port clinical trials that test function nmercial production, basic resear will use the NIH Research Project	vite application pols that addi- gnose, treat, a logies and m domestic or for hership struct c, industrial, a ional research their chosen artnership sho tion a techno en setting. Fu ldress proble defines inno hality, or valion rch projects, or t (R01) award	ons to stimulate er ress problems in b and/or manage di ethods relevant to oreign, for conditi cure that is expect ind other investig h team to work in problem. They ar ould include at lea ology, method, as nding may be req ms in biology, pat vation as likelihoo late performance or straight clinical d mechanism.	fforts to pasic research sease. The o the advance ons and red to help ators. The strategic e expected to ast one say, device, uested to hology, risk od to deliver a in the chosen trials that lack

076579 Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research

National Cancer

PA-18- 07-May-2021

Not



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(R01 Clinical Trial Not Allowed)			Institute/NIH/DHHS	876		Specified
	Contact Name	Dr. Rober	to Flores				
	Contact Telephone	240-276-7	7119				
	Contact Email	floresr2@	<u>)mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-202	1			
	Synopsis	National I science th and disea systems a models th multidisci microbior Project (R	Institutes of Health (NIH) and it nat facilitates the development se; and (2) determine biologica and animal models. This FOA en nat focus on prebiotic/probiotic iplinary collaborations among so mics, genomics, other '-omic' so 801) award mechanism.	s participating Institutes and Cent of effective probiotics or pre-/pro l outcomes for the evaluation of e courages basic and mechanistic st strain selectivity, interaction, and cientists in a wide range of discipl iences, biotechnology, and bioinfo	ers invite application obiotic combination efficacy of pre/prob tudies using in vitro f function. It will als ines including nutri ormatics. This FOA	ons for basic and r is of relevance to piotics in appropria o, in vivo, ex vivo, so encourage inte tional science, im will use the NIH R	nechanistic human health ate test and in silico r and munology, esearch
085422	Integration of Imaging and Fluid-E	Based Tum	or Monitoring in Cancer Therap	y (R01 National Cancer	PAR- 19-363 07	-May-2021	499,999
					15-505		030
	Contact Name	Anne Me	nkens, Ph.D.				
	Contact Telephone	240-270-0					
	Sponsor Website	IIICIIKEIIS					
	Program LIBI	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	07-May-2	021 . 05-Jun-2021 . 07-Sep-202	1			
	Synopsis	National monitorir character mechanis	I Cancer Institute (NCI) invites and ng (liquid biopsy) assays during ization of therapy response and m.	 pplications for research projects t cancer therapy in patients to deted d/or emergence of resistance. This 	hat integrate imager ermine the optimal s FOA will use the N	ing and fluid-base use of those mod NH Research Proje	d tumor alities in the ect (R01) award
071800	Integration of Imaging and Fluid-E Clinical Trial Optional)	Based Tum	or Monitoring in Cancer Therap	y (R01 National Cancer Institute/NIH/DHHS	PA-18- 629	-May-2021	Not Specified
			NIH Funding Opport	unities Due: May 2021			20

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount		
Contact Name Mankana Dh D										
	Contact Name	Anne Mei	nkens, Ph.D.							
	Contact Telephone	240-276-0								
	Contact Ennan	menkense	a@mail.mil.gov							
	Sponsor website	Link to pr	ogram LIDI							
	Program OKL									
	Deadime Dates (ALL)	U/-ividy-ZUZI								
	Synopsis Synopsis. Synopsis Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) av mechanism.									
100707	National Cancer Institute's Investi	gator-Initia	ated Early Phase Clinical Trials for	or	National Cancer	PAR-	07 May 2021	2,499,995		
100707	Cancer Treatment and Diagnosis (R01 Clinica	al Trial Required)		Institute/NIH/DHHS	21-033	07-1V189-2021	USD		
	Contact Name	Lori A. He	nderson, Ph.D.							
	Contact Telephone	240-276-5	5930							
	Contact Email	<u>henderso</u>	nlori@mail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022 , 05·	021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05- b-2023	Oct-2021 , 07-Jan-2022 , 05-Feb-2 3 , 07-May-2023 , 05-Jun-2023 , 07	.022 <i>,</i> 07-N 7-Sep-2023	1ay-2022 , 05-Jun-20 3 , 05-Oct-2023 , 07-	022 , 07-Sep- Jan-2024		
	Synopsis	The purpe (Phase 0, direct rele (DCTD) ar consult th and strate Institutes information	ose of this Funding Opportunity I, and II) investigator-initiated of evance to the research mission and the Office of HIV and AIDS M he NCI DCTD website and/or the egies developed to fight cancer. of Health (NIH) definition of a c on as described in this FOA. This b, applications that propose phas	Anno linical of the aligna OHAI Applio clinical s FOA se III c	uncement (FOA) is to seek researd trials focused on cancer-targeted National Cancer Institute's (NCI) In ncies (OHAM, Office of the Director M website to learn more about the cations submitted to this FOA must trial (see NOT-OD-15-015 for detail does not accept phase III clinical t linical trials will be deemed non-re-	ch projects diagnostic Division of or). Applica e various p st include s ails) and pi rials in any esponsive a	that implement eau cand therapeutic inf Cancer Treatment a ants are strongly en- program goals, resea studies that meet th rovide specific clinic varea of cancer rese and will not be revie	ly phase terventions of and Diagnosis couraged to arch priorities, e National al trial earch; ewed.		
101162	Notice of Special Interest (NOSI):	Tailoring F	ollow-up Care for Survivors Usir	ng	National Cancer	NOT- (07-May-2021	Not		

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Risk-Stratified Pathways		Institute/NIH/DHHS	CA-21- 019		Specified			
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN							
	Contact Telephone	240-276-7621							
	Contact Email	michelle.mollica@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-2022 , 05- b-2023	Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	022 , 07-Sep-			
The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and tes approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.									
077667	Increasing Uptake of Evidence-Bas Clinical Trial Optional)	sed Screening in Diverse Adult Population	s (R01 National Cancer Institute/NIH/DHHS	PA-18- 932 07	'-May-2021	Not Specified			
	Contact Name	Erica S. Breslau, PhD, MPH							
	Contact Telephone	240-276-6773							
	Contact Email	breslaue@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022						
Synopsis Synopsis Synopsis Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understa effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifest this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed diser asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or a									

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount	
		health ca	re providers. This FOA will use t	he NIF	Research Project (R01) award m	echanism			
076909	Advancing Translational and Clinic Research (R01 Clinical Trial Option	cal Probiot nal)	ic/Prebiotic and Human Microb	<u>iome</u>	National Cancer Institute/NIH/DHHS	PA-18- 902	07-May-2021	Not Specified	
	Contact Name	Gabriela	Riscuta, MD, CNS						
	Contact Telephone	240-276-	7118						
	Contact Email	gabriela.r	iscuta@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 05-Jun-2021 , 07-Sep-202	1					
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited t nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biolog chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purp of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or t combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.									
076805	Physical Activity and Weight Cont Effects on Biomarkers of Prognosi	rol Interve s and Surv	ntions Among Cancer Survivors vival (R01 Clinical Trial Optional)	<u>:</u>	National Cancer Institute/NIH/DHHS	PAR- 18-893	07-May-2021	Not Specified	
	Contact Name	Frank M.	Perna, Ed.D., Ph.D.						
	Contact Telephone	240-276-	6782						
	Contact Email	pernafm(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 05-Jun-2021 , 07-Sep-202	1					
	Synopsis	National specific b avoidance	Cancer Institute (NCI) invites ap iological or biobehavioral pathw e of weight gain) may affect can	plicatio vays th cer pro	ons for transdisciplinary and trans rough which physical activity and ognosis and survival. Research ap	slational r l/or weigh plications	esearch that will ider nt control (either wei s should test the effec	ntify the ght loss or cts of physical	

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount	
		activity, a prognosis than insu Because i experience process a fractional expertise use the N	alone or in combination with we s among cancer survivors identif lin/glucose metabolism, especia many cancer survivor population ce early effects of aging, inclusio re also sought. Applications sho I factorial designs), and will inclu , cancer biology, and other basic IIH R01 Research Project Grant a	ight cc ied by ally thc ns will on of bi uld us ude tra c and c award	ontrol (either weight loss or avoid previous animal or observationa ose obtained from tumor tissue so not experience recurrence but w iomarkers of comorbid diseases (e experimental designs (e.g., rand unsdisciplinary approaches that bu clinical science disciplines relevan mechanism.	lance of wei I research o burced from ill die of cor e.g., cardiov domized con ring togethe t to the pat	ght gain), on bioma n established biom repeat biopsies wh norbid diseases or i vascular disease) an ntrolled clinical trial or behavioral interve hways being studie	Irkers of cancer arkers other here available. may id of the aging is (RCTs), ention d. This FOA will	
100708 <mark>C</mark>	ancer Prevention and Control Cli equired)	inical Trial	s Grant Program (R01 Clinical Tr	<u>ial</u>	National Cancer Institute/NIH/DHHS	PAR- 21-035	7-May-2021	Not Specified	
	Contact Name	Brandy H	eckman-Stoddard, Ph.D., M.P.H						
	Contact Telephone	240-276-	7048						
	Contact Email	<u>heckman</u>	bm@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2022 <i>,</i> 05	2021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fel	1 <i>,</i> 05-0 b-2023	Oct-2021 , 07-Jan-2022 , 05-Feb-2 3 , 07-May-2023 , 05-Jun-2023 , 0	2022 <i>,</i> 07-M 7-Sep-2023	ay-2022 , 05-Jun-20 , 05-Oct-2023 , 07)22 , 07-Sep- Jan-2024	
	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or Synopsis survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.								
092626 R	FA-CA-20-031 Strengthening I esearch in Low- and Middle-Inco	nstitutiona ome Count	al Capacity to Conduct Global Ca ries (D43 Clinical Trial Not Allow	<u>ncer</u> /ed)	National Cancer Institute/NIH/DHHS	RFA- CA-20- 0	7-May-2021	1,250,000 USD	

031

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Contact Name	Sudha Siv	aram DrDH MDH									
	Contact Telephone	240-276-	5804									
	Contact Email	nciglobalt	raining@nih.gov									
	Sponsor Website											
	' Program URL	RL Link to program URL										
	Deadline Dates (ALL)	07-May-2 2022	-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep- 22									
	Synopsis	The purpo in global o intensive programs and will le overarchi contributo not allow clinical tri	ne purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training i global cancer research. This program will support research training led by the United States (U.S.)-based cancer research- itensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training rograms will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs nd will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The verarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will ontribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does ot allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a linical trial led by a mentor or co-mentor.									
076806 <mark>-</mark>	Physical Activity and Weight Cont Effects on Biomarkers of Prognosi	rol Interve is and Surv	ntions Among Cancer Survivors ival (R21 Clinical Trial Optional)	National Cance Institute/NIH/	er PAR- DHHS 18-892	7-May-2021	275,000 USD					
	Contact Name	Frank M.	Perna, Ed.D., Ph.D.									
	Contact Telephone	240-276-6	5782									
	Contact Email	pernafm@	Dmail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-202	L								
	National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physica activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other											

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	tha Beu exp pro fra exp use	n insulin/glucose metabolism, especia cause many cancer survivor populatio perience early effects of aging, inclusio cess are also sought. Applications sho ctional factorial designs), and will inclu- ertise, cancer biology, and other basi the NIH R21 Exploratory/Developme	ally those obtained from tumor tissue ns will not experience recurrence but on of biomarkers of comorbid disease ould use experimental designs (e.g., ra ude transdisciplinary approaches that c and clinical science disciplines relevant ntal Research Grant award mechanism	sourced from will die of com s (e.g., cardiova andomized cont bring together ant to the path m.	repeat biopsies wh orbid diseases or r ascular disease) an trolled clinical trial behavioral interve ways being studied	nere available. may d of the aging s (RCTs), ention d. This FOA wil	
083680	Stimulating Innovations in Behavioral Prevention and Control (R21 Clinical T	Intervention Research for Cancer rial Optional)	National Cancer Institute/NIH/DHHS	PAR- 19-309 07	'-May-2021	275,000 USD	
Contact NameTanya Agurs-Collins, Ph.DContact Telephone240-276-6956Contact Emailcollinsta@mail.nih.govSponsor Websiterorgram URLProgram URL07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022Deadline Dates (ALL)07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of ir interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifical intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing an novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral a and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behavior							
085441	RFA-CA-19-051 Revision Application Resistance (U54 Clinical Trial Not Allo	ise of the translational spectrum. <u>Is for Mechanisms of Cancer Drug</u> <u>wed)</u>	National Cancer Institute/NIH/DHHS	RFA- 23 CA-19- [O 051 Ap	-May-2021 ptional][LOI/Pre- pp]	750,000 USD	
	Contact Name Lau Contact Telephone 240	rence (Austin) Doyle, MD)-276-6112		<u> </u>	•		



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
			and the the second								
		Doylela@	mail.nin.gov								
	Sponsor Website	Links and									
		LINK to pr	<u>ogram UKL</u> 2024 [Outlings]][[Outlings].20	2 hur 2024							
	Deadline Dates (ALL)	23-IVIAy-2	Funding Opportunity Appoundement (EOA) is associated with the Peau Diden Cancer MeanshotSM Initiative that is								
	Synopsis	intended ongoing N developm microenv	ended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to going NCI-funded U54 Research Project grants on underlying mechanisms of resistance, preclinical design and foster velopment of single or combination therapies to effectively target resistant/refractory tumors and/or their croenvironment at the clinical level.								
082215	Dissemination and Implementatic Optional)	on Researc	h in Health (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR- 19-275 07	-May-2021	275,000 USD				
	Contact Name	Gila Neta	, Ph.D.								
	Contact Telephone	240-276-0	5785								
	Contact Email	gila.neta(@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	.021 , 16-Jun-2021 , 07-Sep-202	1 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	y-2022					
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.									
082216	Dissemination and Implementation Allowed)	on Researc	h in Health (R03 Clinical Trial No	t National Cancer Institute/NIH/DHHS	PAR- 19-276	-May-2021	50,000 USD				
	Contact Name	Gila Neta	, Ph.D.								
	Contact Telephone	240-276-6	5785								
	Contact Email	gila.neta(<u>@nih.gov</u>								

SPIN ID	Program Title	Sponsor Name	Sponso	r Number		Deadline Date	Funding Amount			
	Sponsor Website									
	Program URL <u>L</u>	ink to program URL								
	Deadline Dates (ALL) 0	07-May-2021 , 16-Jun-2021 , 07-Sep-20	021 <i>,</i> 16-Oc	t-2021 , 07-Jan-2022 , 16-Feb-2	2022 <i>,</i> 07-N	lay-2022				
	۲ Synopsis م الا ع	opsis of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.								
085440	RFA-CA-19-050 Revision Applicati Resistance (U01 Clinical Trial Not Al	ions for Mechanisms of Cancer Drug llowed)	٦ ا	National Cancer nstitute/NIH/DHHS	RFA- 2 CA-19- [050 A	23-May-2021 Optional][LOI/Pre- App]	750,000 USD			
	Contact Name L	aurence (Austin) Doyle, MD								
	Contact Telephone 2	240-276-6112								
	Contact Email	Doylela@mail.nih.gov								
	Sponsor Website									
	Program URL L	ink to program URL								
	Deadline Dates (ALL) 2	23-May-2021 [Optional][LOI/Pre-App],	, 23-Jun-20	21						
	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.									
079333	Exploratory/Developmental Bioeng Trial Optional)	ineering Research Grants (EBRG) (R21	<u>Clinical</u> N	National Cancer nstitute/NIH/DHHS	PAR- 19-150)7-May-2021	275,000 USD			
	Contact Name	Miguel R. Ossandon, Ph.D.								
	Contact Telephone 2	240-276-5714								
	Contact Email <u>c</u>	ossandom@mail.nih.gov								

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount			
	Sponsor Website Program URL Deadline Dates (ALL)	Link to pr 07-May-2	ogram URL 021 , 16-Jun-2021 , 07-Sep-202	1,16-0	Oct-2021 , 07-Jan-2022						
	Synopsis	The purpo Explorato utility of r problems	e purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of oloratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential lity of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to oblems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.								
101459	Notice of Special Interest (NOSI): Data to Study Health Disparities	Leveraging	Population-based Cancer Regis	stry	National Cancer Institute/NIH/DHHS	NOT- CA-21- 0 ⁻ 020	7-May-2021	Not Specified			
	Contact Name	Kathy Cro	nin, Ph.D.								
	Contact Telephone	240-276-6	5836								
	Contact Email	<u>cronink@</u>	mail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2022 , 07- Feb-2023	021 , 05-Jun-2021 , 16-Jun-202: -May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023	1 <i>,</i> 07-9 in-202	Sep-2021 , 05-Oct-2021 , 16-Oct-2 2 , 07-Sep-2022 , 05-Oct-2022 , 1	2021 , 07-Jar 6-Oct-2022 ,	1-2022 , 05-Feb-202 . 07-Jan-2023 , 05-F	22 , 16-Feb- eb-2023 , 16-			
	The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficien use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely colle by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, incom insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Progra and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defir areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outco persist by identifying factors contributing to disparities and their relative importance.										
090500	<u>Center of Excellence for Research</u> <u>Clinical Trial Optional)</u>	on Compl	ementary and Integrative Healt	h (P01	National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 20-138 2	5-May-2021	6,250,000 USD			

SPIN ID	Program Title		Sponsor Name	Spon	sor Number	Deadline D	ate	Funding Amount			
	Contact Name	Craig Hop	p, Ph.D.D								
		301-496-5	0825								
		<u>noppac@</u>	<u>maii.nin.gov</u>								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	eauline Dates (ALL) 25-Way-2021, 25-sep-2021, 25-jan-2022, 25-Way-2022, 25-sep-2022, 25-jan-2023, 25-Way-2023									
	Synopsis	collaborat Excellence highly me supportin the missic propose t effectiver	collaborations blending multiple research approaches from outstanding multidisciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH and high research priority based on the current Strategic Plan. Applications in response to this FOA m propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness.								
067449 <u>F</u>	iundamental Science Research or Optional)	n Mind and	l Body Approaches (R21 Clinical	<u>Trial</u>	National Center for Complementary and Integrative Health/NIH/DHHS	07-May-2021		275,000 USD			
	Contact Name	Wen G. C	hen, PhD								
	Contact Telephone	301-451-3	3989								
	Contact Email	<u>chenw@r</u>	nail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	021								
National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gart and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Researc Grant award mechanism.								damental dy-based chi, qi gong), pproaches I Research			
SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount						
---------	---	--	--	--	-------------------						
101958	Limited Competition for the Contin Clinical Coordinating Center (Colla	nuation or Revision of Multisite Clinical Tr borative UH3 Clinical Trial Optional)	ial National Center for PAR- Complementary and Integrative 21-117 Health/NIH/DHHS	, 15-Mar-2021	Not Specified						
	Contact Name	Wendy Weber, N.D., Ph.D., M.P.H.									
	Contact Telephone	301-402-1272									
	Contact Email	weberwj@mail.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	15-Mar-2021 , 28-May-2021 , 28-Sep-202 2023	21 , 28-Jan-2022 , 27-May-2022 , 28-Sep-2022 ,	27-Jan-2023 , 29-May	2023 , 27-Sep-						
	Synopsis	t (FOA) accepts applications for competing rener by NCCIH or competitive revisions to support a ongoing clinical trial will be supported when the period of follow-up is well justified to assess lon compelling justification for the addition of an a le the design scientific rationale and a compreh to be responsible for project management, part ntific conduct, and dissemination of results. Bot lication should be submitted simultaneously for trial. Applicants are strongly encouraged to con ng clinical trial for which they are planning a con to this FOA.	wal of a Clinical Coord incillary studies to ong re is a need for addition ger term outcomes. Concillary study to an or ensive scientific and on icipant recruitment ar h a Data Coordinating consideration by NCC tact the appropriate mpeting renewal appli	linating Center going NCCIH- onal time to ompetitive ngoing clinical perational plan nd retention Center (DCC) CIH if both are							
067448	Fundamental Science Research on Optional)	Mind and Body Approaches (R01 Clinical	Trial National Center for PA-18- Complementary and Integrative 323 Health/NIH/DHHS	07-May-2021	Not Specified						
	Contact Name	Wen G. Chen, PhD									
	Contact Telephone	301-451-3989									
	Contact Email	chenw@mail.nih.gov									

Sponsor Website

Program URL Link to program URL

SPIN ID	Program Title		Sponsor Name	Spons	sor Number	Deadline Date	Funding Amount				
	Deadline Dates (ALL) Synopsis	07-May-2 National science of approach art and m exclusivel	7-May-2021 National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental cience of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based pproaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), irt and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH Research Project (R01) award mechanism.								
101953	Limited Competition for the Contin Coordinating Center (Collaborative	nuation of e U24 Clin	⁻ Multisite Clinical Trial Data ical Trial Optional)		National Center for Complementary and Integrative PAR- Health/NIH/DHHS	-Mar-2021	Not Specified				
	Contact Name Contact Telephone Contact Email Spopsor Website	Wendy W 301-402-: <u>weberwj@</u>	/eber, N.D., Ph.D., M.P.H. 1272 @mail.nih.gov								
	Program URL	Link to pr 15-Mar-2	ogram URL 021 - 28-May-2021 - 28-Sep-202	21.28	-lan-2022 . 27-May-2022 . 28-Sep-2022 . 27-la	an-2023 . 29-Mav-2	2023 . 27-Sep-				
Deadline Dates (ALL) 15-Mar-2021, 28-May-2021, 28-Sep-2021, 28-Jan-2022, 27-May-2022, 28-Sep-2022, 27-Jan-2023, 29-May-2023, 2 2023 This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, accepts applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials supported by NCCIH. Extension of an exten- period of follow-up is well justified to assess longer term outcomes. The DCC competing renewal application must pro- comprehensive plan for completion of the clinical trial data collection that provides overall project coordination and administrative, data management, and biostatistical support for the ongoing clinical trial. Both a DCC application and corresponding Clinical Coordinating Center (CCC) application can be submitted simultaneously for consideration by NC both are needed to complete the ongoing trial. If clinical trial data collection and follow-up can be completed centrall- DCC and no study visits at clinical sites are needed, a single application for competing renewal for the DCC can be sub- Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial which they are planning a competing renewal application prior to submitting to this FOA.							ns for of an ongoing n extended ust propose a n and on and a n by NCCIH if entrally by the be submitted. cal trial for				
094934	Natural Product Multi-Site Clinical J24 Clinical Trial Required)	Trial Data	Coordinating Center (Collabora	ative	National Center for Complementary and Integrative 20-219 07	'-May-2021	Not Specified				

Health/NIH/DHHS

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website	Wendy W 301-402-: <u>weberwj(</u>	/eber, N.D., Ph.D, M.P.H. 1272 <u>@mail.nih.gov</u>				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2	ogram URL 2021 , 01-Oct-2021 , 07-Jan-202	2 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2	023 , 07-Ma'	y-2023	
This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages application collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clin (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collab Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive provides overall project coordination, and administrative, data management, and biostatistical support for the pro- Synopsis clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and resear of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are plant develop an application prior to submitting to this FOA							ations for a clinical trial laborating sive plan that proposed for 1 and earch priorities are strongly anning to
091405	Investigator Initiated Clinical Trials Interventions Delivered Remotely	<u>s of Comp</u> or via mH	lementary and Integrative ealth (R01 Clinical Trial Require	National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 20-154 07	-May-2021	Not Specified
	Contact Name	Lanay Mu	ıdd, Ph.D				
	Contact Telephone	301-594-9	9346				
	Contact Email	<u>lanay.mu</u>	dd@mail.nih.gov				
	Sponsor Website						
Program URL Link to program URL							
	Deadline Dates (ALL)	07-May-2 2022 , 05	2021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2 b-2023 , 07-May-2023	022 , 07-Ma	y-2022 , 05-Jun-2()22 , 07-Sep-
	Synopsis	This Fund and cond	ling Opportunity Announcemen ucted clinical trials to assess the	t (FOA) encourages applications for inve e efficacy or effectiveness of complemen	stigator-initi tary and inte	ated fully remotel egrative health int	y delivered erventions in

SPIN ID	Program Title		Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount
		NCCIH de delivered mHealth must have participar study; con evidence Scientific, to this FO	signated areas of high research and conducted clinical trial with tools or technologies. To justify e sufficient preliminary data tha nts; demonstration of participan mpletion of final data collection that the intervention has promi /Research contact for the area o A.	priorit n no in the pro t inclu t adhe from a se of c f scien	y. Applications submitted under t -person contact between researc oposed remotely delivered efficat des: demonstration of feasibility erence to the intervention as well any related studies; demonstratio linical benefit. Applicants are enc ace for which they are planning to	his FOA are h staff and s cy or effectiv of remote re as retention n of the safe ouraged to c develop an	expected to propo tudy participants a veness clinical trial cruitment and acc of participants th ety of the interven contact the approp application prior t	ose a remotely and may utilize , applications rual of roughout the tion; and oriate NCCIH o submitting
094929	<u>Clinical Coordinating Center for N</u> Trials of Natural Products (Collabo	CCIH Mult prative UG	i-Site Investigator-Initiated Clini 3/UH3 Clinical Trial Required)	<u>cal</u>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 20-215 07	'-May-2021	Not Specified
	Contact Name	Wendy W	/eber, N.D., Ph.D, M.P.H.					
	Contact Telephone	301-402-2	1272					
	Contact Email	weberwj(@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 01-Oct-2021 , 07-Jan-2022	2,01-J	un-2022 , 07-Sep-2022 , 01-Feb-2	023 <i>,</i> 07-Ma	y-2023	
	Synopsis	This Fund multi-site research multi-site comprehe responsib conduct, phase, mi Coordinat clinical pr (DCC) app	ling Opportunity Announcement c, clinical trials (Phase III and bey priority. Applicants should descr clinical trial. The objective of th ensive scientific and operational ole for project management, par and dissemination of results. Cli ilestone-driven, cooperative agr ting Center application, submitte oject is required. Both a Clinical plication need to be submitted s	t (FOA) rond) t ribe pla ne Clini plan f ticipar nical C eemer ed und Coord imulta	encourages cooperative agreem o study the effects of natural pro- ans for a Clinical Coordinating Cer- cal Coordinating Center is to prov- for the clinical trial. The Clinical Co- to recruitment and retention strat coordinating Center applications s at (UG3/UH3) funding mechanism ler PAR-20-219, proposing a data linating Center application and a co- neously for consideration by NCC	ent applicati ducts in NCC ater to devel vide the desi- pordinating C egies, perfor ubmitted un . In addition analysis and correspondir IH.	ions for investigate IH designated area op and implement gn scientific ration Center is expected rmance milestone ider this FOA will u , an accompanying data managemen ng Data Coordinati	or-initiated, as of high the proposed ale and a to be s, scientific utilize a two- g Data t plan for the ng Center
094930	NCCIH Natural Product Mid Phase	e Clinical Tr	rial Cooperative Agreement (U0	1	National Center for	PAR- 07	'-May-2021	1,750,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	C	Deadline Date	Funding Amount
	Clinical Trial Required)		Complementary and Integr Health/NIH/DHHS	rative 20-216		USD
	Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.				
	Contact Telephone	301-402-1272				
	Contact Email	weberwj@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 01-Oct-2021 , 07-Jan-2022	2,01-Jun-2022,07-Sep-2022,01-	Feb-2023 , 07-May-2	2023	
	Synopsis	phase clinical trials of natural products. A data of bioavailability and documentation biological signature (i.e., measure of the biological signature in the patient popula mechanism of action will this preliminary mid-phase clinical trial to do the following future multi-site clinical trial; or determin natural product to inform inclusion/exclu expected to be hypothesis based, milesto FOA will not support single-site or multi-s for the treatment or prevention of cancer contact for the area of science for which	Il applications submitted under the n that the natural product produce mechanism of action). Only in case tion of interest or when there is a data requirement be waived. App g: determine the optimal dose or f he which patient phenotypes will b sion criteria of a future efficacy str one-driven, and directly related to site efficacy or effectiveness trials, r. Applicants are encouraged to co they are planning to develop an ap	nent applications for is FOA must be supplies a replicable and mess fundamental unders lications submitted formulation of a give e responders versus udy. Clinical trials su the research priorition nor will it support tri ntact the appropriat	r Investigator-In ported by sufficient sible/practical to standing of the p to this FOA show en natural product s non-responder ubmitted under to rials to test natural te NCCIH Sciention ubmitting to this	ent preliminary ent preliminary ct on a o measure a oroduct's ald propose a ict for use in a s to the this FOA are of NCCIH. This iral products fic/Research FOA.
100802	NEI Collaborative Clinical Vision Re (UG1 Clinical Trial Required)	esearch Project: Coordinating Center Gran	t National Eye Institute/NIH/DHHS	PAR- 21-042 07-N	/lay-2021	Not Specified
	Contact Name	Donald Everett, MA				
	Contact Telephone	301-451-2020				
	Contact Email	everettd@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-202	21, 25-Sep-2021, 07-Jan-2022, 25	-Jan-2022 , 07-May-	-2022 , 25-May-	2022,07-Sep-

2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 The NEI uses UG1 cooperative agreement awar transfer, stem cell therapy trials, and other com multifaceted and of high public health significan responsibilities and require careful performanc Announcement (FOA), the proposed study mus preventing, or treating vision disorders, or to co	23 , 07-May-2023 ards to support investigator-initiated omplex or high resource- or safety-ris cance requiring clear delineation of s nce oversight and monitoring. For pu- ust be intended to evaluate interven- compare the effectiveness of two or s a group of single-component comp e Centers, when appropriate. Specific s details of the Coordinating Center!	l large-scale sk clinical tri tudy organiz rposes of th tions aimed more estab anion grant cally, this FO s responsibil	clinical trials, hun als. These project ation including ro is Funding Opport at screening, diag lished interventio awards including A encourages app lities and operatio	nan gene- s are les and tunity nosing, ns. The NEI the Chair's lications for			
UG1-supported studies are typically funded as a Grant, the Coordinating Center, and Resource C the Coordinating Center grant, which provides			-				
100803 <u>NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical</u> <u>Trial Required)</u>	National Eye Institute/NIH/DHHS	PAR- 21-043 07-	May-2021	Not Specified			
Contact Name Donald Everett, MA							
Contact Telephone 301-451-2020							
Contact Email <u>everettd@mail.nih.gov</u>							
Sponsor Website							
Program URL Link to program URL							
Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25 2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023	25-Sep-2021 , 07-Jan-2022 , 25-Jan-2 23 , 07-May-2023	022 <i>,</i> 07-Ma	y-2022 , 25-May-2	2022 , 07-Sep-			
The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The I UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chai Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial other complex or high-risk clinical trial							

100798 NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial 07-May-2021 National Eye PAR-



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
<u>F</u>	Required)			Institute/NIH/DHHS	21-041		Specified
	Contact Nam	e Donald E	verett, MA				
	Contact Telephor	e 301-451-	2020				
	Contact Ema	il <u>everettd</u>	<u>@mail.nih.gov</u>				
	Sponsor Websit	e					
	Program UF	Link to pr	rogram URL				
	Deadline Dates (AL	07-May-2 2022 , 25	2021 , 25-May-2021 , 07-Sep-20 -Sep-2022 , 07-Jan-2023 , 25-Ja)21 , 25-Sep-2021 , 07-Jan-2022 , 25 in-2023 , 07-May-2023	5-Jan-2022 , 07-M	ay-2022 , 25-May-	-2022 , 07-Sep-
	Synops	is Announce preventir UG1-supp the Chair	eted and of high public health si pilities and require careful perforement (FOA), the proposed stung, or treating vision disorders, ported studies are typically funder e Coordinating Center, and Res 's grant, which includes the scie	ignificance requiring clear delineati ormance oversight and monitoring. dy must be intended to evaluate in or to compare the effectiveness of ded as a group of single-componen ource Centers, when appropriate. S entific rationale, study aims and sig	For purposes of t For purposes of t terventions aimed two or more esta t companion gran Specifically, this FO nificance of the re	ization including r his Funding Oppor d at screening, dia blished intervention t awards including DA encourages ap esearch project.	oles and rtunity gnosing, ons. The NEI g the Chair's plications for
076351	NEI Vision Research Epidemiolog	gy Grant (UC	G1 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR- 07 18-864	'-May-2021	Not Specified
	Contact Nam	e Sangeeta	Bhargava, PhD,				
	Contact Telephor	e 301-451-	2020				
	Contact Ema	il <u>bhargava</u>	<u>s@mail.nih.gov</u>				
	Sponsor Websit	e					
	Program UF	Link to pr	ogram URL				
	Deadline Dates (AL	L) 07-May-2	2021 , 25-May-2021 , 07-Sep-20	021			
	Synops	Nationa epidemio Funding (the NIH L	l Eye Institute (NEI) invites app logic studies under the cooper Dpportunity Announcement (F0 JG1 Clinical Research Cooperat	lications for investigator-initiated, c ative agreement mechanism, UG1 a DA) is to support new and innovativ ive Agreements - Single Project awa	complex, multi-cer activity code. Spe ve ocular epidemic ard mechanism.	nter and other hig cifically, the purpo blogy research. Th	h resource risk ose of this is FOA will use

SPIN ID	Program Title	Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount	
081744	NEI Research Grant for Vision-Rela Not Allowed)	ated Secondary Data Analysis (R21 Clinical	<u>Trial</u>	National Eye Institute/NIH/DHHS	PAR- 19-260	7-May-2021	275,000 USD	
	Contact Name	Donald Everett, M.A.						
	Contact Telephone	301-451-2020						
	Contact Email	<u>everettd@mail.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021	, 16-	Oct-2021 , 07-Jan-2022 , 16-Feb-2	022 , 07-Ma	ay-2022		
	Synopsis	analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the spect the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic projects wherein numerous data collection activities are required to meet each project's specific aims. The result of data generated by these studies often provides unique, cost-effective opportunities to investigate additional re- questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are no those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FO secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, b must not be used to support the collection of new data.						
101324	Notice of Special Interest (NOSI): N Identification and Development of Diagnose Dry Eye Disease.	NEI Anterior Segment Initiative (ASI): f New Biomarkers and Effective Methods to	<u>o</u>	National Eye Institute/NIH/DHHS	NOT- EY-21- 05 007	5-Apr-2021	Not Specified	
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Apr-2021 , 07-May-2021 , 05-Jun-2021 2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05	, 16 -2022 5-Jan-	Jun-2021 , 05-Sep-2021 , 07-Sep-2 2 , 05-Apr-2022 , 07-May-2022 , 0 2023 , 07-Jan-2023 , 05-Feb-2023	2021 , 05-Oc 5-Jun-2022 , 16-Feb-20	t-2021 , 16-Oct-20 , 16-Jun-2022 , 05- 23 , 05-Apr-2023 ,	21 , 05-Jan- Sep-2022 , 07- 07-May-2023	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in Synopsis research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.										
081084 <mark>/</mark>	NET Clinical Research Study Plannin Allowed)	<u>g Grant P</u>	rogram (R34 Clinical Trial Not	National Eye Institute/NIH/DHHS	PAR- 19-231	7-May-2021	300,000 USD				
	Contact Name I Contact Telephone 3 Contact Email <u>e</u> Sponsor Website	Donald Ev 301-451-2 everettd@	verett, MA 2020 <u>@mail.nih.gov</u>								
	Program URL <u>L</u> Deadline Dates (ALL) (<u>Link to pr</u> 07-May-2	ogram URL 021 , 16-Jun-2021 , 07-Sep-202	L, 05-Oct-2021, 07-Jan-2022,	16-Feb-2022 , 07-Ma	ay-2022					
The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trial epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to p detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities an environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the developmendetailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be use generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical to research studies.											
100058 <mark> </mark>	Aultidisciplinary Approaches to HIN ntervention Targets (R01 Clinical T	V-Associa Trial Not A	ted Comorbidities and Prioritizi Illowed)	ng National Heart, Lung, a Institute/NIH/DHHS	nd Blood PAR- 21-027 0	7-May-2021	1,920,000 USD				
	Contact Name S Contact Telephone S Contact Email Z Sponsor Website Program URL L Deadline Dates (ALL) C	Shimian Z 301-827-8 20us@ma Link to pr 207-May-2	ou, Ph.D. 3301 <u>il.nih.gov</u> <u>ogram URL</u> 021 , 07-Jan-2022 , 07-May-202	2 , 07-Jan-2023							

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount			
	This Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using Synopsis multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.										
100990 <u> </u>	NHLBI Program Project Applicatio	<u>ns (P01 Cli</u>	nical Trial Optional)	National Heart, Lung, Institute/NIH/DHHS	, and Blood PAR 21-0	- 2	5-May-2021	Not Specified			
	Contact Name Contact Telephone	Denis Bux 301-435-0	ton, Ph.D.)515								
	Contact Email	<u>denis.bux</u>	ton@nih.gov								
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	, 25-May-2022 , 25-Sep-202	22 , 25-Jan-2023	, 25-N	/lay-2023 , 25-Sep-2	2023					
Synopsis Synopsis This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (submission of investigator-initiated Program Project (P01) applications. The proposed programs may add relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blo resources; and sleep disorders. Programs may also include implementation science, health disparities, an research that addresses the mission of the Institute. Each application submitted in response to this FOA r three related research projects that share a common central theme, focus, and/or overall objective. High requested for applications that include at least four projects, one of which includes an Early Stage Investi Leader.							ood Institute (NHLB rams may address s , lung, and blood; b disparities, and tran e to this FOA must in bjective. Higher buo Stage Investigator	I) invites cientific areas lood nslation nclude at least dgets may be as Project			
100447 <u>5</u>	Notice of Special Interest (NOSI): Stage Implementation Research to Disorders	Use of Pred o Address	dictive Analytics to Accelerate La Heart, Lung, Blood, and Sleep	National Heart, Lung, Institute/NIH/DHHS	, and Blood NOT HL-2 815	 20- 0	7-May-2021	Not Specified			
	Contact Name	Rebecca A	A. Roper, MS, MPH								
	Contact Telephone	301-496-1	.051								
	Contact Email	<u>Rebecca.</u>	Roper@nih.gov								
	Sponsor Website										
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-Sep-2022 Oct-2022 , 07-Jan-2023 , 05-Feb	, 05-Oct-2021 , 07-Jan-2022 -2023 , 07-May-2023 , 05-Ju	2 , 05-Feb-2022 , ın-2023 , 07-Sep	07-M -2023	ay-2022 , 05-Jun-20 , 05-Oct-2023 , 07-)22 , 07-Sep- Jan-2024			

SPIN ID	Program Title	Sponsor Name	Spons	sor Number		Deadline Date	Funding Amount			
	NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sl (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.									
074657	The Mechanistic Role of the Microbiom Blood, and Sleep Diseases (R01 - Clinica	in the Pathobiology of Heart, Lung Trial Not Allowed)	5	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-18- 784 07	'-May-2021	Not Specified			
	Contact Name Lis Ca Contact Telephone 301-4 Contact Email <u>lis.ca</u> Sponsor Website Program URL Link	er, Ph.D. 35-0222 er@mail.nih.gov o program URL								
	Deadline Dates (ALL) 07-N	ay-2021 , 05-Jun-2021 , 07-Sep-202	1							
National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused of understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their comp the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translatic approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiolo pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial e biotechnology, and bioinformatics. This FOA will use the NIH Research Project (B01) award mechanism.							sed on , oral, _BS) biology .tro, in vivo omponents in slational ages diology, bial ecology,			
079552	Implementation of Shared Decision Ma (R01 Clinical Trial Optional)	ing for HLBS Diseases and Conditio	<u>ns</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19- 166 07	7-May-2021	2,499,995 USD			
	Contact Name Susar Contact Telephone 301-4 Contact Email <u>sher</u> c	T. Shero, BSN, MS 96-1051 s <u>@nih.gov</u>								

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2	022 , 07-May-2022					
	shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lublood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research health information technology, behavioral science, behavioral economics, workflow design, and organizational engineer are encouraged to apply.								
099803	Notice of Special Interest (NOSI): Diseases	Palliative Care in Heart, Lung, Blood, and S	Sleep National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-20- 07-May-2021 737	Not Specified				
	Contact Name	Lora Reineck, MD, MS							
	Contact Telephone	301-435-0222							
	Contact Email	lora.reineck@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2 b-2023 , 07-May-2023 , 05-Jun-2023	022 , 07-May-2022 , 05-Jun-20	022 , 07-Sep-				
	Synopsis	Providing care that is consistent with a painterdisciplinary patient-centered approar families. Palliative care focuses on severa and treatment options in the context of p Palliative care is not synonymous with ho serious illness from diagnosis through ter withholding or curbing treatment. Relief concordant care may, in fact, involve opt palliative care into the management of the benefits of treatment and interventions,	atient's values, preferences, and goals is ach that aims to improve quality of life for al objectives including relief of symptoms patients' goals, and coordination of care ospice or end-of-life care. Rather, palliatir rminal stages of diseases. Moreover, pall of symptoms, enhancing quality of life, a imal medical or surgical treatment of dis ne patient's disease is a better quality of and medical treatment decisions that ali	a cornerstone of palliative car or persons with advanced illnes and suffering, communicatio within and across healthcare s ve care addresses the spectrum iative care does not necessaril and many other specific aspect eases. The expected outcome life, a realistic understanding gn with the patient's goals, pr	re, an ss and their n of prognosis settings. m of care for ly entail cs of goal- of integrating of risks and eferences, and				

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		values. M (COPD), p limiting, r and qualit cardiolog Additiona even in di the qualit	any heart, lung, blood, and slee ulmonary fibrosis, pulmonary h non-curable illnesses. These and ty of life, in addition to care focu y, pulmonary, hematology, and lly, symptoms of HLBS diseases seases that are not life-limiting. y of life for all patients with HLE	p (HLB yperte other used or critical such a Resea 3S disea	S) diseases, including heart failur nsion, cystic fibrosis, myelodyspla HLBS diseases may benefit from n slowing or halting progression of care practice is recommended b s cough, shortness of breath, and irch to improve burdensome sym ases, not just those with life-limit	e, chronic ol astic syndroi care focused of diseases. I y multiple pi I fatigue may ptoms has tl ing disease.	bstructive pulmona mes, and aplastic a d on improvement integration of pallia rofessional societie y be especially bure he potential to gre	ary disease nemia are life- of symptoms ative care into as. densome, atly improve
100825 <u>D</u>	lotice of Special Interest (NOSI): Data (Parent RO1 Clinical Trial No	Integrative t Allowed)	e Omics Analysis of NHLBI TOPM	led	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-20- 07 823	7-May-2021	Not Specified
	Contact Name	Weiniu G	an, Ph.D.					
	Contact Telephone	301-435-0)202					
	Contact Email	ganw2@r	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 05·	021 , 05-Jun-2021 , 07-Sep-2022 Oct-2022 , 07-Jan-2023 , 05-Feb	1 <i>,</i> 05-0 b-2023	Dct-2021 , 07-Jan-2022 , 05-Feb-2 , 07-May-2023	2022 <i>,</i> 07-Ma	ay-2022 , 05-Jun-20	22,07-Sep-
	Synopsis	The symp years, yet Furtherm Therefore high throus sequence "omics" d genome s turn its at pathobiol ability to insights fr uncoverir	tom-based diagnosis and treatm an understanding of the molec ore, in most cases the impact of e, the NHLBI has recently created ughput omics to characterize a v from over 130,000 well-phenot ata (e.g. RNA, DNA methylation equence information. Having pr tention to effectively leveraging ogy. Although lower costs and t generate large volumes of omics om them remains challenging. So by the underlying biological network	nent of ular m f genet d the T variety typed i n, meta roduce g this re s data, System works, s	f heart, lung, blood, and sleep (HI echanisms underlying many of th cic variation on severity of disease rans Omics for Precision Medicin of HLBS diseases. TOPMed is wel ndividuals and is currently genera bolites, and proteins) from many ed an unprecedented volume of h esource through novel systems b logical improvements in sequence the ability to analyze such large of as level models incorporating trans gene-gene and gene-environment	LBS) diseases ese diseases and treatm e (TOPMed) Il on its way ating high-th of these inc igh-through iology analys ing technolo datasets to e is-omics ana it interaction	s has vastly improv s has remained elu- ient outcomes rem program, which ai to collecting whole roughput expressi dividuals to comple put data, TOPMed ses to uncover dise ogy have vastly exp extract biologically lyses will be an imposed in the second set on the second	ed in recent sive. ains unknown. ms to utilize genome on and other ment whole now seeks to ease anded our meaningful portant step in ase and

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		treatmen thousand	t outcomes. Thus, advanced and s of individuals are required to r	alyses that incorporate genotype and pl move TOPMed to the next phase of disc	nenotype dat covery.	asets from thousa	nds to tens of
086465	RFA-HL-20-029 Limited Compet K01/K08/K23 Recipients (R03 - Cli	ition: Sma nical Trial	ll Grant Program for NHLBI Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-20- 10 029	-May-2021	100,000 USD
	Contact Name	Roya Kala	intari, PhD				
	Contact Telephone	301-480-2	1989				
	Contact Email	<u>roya.kala</u>	ntari@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	10-May-2	021 , 08-Jun-2021 , 08-Sep-202	1 , 08-Oct-2021 , 10-Jan-2022			
	Synopsis	The purpo expand th award. Ac their K aw R03 start the capab independ studies; s and devel applicatio that can b subseque	be of this FOA is to solicit current neir current research objectives ctive NHLBI K01, K08, and K23 ar vard. Recently completed NHLBI date falls within 2 years of their pility of NHLBI K01, K08, and K23 ent investigator status. The R03 econdary analysis of existing da opment of new research techno on may or may not include patie be carried out in a short period of nt R01, or equivalent, applicatio	ent or recently completed NHLBI K01, KC or to branch out to a study that resulte wardees may apply for R03 support to r I K01, K08, and K23 awardees are eligibl r prior NHLBI K award Project Period end award recipients to conduct research a grant mechanism supports different ty ta; small, self-contained research projec ology. For current and previous K23 awa nt-oriented research.The R03 is, therefor of time with limited resources and that	28, and K23 a d from the re- un concurrer e to apply fo d date. Thus, as they comp pes of projec cts; developn ardees, resea ore, intended provide prelin	wardees for grant esearch conducted offy with the final f r the R03 if the ea this FOA is intend lete their transitio ets, including pilot nent of research m rch proposed in th I to support resear minary data to sup	support to under the K two years of rliest possible ed to enhance in to fully and feasibility nethodology; ne R03 rch projects oport a
100811	NHLBI Clinical Trial Pilot Studies (F	R34 Clinica	<u>l Trial Optional)</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 21-079 07	-May-2021	450,000 USD
	Contact Name	Patrice De	esvigne-Nickens, MD				
	Contact Telephone	301-435-0	0504				
	Contact Email	gweinma	nn@nih.gov				
	Sponsor Website	Link to sp	onsor website				

SPIN ID	Program Title	SI	ponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program URL	Link to prog	ram URL								
	Deadline Dates (ALL)	07-May-202 2022 , 16-0	21 , 16-Jun-2021 , 07-Sep-202 ct-2022 , 07-Jan-2023 , 16-Fe	1 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2 b-2023 , 07-May-2023 , 16-Jun-2023 , 0	2022 , 07-Ma 7-Sep-2023 ,	y-2022 , 16-Jun-20 16-Oct-2023 , 07-)22 , 07-Sep- Jan-2024				
	Synopsis	This Funding planning of planned clin the subsequ sufficient to test the effic heart, lung, for clinical to trials-optimi question(s) Regardless o	This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describ planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or he subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will le ufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intenderest the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment neart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportuni or clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.								
076311	FA-HL-19-026 Mentored Caree iversity in Biomedical Research (er Developme K01 Indepen	ent Award to Promote Facult Ident Clinical Trial Not Allowe	y National Heart, Lung, and Blood d) Institute/NIH/DHHS	RFA- HL-19- 06 026	5-May-2021	750,000 USD				
	Contact Name	Jane D. Scot	t, ScD, MSN, FAHA								
	Contact Telephone	301-435-053	35								
	Contact Email	<u>scottj2@nhl</u>	lbi.nih.gov								
	Sponsor Website										
	Program URL	Link to prog	ram URL								
	Deadline Dates (ALL)	06-May-202	21								
	Synopsis	National He diverse back developmer leading to re are grounde pulmonary, applications	art, Lung, and Blood Institute kgrounds, including those from nt will take place under the gu esearch independence. It is take and hematologic diseases an s from institutions with eligible	e (NHLBI) invites applications to enhance m groups underrepresented in research uidance of an experienced mentor in the argeted toward individuals whose basic, and experimental approaches needed to d sleep disorders in the general and hea le faculty members to undertake specia	e the pool of areas of inte biomedical, clinical, and solve proble alth disparitie I study and su	highly trained inve erest to the NHLBI , behavioral or clin translational rese ems related to car es populations. Th upervised researc	estigators from . The career nical sciences arch interests diovascular, is FOA invites h under a				

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		mentor w investigat clinical tri developm mentor. 1	who is an accomplished investiga cors. This FOA is designed specifial, a clinical trial feasibility study nent. Applicants to this FOA are This FOA will utilize the NIH K01	tor in fically	the research area proposed and h or applicants proposing research separate ancillary clinical trial, as ted to propose research experier rch Scientist Development Award	as experie that does part of the ce in a clir - Research	nce in developing in not involve leading a eir research and car nical trial led by a m n & Training award r	ndependent an independent eer entor or co- nechanism.
076292	FA-HL-19-025 Mentored Caree Diversity in Biomedical Research	er Develop K01 Indep	ment Award to Promote Faculty endent Clinical Trial Required)	<u>'</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-19- (025)6-May-2021	750,000 USD
	Contact Name	Jane D. So	cott, ScD, MSN, FAHA					
	Contact Telephone	301-435-0	0535					
	Contact Email	scottj2@	nhlbi.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	06-May-2	.021					
	Synopsis	National diverse ba developm leading to are groun pulmonar applicatio mentor w investigat clinical tri developm mechanis	Heart, Lung, and Blood Institute ackgrounds, including those from nent will take place under the gu oresearch independence. It is ta aded in the advanced methods a ry, and hematologic diseases and ons from institutions with eligible who is an accomplished investiga cors. This FOA is designed specifi ial, a clinical trial feasibility study nent. This FOA will utilize the NII sm.	(NHLE m grou iidance rgetec nd exp d sleep e facul tor in fcally f r, or a H KO1 I	I) invites applications to enhance ps underrepresented in research of an experienced mentor in the l toward individuals whose basic, perimental approaches needed to o disorders in the general and hea ty members to undertake special the research area proposed and h or applicants proposing to serve a separate ancillary clinical trial, as Research Scientist Development A	the pool of areas of ir biomedic clinical, ar solve prol lth dispari study and as experie s the lead part of the ward - Re	of highly trained invo iterest to the NHLBI al, behavioral or clir id translational rese plems related to car ties populations. Th supervised research ince in developing ir investigator of an ir eir research and car search & Training av	estigators from . The career nical sciences arch interests diovascular, is FOA invites n under a ndependent ndependent eer ward
074423 <u>T</u>	IHLBI Career Transition Award for rainees (K22 Independent Clinica	e <mark>r Intramur</mark> al Trial Not	al Postdoctoral Fellows and Res Allowed)	<u>earch</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 18-772)7-May-2021	Not Specified
	Contact Name Contact Telephone	Herbert N 301-451-9	Л. Geller, Ph.D. 9440					
Icahn S	School of Medicine at		NIH Funding Opportu	nities	Due: May 2021			52

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Contact Email	direducation@nhlbi.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021	May-2021								
	Synopsis	National Heart, Lung, and Blood Institute (NHLBI) provides highly qualified postdoctoral fellows and other doctoral- researchers still in trainingin the NHLBI Division of Intramural Research the opportunity to transition their research to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award w two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for five years of combined support. Transition from the intramural phase of support to the extramural phase is not aut Approval of the transition will be based on the success of the awardee's research program during the mentored pha- determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at th extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants propo- research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate and clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor of mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K22 Career Transition Award mechanis									
074422	IHLBI Career Transition Award fo rainees (K22 Clinical Trial Require	r Intramural Postdoctoral Fellows and Res ed)	search National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 18-771 07	-May-2021	Not Specified					
	Contact Name	Herbert M. Geller, Ph.D.									
	Contact Telephone	301-451-9440									
	Contact Email	direducation@nhlbi.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021									
	Synopsis	National Heart, Lung, and Blood Institute researchers still in trainingin the NHLBI D to extramural institutions as junior inves- two phases of research: a mentored intra five years of combined support. Transition Approval of the transition will be based of determined by an NHLBI progress review	(NHLBI) provides highly qualified postd ivision of Intramural Research the oppo- tigators. To achieve these objectives, th amural phase (up to two years) and an e on from the intramural phase of support on the success of the awardee's research or, which will include an evaluation of a re	octoral fellow rtunity to tra e NHLBI Care extramural ph to the extrar n program du esearch plan	ws and other docto insition their resea er Transition Awan hase (three years), mural phase is not iring the mentored to be carried out a	oral-level arch programs rd will support for a total of automatic. d phase as at the					

SPIN ID	Program Title		Sponsor Name	Spon	sor Number		Deadline Date	Funding Amount
		extramur serve as t trial, as pa K22 Caree	al institution. This Funding Oppo he lead investigator of an indep art of their research and career er Transition Award mechanism	ortuni ende devel	ty Announcement (FOA) is designent nt clinical trial, a clinical trial feasik opment. This Funding Opportunity	ed specifica pility study, y Announce	lly for applicants pr or a separate ancill ment (FOA) will uti	oposing to lary clinical lize the NIH
084638	Clinical Coordinating Center for M (Collaborative UG3/UH3 Clinical T	<u>lulti-Site Ir</u> rial Requir	ivestigator-Initiated Clinical Tria ed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 19-329 1	1-May-2021	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website	Nancy Dif 301-435-0 <u>difronzon</u>	Fronzo, PhD 2065 @nhlbi.nih.gov					
	Program URL Deadline Dates (ALL)	Link to pr 11-May-2 2022	ogram URL 021 , 10-Jun-2021 , 08-Sep-202	1,14-	Oct-2021 , 14-Jan-2022 , 11-Feb-2	2022 , 11-M	ay-2022 , 10-Jun-20)22 , 08-Sep-
	Synopsis	This Fund Center (C implemer preventio NIH defin research milestone applicatio present th applicatio conduct o submittee	ing Opportunity Announcement CC) for investigator-initiated mu- ntation research clinical trials. Th in strategies. Trials for which thi ition of a clinical trial (see NOT- priorities of the NHLBI, applican e-driven cooperative agreement ons for a collaborating Data Coop ne scientific rationale for the clin on should address project manage of the trial, and dissemination of d on the same application due d	t (FOA ulti-sit nese t s FOA OD-15 ts are mech rdinat nical t gemen resul ate fo	a) supports applications to develop e clinical trials including efficacy, of rials may include ones that test di applies must be relevant to the re 6-015) . For additional information encouraged to consult the NHLBI panism of award and runs in parall ing Center (DCC) (PAR-19-330). T rial and a comprehensive scientifient, subject recruitment and retent ts. Both a CCC application and a con or consideration by NHLBI.	o and imple comparative fferent the esearch mis about the website. Th el with a co he objectiv c and opera ion, perforr ollaborating	ment a Clinical Coo e effectiveness, pra rapeutic, behaviora sion of the NHLBI a mission, strategic v his FOA will utilize a mpanion FOA that e of the CCC applica tional plan that des nance milestones, so DCC application m	rdinating gmatic and/or I, and/or Ind meet the ision, and bi-phasic, encourages ation is to scribes it. The scientific nust be
084646	Data Coordinating Center for Mul (Collaborative U24 Clinical Trial R	<u>ti-Site Inve</u> equired)	estigator-Initiated Clinical Trials		National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 19-330	1-May-2021	Not Specified
	Contact Name Contact Telephone	Nancy Dif 301-435-0	Fronzo, PhD 0065					



SPIN ID	Program Title	Sponsor Name	Spons	or Number		Deadline Date	Funding Amount			
	Contact Email	difronzon@nhlbi.nih.gov								
	Sponsor website	Link to program LIRI								
	Deadline Dates (ALL)	11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 2022								
	Synopsis	This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementati research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strateg Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechan of award and runs in parallel with a companion FOA (PAR-19-329) that encourages applications for a collaborating Clinica Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall procoordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborati CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application d date for consideration by NHLBI								
084637 <u>S</u>	ingle-Site Investigator-Initiated C	Clinical Trials (R61/R33 Clinical Trial Require	<u>ed)</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 19-328 ¹¹	-May-2021	Not Specified			
	Contact Name	Nahed El Kassar, MD								
	Contact Telephone	301-435-0065								
	Contact Email	nahed.elkassar@nih.gov								
	Sponsor Website	2								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	11-May-2021 , 10-Jun-2021 , 08-Sep-2021 2022	1,14-0	Dct-2021 , 14-Jan-2022 , 11-Feb-2	022 <i>,</i> 11-Ma	y-2022 , 10-Jun-20)22 , 08-Sep-			
	Synopsis	This Funding Opportunity Announcement site clinical trials including efficacy, comp These trials may include ones that test dif FOA applies must be relevant to the resea 15-015). For additional information abour	t (FOA) arative fferent arch m t the n	supports applications to develop e effectiveness, pragmatic and/or t therapeutic, behavioral, and/or ission of the NHLBI and meet the nission, strategic vision, and resea	and implen implementa prevention s NIH definition rch prioritie	nent investigator-i ation research clini strategies. Trials fo on of a clinical tria s of the NHLBI, ap	nitiated single cal trials. r which this l (see NOT-OD- plicants are			

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		encourag objective operatior performa encourag and coord	ed to consult the NHLBI website of the application is to present al plan that describes it. The ap nce milestones, scientific condu ed but not required. Applicants lination.	. This F the scie plicatic ct of th are ene	FOA will utilize a bi-phasic, milest entific rationale for the clinical tri on should address project manage ne trial, and dissemination of resu couraged to include a PD/PI with	one-driven ial and a co ement, sub ults. The mu expertise in	mechanism of awa mprehensive scient ject recruitment an Iltiple PD/PI model n biostatistics, clinic	rd. The ific and d retention, is strongly al trial design,
092824	RFA-HL-22-006 Implementation Screening, and Treatment for Fan Clinical Trial Required)	Research nilial Hyper	to Improve Case Finding, Cascad ccholesterolemia (FH) (R61/R33	<u>le</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-22- 0 006	7-May-2021	2,060,000 USD
	Contact Name	Cheryl An	ne Boyce, Ph.D.					
	Contact Telephone	301-496-3	1051					
	Contact Email	<u>cheryl.bo</u>	<u>yce@mail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	This miles address b familial h inheritan scalability mining te and healt	stone-driven Funding Opportuni arriers that impede population- ypercholesterolemia (FH) index ce); (2) explore implementation of family-based cascade screer chniques to find high-risk indivio h outcomes.	ty Ann level ir cases a science ing pro luals u	ouncement (FOA) invites applicat nplementation of case finding an are systematically contacted base e methodologies to assess the up ograms for FH; (3) develop or imp sing Electronic Health Records (E	tions for sin d cascade s d on their r otake, cost-e orove mach HRs); and (4	gle site clinical trial creening (i.e., blood isk according to the effectiveness, feasik ine learning algorith 4) optimize treatme	s to: (1) d relatives of e pattern of pility, and hms and data ent strategies
085485	RFA-HL-20-028 Catalyze: Produce Design Modification, Diagnostic D Characterization, and Research To Not Allowed)	ct Definition isease Tar pol Testing	n – Device Prototype Testing ar get Assay Development and Des and Validation (R33 - Clinical Tr	i <u>d</u> ign ials	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-20- 1 028	1-May-2021	500,000 USD
	Contact Name	Kathleen	Rousche, Ph.D.					
	Contact Telephone	301-827-	7981					
	Contact Email	<u>kathleen.</u>	rousche@nih.gov					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	11-May-2	021 , 09-Jun-2021 [Optional][LC	DI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Fundi testing/de the treatn the point developm	ing Opportunity Announcement esign modification, assay develo nent of HLBS diseases and disor where they can meet the entry ent support from other federal	t (FOA) will provide the early stage trans opment for diagnostic disease targets, a ders. This FOA is part of a suite of Catal criteria for the NHLBI Catalyze Preclinic or private partners for preclinical produ	slational sup nd developn yze innovati al program c uct optimiza	port needed for pr nent of research to on grants to advan or attract independ tion and character	ototype ols for use in ce projects to lent ization.
085483 <mark>F</mark>	RFA-HL-20-027 Catalyze: Produce Preliminary Product/Lead Series Id	<u>ct Definitio</u> dentificatio	n for Small Molecules and Biolo on (R33 - Clinical Trial Not Allow	ogics - National Heart, Lung, and Blood red) Institute/NIH/DHHS	RFA- HL-20- 11 027	May-2021	700,000 USD
	Contact Name	Kathleen I	Rousche, Ph.D.				
	Contact Telephone	301-827-7	/981				
	Contact Email	kathleen.	rousche@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	11-May-2	021 , 09-Jun-2021 [Optional][LC	DI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Fundi compound disorders. entry crite private pa	ing Opportunity Announcement d series toward development of This FOA is part of a suite of Ca eria for the NHLBI Catalyze Prec ortners for preclinical optimizati	t (FOA) will provide the early stage trans f potential therapeutic agents to treat h atalyze innovation grants to advance pro linical program or attract independent o on and development of therapeutic age	slational sup eart, lung, b ojects to the developmen ents.	port needed to ide lood, and sleep dis point where they t support from oth	ntify a lead eases and can meet the er federal or
102462 <mark>-</mark>	RFA-HL-22-002 Lung Transplant Trial Not Allowed)	Consortiu	m - Clinical Centers (U01 - Clinic	al National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- 15 HL-22- [O 002 Ap	i-May-2021 ptional][LOI/Pre- pp]	1,375,000 USD
	Contact Name	Matt Crai	g, PhD				
	Contact Telephone	301-827-7	7841				
	Contact Email	matt.craig	<u>g@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Sponsor Website Program LIBL	Link to program LIRI									
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021									
	This Funding Opportunity Announcement (FOA) seeks applications from lung transplant clinical centers (CCs) to form cooperative multi-site Lung Transplant Consortium (LTC). The LTC will support CCs in conducting observational and complementary mechanistic clinical research studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes the development of primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD) in recipients. Each C application must consist of a multidisciplinary investigative team that includes a lung transplant surgeon and a lung transplant pulmonologist, and be comprised of primary and subsites that have a combined annual lung transplant vo at least 100 transplants. Each CC application should propose hypothesis-driven scientific questions to assess certain of and/or recipient clinical practices and their impact on donor lung utilization, PGD, ALAD or other relevant short-term outcomes that can be addressed through observational data and/or biospecimen collection and analysis at the sites in their application. In addition, the CCs will be expected to enroll participants and contribute to a core set of data ar biospecimens to be collected across all participating consortium sites through the implementation of a common rese protocol under the auspices of a centralized Data Coordinating Center (DCC) and a Steering Committee (SC). By lever this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important re questions involving lung transplantation. This FOA runs in parallel with the LTC Data Coordinating Center (see RFA-HI 002)										
102465 <u>R</u> <u>C</u>	FA-HL-22-002 Lung Transplant linical Trial Not Allowed)	Consortium - Data Coordinating Center (U.	24 - National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- 15 HL-22- [O 003 Ap	5-May-2021 0ptional][LOI/Pre- op]	3,500,000 USD					
	Contact Name	Matt Craig, PhD									
	Contact Telephone	301-827-7841									
	Contact Email	matt.craig@nih.gov									
	Sponsor Website										
	Program URL	L Link to program URL									
	Deadline Dates (ALL)	.) 15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021									
	Synopsis	This Funding Opportunity Announcement support the research activities of a cooper	(FOA) invites applications to serve as t rative multi-site Lung Transplant Conso	he Data Coo rtium (LTC).	ordinating Center (The primary respo	DCC) that will onsibility of the					

SPIN ID	Program Title	Sr	ponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		DCC will be t involving lur LTC. The NH administratir and storage, biospecimer promote col engaging fou for integratin observationa as primary a Steering Con collection of longitudinal involving lur	to oversee the conduct of mu ng transplantation performed ILBI anticipates that the DCC w ive activities, common researce , the reporting of study result ns for secondary analyses by t Ilaboration and communication undations, societies, and other ng the efforts of 8 Clinical Cer al research studies to identify and acute lung allograft dysfur mmittee, will oversee the creat f a core set of data and biosper resource, LTC investigators w ng transplantation. This FOA r	Itiple observational and complementar under a common research protocol by will collaborate strategically with the CC ch protocol development, statistical dat s through publication in a timely manne the broader research community at the on among LTC investigators and will coo er entities with a shared interest in lung neter awards consisting of approximately factors that impact donor lung utilizati nction in lung transplant recipients. In a ation and implementation of a common ecimens across all participating consorti vill have the tools to identify and answe uns in parallel with the LTC Clinical Cem	y mechanisti awarded Clir is to provide ta analysis, da er, and the di conclusion o rdinate outre transplantat v 24 sites per on and early ddition, the f research pro um sites. By r additional i ters (see RFA	c clinical research nical Centers (CCs) support for regula ata and biospecim issemination of da f the program. The each activities incl ion. The DCC will I forming local site- post-transplant of DCC, in partnershi ptocol to enroll pa leveraging this sha mportant research A-HL-22-002).	studies within the tory and en collection tasets and e DCC will uding be responsible specific utcomes such p with the LTC rticipants for ared n questions	
085482	RFA-HL-20-024 Catalyze: Produc Testing, Diagnostic Disease Target Research Tool Development (R61,	ct Definition - : Identificatio /R33 - Clinica	 Device Prototype Design an on and Assay Development, ar Il Trial Not Allowed) 	d nd National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-20- 11 024	-May-2021	500,000 USD	
	Contact Name Contact Telephone	Kathleen Ro 301-827-798	ousche, Ph.D. 81					
	Contact Email	<u>kathleen.rou</u>	usche@nih.gov					
	Sponsor Website	the balance of the						
	Program URL	LINK TO Progi	ram UKL 21 09-lup-2021 [Optiopal][[]C	NI/Pro-App] 00-101-2021 11-Aug 2021				
This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational su needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclin program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.								

SPIN ID	Program Title	Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
085480	<u>RFA-HL-20-022 Enabling Techno</u> <u>Research (R33 - Clinical Trials Not</u>	blogies and Transformative Platforms for H Allowed)	<u>LBS</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-20- 12 022	1-May-2021	600,000 USD
	Contact Name	Margaret Ochocinska, PhD					
	Contact Telephone	301-827-8285					
	Contact Email	ochocinm@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LO	I/Pre-	App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	transformative platforms to catalyze next blood, and sleep (HLBS)-related disorders enabling technology or transformative pla data, but still requires further developme adoption.	and d atform	ration predictive, diagnostic and t iseases. This FOA solicits R33 app have already been overcome, as l rigorous validation to encourage	herapeutic lications wh demonstra downstrea	products to addres here major feasibili ted with supportiv m demonstration,	ty gaps for the e preliminary utilization and
085481	RFA-HL-20-023 Catalyze: Product Target Identification and Validation Identification (R61/R33 – Clinical 1	ct Definition for Small Molecules and Biolo on, and Preliminary Product/Lead Series Trials Not Allowed)	<u>gics -</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-20- 1: 023	1-May-2021	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.					
	Contact Telephone	301-827-7981					
	Contact Email	kathleen.rousche@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LO	I/Pre-	App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement characterize potential therapeutic candid disorders. This FOA is part of a suite of Ca entry criteria for the NHLBI Catalyze Precl private partners for preclinical optimization	(FOA) ates (c talyze inical on anc	will provide the early stage trans compound and lead series) to trea innovation grants to advance pro program or attract independent d I development of therapeutic can	lational sup It heart, lun jects to the levelopmen didates.	pport needed to ide g, blood, and sleep point where they t support from oth	entify and o diseases and can meet the ner federal or

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
100053	Notice of Special Interest (NOSI): Elements in NHGRI Applications S NRSA Institutional Research Train	Clarification ubmitted ing Grants	on of the Objectives and Program in Response to the "Ruth L. Kirse (Parent T32)"	n Chstein Research Institute	Genome e/NIH/DHHS	NOT- HG-21- 010	25-May-2021	Not Specified
	Contact Name Contact Telephone	Luis A. Cu 301-480-	ıbano, Ph.D. 3435					
	Contact Email Sponsor Website Program LIBL	luis.cuba	no@nih.gov					
	Deadline Dates (ALL)	25-May-2 2022 , 07	2021 , 07-Sep-2021 , 25-Sep-202 -Jan-2023 , 25-Jan-2023 , 07-Ma	1 , 07-Jan-2022 , 25-Jan-2 ay-2023	2022 , 07-May-	-2022 , 25	-May-2022 , 07-Sep-2	2022 , 25-Sep-
	Synopsis	The Natio applicatio bioinform understa Ethical, L disciplina	onal Human Genome Research I ons focused in the following are natics, and technology developr nding of when, where, and how egal and Social Implications (ELS ry conceptual and methodologi	nstitute (NHGRI) is issuing a(s): Genome sciences to nent; Genomic medicine best to implement the us SI) of Genomic Research t cal skills necessary to pur	g this Notice to support traini to support trai se of genomic o support train sue independe	o highlight ng with a t ning with information ning with a ent career	interest in receiving focus on the quantita a focus on innovatio on and technologies a focus on developing s as ELSI researchers	grant ative sciences, n and in clinical care; g multi-
079894	Initiative to Maximize Research Ed Not Allowed)	ducation i	n Genomics: Courses (R25 Clinic	al Trial National Human (Research Institute	Genome e/NIH/DHHS	PAR- 19-185	25-May-2021	Not Specified
	Contact Name	Bettie J.	Graham, Ph.D.					
	Contact Telephone	301-496-	7531					
	Contact Email	bettie_gr	aham@nih.gov					
	Sponsor Website							
	Program URL	Link to p	ogram URL					
	Deadline Dates (ALL)	25-May-2	2021 , 25-Sep-2021 , 25-Jan-202	2				
	Synopsis	The NIH arching g workforc goal, this	Research Education Program (R2 oal of this NHGRI R25 program e to meet the nation's biomedic FOA will support creative educa	25) supports research edu s to support educational cal, behavioral and clinica ational activities with a pr	acation activition activities that I research nee rimary focus on	es in the n compleme ds. To acc n Courses	nission areas of the N ent and/or enhance t complish the stated c for Skills Developme	NIH. The over- the training of a over-arching nt.
085902	Initiative to Maximize Research Ed	ducation i	n Genomics: Diversity Action Pla	n National Human	Genome	PAR-	25-May-2021	1,500,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	<u>(R25)</u>		Research Institute/NIH/DH	HS 19-380	1	USD
	Contact Name	Tina Gatlin, Ph.D.				
	Contact Telephone	301-480-2280				
	Contact Email	gatlincl@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021 , 25-Ja	in-2022 , 25-May-2022 , 25-Sep-2022			
	Synopsis	overarching goal of this NHGRI Div diversity of the biomedical, behavi announcement seeks to expose stu backgrounds, including those from them to pursue careers that span a society. For the purposes of this FC	ersity Action Plan (DAP) R25 program is t oral, social and clinical research workford udents at the undergraduate, post-baccal underrepresented groups, to the founda all areas of interest to NHGRI - genome so DA, the term "genomics" encompasses is:	o support edu e in genomic aureate and g itional science iences, genor sues and activ	ucational activities tha s. This funding opport graduate levels who ar es relevant to genomic mic medicine and geno vities in these three ar	t enhance the unity re from diverse cs to enable omics and eas.
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101174	Notice of Special Interest (NOSI): Development for Research and Cl	Advancing Genomic Technology inical Application	National Human Genome Research Institute/NIH/DHHS	NOT-HG- 21-018	05-Apr-2021	Not Specified
	Contact Name	Michael W. Smith, Ph.D.				
	Contact Telephone	301-480-3413				
	Contact Email	smithmw@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		05-Apr-2021, 07-May-2021, 05-Ju	ın-2021 , 16-Jun-2021 , 07-Sep-2021 , 07-	Sep-2021,05	5-Oct-2021 , 16-Oct-20	21,05-Jan-

Deadline Dates (ALL) Deadline Dates (ALL) Superside The National Human Conomo Research Institute (NHCRI) is issuing this Nation of Special Interact (NOSI) to encourage

Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage

SPIN ID	Program Title	s	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		applications and clinical	s focused on developing applications in human g	novel laboratory-focused tools and tee enomics.	chnologies tha	at enable new lines of s	cientific inquiry
101030	Notice of Special Interest (NOSI):	Clone Progra	am (Defunct)	National Human Genome Research nstitute/NIH/DHHS	NOT-HG- 21-004	07-May-2021	Not Specified
	Contact Name	Colin Fletch	ner, Ph.D.				
	Contact Telephone	301-496-75	531				
	Contact Email	l <u>fletcherc2@</u>	@mail.nih.gov				
	Sponsor Website	2					
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)	07-May-202 2022 , 07-N Feb-2023 , 0	21 , 05-Jun-2021 , 16-Jun /lay-2022 , 05-Jun-2022 , 07-May-2023 , 05-Jun-20	-2021 , 07-Sep-2021 , 05-Oct-2021 , 16 05-Jun-2022 , 07-Sep-2022 , 05-Oct-20 023 , 05-Jun-2023 , 07-Sep-2023 , 05-O	5-Oct-2021 , 0)22 , 05-Oct-2 ct-2023 , 05-C	8-Jan-2022 , 05-Feb-20 022 , 07-Jan-2023 , 05- 0ct-2023 , 07-Jan-2024	22 , 05-Feb- Feb-2023 , 05-
	Synopsis	The Nationa applications to elucidate	al Human Genome Resea s focused on developing e the functional consequ	arch Institute (NHGRI) is issuing this No novel methods to perform high-throu ences of DNA variation.	tice of Specia ghput molecul	l Interest (NOSI) to enc lar and cellular phenoty	ourage yping in order
080381	Next Generation Multipurpose Pr Clinical Trial Optional)	revention Teo	<u>chnologies (NGM) (R01</u> I	National Institute of Allergy and nfectious Diseases/NIH/DHHS	PAR-19- 209	06-May-2021	Not Specified
	Contact Name	Jim A. Turpi	in, Ph.D.				
	Contact Telephone	301-451-27	/32				
	Contact Email	l jturpin@nia	aid.nih.gov				
	Sponsor Website	2					
	Program URL	Link to prog	gram URL				
	Deadline Dates (ALL)) 06-May-202	21				
	Synopsis	The objectiv demand, ev developme transmitted Application	ve of this Funding Oppor vent -driven and long-act nt of MPTs that prevent d infections (STI) and pre- ts for MPT development	tunity Announcement (FOA) is to supp ing systemic and non-systemic multipo HIV infection and pregnancy (hormona gnancy, and (HIV/STI) and non-HIV STI may involve pharmacokinetic (PK), pha	oort the develourpose preven al and non-hou MPTs in cis ar armacodynam	opment of new and inn Ition technologies (MP ⁻ rmonal methods); sexu nd trans males and fem ic (PD), safety and, dru	ovative on- (). It supports ally ales of all ages. g-drug

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		interactior supported (look, feel, MPT adop	ns (DDI) studies using drug are biobehavioral and be effectiveness, safety and tion and use.	development and formulation scient havioral/social studies to identify MP duration of action) and other behavio	ce supported by T user-desired rh pral/social factor	animal model testing. eological and biophysi s that could promote i	Also cal factors ncreased
087001	Transgender People: Immunity, P Clinical Trial Not Allowed)	revention, a	and Treatment (R21	National Institute of Allergy and nfectious Diseases/NIH/DHHS	PAR-20- 054	L1-May-2021	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Jim A. Tur 301-451-2 <u>jturpin@n</u> Link to pro 11-May-20 The purpo people wit	pin, Ph.D. 732 <u>jaid.nih.gov</u> 9 <mark>gram URL</mark> 921 se of this Funding Opport th the objective of charact	unity Announcement (FOA) is to supp erizing the biological and immunolog	ort hypothesis-g	enerating research in t e interventions (hormo	ransgender nes. drugs
		and surgic (STI).	al) used for gender reassig	nment and their impact on susceptib	ility to HIV and o	other sexually transmit	ted infections
101626	RFA-AI-20-077 Immune Develop Clinical Trial Not Allowed)	and surgic (STI). oment in Ea	al) used for gender reassigned to the sense of the sense	nment and their impact on susceptib National Institute of Allergy and nfectious Diseases/NIH/DHHS	ility to HIV and o RFA-AI- 20-077	other sexually transmit 05-May-2021 Optional][LOI/Pre-App	2,500,000] USD

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadlin	ne Date	Funding Amount
		immunolo developin and immu	ogists, neonatologists, p g immune system. Knov inotherapies to combat	ediatrici wledge c infectio	ans, systems biologists, and micro obtained through this program ma ns or treat/prevent immune-med	biologists to y be applied ated disease	expand our k to the design s in this vulne	nowledge c of improve rable popu	of the d vaccines lation.
101637	RFA-AI-20-078 Immune Develo Clinical Trial Not Allowed)	oment in E	arly Life (IDEaL) (U19	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	RFA-AI- 20-078	05-May-202 [Optional][L	21 .OI/Pre-App	5,000,000] USD
	Contact Name	Mercy Pra	abhuDas, Ph.D., M.B.A.						
	Contact Telephone	240-627-3	8534						
	Contact Email	mprabhu	das@niaid.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	05-May-2	021 [Optional][LOI/Pre-	App], 04	I-Jun-2021				
_	Synopsis	The purpo establishr including environm immunolo developin and immu	ose of this Funding Oppo nent, development, and the impact of pathogen ental pollutants on imm ogists, neonatologists, p g immune system. Know	ortunity I mainte ic or cor nune ont ediatrici wledge c infectio	Announcement is to support rese nance of immunity throughout ch nmensal microbes or vaccination cogeny and function. This program ans, systems biologists, and micro obtained through this program ma ns or treat/prevent immune-medi	arch to defin ildhood (fror against infect will establis biologists to y be applied ated disease	e the mechan n birth to less ious diseases n collaboratio expand our k to the design s in this vulne	isms regula than 18 ye , allergens, ns among nowledge c of improve trable popu	ating the ars of age), and of the d vaccines lation.
090119	Research Towards Developing a C Infection (R21 Clinical Trial Not Al	<u>Cure for HB</u> lowed)	V in HIV/HBV Co-	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	PAS-20- 121	07-May-202	21	275,000 USD
	Contact Name	Chris Lam	bros, PhD						
	Contact Telephone	240-627-3	8093						
	Contact Email	clambros	<u>@niaid.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021,07-Sep-2021,07-J	lan-2022	2				
	Synopsis	The purpo translatio	ose of this Funding Oppo nal, and clinical researc	ortunity h to ider	Announcement (FOA) is to invite antify and address the challenges to	applications achieving h	or support of epatitis B viru	innovative s (HBV) cur	basic, e in the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		presence o	of human immunodefic	iency virus (HIV).			
097705	NIAID Clinical Trial Planning Grant	t (R34 Clinic	al Trials Not Allowed)	National Institute of Allergy an Infectious Diseases/NIH/DHHS	nd PAR-20- 5 270 12	2-May-2021	150,000 USD
	Contact Name	Greg Deye	<i>,</i> M.D.				
	Contact Telephone	240-627-3	371				
	Contact Email	gregory.de	eye@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	12-May-20	021 , 14-Sep-2021 , 12-J	an-2022 , 13-May-2022 , 14-Sep	-2022 , 13-Jan-2023 , 12-N	May-2023	
	Synopsis	preparatio hypothesis Institute. I high-priori	ng Opportunity Amoun on of the documentatio s-driven, milestone-def nvestigators are encou ity research areas of the	n necessary for implementation ined, related to the research mis raged to visit the NIAID website e NIAID (https://www.niaid.nih.	of investigator-initiated cl ssion of the NIAID and con for additional information gov/research/role).	linical trials. The tria sidered high-priorit about the research	als should be by by the n mission and
073919	Harnessing Big Data to Halt HIV (F	R01 Clinical	Trial Optional)	National Institute of Allergy an Infectious Diseases/NIH/DHHS	nd PAR-18- 5 764 07	7-May-2021	Not Specified
	Contact Name	Rosemary	McKaig, M.P.H, Ph.D.				
	Contact Telephone	240-627-3	214				
	Contact Email	<u>rm434n@</u>	nih.gov				
	Sponsor Website	à					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20)21				
	Synopsis	National Ir understan support pr visualizatio area is gui	nstitutes of Health (NIH ding of HIV transmissio ojects to assemble dive ons of big data, as well ded by ethical principle) and its participating Institutes n, the HIV care continuum, and erse big data sources, conduct ro as, engage ethical experts where s. This FOA will use the NIH Rese	and Centers invite applica HIV comorbidities using Bi obust and reproducible an e appropriate to ensure th earch Project (R01) award	tions for research thig Data Science (BDS alyses, and create n e development of t mechanism.	hat transforms S). This FOA will neaningful his scientific
073662	Novel Biomarkers for the Develop	oment of HI	V Incidence Assays with	n National Institute of Allergy ar	nd PA-18-753 07	7-May-2021	275,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding Mount
	Improved Specificity (R21 Clinical	Trial Not Allowed)	Infectious Diseases/NIH/DHHS			USD
	Contact Name	Usha Sharma, Ph.D., M.P.H.				
	Contact Telephone	240-292-4809				
	Contact Email	usharma@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	National Institute of Allergy and Inf biomarkers and improved HIV incid first 12 months) from chronic HIV ir	ectious Diseases (NIAID) invites appli ence assays and algorithms with incr nfections. This FOA will use the NIH R	cations to support the eased specificity for d esearch Project (R01)	e development of no istinguishing recent award mechanism.	ovel (within the
073660	Novel Biomarkers for the Develop Improved Specificity (R01 Clinical	ment of HIV Incidence Assays with Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-753 07-N	/lay-2021	Not Specified
	Contact Name	Usha Sharma, Ph.D., M.P.H.				
	Contact Telephone	240-292-4809				
	Contact Email	usharma@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	National Institute of Allergy and Inf biomarkers and improved HIV incid first 12 months) from chronic HIV ir	ectious Diseases (NIAID) invites appli ence assays and algorithms with incr nfections. This FOA will use the NIH R	cations to support the eased specificity for d esearch Project (R01)	e development of no listinguishing recent award mechanism.	ovel (within the
101499	RFA-AI-21-001 Tuberculosis Res Clinical Trials Not Allowed)	earch Advancement Centers (P30	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 16-N 21-001 [Opt	/lay-2021 ional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Lakshmi Ramachandra, MSc, PhD				
	Contact Telephone	301-669-5061				
	Contact Email	Lakshmi.ramachandra@mail.nih.go	<u>vv</u>			
	Sponsor Website					

SPIN ID	Program Title		Sponsor Name	9	Sponsor Number		Deadline Date	Funding Amount		
	Program URL Deadline Dates (ALL)	Link to pr 16-May-2 The purpo	ogram URL 021 [Optional][LOI/Pre-/ ose of this Funding Oppo	App], 15- ortunity A	Jun-2021 Announcement (FOA) is to solicit	meritorious ap	plications for the Tub	perculosis		
	Synopsis	Research research New Inve program.	Advancement Centers (support to foster and ele stigators. TRACs will pro	TRACs) p evate mu ovide core	rogram. The main goal of these c Itidisciplinary tuberculosis (TB) re facilities, services and mentorin	enters is to pro esearch and pro g opportunities	vide administrative a ovide exceptional me to achieve the goals	and shared ntorship to s of the		
099870 [NIAID Research Education Progra	m (R25 Cliı	nical Trial Not Allowed)	Nation Infectio	al Institute of Allergy and ous Diseases/NIH/DHHS	PAR-20- 289	5-May-2021	1,625,000 USD		
	Contact Name									
	Contact Telephone									
	Contact Email	<u>AITraining</u>	gHelpDesk@niaid.nih.go	<u>vv</u>						
	Sponsor Website									
	Program URL	Link to pr	ink to program URL							
	Deadline Dates (ALL)	25-May-2	021,07-Sep-2021,25-N	May-2022	2,07-Sep-2022					
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. Th overarching goal of this R25 program is to support educational activities that complement and/or enhance the trainin workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arc goal, this FOA will support creative educational activities related to NIAID's mission areas with a primary focus on: The overarching goal of this NIAID R25 program is to support educational activities that complement and/or enhance the of a workforce to meet the nation's biomedical, behavioral and clinical research needs of NIAID mission areas Courses Skills Development Research Experiences Mentoring Activities									
087230	NIAID Resource-Related Research Allowed)	<u>n Projects (</u>	R24 Clinical Trial Not	Nation Infectio	al Institute of Allergy and ous Diseases/NIH/DHHS	PAR-20- 063	17-May-2021	Not Specified		
	Contact Name	Martin Gu	utierrez, Ph.D.							
	Contact Telephone	240-292-4	1844							
	Contact Email	mgutierre	ez@niaid.nih.gov							
	Sponsor Website									

SPIN ID	Program Title	Sponse	or Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program I	JRL						
	Deadline Dates (ALL)	07-May-2021 , 25 2022 , 25-Sep-20	-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep- 22 , 25-Sep-2022 , 07-Jan-2023						
	This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NI invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must p a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the b scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biolo pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and al diseases.								
101691	NIAID SBIR Phase II Clinical Trial Ir Agreement (U44 Clinical Trial Req	nplementation Co uired)	o <u>operative</u> Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	PAR-21- 082 14-1	May-2021	Not Specified		
	Contact Name	Natalia Kruchinin	, Ph.D.						
	Contact Telephone	240-669-2919							
	Contact Email	NIAIDU44@mail.	nih.gov						
	Sponsor Website								
	Program URL	Link to program I	<u>JRL</u>						
	Deadline Dates (ALL)	14-May-2021 , 13 2024	3-Sep-2021 , 14-Jan-202	2 , 13-May-2022 , 13-Sep-2022 , 13	-Jan-2023 , 13-Ma	ay-2023 , 14-Sep-2	023 , 13-Jan-		
	Synopsis	This Funding Opp from small busing mission of the NI trials not conside human subject o non-routine inter unapproved indic	oortunity Announcemen ess concerns (SBCs) that AID. This program provi- red high-risk may be pro r patient risk, but rather eventions, administration cation. Mechanistic stud	t (FOA) encourages Small Business propose to implement investigato des support for hypothesis-driven, poosed, this program encourages h defines a study that contains one o n of an unlicensed product, or adm ies are also encouraged and may b	Innovation Resea r-initiated clinical milestone-driven igh-risk clinical stu or more of the foll inistration of a lice e proposed under	rch (SBIR) grant ap trials related to th clinical trials. Altho udies. High-risk do lowing unique feat ensed product for this program.	plications le research ough clinical es not imply tures: involves an		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101688	NIAID Clinical Trial Implementatio Clinical Trial Required)	n Cooperative Agreement (U01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21- 083 14	-May-2021	Not Specified
	Contact Name	Greg Deye, M.D.				
	Contact Telephone	240-627-3371				
	Contact Email	gregory.deye@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-May-2021 , 13-Sep-2021 , 14-Ja 2024	an-2022 , 13-May-2022 , 13-Sep-202	.2 , 13-Jan-2023 , 13-N	1ay-2023 , 14-Sep-2	023 , 13-Jan-
	Synopsis	This Funding Opportunity Announ investigator-initiated, high-risk clir in clinical trials may be of great va future therapeutic modalities. Inve research mission and high-priority trial may be proposed in each NIA	cement (FOA) encourages cooperation nical trials and mechanistic studies a lue because it promotes the undersi estigators are encouraged to visit the research areas of the NIAID (https:/ ID Clinical Trial Implementation Coo	ve agreement applicat ssociated with high-ris tanding of human dise e NIAID website for ac //www.niaid.nih.gov/r perative Agreement (I	tions for implement sk clinical trials. Me ases and the develo ditional informatio research/role). Only J01) application.	tation of chanistic work opment of on about the one clinical
102077	RFA-AI-20-080 Human Immuno	logy Project Consortium (HIPC)	National Institute of Allergy and	RFA-AI- 05	-May-2021	Not
102077	Coordinating Center (U01 Clinical	Trial Not Allowed)	Infectious Diseases/NIH/DHHS	20-080 [O	ptional][LOI/Pre-Ap	p] Specified
	Contact Name	Alison Deckhut Augustine, Ph.D.				
	Contact Telephone	240-627-3475				
	Contact Email	NIAIDHIPCU19@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-A	App], 04-Jun-2021			
	Synopsis	The goal of this FOA is to support a HIPC program, supported through that will measure the diversity and longitudinally using high-throughp characterized human cohorts. The cross-HIPC data integration, analys	a Coordinating Center for the Huma a separate FOA, will consist of 5-8 r d commonalities of human immune but systems immunology approaches e HIPC Coordinating Center supporte sis, and visualization; developing and	n Immunology Project nulti-project cooperati responses under a var s coupled with detailed d by this FOA will be r d maintaining a public	Consortium (HIPC) ive agreement (U19 iety of conditions a d clinical phenotypi esponsible for: coo HIPC website and k	program. The awardees nd ng in well- rdinating knowledgebase

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		to support cross-HIPC data analysi managing the HIPC subcommittee	is and visualization; and fostering collat is and an Infrastructure and Opportunit	orations amongst H y Fund to support c	IIPC-funded investig ollaborative studies	ators by
078717	Novel Approaches to Understand coccidioidomycosis (Valley Fever) Infections (R21 Clinical Trial Not A	, Prevent, Treat, and Diagnose and Other Select Endemic Fungal Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-083 07-	May-2021	275,000 USD
	Contact Name	Dona Love, Ph.D.				
	Contact Telephone	301-761-7788				
	Contact Email	dona.love@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Se	ep-2021 , 16-Oct-2021 , 07-Jan-2022			
_	Synopsis	understanding of coccidioidomyco histoplasmosis and blastomycosis. 1) pathogenesis; 2) host response; disease; 5) vaccines; 6) diagnostics the improved detection, preventio	 and treatment of select endemic more select endemices bis commonly known as Valley Fever, a This research opportunity encourages disease transmission; 4) natural hist and 7) therapeutics; with the ultimate 	and other select end studies that addres ory and environme goal of advancing coses.	demic fungal disease s diverse scientific ntal factors contribu the field towards so	ine overall es including areas such as: uting to lutions for
102326	RFA-AI-21-007 Innovation for T (ITVD) (R61/R33 Clinical Trial Not	uberculosis Vaccine Discovery Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 31- 21-007 [Or	May-2021 htional][1 OI/Pre-Apr	Not D Specified
	Contact Name	Katrin Fichelberg MSc PhD			- JL - 7 PP	
	Contact Telephone	240-669-2921				
	Contact Email	keichelberg@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-May-2021 [Optional][LOI/Pre-A	App], 30-Jun-2021			
	Synopsis	To support the design of novel tub advancement into preclinical anim mechanism to fund high risk/explo	perculosis (TB) vaccine candidates that on nal model testing. This funding opportu pratory research. Transition to the seco	exploit innovative a hity will use a miles nd phase depends o	oproaches and their tone driven, biphasi on the successful co	c award mpletion of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		milestone	25.					
078301	Engaging Men in HIV Testing, Prev Optional)	vention, ar	nd Care (R21 Clinical Trial Nation Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	PA-19-050 07-1	May-2021	275,000 USD	
	Contact Name	Adeola Ad	deyeye, M.D.					
	Contact Telephone	240-669-5	5005					
	Contact Email	<u>adeyeyea</u>	<u>o@niaid.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	.021,07-Sep-2021					
	Synopsis	of men in rates of e that may technique behaviora	HIV prevention and care within ngagement and retention in HIV involve considerable risk but ma es, agents, methodologies, mode al, or clinical research.	a global settings and among US do / prevention and care. The R21 Ex ay lead to a breakthrough in a par els; or applications that could hav	prestic populations ploratory/Develop ticular area; or to t a major impact o	s who have eviden mental Grant sup he development on a field of biome	ports studies of novel dical,	
078292	Engaging Men in HIV Testing, Prev Optional)	vention, ar	nd Care (R01 Clinical Trial Nation Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	PA-19-042 07-1	May-2021	Not Specified	
	Contact Name	Adeola Ad	deyeye, M.D.					
	Contact Telephone	240-669-5	5005					
	Contact Email	adeyeyea	o@niaid.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021,07-Sep-2021					
	Synopsis	The purpe of men in rates of e specified, interest a	ose of this Funding Opportunity HIV prevention and care within ngagement and retention in HIV circumscribed project to be per nd competencies.	Announcement (FOA) is to devel global settings and among US do / prevention and care. The R01 m rformed by the named investigate	op and test strateg mestic populations echanism is intend or(s) in an area repu	ies to increase the s who have eviden ed to support a di resenting his or he	e engagement nced lower screte, er specific	
SPIN ID	Program Title	Sponsor Name	S	ponsor Number		Deadline Date	Funding Amount	
--	---	--	-------------------------	---	----------------------------------	--------------------	-------------------	--
094378	NIAID Physician-Scientist Pathway (K99/R00 Clinical Trial Required)	to Independence Award	Nationa Infectio	l Institute of Allergy and us Diseases/NIH/DHHS	PAR-20- 209 07-	May-2021	Not Specified	
	Contact Name Contact Telephone	Deborah Philip, Ph.D. 301-761-7776						
	Contact Email Sponsor Website	AITrainingHelpDesk@niaid.nih.gov	v					
	Program URL Deadline Dates (ALL)	Link to program URL 07-May-2021, 12-Jun-2021, 07-Se 2022, 12-Oct-2022, 07-Jan-2023	ep-2021 , 12-Feb-2	12-Oct-2021 , 07-Jan-2022 , 12-Fe 2023	eb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-	
The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase a a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a time transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIA support during this transition to help awardees launch competitive, independent research careers in biomedical thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announce is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, n companion EQA (PAB-20-210)								
099832	Limited Competition: Exploratory Grant Program for NIAID K01/K08 Not Allowed)	and Developmental Research /K23 Recipients (R21 Clinical Trial	Nationa Infectio	l Institute of Allergy and us Diseases/NIH/DHHS	PAR-20- 291 07-	May-2021	275,000 USD	
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.						
	Contact Telephone	240-627-3566						
	Contact Email	tglewis@mail.nih.gov						
	Sponsor Website							
	Program URL Deadline Dates (ALL)	LINK TO Program URL 07-May-2021 , 16-Jun-2021 , 07-Se 2022 , 16-Oct-2022 , 07-Jan-2023 ,	ep-2021 , , 16-Feb-2	16-Oct-2021 , 07-Jan-2022 , 16-Fe 2023 , 07-May-2023 , 16-Jun-2023	eb-2022 , 07-Ma , 07-Sep-2023	y-2022 , 16-Jun-20	122 , 07-Sep-	

SPIN ID	Program Title	Sp	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Th KC so Synopsis in fe m th	ne Nationa D8, and K23 ome point o pability of vestigator asibility sto ethodolog nat may pro	al Institute of Allergy and 3 recipients with the opp during the final two year f its K01, K08, and K23 aw status (e.g., R01 support cudies; secondary analysis gy; and development of n ovide preliminary data to	Infectious Diseases (NIAID) announce ortunity to apply for Exploratory and s of their K award. Through the use or vard recipients to conduct research as .). The R21 grant mechanism supports s of existing data; small, self-containe ew research technology. The R21 is, t support a subsequent R01, or equiva	es a program that p Developmental Re f this mechanism, N s they complete the s different types of d research projects therefore, intended alent, application.	rovides NIAID-supp search Grant (R21) IIAID seeks to enha ir transition to full projects, including ; development of u to support resear	ported K01, support at ance the y independent pilot and research ch projects
099831	Limited Competition: Small Research K01/K08/K23 Recipients (R03 Clinica	n Grant Pro Il Trial Not	ogram for NIAID N Allowed) Ir	ational Institute of Allergy and fectious Diseases/NIH/DHHS	PAR-20- 290	May-2021	100,000 USD
	Contact Name St Contact Telephone 24 Contact Email fe Sponsor Website Program URL Lin Deadline Dates (ALL) Th KC Synopsis Synopsis ar ne pe	acy E. Ferg 40-627-350 argusont@i nk to progr 7-May-202 022, 16-00 ne Nationa 08, and K23 vo years of ward recipi upport). Th nalysis of e ew researc eriod of tim oplication.	guson, Ph.D. 04 <u>niaid.nih.gov</u> <u>gram URL</u> 21 , 16-Jun-2021 , 07-Sep- ct-2022 , 07-Jan-2023 , 10 al Institute of Allergy and 3 recipients with the opp f their K award. Through ients to conduct research he R03 grant mechanism s existing data; small, self-c ch technology. The R03 is ne with limited resources	2021 , 16-Oct-2021 , 07-Jan-2022 , 16 5-Feb-2023 , 07-May-2023 , 16-Jun-20 Infectious Diseases (NIAID) announce ortunity to apply for Small Research (the use of this mechanism, NIAID see n as they complete their transition to supports different types of projects, in ontained research projects; developn , therefore, intended to support resea s and that may provide preliminary da	5-Feb-2022 , 07-Ma 023 , 07-Sep-2023 es a program that p Grant (R03) suppor ks to enhance the c fully independent i ncluding pilot and f nent of research mo arch projects that c ata to support a sub	y-2022 , 16-Jun-20 rovides NIAID-supp t at some point du capability of its K02 nvestigator status easibility studies; s ethodology; and do an be carried out i osequent R01, or e	22 , 07-Sep- borted K01, ring the final L, K08, and K23 (e.g., R01 secondary evelopment of n a short quivalent,
094380	NIAID Physician-Scientist Pathway to (K99/R00 Independent Clinical Trial I	o Independ Not Allowe	dence Award N ed) Ir	ational Institute of Allergy and nfectious Diseases/NIH/DHHS	PAR-20- 210 07-	May-2021	Not Specified
	Contact Name Sh Contact Telephone 30	nawn Drew 01-761-777	v Gaillard, Ph.D. 76				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Contact Email	AITraining	gHelpDesk@niaid.nih.go	<u>v</u>								
	Sponsor Website											
	Program URL	Link to pr	ink to program URL									
	Deadline Dates (ALL)	07-May-2 2022 , 12	7-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep- 022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023									
Synopsis Syn												
081206	Novel RNAs in Virology (including Basic Science and Therapeutic Dis Allowed)	HIV) and I covery (R2	mmune Regulation: 21 Clinical Trial Not	National Institute of Allergy Infectious Diseases/NIH/DH	and PA-19-237 0	7-May-2021	275,000 USD					
	Contact Name	Chao Jian	g, Ph.D.									
	Contact Telephone	301-761-7	7802									
	Contact Email	chao.jian	g@nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-S	ep-2021 , 16-Oct-2021 , 07-Ja	an-2022 , 16-Feb-2022 , 07-N	1ay-2022						
	Synopsis	The purpo studies to (including	ose of this Funding Oppo therapeutic discovery a HIV biology) and immu	ortunity Announcement (FOA and development, in novel bio ne regulation.) is to support basic science blogically active viral and/or	research, from early host RNAs involved i	exploratory in virology					
085477	NIAID Career Transition Award (K. Allowed)	22 Indepei	ndent Clinical Trial Not	National Institute of Allergy Infectious Diseases/NIH/DH	and PAR-19- IHS 371 0	7-May-2021	Not Specified					

SPIN ID	Program Title	S	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Name S	hawn Dre	w Gaillard, Ph.D.					
	Contact Telephone 2	40-627-38	857					
	Contact Email <u>S</u>	<u>hawn.Gail</u>	<u>llard@nih.gov</u>					
	Sponsor Website							
	Program URL	ink to pro	gram URL					
	Deadline Dates (ALL) 0	7-May-20)21 , 12-Jun-2021 , 07-S	Sep-202	1, 12-Oct-2021, 07-Jan-2022			
Synopsis initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcer will utilize the NIH Career Transition Award (K22) mechanism.								
102076	RFA-AI-20-079 Human Immunolog	gy Project	<u>t Consortium (HIPC)</u>	Natio	nal Institute of Allergy and	RFA-AI- 05-	May-2021	7,500,000
102070	(U19 Clinical Trial Optional)			Infect	ious Diseases/NIH/DHHS	20-079 [Op	otional][LOI/Pre-Ap	o] USD
	Contact Name A	lison Decl	khut Augustine, Ph.D.					
	Contact Telephone 2	40-627-34	475					
	Contact Email <u>N</u>	IIAIDHIPC	<u>U19@mail.nih.gov</u>					
	Sponsor Website							
	Program URL L	ink to pro	gram URL					
	Deadline Dates (ALL) 0	5-May-20	021 [Optional][LOI/Pre-	4pp] <i>,</i> 0	1-Jun-2021			
	T fr g re ir Synopsis ir cu m v a d d	his Fundir rom single roups in t esponses/ mmune pr mmune re oupled wi nolecular s accinatior ccess to H	ng Opportunity Annour e institutions, or consor the area of infectious di mechanisms elicited b rofiling technologies. St esponses under a variet ith detailed clinical phe signatures that define in ns, vaccine adjuvants o IIPC-supported data an ent and operation of a	ncemen rtia of ir iseases, y vaccin tudies su tudies su tudies su tudies su tudies su tudi su tudies su tudies su tu	t (FOA) for the Human Immunolo istitutions, to participate in a net including HIV. The purpose of th ations, vaccine adjuvants or natu upported under this FOA will mean iditions and longitudinally using g in well-characterized human co e response profiles and identify b I infections in humans. An additi- data through public portals such ordinating Center that will be response	agy Project Consort work of human im- is FOA is to charact ural infections by ca asure the diversity high-throughput sy phorts. The resultin iomarkers that cor- onal goal of this pro- as ImmPort. A con- sponsible for foster	ium (HIPC) solicits a munology profiling perize human immun apitalizing on recent and commonalities stems immunology g data will be used relate with the outco ogram is to promote mpanion FOA will su	pplications research advances in of human approaches to develop omes of e rapid public upport mongst HIPC-

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	unding Amount
		funded inv developm research a	vestigators; facilitating p ent or adoption of new, nd development in this	oublic di robust field.	ssemination of integrated HIPC fi methods for data integration, an	ndings and kno alysis, presenta	owledge; and supporting ation, and visualization t	s o further
102629	RFA-AI-21-005 Tropical Medicir Center (U01 Clinical Trial Not Allo	ie Research wed)	Centers Coordinating	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	RFA-AI- 21-005	19-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Malla Rao	, Ph.D.					
	Contact Telephone	240-627-3	352					
	Contact Email	mrao@nia	<u>iid.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	19-May-20	021 [Optional][LOI/Pre-A	App], 18	3-Jun-2021			
	Synopsis	Center (TN across the maintenar by junior a stakeholde	ARC CC) for the Tropical TMRCs related to data face of a virtual sample re and early-stage investiga	Medici manage eposito ators, ar	ne Research Centers (TMRC). The ement, data and specimen sharing ry, organizing annual meetings, m nd liaising with United States Gov	e TMRC CC will g, scientific coll hanaging an Op ernment (USG)	oversee and coordinate laboration, creation and portunity Fund to support) counterparts and other	efforts ort research
102623	RFA-AI-21-004 Tropical Medicir Trial Not Allowed)	e Research	Centers (U01 Clinical	Natio Infect	nal Institute of Allergy and ious Diseases/NIH/DHHS	RFA-AI- 21-004	19-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Malla Rao	, Ph.D.					
	Contact Telephone	240-627-3	352					
	Contact Email	mrao@nia	iid.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	19-May-20	021 [Optional][LOI/Pre-A	App], 18	3-Jun-2021			
	Synopsis	This fundir pathogene (NTDs) in e	ng opportunity announc esis, clinical manifestatic endemic areas. The Trop	ement ons, dia pical Me	(FOA) solicits research application gnosis, prevention, treatment an edicine Research Centers (TMRCs)	ns focused on t d control of sel are intended	he etiology, epidemiolog ect Neglected Tropical D to advance NIAID's globa	gy, Diseases al research

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		effort by unique ne research investigat evaluate	targeting research endeav eeds of low and middle-ind capacity; stimulate scienti fors to conduct research o new drugs, diagnostics, va	ors to: develop novel diagnostic, preve come countries (LMICs), as classified by fic collaboration and global partnership n NTDs; and facilitate sample sharing to occines, therapeutics, and/or vector con	ntion and therape the World Bank; o s; provide opporto support translati trol strategies.	utic strategies ada create and sustain unities for junior ar onal research to de	oted for the in-country าd early-stage evelop or
101127	<u>RFA-AR-22-001 Centers of Rese</u> <u>Clinical Trial Not Allowed</u>)	arch Trans	lation (CORT) (P50	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR- 11- 22-001 [Op	Apr-2021 otional][LOI/Pre-Ap	5,000,000 p] USD
	Contact Name	Aron Mar	quitz, Ph.D.				
	Contact Telephone	301-435-2	1240				
	Contact Email	aron.mar	quitz@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	11-Apr-20	021 [Optional][LOI/Pre-Ap	p], 11-May-2021			
Deadline Dates (ALL) 11-Apr-2021 [Optional][LOI/Pre-App], 11-May-2021 This Funding Opportunity Announcement (FOA) invites applications for Centers of Resea CORT research program should be carried out by a synergistic team of scientists who, thr science approach, will address a highly significant translational research challenge in a sir disease(s) or condition(s) within the mission of the NIAMS. The focus of research could be translational theme addressed by synergistic Research Projects with optional Research Co translational research question addressed through a single collaborative Research Project interactive Research Cores whose work is integrated during the development and implem must have a minimum of three highly meritorious research components consisting of one Projects and optional Research Cores. An Administrative Core is required in all application team science approach, the lead investigators of the research components must be draw different research disciplines, and may be based in different departments, divisions, and/ projects and cores will generate new knowledge that will improve our understanding of h identification of new targets, other tangible products or deliverables, and development of the development of the d). Overall, a ary team ly-related rgeted elated critical r of highly ct. A CORT I Research erdisciplinary is appropriate, ned, the sy and lead to ment,
067950	Research Grants Using the Resou Initiative (OAI) (R21 Clinical Trial	rces from t Not Allowe	<u>he Osteoarthritis</u> d)	National Institute of Arthritis and Musculoskeletal and Skin	PA-18-408 07-	May-2021	275,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
			Dis	eases/NIH/DHHS								
	Contact Name	Gayle E. L	ester, Ph.D.									
	Contact Telephone	301-594-3	01-594-3511									
	Contact Email	lester1@	ester1@mail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ink to program URL									
	Deadline Dates (ALL)	07-May-2	7-May-2021									
	Synopsis	National applicatic images. 1 publicatic NIAMS ar grant mee	Institute of Arthritis and Mus ons for research awards that This FOA seeks to expand the on of this FOA to the research nd others have placed on the chanism.	sculoskeletal and Skin Diseases (NIA are focused on the use of the Ostec use of these resources by investiga community indicates to investigat use of the OAI resources. This FOA	AMS) and National In parthritis Initiative (C ators in the broader fors and peer reviewe A will use the NIH Exp	nstitute on Aging (DAI) database, clin research commun ers the importanc ploratory/Develop	NIA) invite ical data and ity. The e that the mental (R21)					
067972	Research Grants Using the Resour Initiative (OAI) (R01 Clinical Trial N	r <u>ces from t</u> Not Allowe	the Osteoarthritis Na (d) Dis	tional Institute of Arthritis and Isculoskeletal and Skin eases/NIH/DHHS	PA-18-409 07-N	May-2021	275,000 USD					
	Contact Name	Gayle E. L	ester, Ph.D.									
	Contact Telephone	301-594-3	3511									
	Contact Email	lester1@	mail.nih.gov									
	Sponsor Website											
	Program URL	Link to pr	ogram URL									
	Deadline Dates (ALL)	07-May-2	.021									
	Synopsis	National applicatic images. 1 publicatic NIAMS ar mechanis	Institute of Arthritis and Mus ons for research awards that This FOA seeks to expand the on of this FOA to the research ad others have placed on the sm.	sculoskeletal and Skin Diseases (NIA are focused on the use of the Osteo use of these resources by investiga community indicates to investigat use of the OAI resources. This FOA	AMS) and National In parthritis Initiative (C ators in the broader fors and peer reviewe A will use the NIH RO	nstitute on Aging (DAI) database, clin research commun ers the importanc 1 Research Projec	NIA)invite ical data and ity. The e that the t Grant award					
101494	Notice of Special Interest (NOSI):	Promoting	Research on COVID-19 Na	tional Institute of Arthritis and	NOT-AR- 07-N	May-2021	Not					

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	and Rheumatic, Musculoskeletal a	and Skin D	iseases	Muscu Diseas	uloskeletal and Skin ses/NIH/DHHS	21-012		Specified
	Contact Name Contact Telephone	Marie Ma 301-594-5	ncini, Ph.D. 5032					
	Contact Email Sponsor Website	mancinim	2@mail.nih.gov					
	Program URL Deadline Dates (ALL)	07-May-2	ogram URL 021 , 15-Jun-2021 , 16-Ju ose of this Notice is to an	in-2021	. , 07-Sep-2021 , 05-Oct-2021 , 16-C	oct-2021	Arthritis and Musc	uloskeletal
	Synopsis	and Skin I NIAMS m	Diseases (NIAMS) an inter ission.	rest in I	research on the impact of COVID-19	as related to dis	seases and condition	ons within the
080488	Team-Based Design in Biomedical Clinical Trial Not Allowed)	Engineeri	ng Education (R25	Natior and Bi	nal Institute of Biomedical Imaging oengineering/NIH/DHHS	PAR-19- 215 28-1	May-2021	200,000 USD
	Contact Name	Zeynep Ei	rim, Ph.D.					
	Contact Telephone	301-451-4	1792					
	Contact Email	<u>erimz@m</u>	<u>ail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	28-May-2	021					
	Synopsis	The NIH F arching go workforce goal, this seeks to s ensure a f technolog based des with biom engineeri	tesearch Education Progr bal of this NIBIB R25 prog to meet the nation's bio FOA will support creative upport programs that in future workforce that car gies. Applications are en sign courses or programs nedical engineering tracks ng/bioengineering stude	am (R2 gram is pmedica e educa clude in meet courage in unde s/mino nts in a	5) supports research education acti to support educational activities the al, behavioral and clinical research r tional activities with a primary focu nnovative approaches to enhance b the nation's needs in biomedical re ed from institutions that propose to ergraduate biomedical engineering rs. This FOA targets the education o team-based environment. While cu	vities in the miss at complement a needs. To accom s on Courses for iomedical engine search and healt establish new o departments or o f undergraduate urrent best pract	ion areas of the N nd/or enhance the plish the stated ov Skills Developmer eering design educ hcare r to enhance exist other degree-gran biomedical ices such as	IH. The over- e training of a ver-arching nt. This FOA cation to ing team- ting programs

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		multidisci commerc FOA also of the nex	plinary/interdisciplinary ec ialization of medical device challenges institutions to p <t biomedica<="" generation="" of="" th=""><th>lucation, introduction to the regulatory p is, and clinical immersion remain encoura ropose other novel, innovative and/or gr l engineering design education.</th><th>oathway and oth aged component round-breaking a</th><th>er issues related to s of a strong BME ctivities that can f</th><th>o the program, this orm the basis</th></t>	lucation, introduction to the regulatory p is, and clinical immersion remain encoura ropose other novel, innovative and/or gr l engineering design education.	oathway and oth aged component round-breaking a	er issues related to s of a strong BME ctivities that can f	o the program, this orm the basis
079361	Bioengineering Research Grants (Allowed)	<u>BRG) (R01</u>	<u>Clinical Trial Not</u> N a	lational Institute of Biomedical Imaging nd Bioengineering/NIH/DHHS	PAR-19- 158 07-1	May-2021	Not Specified
	Contact Name	Seila Selir	novic, Ph.D. Program Direc	tor			
	Contact Telephone	301-451-4	1577				
	Contact Email	seila.selin	novic@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	The purpo that: 1) ap validate, t clinical pr developm approach	ose of this funding opportu oply a multidisciplinary bio cranslate or otherwise acce oblem in basic, translation iental, discovery-driven, or to increase our understand	nity announcement is to encourage colla engineering approach to the solution of a lerate the adoption of promising tools, n al, or clinical science and practice. An app hypothesis-driven research and is appro- ding of and solve problems in biological,	aborations betwe a biomedical pro nethods and tech plication may pro opriate for small t clinical or transla	en the life and ph blem; and 2) integ iniques for a spec pose design-direc eams applying an itional science.	ysical sciences rate, optimize, fic research or ted, integrative
079367	Bioengineering Research Partners Allowed)	hips (U01	<u>Clinical Trial Not</u> N a	lational Institute of Biomedical Imaging nd Bioengineering/NIH/DHHS	PAR-19- 156 07-1	/lay-2021	Not Specified
	Contact Name	Seila Selir	novic, Ph.D. Program Direc	tor			
	Contact Telephone	301-451-4	1577				
	Contact Email	seila.selin	novic@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep	-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	This Fund and adop	ing Opportunity Announce tion of promising tools and	ment (FOA) encourages bioengineering a technologies that can address importan	applications that t biomedical pro	will accelerate the blems. The object	e development ives are to

SPIN IDProgram TitleSponsor NameSponsor NumberDeadline	ne Date Funding Amount
establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet ne enhancing our understanding of life science processes or the practice of medicine. Awards will focus multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing engage biomedical researchers or clinicians throughout the project. The goal of the program is to su realize meaningful solutions within 5 – 10 years.	ed and are capable of on supporting g technologies, and pport projects that can
079366Bioengineering Research Partnerships (U01 Clinical Trial Required)National Institute of Biomedical ImagingPAR-19- 15707-May-202and Bioengineering/NIH/DHHS157	Not Specified
Contact Name Seila Selimovic, Ph.D. Program Director	
Contact Telephone 301-451-4577	
Contact Email <u>seila.selimovic@nih.gov</u>	
Sponsor Website	
Program URL Link to program URL	
Deadline Dates (ALL) 07-May-2021	
This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accurate and adoption of promising tools and technologies that can address important biomedical problems. Synopsis enhancing our understanding of life science processes or the practice of medicine. Awards will focus multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing engage biomedical researchers or clinicians throughout the project. The goal of the program is to sur realize meaningful solutions within 5 – 10 years.	elerate the development The objectives are to ed and are capable of on supporting g technologies, and pport projects that can
079360Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)National Institute of Biomedical ImagingPAR-19- 15907-May-202and Bioengineering/NIH/DHHS159	1 Not Specified
Contact Name Seila Selimovic, Ph.D. Program Director	
Contact Telephone 301-451-4577	
Contact Email <u>seila.selimovic@nih.gov</u>	
Sponsor Website	
Program URL Link to program URL	



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpo that: 1) ap validate, t clinical pr developm approach	ose of this funding oppor oply a multidisciplinary b translate or otherwise ac oblem in basic, translatic nental, discovery-driven, to increase our understa	rtunity a ioengir ccelerat onal, or or hypo anding o	announcement is to encourage colla neering approach to the solution of the the adoption of promising tools, r clinical science and practice. An ap othesis-driven research and is appro of and solve problems in biological,	aborations betwe a biomedical pro methods and tec plication may pro opriate for small clinical or transla	een the life and ph blem; and 2) integ nniques for a spec opose design-direc teams applying an ational science.	ysical sciences rate, optimize, ific research or :ted, integrative
088092	NIBIB Trailblazer Award for New a Clinical Trial Optional)	and Early S	tage Investigators (R21	Natio and B	nal Institute of Biomedical Imaging ioengineering/NIH/DHHS	PAR-20- 084 07-	May-2021	400,000 USD
	Contact Name Contact Telephone	Randy Kin 301-451-0	ng, Ph.D.)707					
	Contact Email	Randy.Kir	ng@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16-	021 , 16-Jun-2021 , 07-So -Oct-2022 , 07-Jan-2023	ep-202:	1 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis	This Trail (https://g integrate explorato driven, or prelimina if availabl independ limited to one figure	plazer Award is an oppor grants.nih.gov/policy/ear engineering and the phy ry, developmental, proo hypothesis-driven. Impo ry data. A distinct feature e, minimal preliminary d ently produced and not one-half page, which ma e will be considered none	tunity f ly-inves vsical sc f of con ortantly e for th ata are yet pub ay inclu complia	for NIH-defined New and Early Stage stigators/index.htm) to pursue rese iences with the life and/or biomedi ncept, or high risk-high impact, and v, applicants must propose research is FOA is that no preliminary data a allowed. Preliminary data are defir ilished in a peer-reviewed journal.A ide one figure. Applications includin ant with the FOA instructions and w	e Investigators arch programs of cal sciences. A Tr may be technolo approaches for re required, expe ned as material w Il preliminary dat ng data more tha ill not go forward	high interest to the ailblazer project n gy design-directed which there are m ected, or encourag hich the applicant a should be clearly n one-half page or to review.	ne NIBIB that nay be , discovery- inimal or no ed. However, has y marked and more than
081819	Chemical Screening and Optimiza Allowed)	<u>tion Facilit</u>	y (X01 Clinical Trial Not	Natio Huma	nal Institute of Child Health and In Development/NIH/DHHS	PAR-19- 261 03-	May-2021	Not Specified
	Contact Name Contact Telephone	Christoph 301-435-6	er C. Lindsey, PhD 5907					



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Email	chris.linds	sey@nih.gov					
	Sponsor Website		<u>, </u>					
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	03-May-2	021 , 13-Dec-2021					
	Synopsis	The NICH hormonal Device Ex screening is to provi program	D has a state-of-the-art C l contraception developm emption (IDE) or Investig , structure activity relatic ide investigators with a m for either male or female	Chemica nent wi ational onships nechan contra	al Synthesis and Optimization Facili th the capabilities and capacity for I New Drug (IND)-enabling studies (a, hit-to-lead generation, drug meta ism to request services from this fa aceptives.	ty for advancing r preclinical service e.g., protein gene bolism, fertility st acility that would a	male and/or femal es including Invest eration, high throu tudies). The purpo advance their deve	e non- igational ghput se of this FOA elopment
097282	Fertility Status as a Marker for Ov	verall Healt	h (R21 Clinical Trial Not	Natio	nal Institute of Child Health and	PA-20-282	May-2021	275,000
	Allowed)			пипа	n Development/Nin/Drns	ĮOpi	tional][LOI/Pre-Ap	pj usp
	Contact Name	Susan Tay	imans, PhD					
	Contact Telephone	301-496-t	o51/					
	Contact Email	Taymanss	<u>@mail.nin.gov</u>					
	Sponsor website							
	Program URL	LINK to pr					Cab 2022 10 Ca	- 2022
	Deadline Dates (ALL)	[Optional]	[LOI/Pre-App], 19-Oct-20	022 , 19	9-Jun-2021 , 19-Jan-2022 [Optional] 9-May-2023 [Optional][LOI/Pre-Apt	j[LOI/Pre-App], 19 p], 19-Jun-2023	J-FeD-2022,19-Se	p-2022
	Synopsis	National (NIEHS), a premise t obesity ca overall he physiolog between strongly s marker fo the scope	Institute of Child Health and Office of Disease Prev hat fertility status can be an impair fertility, howeve ealth. Data suggest that in ically or genetically linked fertility status in both ma uggest that fertility status or overall health and there e of this program. This FO.	and Hu vention a marl er less nfertilit d with alles and s can b efore a A will u	uman Development (NICHD), Nation (ODP) invite applications for explo- ker for overall health. It is clear that is known about the extent to which ty is not necessarily a unique diseas other diseases and conditions. Rec d females and various somatic diseases are a window into overall health. Thi pplications that look at the effects use the NIH R21 Exploratory/Develo	nal Institute of En pratory/developm t chronic condition fertility status ca se of the reproduc ent epidemiologic ases and disorders s FOA focuses on of a disease or dis opmental Researc	vironmental Healt ental research tha ns such as cancer, an impact or act as ctive axis, but is of c studies demonst s. Taken together studies evaluating sorder on fertility h Grant award me	h Sciences t explores the diabetes, and a marker for ten rate links , these data g fertility as a are outside echanism.

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
097283	Fertility Status as a Marker for Ov Optional)	erall Healt	h (R01 Clinical Trial	Natio Huma	nal Institute of Child Health and In Development/NIH/DHHS	PA-20-281 [Op	May-2021 otional][LOI/Pre-Ap	Not p] Specified		
	Contact Name	Susan Tay	vmans, PhD							
	Contact Telephone	301-496-6	5517							
	Contact Email	Taymanss	@mail.nih.gov							
	Sponsor Website									
	Program URL Link to program URL									
Deadline Dates (ALL) [0ptional][LOI/Pre-App], 19-Jun-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 19-Feb-2022 , 19-Sep-2022 , 19-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023]										
	Synopsis	 National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program. 								
096510	NICHD Research Education Progra	ams (R25 C	linical Trial Not Allowed) Natio Huma	nal Institute of Child Health and in Development/NIH/DHHS	PAR-20- 250 25-	May-2021	750,000 USD		
	Contact Name	Dennis A.	Twombly, Ph.D.							
	Contact Telephone	01-301-45	51-3371							
	Contact Email	dtwombly	<u>/@mail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	25-May-2	021 , 25-Sep-2021 , 25-J	lan-202	2 , 25-May-2022					
	Synopsis	The NIH R overarchi	Research Education Prog ng goal of this R25 prog	ram (R2 ram is to	25) supports research education action action action activities that activi	tivities in the mis t complement ar	sion areas of the N nd/or enhance the	IH. The training of a		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
		workforce to meet the nation's bigoal, this FOA will support creative	iomedical, behavioral and clinical research re educational activities with a primary for	n needs. To acco cus on: Courses	omplish the stated ov for Skills Developme	er-arching nt				
090064	NICHD Resource Program Grants Not Allowed	in Bioinformatics (P41 Clinical Tria	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 126	7-May-2021	8,750,000 USD				
	Contact Name	e James N. Coulombe, PhD								
	Contact Telephone	e 301-451-1390								
	Contact Emai	Il <u>CoulombeJ@mail.nih.gov</u>								
	Sponsor Website	2								
	Program URI	L Link to program URL								
Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 25-May-2022 , 25-May-2022 , 07-Jan-2023 , 07-May-2023										
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the resource, user training and services, provision of community-generated data storage and archiving, wi dissemination of the tools and/or resources, and establishment of interoperability with other NIH bioinformatics resources								
102078	RFA-RM-21-011 Expert-Driven Gabriella Miller Kids First Discove	Small Projects to Strengthen ery (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-RM- 1 21-011 [0	8-May-2021 Optional][LOI/Pre-Ap	200,000 p] USD				
	Contact Name	e								
	Contact Telephone	e								
	Contact Emai	a de la companya de la								
	Sponsor Website	e								
	Program URI	L Link to program URL								
	Deadline Dates (ALL) 18-May-2021 [Optional][LOI/Pre-	App], 18-Jun-2021							
	Synopsis	The NIH Common Fund has estab alleviating suffering from childhor etiology of these diseases and sup and continues to develop a Data I	lished the Gabriella Miller Kids First Pedia od cancer and structural birth defects by f oporting data sharing within the pediatric Resource including a large collection of cu	tric Research Pr ostering collabo research comm rated genomic a	ogram (Kids First) wit prative research to ur unity. Kids First has e and phenotypic data	th the vision of ncover the established from				

SPIN ID	N ID Program Title		Sponsor Name	Sponsor I	lumber		Deadline Date	Funding Amount		
		childhood to the res childhood phenotyp researche affected b Office of S initiatives Health an	cancer and structural bin earch community. This FO cancer and/or structural ic datasets and resources r community with the ult by these conditions. This F Strategic Coordination (ht . The FOA will be adminis d Human Development (I	rth defects cohor OA is intended to I birth defects ge s. These activities timate goal of im FOA is a Commor ttps://dpcpsi.nih stered by a trans- NICHD)	ts and a central portal w engage experts in a vari nomic datasets generate should strengthen futur proving diagnostic capab n Fund initiative (Commo gov/). All NIH Institutes NIH team led by the Eun	where these data iety of activities ied by the Kids Fir re analyses of Kid pilities and thera on Fund) through and Centers part ice Kennedy Shr	and analysis tools a that will enhance th st program and/or ls First datasets by pies for children an the NIH Office of t icipate in Commor iver National Institu	are accessible ne utility of associated the broader d their families he Director, Fund ute of Child		
072586	nnovative Therapies and Tools for Newborns (R21 Clinical Trial Option	o <mark>r Screenat</mark> onal)	ole Disorders in	National Institut Human Develop	e of Child Health and ment/NIH/DHHS	PAR-18- 691	-May-2021	275,000 USD		
	Contact Name	Melissa P	arisi, MD, PhD							
	Contact Telephone	301-435-6	5880							
	Contact Email	parisima@	<u>@mail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	<u>.ink to program URL</u> D7-May-2021							
	Deadline Dates (ALL)	07-May-2								
	Synopsis	National I developm newborn future. De panel; the significant Research	nstitutes of Health (NIH) eent of therapeutic interv screening, as well as "hig emonstrating the benefits erefore, for this FOA, a "h tly benefit from early ideu Grant award mechanism.	and its participat rentions for poten th priority" genet s of treatment is high priority" cont ntification and tr	ing Institutes and Centern ntially fatal or disabling c ic conditions where scree often a primary criterion dition is one where scree eatment. This program v	rs invite applicat conditions that h ening may be po for including a c ening is not curre will use the NIH I	ions for research re ave been identified ssible in the near ondition on a new ntly recommendec R21 Exploratory/De	elevant to the through born screening but would evelopmental		
079181	Academic Research Enhancemen Focused Institutions (R15 - Clinica	t Award for Il Trial Requ	<u>r Undergraduate-</u> uired)	National Institut Human Develop	e of Child Health and ment/NIH/DHHS	PAR-19- 133 07	-May-2021	300,000 USD		
	Contact Name	Mahua M	ukhopadhyay, PhD							
	Contact Telephone	301-435-6	5886							
	Contact Email	<u>mukhopa</u>	m@mail.nih.gov							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Sponsor Website										
	Program URL	Link to pr	ink to program URL								
	Deadline Dates (ALL)	07-May-2	7-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022								
Synopsis Syn											
072577	Innovative Therapies and Tools fo Newborns (R01 - Clinical Trial Opt	r Screenat ional)	<u>ble Disorders in</u> Na Hu	tional Institute of Child Health and man Development/NIH/DHHS	PAR-18- 689	May-2021	Not Specified				
	Contact Name	Melissa P	arisi, MD, PhD								
	Contact Telephone	301-435-6	5880								
	Contact Email	parisima@	arisima@mail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2	021								
	Synopsis	National I developm newborn future. De panel; the significan mechanis	Institutes of Health (NIH) and nent of therapeutic intervent screening, as well as "high pr emonstrating the benefits of erefore, for this FOA, a "high tly benefit from early identifi m.	its participating Institutes and Cente ions for potentially fatal or disabling o iority" genetic conditions where scre treatment is often a primary criterior priority" condition is one where scree cation and treatment. This program	rs invite application conditions that ha ening may be pos n for including a co ening is not currer will use the NIH R	ons for research re ve been identified sible in the near ondition on a newk otly recommended esearch Project (Re	levant to the through porn screening but would 01) award				
072588	Innovative Therapies and Tools fo Newborns (R03 Clinical Trial Optic	r Screenat onal)	b <u>le Disorders in</u> Na Hu	tional Institute of Child Health and man Development/NIH/DHHS	PAR-18- 690 07-1	May-2021	100,000 USD				
	Contact Name	Melissa P	arisi, MD, PhD								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-435-6 parisima@ Link to pr 07-May-2 National I developm newborn future. De panel; the	6880 <u>mail.nih.gov</u> ogram URL 2021 Institutes of Health (NIH) and i nent of therapeutic interventic screening, as well as "high price emonstrating the benefits of the erefore, for this FOA, a "high p	ts participating Institutes and Cente ons for potentially fatal or disabling o prity" genetic conditions where scre reatment is often a primary criterior riority" condition is one where scree	rs invite applicatio conditions that hav ening may be poss of for including a co ening is not curren	ons for research reveloced to the second to	elevant to the through porn screening
075836	Role of Gut Microbiome in Regula on Fertility Status in Women Livin Clinical Trial Optional)	mechanis	bduction and Its Impact Nati	onal Institute of Child Health and nan Development/NIH/DHHS	PA-18-838 07-N	May-2021	2,499,995 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Ravi Ravii 301-435-6 <u>ravindrn@</u> Link to pr	ndranath, PhD 6889 @mail.nih.gov rogram URL				
	Deadline Dates (ALL) Synopsis	07-May-2 National the gut m gain fund pituitary- The result metabolic biology, fr intervent HPA, and	2021, 05-Jun-2021, 07-Sep-20 I Institute of Child Health and I nicrobiome in regulating metak amental insight into the possil gonadal (HPG), hypothalamo-p ts of the study could lead to de c failure. The project is pertine ertility preservation, assisted r ions to infertility. The emphasi HPT axes leading to obesity, n	21 Human Development (NICHD) invite polism and reproduction, and its imp ple role of the gut microbiome in reg pituitary-adrenal (HPA), and hypotha evelopment of diagnostic markers (s nt to multiple portfolios in the Ferti eproductive technology, spermatog s on the gut microbiome and its imp netabolic syndrome, stress disorders	s applications for r pact on fertility sta gulating reproduct alamo-pituitary-th ignature microbio lity and Infertility R enesis and sperm pact on reproducti s, infection and an	research related to tus. The overarchi ion through hypot yroid (HPT) axes ir mes) for reproduc Branch, e.g., basic function, and ther on through its effe xiety is also of inte	o the role of ing goal is to thalamo- n the brain. tive and ovarian rapeutic ects on HPG, erest to the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Dat	e Funding Amount						
		Maternal and Pediatric infectious of Disabilities Branch. This FOA will us	disease Branch, Pediatric Growth and Nu se the NIH Research Project (R01) award	trition Branch and Intellectual ar mechanism.	าd Developmental						
072575	Developmental Pharmacodynami Pediatrics (R01 Clinical Trial Optic	<u>cs and Models of Drug Effects in</u> onal)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-688 07-May-2021	Not Specified						
	Contact Name	George P. Giacoia MD									
	Contact Telephone	301-496-5589									
	Contact Email	giacoiag@exchange.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021									
	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental Synopsis pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmenta pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH Research Project (R01) award mechanism.										
074832	Patient Safety in the Context of Pe Care (R01 - Clinical Trial Optional)	erinatal, Neonatal, and Pediatric	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-790 07-May-2021	Not Specified						
	Contact Name	Marion Koso-Thomas, M.D, MPH									
	Contact Telephone	301-435-6873									
	Contact Email	kosomari@mail.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Se	p-2021								
	Synopsis	ates (ALL) 07-May-2021, 05-Jun-2021, 07-Sep-2021 National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital Synopsis settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical									

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		errors. It is anticipated that knowled healthcare to all newborn infants an Project (R01) award mechanism.	lge gained from these projects will help id children with utmost safety and effe	develop strategie ctiveness. This FO	es to deliver highe A will use the NIH	st quality of Research
074138	Identification and Management o Mental Health Conditions in Indiv (R01 - Clinical Trial Optional)	<u>f Behavioral Symptoms and</u> iduals with Intellectual Disabilities H	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18- 766 07-	May-2021	Not Specified
	Contact Name	Tracy King, MD, MPH				
	Contact Telephone	301-402-1822				
	Contact Email	tracy.king@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep	-2021			
	Synopsis	National Institute of Child Health an management of behavioral sympton areas of interest for this funding opp identify behavioral symptoms or dia pharmacokinetics, safety and efficac health conditions in individuals with	nd Human Development (NICHD) invite ns and mental health conditions in indi- portunity are (1) applications to develop gnose mental health conditions in indiv cy of specific psychotropic medications ID. This FOA will use the NIH Research	s applications foc viduals with intelle o and validate asso viduals with ID, an for treatment of k Project (R01) awa	using on identifica ectual disabilities (essment tools that d (2) applications behavioral sympto and mechanism.	tion and ID). Specific reliably studying the ms or mental
070059	NICHD Research Project Grant (R	N <u>1 - Clinical Trial Required)</u>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-480 07-	May-2021	Not Specified
	Contact Name	NICHD Referral Office				
	Contact Telephone					
	Contact Email	NICHDReferral@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	National Institute of Child Health ar NICHD mission. This FOA will use the	nd Human Development (NICHD) invite e NIH Research Project (R01) award me	s applications for chanism.	clinical trials that t	all within the

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
070412	Drug Repurposing for Conditions / Women (R01 Clinical Trial Optiona	Affecting N al)	leonates and Pregnant	Natio Huma	nal Institute of Child Health and In Development/NIH/DHHS	PAR-18- 506 07	-May-2021	Not Specified
	Contact Name	Ekaterini	Tsilou. MD					
	Contact Telephone	301-496-6	5287					
	Contact Email	<u>tsiloue@r</u>	<u>mail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	National drugs for developm populatio	Institute of Child Health new neonatal and obste ent of drugs appropriate ns. This FOA will use the	and Hi tric ind for us NIH Re	uman Development (NICHD) invites ications, in order to overcome the c e in neonates and pregnant women esearch Project (R01) award mechar	applications to lifficulties associ and facilitate t lism.	repurpose already iated with the trad reatment of these v	FDA approved itional vulnerable
072576	Developmental Pharmacodynamic Pediatrics (R03 Clinical Trial Optio	<u>cs and Mo</u> nal)	dels of Drug Effects in	Natio Huma	nal Institute of Child Health and In Development/NIH/DHHS	PA-18-687 07	-May-2021	100,000 USD
	Contact Name	George P.	Giacoia MD					
	Contact Telephone	301-496-5	5589					
	Contact Email	giacoiag@	exchange.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL) Synopsis	07-May-2 National applicatic pharmacc pharmacc relationsh	021 Institute of Child Health ons for multidisciplinary, odynamics. This FOA seel odynamics in the pediatri hip of drugs used in this p	and Hi investig ks gran ic age g oopulat	uman Development (NICHD) and Na gator-initiated basic translational an t applications that propose studies t groups and allows the determination ion. This FOA will use the NIH RO3 S	tional Institute d clinical resea o increase and o of pharmacok mall Grant Prop	of Mental Health (I rch in development establish data on d inetic-pharmacodyi gram award mechai	NIMH) invite al evelopmental namic nism.
100064	Notice of Special Interest (NOSI): Analyses of Existing Data Sets and	Small Grar	its for Secondary ospecimens	Natio Huma	nal Institute of Child Health and In Development/NIH/DHHS	NOT-HD- 20-022 07	-May-2021	Not Specified
	Contact Name	Regina Bu	ires, PhD					

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-106 0	0485					
	Contact Fmail	regina hu	res@nih gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
Deadline Dates (ALL) 2022, 16-Oct-2022, 07-Jan-2023, 16-Feb-2023, 07-May-2023, 16-Feb-2023, 07-May-2023								22 , 07-Sep-
This Notice of Special Interest (NOSI) encourages applications that propose to conduct secondary analyses using public available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost- effective research utilizing data and biospecimens collected with NICHD resources.								
101700	Notice of Special Interest (NOSI): I	Biophysica	l and Biomechanical	Natior	hal Institute of Child Health and	NOT-HD- 07-I	May-2021	Not
	Aspects of Embryonic Developmen	<u>nt (R21)</u>		Huma	n Development/NIH/DHHS	21-004	-, -	Specified
	Contact Name	Mahua M	ukhopadhyay, PhD					
	Contact Telephone	301-435-6	5886					
	Contact Email	<u>mukhopa</u>	m@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16-	021 , 16-Jun-2021 , 07-Se ·Oct-2022	p-2021	L , 16-Oct-2021 , 07-Jan-2022 , 16-	⁻ eb-2022 <i>,</i> 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-
	Synopsis The Notice of Scientific Interest (NOSI) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program explore approaches and concepts new to the area of developmental tissue mechanics, research and development of technologies, or initial research and development of data upon which significant future research may be built. The focus of this NOSI is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.							
070064	NICHD Small Grant Program (R03	Clinical Tri	al Optional)	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	PA-18-481 07-	May-2021	100,000 USD
	Contact Name Contact Telephone	NICHD Re	ferral Office					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Frail		forral@mail.nih.gov							
	Contact Emain	NICHDRE	ierrai@mail.nin.gov							
	Program LIPI	Link to pr	ogram LIRI							
		$\frac{\text{LITK to pr}}{07 - May - 2}$								
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for small research probe carried out in a short period of time with limited resources. The RO3 activity code supports different types of including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research project development of research methodology; and development of new research technology. This FOA will use the NI Grant Program award mechanism.								
075841	Role of Gut Microbiome in Regula on Fertility Status in Women Livin Clinical Trial Optional)	ting Repro	oduction and Its Impact Without HIV (R21 H	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-839 07-1	May-2021	275,000 USD			
	Contact Name	Ravi Ravii	ndranath, PhD							
	Contact Telephone	301-435-6	6889							
	Contact Email	<u>ravindrn@</u>	<u>စာmail.nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	.021 , 16-Jun-2021 , 07-Sep	-2021						
	Synopsis	National the gut m gain fund pituitary- The result metabolic biology, for intervent HPA, and Maternal Disabilitie	I Institute of Child Health an icrobiome in regulating me amental insight into the po gonadal (HPG), hypothalan ts of the study could lead to c failure. The project is perf ertility preservation, assiste ions to infertility. The empl HPT axes leading to obesit and Pediatric infectious dis es Branch. This FOA will use	nd Human Development (NICHD) invite etabolism and reproduction, and its imp ossible role of the gut microbiome in reg no-pituitary-adrenal (HPA), and hypotha o development of diagnostic markers (s tinent to multiple portfolios in the Ferti ed reproductive technology, spermatog hasis on the gut microbiome and its imp y, metabolic syndrome, stress disorders sease Branch, Pediatric Growth and Nut e the NIH R21 Exploratory/Development	s applications for i pact on fertility sta gulating reproduct alamo-pituitary-th signature microbio lity and Infertility I genesis and sperm pact on reproducti s, infection and an trition Branch and tal Research Grant	research related to itus. The overarch tion through hypot yroid (HPT) axes in omes) for reproduc Branch, e.g., basic function, and the ion through its effor xiety is also of inte Intellectual and D t award mechanisr	o the role of ing goal is to thalamo- n the brain. ctive and ovarian rapeutic ects on HPG, erest to the revelopmental m.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
074839	Patient Safety in the Context of Pe Care (R03 - Clinical Trial Optional)	erinatal, Neonatal, and Pediatric	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-791 07-I	May-2021	100,000 USD					
	Contact Name Contact Telephone	Marion Koso-Thomas, M.D, MPH 301-435-6873									
	Contact Email Sponsor Website	kosomari@mail.nih.gov									
	Program URL Deadline Dates (ALL)	<u>Link to program URL</u> 07-May-2021 , 16-Jun-2021 , 07-S	ep-2021								
	Synopsis	Synopsis Syn									
087240	Archiving and Documenting Child Data Sets (R03 Clinical Trial Not Al	Health and Human Development llowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 064 07-I	May-2021	100,000 USD					
	Contact Name	Regina Bures, Ph.D. 301-496-9485									
	Contact Email	regina.bures@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S 2022 , 16-Oct-2022 , 07-Jan-2023	ep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-I	eb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-					
	Synopsis	The purpose of this funding oppor sets within the scientific mission of (NICHD) in order to enable second original data collected with NICHE	D22 , 16-Oct-2022 , 07-Jan-2023 The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing dat ets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development VICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive riginal data collected with NICHD funding.								

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
085590	Small Research Grants for Analyse Pediatric Research Data (R03 Clini	s of Gabrie cal Trial No	ella Miller Kids First ot Allowed)	Natior Huma	nal Institute of Child Health and n Development/NIH/DHHS	PAR-19- 375 07-	May-2021	200,000 USD
	Contact Name							
	Contact Telephone 301-451-1390							
	Contact Email	<u>Coulombe</u>	J@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May- 2022 , 16-Oct-2022 , 07-Jan-2023							
	Synopsis	The NIH C pediatric r communit Gabriella I childhood accessible collaborat support m birth defe Developm structural	ommon Fund has establ research data resource p ries of investigators who Miller Kids First Pediatric cancer and birth defect to the research commu ion leading to more refineritorious small researc cts datasets that are par ent of statistical method birth defects may also b	ished the opulate study t Data R s cohor nity. Ac ned dia h projec t of the dology a pe propo	ne Gabriella Miller Kids First Pediatr ed by genome sequence and pheno he genetics of childhood cancers an esource is to build a collection of c ts and provide a central portal whe cess to these data will promote cor gnostic capabilities and ultimately r cts focused on the development an Kids First Data Resource or could b appropriate for analyzing genome-v osed.	ic Research Prog type data that w nd/or structural urated genomic re data and anal mprehensive and nore targeted th d analyses of chi be included in th vide data relevan	gram (Kids First) to vill be of high value birth defects. The and phenotypic da ysis tools will be re cross-cutting rese erapies. This FOA Idhood cancer and e Kids First Data Re nt to childhood can	develop a for the goal of the ta from eadily earch and is intended to d/or structural esource. ncer and/or
101701	NIDCR Dual Degree Dentist Scienti Transition Award (F99/K00 Indepe	ist Predoct Indent Clin	oral to Postdoctoral ical Trial Not Allowed)	Natior Cranic	nal Institute of Dental and facial Research/NIH/DHHS	PAR-21- 108	Apr-2021	Not Specified
	Contact Name	Leslie A. F	rieden, Ph.D					
	Contact Telephone	301-496-4	263					
	Contact Email	leslie.fried	len@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	08-Apr-20 2022 <i>,</i> 07-	21 , 07-May-2021 , 08-A Sep-2022 , 08-Dec-2022	ug-202 , 07-Jai	1 , 07-Sep-2021 , 08-Dec-2021 , 07- n-2023 , 08-Apr-2023 , 07-May-202	Jan-2022 , 08-Ap 3 , 08-Aug-2023	or-2022 , 07-May-2 , 07-Sep-2023 , 08	2022 , 08-Aug- -Dec-2023 , 07-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Jan-2024 The purpose of the NIDCR Dual Deserver and mentorship to outstand during the transition from predoct of predoctoral dual degree dentist and craniofacial research (K00). It degree dentist scientists' research applicants to propose to lead an in clinical trial led by a sponsor or compose to compose t	egree Dentist Scientist Predoctoral to F anding students enrolled in integrated o storal student to postdoctoral scholar. ² it scientist training (F99) and progressio is anticipated that successful completi in career trajectories This Funding Oppo ndependent clinical trial, but does allow o-sponsor.	Postdoctoral Transiti dual degree dental (This phased award p on to mentored post ion of this phased aw ortunity Announcem w applicants to prop	ion Award (F99/K00 DDS/DMD) and PhI program will facilita tdoctoral positions i ward program will e ent (FOA) does not pose research exper)) is to provide D programs te completion in dental, oral enhance dual allow rience in a
102061	NIDCR Predoctoral to Postdoctora Dental, Oral and Craniofacial Rese Independent Clinical Trial Not Allo	al Transition Award for a Diverse earch Workforce (F99/K00 owed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 060 08	-Apr-2021	Not Specified
	Contact Name	Leslie A. Frieden, Ph.D.				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-A 2022 , 07-Sep-2022 , 08-Dec-2022 Jan-2024	Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 2 , 07-Jan-2023 , 08-Apr-2023 , 07-May-	, 07-Jan-2022 , 08-A -2023 , 08-Aug-2023	pr-2022 , 07-May-2 3 , 07-Sep-2023 , 08	022 , 08-Aug- -Dec-2023 , 07-
	Synopsis	The purpose of the NIDCR Predoct Workforce (F99/K00) is to support underrepresented in biomedical, research training. This phased awa programs (F99) and progression to anticipated that successful comple faculty position and subsequent N Announcement (FOA) does not all to propose research experience in	toral to Postdoctoral Transition Award t outstanding graduate students from a clinical, behavioral and social sciences, ard program will facilitate completion o mentored postdoctoral positions in a etion of this phased award program wi NIDCR career development and researc low applicants to propose to lead an in n a clinical trial led by a sponsor or co-s	for a Diverse Denta diverse backgrounds over the transition of graduate PhD or o lental, oral and cran Il enable achieveme h project awards. Th dependent clinical t ponsor.	I, Oral and Craniofa s, including those fr from predoctoral to dual degree clinician iofacial research (K ent of an independe his Funding Opportu crial, but does allow	cial Research om groups o postdoctoral n scientist 00). It is nt research unity applicants



SPIN ID	Program Title		Sponsor Name	s	ponsor Number		Deadline Date	Funding Amount
	Investigators (K22 Independent C	linical Trial	Not Allowed)	Craniof	acial Research/NIH/DHHS	152		Specified
	Contact Name	Leslie A. F	rieden, PhD					
	Contact Telephone	301-496-4	4263					
	Contact Email	leslie.frie	den@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 12-Jun-2021 , 07-Se	ep-2021 ,	, 12-Oct-2021 , 07-Jan-2022			
	Synopsis	highly qua research that does Applicant Applicant Trial Requ as "prosp Studies w	alified dentists in NIH Intr experiences in the NIH Int funding. This Funding Op not involve leading an in s to this FOA are permitte s proposing a clinical trial uired' FOA (PAR-18-360). ective basic science studi ith Humans FOA (PAR-19	ramural portunity oportunity odepende red to pro- il or an ar Applican ies involv 9-151).	postdoctoral fellowship positions I program to extramural institution y Announcement (FOA) is design ent clinical trial, a clinical trial fea ppose research experience in a clinical trial fea phose research experience in a clinical trial sead invest ins proposing basic experimental ving human participants" should a	with opportunity ons as new investig ed specifically for a sibility study, or a inical trial led by a igator, should app studies in humans apply to the comp	to transition from gators with indepo applicants propos n ancillary clinical mentor or co-me ly to the compani s referred to in NC anion Basic Exper	i mentored endent ing research trial. ntor. on 'Clinical)T-OD-18-212 imental
079337	NIDCR Dentist Scientist Career Tra Investigators (K22 Independent Ba Humans Required)	ansition Av asic Experi	vard for Intramural mental Studies with	Nationa Craniofa	al Institute of Dental and acial Research/NIH/DHHS	PAR-19- 151 07-N	May-2021	Not Specified
	Contact Name	Leslie A. F	rieden, PhD					
	Contact Telephone	301-496-4	4263					
	Contact Email	leslie.frie	den@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 12-Jun-2021 , 07-Se	ep-2021 ,	, 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpo highly qua research	ose of the NIDCR Dentist alified dentists in NIH Intr experiences in the NIH In	Scientist ramural p ntramural	Career Transition Award for Intr postdoctoral fellowship positions I program to extramural institution	amural Investigate with opportunity ons as new investig	ors (K22) program to transition from gators with indepo	is to provide 1 mentored endent

SPIN ID	Program Title		Sponsor Name		Sponsor Number		De	eadline Date	Funding Amount
		research studies in These stu that shou experime purpose of products companic gain resea	funding. This Funding Op volving humans, referred dies fall within the NIH o ld submit under this FOA ntally manipulate indepe of understanding the fun in mind. Studies conduct on 'Clinical Trial Required arch experience in a clini	oportuni d to in N definitio A include endent v dament ted with d' FOA (F ical trial	ty Announcement (FOA) is desig IOT-OD-18-212 as "prospective b n of a clinical trial and also meet e studies that prospectively assig variables) and that assess biomed al aspects of phenomena withou specific applications toward pro PAR-18-360). Applicants not plan led by another investigator, mus	ned specifical basic science s the definitior n human part dical or behav dical or behav dit specific app cesses or pro ning an indep t apply to cor	ly for bas studies in of basic ticipants f vioral out lication t ducts in r endent c mpanion	sic science expension research. Type to conditions (i comes in huma cowards proces mind should ap clinical trial, or p FOA (PAR-19-1	erimental participants." es of studies .e., ns for the ses or ply to the proposing to 52).
087115 <u> </u>	mproving Oral Health and Reduc Clinical Trial Not Allowed)	ing Dispari	ties in Adolescents (R21	Natior Cranio	al Institute of Dental and facial Research/NIH/DHHS	PAR-20- 059	07-May	y-2021	275,000 USD
	Contact Name	Darien W	eatherspoon, DDS, MPH						
	Contact Telephone	301-594-5	5394						
	Contact Email	darien.we	eatherspoon@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2022 , 16	.021 , 16-Jun-2021 , 07-S -Oct-2022 , 07-Jan-2023	ep-2021	. , 16-Oct-2021 , 07-Jan-2022 , 16	5-Feb-2022 , C)7-May-2	022 , 16-Jun-2(022 , 07-Sep-
	Synopsis	The purpo improve t this popu	ose of this Funding Oppo the oral health of adolese lation. This FOA defines	ortunity cents in "adolese	Announcement (FOA) is to encou the United States, and to reduce cents" as those individuals betwe	urage explora observed ora een the ages o	tory or de al health of 10 and	evelopmental r disparities and I 19.	esearch to inequities in
086963	NDCR Small Research Grants for Data (R03 Clinical Trial Not Allowe	Analyses o ed)	f Existing Genomics	Natior Cranio	al Institute of Dental and facial Research/NIH/DHHS	PAR-20- 046	07-May	y-2021	200,000 USD
	Contact Name	Lu Wang.	Ph.D.						
	Contact Telephone	301-594-4	1846						
	Contact Email	wanglu@	nidcr.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	.021 , 16-Jun-2021 , 07-S	ep-2021	., 16-Oct-2021, 07-Jan-2022, 16	5-Feb-2022 , C)7-May-2	.022 , 16-Jun-20)22 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	2022 , 16 The purpe human de using stat methods	-Oct-2022 , 07-Jan-2023 ose of this FOA is to announce s ental, oral, or craniofacial (DOC) istical and computational appro to be developed in the same pr	upport for meritorious research pro conditions or traits through analys baches. Data analysis for each proje oject, including machine learning-b	ojects that addres is of existing and ect can be perform ased methods (M	s research questic publicly available ned using existing L).	ons relevant to genomics data and/or novel
079222	NIDCR Dual Degree Dentist Scient Award (K99/R00 Independent Bas Humans Required)	ist Pathwa sic Experin	ay to Independence Natio Dental Studies with Cranic	nal Institute of Dental and of action of the off off off off off off off off off of	PAR-19- 07-1 141	May-2021	Not Specified
	Contact Name	Leslie A. F	Frieden, PhD				
	Contact Telephone	301-496-4	4263				
	Contact Email	leslie.frie	den@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Synopsis	The purper strong co transition tenure-traindepend an advant This Fund 18-212 as clinical trai that prosponse assess bio phenome toward pu Applicant investigat	beso of the NIDCR Dentist Scienti hort of new and talented indep of outstanding dual degree der ack or equivalent faculty positio ent research. The option for five ced specialty education program ing Opportunity Announcemen s "prospective basic science stud al and also meet the definition pectively assign human participation medical or behavioral outcome ma without specific application rocesses or products in mind shares s not planning an independent cor, must apply to companion Fo	ist Pathway to Independence Award endent dual degree dentist scientist ntist scientists from mentored, post ons by providing support for two yea e years of independent (R00) support n at no more than 3 person-months t is for basic science experimental s dies involving human participants." of basic research. Types of studies t ants to conditions (i.e., experimenta es in humans for the purpose of und towards processes or products in m ould submit under the appropriate clinical trial, or proposing to gain re DA (PAR-19-144).	d (K99/R00) progr ts.This program is tdoctoral research ars of mentored t ort is available to a s effort (25% effor tudies involving h These studies fall that should subm ally manipulate in derstanding the fu hind. Studies cond 'Clinical Trials Rec search experience	am is to increase designed to facili positions to inde- raining and three accommodate clin rt) in any year of t within the NIH de- it under this FOA i dependent variab indamental aspec lucted with specif quired' FOA (PAR- e in a clinical trial	and maintain a itate a timely pendent, to five years of nical training in he R00 phase. to in NOT-OD- efinition of a include studies oles) and that ts of ic applications 18-432). led by another

079369 NIDCR Mentored Career Development Award to Promote Diversity National Institute of Dental and PAR-19- 07-May-2021 Not



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	in the Dental, Oral and Craniofacia Basic Experimental Studies with Hu	al Workforce (K01 Independent umans Required)	Crani	ofacial Research/NIH/DHHS	161		Specified
	Contact Name	Lynn Mertens King, Ph.D.					
	Contact Telephone	301-594-5006					
	Contact Email	<u>lynn.king@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07	-Sep-202	1 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this NIDCR Men dental, oral and craniofacial res fellows and early career faculty biomedical and behavioral scier for intensive research career de Announcement is for basic scier basic science studies involving h meet the definition of basic rese assign human participants to co or behavioral outcomes in huma application towards processes of products in mind should submit planning an independent clinica must apply to companion NIDCI	tored Car earch wo from dive nces. This evelopme nce exper numan pa earch. Ty nditions for ans for th or produc cunder th al trial, or R K01 PAF	eer Development Award is to enha rkforce by providing a mentored re erse backgrounds, including those v award provides salary and research in under the guidance of an experie imental studies involving humans, rticipants." These studies fall withi pes of studies that should submit u (i.e., experimentally manipulate ind e purpose of understanding the fur ts in mind. Studies conducted with he appropriate 'Clinical Trial Require proposing to gain research experie R-19-160 Clinical Trial Not Allowed.	nce the diversity search experience who are from grou in support for a support for a support enced mentor. The referred to in NO in the NIH definition inder this FOA inco lependent variab indamental aspect specific application ed' NIDCR KO1 PA ince in a clinical tr	of the independer e for eligible posto ups underrepreser istained period of is Funding Opport T-OD-18-212 as "p ion of a clinical tria clude studies that p les) and that asses ts of phenomena v ons toward proces R-18-359). Applica- ial led by another	Itly funded loctoral Inted in the protected time unity prospective al and also prospectively is biomedical vithout specific isses or ants not investigator,
079322	NIDCR Small Research Grants for C Statistical Methodology Developm Allowed)	Dral Health Data Analysis and Nent (RO3 Clinical Trial Not	Natio Crani	nal Institute of Dental and of a contract of Dental and of a contract of the second of	PAR-19- 145 07-	May-2021	200,000 USD
	Contact Name	Darien Weatherspoon, DDS, MF	РΗ				
	Contact Telephone	301-594-5394					
	Contact Email	darien.weatherspoon@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) 07 Th Synopsis ar ar ar	-May-2021 , 16-Jun-2021 , 07-Sep-20 e goal of this funding opportunity an alyses of existing oral or craniofacial d craniofacial data using existing oral d amount for studies in categorical p	21 , 16-Oct-2021 , 07-Jan-2022 nouncement is to support meritoriou database resources, or to develop ne or craniofacial databases. The R03 g rogram areas.	is research projec eded statistical m rant mechanism s	ts that involve sec nethodology for ar supports research	ondary data aalyzing oral limited in time
096097	Enabling Technologies to Accelerate Biodevices (R01 Clinical Trial Not Allo	Development of OralNationowed)Crar	onal Institute of Dental and iofacial Research/NIH/DHHS	PAR-20- 233 07-N	Лау-2021	Not Specified
	Contact Name Or Contact Telephone 30 Contact Email <u>or</u> Sponsor Website	lando Lopez, PhD 1-402-4243 lando.lopez@nih.gov				
	Program URL Lin Deadline Dates (ALL)	nk to program URL '-May-2021 , 05-Jun-2021 , 07-Sep-20 22 , 05-Oct-2022 , 07-Jan-2023 , 05-F	21 , 05-Oct-2021 , 07-Jan-2022 , 05-F eb-2023 , 07-May-2023	eb-2022 , 07-May	<i>ı-</i> 2022 , 05-Jun-20	22 , 07-Sep-
	Th te tra us co Synopsis bi re ar bi co be	is Funding Opportunity Announceme chnical challenges associated with ne anslation of intraoral biodevices. Prop e, including but not limited to: precis nditions, and measurement of patier clude engineering approaches that all odevices that are safe and effective for search will be functional biodevices a d effective performance in support o odevices that advance precision medi llaborations across engineering, mult tween academia and industry.	nt (FOA) invites applications that pro w development, substantial optimiza osed technologies are expected to a on medicine-based detection, diagno t functional status and clinical outcor ow integration of electronic, physical or detection, diagnosis and treatment nd integrated approaches thoroughly f specific intended clinical application cine-based approaches in clinical pra ifunctional sensors, pharmacology, cl	pose transformat tion of existing te dvance developm osis and treatmen me assessment. A I, and biological sy t of oral and syste v characterized to ns. To streamline to ctice, this FOA en hemistry, medicin	ive engineering so echnologies and cli ent of oral biodev t of oral and overa reas of interest in ystems into function mic disease. Produ- demonstrate predu- the development of courages interdisco re, and dentistry, a	olutions to nical ices for clinical all health this FOA onal ucts of this clinical safety of oral ciplinary as well as
076573	Biologic Factors Underlying Dental, C Disparities (R01 - Clinical Trial Not Al	Dral, and Craniofacial Health National Natio	onal Institute of Dental and iofacial Research/NIH/DHHS	PAR-18- 875 07-N	/lay-2021	Not Specified

Contact Name Darien Weatherspoon, DDS, MPH

SPIN ID	Program Title		Sponsor Name	9	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-594-5	5394					
	Contact Email	darien.we	eatherspoon@mail.nih.g	gov				
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	021,05-Jun-2021,07-S	Sep-2021				
	Synopsis	National Disparitie (microbial persistend	Institute of Dental and s (NIMHD) invite applica I, immune, genetic) that ce. This FOA will use the	Craniofac ations for t contribu e NIH Reso	cial Research (NIDCR) and Nation investigator-initiated studies des ute to disparities in dental, oral, a earch Project (R01) award mecha	al Institute on signed to iden nd craniofacia nism.	Minority Health and I tify and understand b al disease onset, progr	Health ologic factors ession, and
087123	NIDCR Prospective Observational Cooperative Agreement (U01 Clin	<u>or Biomarl</u> ical Trial N	<u>ker Validation Study</u> ot Allowed)	Nation Cranio	al Institute of Dental and facial Research/NIH/DHHS	PAR-20- 060	07-May-2021	Not Specified
	Contact Name	Dena Eisc	her DDS MSD MS					
	Contact Telephone	301-594-4	1876					
	Contact Email	dena fisch	ner@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-S Oct-2022 , 07-Jan-2023	Sep-2021 3	, 05-Oct-2021 , 07-Jan-2022 , 05-	Feb-2022 , 07	-May-2022 , 05-Jun-20)22 , 07-Sep-
	This Funding Opportunity Anr Synopsis initiated observational studies continued analysis of data/bio				(FOA) will support, through the c er validation studies that require collected as part of a previous NII	ooperative ag prospective c DCR award.	reement mechanism, ollection of data/biosį	investigator- pecimens or
087114	Improving Oral Health and Reduci Clinical Trial Not Allowed)	ing Dispari	ties in Adolescents (R01	L Nation Cranio	al Institute of Dental and facial Research/NIH/DHHS	PAR-20- 058	07-May-2021	Not Specified
	Contact Name	Darien W	eatherspoon, DDS, MPH	1				
	Contact Telephone	301-594-5	5394					
	Contact Email	darien.we	atherspoon@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-S ·Oct-2022 , 07-Jan-2023	Sep-202	1 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	ıy-2022 , 05-Jun-2()22 , 07-Sep-		
	Synopsis	The purpo adolescer defines "a	urpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of scents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA se "adolescents" as those individuals between the ages of 10 and 19.							
074728	Precision Imaging of Oral Lesions	(R01- Clini	cal Trial Not Allowed)	Natio Cranio	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-18- 787 07-	May-2021	Not Specified		
	Contact Name	Chiayeng	Wang, Ph.D.							
	Contact Telephone	301-827-4	1647							
	Contact Email	chiayeng.	wang@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	021,05-Jun-2021,07-S	Sep-202	1					
	Synopsis	National adaptatio diagnosis, use the N	Institutes of Health (NII n, optimization, and vali treatment, and treatme IH Research Project (RO	H) and it idation ent mor 1) aware	ts participating Institutes and Center of accurate, reproducible, specific, a hitoring for diseases and conditions d mechanism.	ers invite applicat and sensitive ima in the oral cavity	tions for the develo aging approaches t y and oropharynx.	opment, o improve This FOA will		
083076 <u>(</u>	Mechanistic Studies of Gene-Envi Craniofacial, and Other Diseases (Not Allowed)	ronment Ir and Condit	nterplay in Dental, Oral, ions (R01 Clinical Trial	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-19- 292 07-	May-2021	Not Specified		
	Contact Name	Kathryn S	tein, Ph.D.							
	Contact Telephone	301-827-4	1653							
	Contact Email	kathryn.st	tein@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022	021 , 05-Jun-2021 , 07-S	Sep-202	1 , 05-Oct-2021 , 07-Jan-2022 , 05-F	eb-2022 , 07-Ma	y-2022 , 05-Jun-20)22 , 07-Sep-		
	Synopsis	This Fund	ing Opportunity Annour	ncemen	t (FOA) is intended to foster researd	ch towards a bet	ter understanding	of the		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		biological NIEHS, an investigat diseases a	mechanisms of gene-en d NICHD solicit application ion of the interplay of ge and conditions.	vironment interplay in human diseases ons that use animal models, in vitro sys enes/gene networks and environmenta	and condition tems, or ex viv l factors in der	s. Through this FOA, th o approaches to cond atal, oral, craniofacial (e NIDCR, uct mechanistic DOC), and othe
081268	Clinical Research to Improve the Clinical Trial Not Allowed	<u>Oral Health</u>	of Older Adults (R01	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19- 239	07-May-2021	Not Specified
	Contact Name Contact Telephone Contact Emai Sponsor Website	Darien W 301-594-5 darien.we	eatherspoon, DDS, MPH 5394 eatherspoon@mail.nih.				
	Program URL Deadline Dates (ALL)	Link to pr 07-May-2	ogram URL 021 , 05-Jun-2021 , 07-Se	ep-2021 , 05-Oct-2021 , 07-Jan-2022 , 0	5-Feb-2022 , C)7-May-2022 , 05-Jun-2	022 , 07-Sep-
	Synopsis	The purport related to managem "older ad	ose of this Funding Oppo the risk factors, access t ent of dental, oral, and o ults" as those individuals	rtunity Announcement (FOA) is to stim to care barriers, oral health promotion a craniofacial (DOC) diseases more comm age 65 years and older.	ulate research and disease pr only experiend	to address gaps in our evention strategies, ar ced by older adults. Th	knowledge Id clinical Is FOA defines
072035	NIDCR Behavioral and Social Inter Implementation Cooperative Agr Required)	rvention Cl eement (U	inical Trial Planning and G3/UH3 Clinical Trial	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 656	07-May-2021	Not Specified
	Contact Name	Melissa W	/. Riddle, PhD				
	Contact Telephone	301-451-3	3888				
	Contact Emai	riddleme	@mail.nih.gov				
	Sponsor Website						
	Program URL	LINK to pr	Ogram UKL				
	Synopsis	National behaviora	Institute of Dental and C and social intervention	raniofacial Research (NIDCR) invites re clinical trials. Studies appropriate for t	search applica his announcer:	tions to plan and imple nent include tradition	ement al clinical trials

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to develop as interve initially su implement requirement the instru scientific feasibility acceptabit interventition	p and test behavior change inte entions that are used as tools to upport a milestone-driven plane ntation phase of up to five years ents may transition to the UH3 actions described in this FOA. T and operational planning activity and/or acceptability of a plane lity of study content or mode o ion training and fidelity monitor pent of: the final clinical protoco	erventions for preventing and treating dental, oral, o o understand mechanisms of behavior change. Award ning phase (UG3) for up to 2 years, with possible tran s (UH3). Only UG3 projects that have met the scienti- phase. The UG3/UH3 application must be submitted he UG3 phase for behavioral and social intervention ties. Scientific planning activities include small-scale ned behavioral or social intervention and associated s of delivery; feasibility of proposed data collection pro ring procedures). Operational planning activities include of the intervention manual or equivalent: the data m	r craniofacial conc ls made under this isition to a clinical fic milestones and as a single applica clinical trials will p data collection to study procedures (cedures; prelimina ude, at a minimun	litions, as well s FOA will trial feasibility ation, following bermit both assess the (e.g., ary testing of n, m and other

National Dental Practice-Based Research Network Clinical Trial or National Institute of Dental and PAR-20-Not 100184 Observational Study Planning and Implementation Cooperative 07-May-2021 Craniofacial Research/NIH/DHHS 306 Specified Agreement (UG3/UH3 Clinical Trial Optional) Contact Name Dena Fischer, DDS, MSD, MS Contact Telephone 301-594-4876 Contact Email dena.fischer@nih.gov Sponsor Website Program URL Link to program URL 07-May-2021, 09-Jun-2021, 07-Sep-2021, 08-Oct-2021, 09-Feb-2022, 07-May-2022, 09-Jun-2022, 07-Jul-2022, 07-Sep-Deadline Dates (ALL) 2022, 07-Oct-2022, 07-Jan-2023, 09-Feb-2023, 07-May-2023, 09-Jun-2023, 07-Sep-2023 The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a

Agreement award mechanism.

Synopsis dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational

tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stage 0 & I) through implementation and cost-effectiveness research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	st m ar tra de th im pa pr	udies to techanis and resou ansition epender te resea pplemer atients, f	be conducted in the National m. Each UG3/UH3 award will s irces for study planning and im to a UH3 implementation pha nt on success in meeting UG3 n rch, NIDCR program priorities, ntation of national oral health r to provide evidence useful in d This FOA encourages applicatio	Dental PBRN through a milestone-oupport an individual project which plementation. This FOA supports a se. Progression to the UH3 phase is nilestones, consideration of the der and availability of funds. The main research studies in dental practices aily patient care, and to facilitate the ons proposing research studies that	driven UG3/UH3 co will utilize the Nat UG3 clinical study based on an adm ntal PBRN as an ap goals of the denta on topics of impo ne translation of ro align with the goa	ooperative agreen tional Dental PBRN planning phase a inistrative review propriate venue fo I PBRN are to strea rtance to practitio esearch findings in als of the dental PE	nent I infrastructure nd potential and is or conduct of amline the ners and their to clinical BRN.
079225	NIDCR Dual Degree Dentist Scientist Ward (K99/R00 Independent Clinica	<u>Pathwa</u> al Trial N	i <u>y to Independence</u> Nation Not Allowed) Cran	onal Institute of Dental and iofacial Research/NIH/DHHS	PAR-19- 144 07-I	May-2021	Not Specified
	Contact Name Le Contact Telephone 30 Contact Email le Sponsor Website Program URL Li Deadline Dates (ALL) 07 T in ar tri ba Synopsis Ni ne ou ec re sp	eslie A. F D1-496-4 slie.fried nk to provide to provide the provide the provide the permination of the permi	Frieden, PhD 4263 den@nih.gov 0gram URL 021 , 12-Jun-2021 , 07-Sep-202 ding Opportunity Announceme ading an independent clinical t itted to propose research expe ancillary clinical trial as lead in erimental studies in humans re nts" should apply to the compa ntist Scientist Pathway to Inde calented independent dual deg ng dual degree dentist scientis t faculty positions by providing The option for five years of inc education program at no more	21, 12-Oct-2021, 07-Jan-2022 nt (FOA) is designed specifically for rial, a clinical trial feasibility study, rience in a clinical trial led by a mer ovestigator, should apply to the con ferred to in NOT-OD-18-212 as "pro nion Basic Experimental Studies wir pendence Award (K99/R00) progra ree dentist scientists. This program ts from mentored, postdoctoral res g support for two years of mentored lependent (R00) support is available than 3 person-months effort (25%	applicants propos or an ancillary clim ntor or co-mentor npanion FOA (PAR ospective basic sci th Humans FOA (P m is to increase ar is designed to fac search positions to d training and thre e to accommodate effort) in any year	sing research that nical trial. Applican Applicants propo -18-432). Applicar ence studies invol AR-19- 141). The p nd maintain a stron cilitate a timely tra p independent, ten e to five years of i e clinical training in r of the R00 phase	does not ts to this FOA sing a clinical its proposing ving human ourpose of the ng cohort of nsition of ure-track or ndependent n an advanced

079378 NIDCR Mentored Career Development Award to Promote Diversity National Institute of Dental and PAR-19- 07-May-2021 Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	in the Dental, Oral and Craniofaci Clinical Trial Not Allowed)	al Workforce (K01 Independent	Craniofacial Research/NIH/DHHS	160		Specified	
	Contact Name Contact Telephone	Lynn Mertens King, Ph.D. 301-594-5006					
	Contact Email Sponsor Website	<u>lynn.king@nih.gov</u>					
	Program URL Deadline Dates (ALL)	Link to program URL 07-May-2021 , 12-Jun-2021 , 07-Se	ep-2021 , 12-Oct-2021 , 07-Jan-2022				
	Synopsis	dental, oral and craniofacial reseau fellows and early career faculty fro biomedical and behavioral science for intensive research career deve Announcement (FOA) is designed a clinical trial, a clinical trial feasibilit propose research experience in a c study to an ongoing clinical trial as	rch workforce by providing a mentore om diverse backgrounds, including the s. This award provides salary and rese lopment under the guidance of an ex specifically for applicants proposing re ty study, or an ancillary study to a clir clinical trial led by a mentor or co-me s lead investigator, should apply to th	ed research experier ose who are from gree earch support for a seperienced mentor . esearch that does no lical trial. Applicants ntor. Applicants pro e companion FOA (F	nce for eligible post oups underreprese sustained period of This Funding Oppor ot involve leading a to this FOA are per posing a clinical tria PAR-18-359).	doctoral nted in the protected time tunity n independent mitted to al or an ancillary	
053538	Precision Imaging of Oral Lesions	(R21-Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18- 788 07	7-May-2021	275,000 USD	
	Contact Name Contact Telephone	Chiayeng Wang, Ph.D. 301-827-4647					
	Contact Email Sponsor Website	chiayeng.wang@nih.gov					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Se	ep-2021				
	Synopsis	National Institute of Dental and C optimization, and validation of acc treatment, and treatment monitor R21 Exploratory/Developmental R	Craniofacial Research (NIDCR) invites a curate, reproducible, specific, and sen ring for diseases and conditions in the seearch Grant award mechanism.	applications for the ositive imaging appro oral cavity and oro	development, adap baches to improve o pharynx. This FOA v	tation, Jiagnosis, vill use the NIH	
SPIN ID	Program Title	Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
---------	--	---	---	---	--	---	---
076575	Biologic Factors Underlying Denta Disparities (R21 - Clinical Trial Not	al, Oral, and Craniofacial Health t Allowed)	National Insti Craniofacial F	tute of Dental and esearch/NIH/DHHS	PA-18-874 0	7-May-2021	275,000 USD
	Contact Name	Darien Weatherspoon, DDS, MPH					
	Contact Telephone	301-594-5394					
	Contact Email	darien.weatherspoon@mail.nih.g	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S	ep-2021				
	Synopsis	National Institute of Dental and Disparities (NIMHD) invite applica (microbial, immune, genetic) that persistence. This FOA will use the	Craniofacial Re itions for invest contribute to o NIH R21 Explo	earch (NIDCR) and Nation igator-initiated studies de lisparities in dental, oral, a ratory/Developmental Res	nal Institute on N esigned to identif and craniofacial o search Grant awa	Inority Health and H y and understand bi disease onset, progr ard mechanism.	lealth ologic factors ession, and
	Development of Novel and Robus	t Systems for Mechanistic Studies	National Insti	tute of Dental and			275 000
083077	of Gene-Environment Interplay in	Dental, Oral, Craniofacial, and	Craniofacial F	esearch/NIH/DHHS	293 O	7-May-2021	273,000 USD
	Other Diseases and Conditions (R	21 Clinical Trial Not Allowed)					
	Contact Name	Kathryn Stein, Ph.D.					
	Contact Telephone	301-827-4653					
	Contact Email	<u>kathryn.stein@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-S 2022	ep-2021 , 16-0	ct-2021 , 07-Jan-2022 , 16	-Feb-2022 , 07-N	/lay-2022 , 16-Jun-20	022 , 07-Sep-
	Synopsis	This Funding Opportunity Annour biological mechanisms of gene-er , and NICHD solicit applications to human epidemiologic or in vivo st craniofacial, and other diseases a	ncement (FOA) nvironment inte develop novel cudies to facilita nd conditions.	s intended to foster resea rplay in human diseases a and robust experimental te mechanistic investigat	arch towards a be and conditions. T systems that offe ion of gene-envir	etter understanding hrough this FOA, the er approaches comp ronment interplay in	of the NIDCR, NIEHS lementary to dental, oral,
086959	NIDCR Research Grants for Analys Clinical Trial Not Allowed)	ses of Existing Genomics Data (R01	National Insti Craniofacial F	tute of Dental and esearch/NIH/DHHS	PAR-20- 045	7-May-2021	Not Specified
Icahr	n School of Medicine at	NIH Funding	Opportunities D	ue: May 2021			109

SPIN ID	Program Title	S	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount	
	Contact Name	Lu Wang, P	n.D.						
	Contact Telephone	301-594-40	ider nih gov						
	Contact Email	wangiu@n							
	Sponsor website	Link to prov	gram LIBI						
	Deadline Dates (ALL)	07-May-20 2022 , 05-C	921 , 05-Jun-2021 , 07-Se Oct-2022 , 07-Jan-2023	Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	122 , 07-Sep-			
	The purpose of this FOA is to announce support for meritorious research projects that address research questions releve human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomic using statistical and computational approaches. Data analysis for each project can be performed using existing and/or response Synopsis methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified can causal genetic variants is highly encouraged.								
069107	NIDCR Mentored Career Develops in the Dental, Oral and Craniofacia Clinical Trial Required)	ment Award al Research	<u>l to Promote Diversity</u> Workforce (K01-	Natior Cranic	nal Institute of Dental and offacial Research/NIH/DHHS	PAR-18- 359 07-1	May-2021	625,000 USD	
	Contact Name	Lynn Merte	ens King, PhD						
	Contact Telephone	301-594-50	006						
	Contact Email	lynn.king@	<u>)nih.gov</u>						
	Sponsor Website	2							
	Program URL	Link to prop	gram URL						
	Deadline Dates (ALL)	07-May-20	21 , 12-Jun-2021 , 07-Se	ep-2021	1 , 12-Oct-2021 , 07-Jan-2022				
	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Announce clinical tri career de mechanis	ement (FOA) is designed speci al, a clinical trial feasibility stu velopment. This FOA will use m.	fically for applicants proposing to se dy, or a separate ancillary study to he NIH K01 Research Scientist Deve	rve as the lead in an existing trial, a lopment Award -	vestigator of an ind s part of their rese Research & Trainir	dependent arch and ng award
069114	NIDCR Dentist Scientist Career Tra Investigators (K22 Clinical Trial Re	ansition Av quired)	vard for Intramural Nati Crar	onal Institute of Dental and hiofacial Research/NIH/DHHS	PAR-18- 360	May-2021	Not Specified
	Contact Name	Leslie A. F	rieden, PhD				
	Contact Telephone	301-496-4	4263				
	Contact Email	leslie.frie	den@mail.nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 12-Jun-2021 , 07-Sep-20	21 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	National I Transitior fellowship and then investigat proposing ancillary s Transitior	nstitute of Dental and Cranion Award for Intramural Investi positions with an opportunit to provide them with indeper fors at extramural institutions to serve as the lead investiga study to an existing trial, as pa a Award mechanism.	acial Research (NIDCR) invites appli gators (K22) program. provide highly y to receive further mentored resea dent funding to facilitate the transit This Funding Opportunity Announc tor of an independent clinical trial, rt of their research and career deve	cations for the NI y qualified dentis irch experience ir cion of their resea ement (FOA) is de a clinical trial feas lopment. This FO	DCR Dentist Scient ts in NIH Intramura the NIH Intramura irch programs as ne esigned specifically sibility study, or a s A will utilize the NII	st Career I postdoctoral Il program, ew for applicants eparate H K22 Career
096105	Enabling Technologies to Accelera Biodevices (R21 Clinical Trial Not	ate Develo Allowed)	pment of Oral Nati Crar	onal Institute of Dental and nofacial Research/NIH/DHHS	PAR-20- 232 07-	May-2021	Not Specified
	Contact Name	Orlando L	.opez, PhD				
	Contact Telephone	301-402-4	1243				
	Contact Email	orlando.lo	opez@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 16	021 , 16-Jun-2021 , 07-Sep-20 -Oct-2022 , 07-Jan-2023 , 16-F	21 , 16-Oct-2021 , 07-Jan-2022 , 16- eb-2023 , 07-May-2023	Feb-2022 , 07-Ma	ay-2022 , 16-Jun-20	022 , 07-Sep-

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Synopsis a F Synopsis a F C C C C C C C C C C C C C C C C C C	This Fund engineeri technolog oral biode oral and c nterest ir essential oral and s associated applicatio oractice, t chemistry	ing Opportunity Annound ng solutions to technical gies and clinical translatio evices to clinical use, inclu- overall health conditions, in this FOA include engine to the development of fur ystemic disease. Product d core technologies that ns. To streamline the dev shis FOA encourages inte to medicine, and dentistry	cement challen on of ini uding b and m ering a unctiona ts of thi enable velopm rdiscipl y, as we	t (FOA) invites exploratory/develop ages associated with meaningful de traoral biodevices. Proposed techr ut not limited to: precision medici easurement of patient functional s pproaches that allow integration of al biodevices that are safe and effective development of safe and effective ent of oral biodevices that advanc- inary collaborations across engine ell as between academia and indus	omental applic evelopment, so nologies are ex ne-based dete status and clin of electronic, p ective for dete t prototype bi e intra-oral bio e precision me ering, multifun try.	ations that propose t ubstantial optimizatio pected to advance de ction, diagnosis and t cal outcome assessm hysical, and biologica ction, diagnosis and to odevices, dedicated b devices intended for edicine-based approact nctional sensors, phar	ransformative n of existing evelopment of reatment of ent. Areas of l systems reatment of iosensors and specific clinical ches in clinical macology,
100931	NIDCR Small Grant Program for New Not Allowed)	w Investi	gators (RO3 Clinical Trial	Natior Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-21- 084	07-May-2021	200,000 USD
	Contact Name F	Preethi Cł	hander, PhD					
	Contact Telephone	301-827-4	1620					
	Contact Email g	preethi.ch	nander@nih.gov					
	Sponsor Website							
	Program URL <u>I</u>	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16-	021 , 16-Jun-2021 , 07-Se ·Oct-2022 , 07-Jan-2023 ,	ep-2022 , 16-Feb	1 , 16-Oct-2021 , 07-Jan-2022 , 16- o-2023 , 07-May-2023 , 16-Jun-202	Feb-2022 , 07- 3 , 07-Sep-202	May-2022 , 16-Jun-20 23 , 16-Oct-2023 , 07-)22 , 07-Sep- Jan-2024
	۲ Synopsis د	This NIDC the early supports data for a	R Small Grant Program fo stages of establishing an pilot or feasibility studies subsequent investigator	or New indepe and de - initiat	Investigators supports basic and c indent research career in oral, den evelopmental research projects wi ted Research Project Grant (R01) o	linical researc tal and cranio th the intentic r equivalent a	n conducted by scient acial research. This R n of obtaining sufficie oplication.	ists who are in 03 program ent preliminary
081272	Clinical Research to Improve the Or Clinical Trial Not Allowed)	ral Health	of Older Adults (R21	Natio Cranic	nal Institute of Dental and ofacial Research/NIH/DHHS	PAR-19- 240	07-May-2021	275,000 USD
	Contact Name	Darien W	eatherspoon, DDS, MPH					
	Contact Telephone	301-594-5	5394					

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	darien.we	atherspoon@mail.nih.								
	Sponsor Website										
	Program URL	Link to pro	nk to program URL								
	Deadline Dates (ALL)	07-May-2 2022	021 , 16-Jun-2021 , 07-S	ep-202	1 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	y-2022 , 16-Jun-20	22 , 07-Sep-			
Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental resear address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA "older adults" as those individuals age 65 years and older.								esearch to al FOA defines			
081212	Short-term Mentored Career Enhand And Craniofacial Research for Mid K18 Independent Clinical Trial No	ancement I-Career an ot Allowed)	Award in Dental, Oral ad Senior Investigators	Natio Cranio	nal Institute of Dental and of a contract of Dental and of a contract of the second of	PAR-19- 238 07-1	May-2021	Not Specified			
	Contact Name	Lynn Mer	tens King, PhD								
	Contact Telephone	301-594-5	5006								
	Contact Email	Lynn.King	@nih.gov								
	Sponsor Website										
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	07-May-2	021 , 12-Jun-2021 , 07-S	ep-202	1 , 12-Oct-2021 , 07-Jan-2022 , 12-F	eb-2022 <i>,</i> 07-Ma	y-2022				
	Synopsis	This Fund awards in genomics, investigat enhance t investigat and (b) es introducti specificall feasibility trial led b	ing Opportunity Announ dental, oral and craniof , bioinformatics and com ors with short-term train their existing research pr ors who seek training with tablished investigators i fon of DOC research into y for applicants proposin study, or an ancillary cli y a mentor or co-mentor	acemen facial (D nputatio ning in f rogram. ith inve n other o an exis ng resea nical tri r.	t (FOA) encourages applications for OC) research with a focus on behav onal biology research. The intent of the theories, tools, methods or appr . Two categories of candidates are to stigators from another field, in order fields who seek training with DOC r sting research program. This Fundin arch that does not involve leading a ial. Applicants to this FOA are permi	short-term mentioral and social s this program is t roaches of anoth argeted: (a) estal er to enrich their research investig og Opportunity A n independent cl tted to propose	tored career enhanciences, and on ge o provide mid-care er scientific area, i blished DOC resea existing DOC resea ators in order to fa nnouncement (FO linical trial, a clinic research experience	ncement (K18) enetics, eer and senior in order to rch arch program; acilitate the A) is designed al trial ce in a clinical			

SPIN ID	Program Title	Spor	nsor Name		Sponsor Number		Deadline Date	Funding Amount	
100821	<u>RFA-DK-20-025 Diabetes Reseau</u> <u>Optional)</u>	rch Centers (P3C) Clinical Trial	Natior Digest Diseas	nal Institute of Diabetes and ive and Kidney ses/NIH/DHHS	RFA-DK- 20-025	20-Apr-2021 [Optional][LOI/Pre-Ap	6,250,000 o] USD	
	Contact Name	Corinne M. Silv	a, Ph.D.						
	Contact Telephone	301-451-7335							
	Contact Email	<u>silvacm@mail.</u> ı	nih.gov						
	Sponsor Website								
	Program URL	Link to progran	n URL						
	Deadline Dates (ALL)	20-Apr-2021 [C	Optional][LOI/Pre-A	.pp], 20-	May-2021				
	Synopsis	support and en diseases. Diabo Feasibility (P ar productivity, ef Diabetes Resea documented po Centers progra	hance the national etes Research Cent nd F) program. All ffectiveness, and m nrch Centers progra rograms of exceller m may be found at	l researd ers supp activities nultidisci am in 20 nce in di www.d	ch effort in diabetes, its complicati port two primary research-related s pursued by Diabetes Research Ce plinary nature of research in Diabe 18 consists of 16 Centers each loca abetes-related research. General iabetescenters.org.	ons, and relat activities: Re enters are des etes Research ated at outsta information a	ed endocrine and met search Core services a signed to enhance the conter topic areas. The anding research institut bout the NIDDK Diabet	abolic nd a Pilot and efficiency, ne NIDDK ions with ces Research	
101487	RFA-DK-20-032 Pilot and Feasib Diabetes Self-Management Educa Diabetes Care (R34 Clinical Trial R	ility Studies to F tion and Suppo equired)	acilitate the Use of rt to Improve	f Nation Digest Diseas	nal Institute of Diabetes and ive and Kidney res/NIH/DHHS	RFA-DK- 20-032	22-May-2021 [Optional][LOI/Pre-Ap	600,000 o] USD	
	Contact Name	Henry B. Burch	<i>,</i> M.D						
	Contact Telephone	301-827-0827							
	Contact Email	<u>henry.burch@r</u>	nih.gov						
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	22-May-2021 [[Optional][LOI/	Optional][LOI/Pre-/ 'Pre-App], 22-Jun-2	App], 22 2023	-Jun-2021 , 22-May-2022 [Optiona	al][LOI/Pre-Ap	op], 22-Jun-2022 , 22-N	lay-2023	
	Synopsis	The purpose of barriers to and	this funding oppoi facilitate greater u	rtunity a ise of dia	innouncement (FOA) is to test an i abetes self-management education	nnovative and n and support	d pragmatic approach t t (DSMES) by people liv	o address ing with	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		diabetes with the J in suppor	mellitus. Research applica potential for disseminatio t of a future, full-scale tria	ations should engage key stakeholders i n. The pilot trial of the proposed strate al to study broader dissemination and i	n cultivating a p gy should be de nplementation	ractical and sustainal signed to generate pi to expand the use of	ole strategy reliminary data DSMES.
085817	Bioinformatics Interdisciplinary Po Endocrinology and Metabolic Dise	ostdoctora eases (F32	<u>Il Fellowship in Diabetes,</u>)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 379	08-Apr-2021	Not Specified
	Contact Name	Arthur L.	Castle, Ph.D.				
	Contact Telephone	301-594-1	7719				
	Contact Email	castlea@	<u>niddk.nih.gov</u>				
	Sponsor Website						
	Deadline Dates (ALL)	08-Apr-20	ogram ORL 021 , 07-May-2021 , 08-Au -Sep-2022	ug-2021 , 07-Sep-2021 , 08-Dec-2021 , 0)7-Jan-2022 , 08	-Apr-2022 , 07-May-2	2022 , 08-Aug-
	Synopsis	This Fund from outs Diabetes, metabolid disorders plan shou related to applicant clinical tri	ding Opportunity Annouce standing faculty sponsors Endocrinology and Meta c disease disciplines. In or , NIDDK invites applicatio Id focus on interdisciplina o diabetes, endocrinology s to propose to lead an in ial led by a sponsor or co-	ement (FOA) is to enable promising pos- in bioinformatics and scientific research bolic Diseases (DDEMD). This training w rder to advance bioinformatics science ns from individuals with novel individual ary approaches and mentorship among and metabolic diseases. This Funding C dependent clinical trial, but does allow sponsor.	tdoctoral fellow n relevant to the vill require men and encourage al development data or comput opportunity Ann applicants to pr	vs to obtain interdisci e mission of NIDDK's torship in both bioinf its application to thes plans (IDP). The fello er science and medic ouncement (FOA) do opose research expe	plinary training Division of ormatics and e diseases and wship training ine in topics es not allow rience in a
085810	Bioinformatics Interdisciplinary Pl Endocrinology and Metabolic Dise	redoctoral eases (F31	Fellowship in Diabetes,	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 378	08-Apr-2021	Not Specified
	Contact Name	Arthur L.	Castle, Ph.D.				
	Contact Telephone	301-594-	7719				
	Contact Email	castlea@	<u>niddk.nih.gov</u>				
	Sponsor Website						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program URL	Link to pr	ogram URL		2021 07 107 2022 09 4	an 2022 07 May 2	022 00 4				
	Deadline Dates (ALL)	2022 , 07	J8-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug- 2022 , 07-Sep-2022								
	Synopsis	This fund dissertation mission of mentorsh encourag developm data or co Opportun applicants	ling opportunity is to ena on phase of their training f NIDDK's Division of Dial nip in both bioinformatics e its application to these nent plans (IDP). The fell omputer science and med nity Announcement (FOA s to propose research ex	able promising predoctoral fellow g from outstanding faculty sponse betes, Endocrinology and Metabo s and metabolic disease discipline diseases and disorders, NIDDK ir owship training plan should focus dicine in topics related to diabete) does not allow applicants to pro perience in a clinical trial led by a	vs to obtain interdisciplinations in bioinformatics and obic Diseases (DDEMD). Tes. In order to advance binvites applications from interdisciplinary apples, endocrinology and metopose to lead an independent sponsor or co-sponsor.	ary training during t scientific research r his training will req oinformatics scienc ndividuals with nove roaches and mento tabolic diseases. Th dent clinical trial, bu	he elevant to the uire e and el individual rship among is Funding ut does allow				
101621	Pilot Studies of Biological, Behavio Contributing to HIV Pathogenesis (R21 Clinical Trial Not Allowed)	oral and So Within the	ocial Mechanisms e Mission of the NIDDK	National Institute of Diabetes a Digestive and Kidney Diseases/NIH/DHHS	nd PAR-21- 07 062	-May-2021	275,000 USD				
	Contact Name	Peter J. P	errin, Ph.D.								
	Contact Telephone	301-451-3	3759								
	Contact Email	Peter.Per	rin@nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	07-May-2 2024	2021 , 07-Sep-2021 , 07-Ja	an-2022 , 07-May-2022 , 07-Sep-3	2022 , 07-Jan-2023 , 07-N	1ay-2023 , 07-Sep-2	023 , 07-Jan-				
	Synopsis	This Fund projects v recently c Guideline priorities. coinfectic interrogat strategies	ing Opportunity Announ within the mission of the outlined by the NIH Office is for Determining HIV/AI . These include elucidatic ons, and complications (C tions into biological mech s for long-term viral supp	cement (FOA) invites application NIDDK that are aligned with NIH e of AIDS Research (OAR) in NOT- DS Funding, scientific priorities. I on of unique pathophysiological n CCCs) affecting organs, tissues, an hanisms underlying HIV reservoir ression or eradication. Finally, he	s for innovative basic and HIV/AIDS research priorit 20-018, UPDATE: NIH HIV Potential topics could add nechanisms contributing d processes within the m s in NIDDK-relevant tissue ealth-impeding social dete	translational pilot ties. These priorities //AIDS Research Pri dress multiple overa to HIV comorbiditie ission of the NIDDK es are important for erminants of health	research were most orities and rching s, . Likewise, r developing may affect				

SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
		CCCs or v	iral reservoirs within NID	DK's m	ission through multiple pathways.			
101528	Priority HIV/AIDS Research within Clinical Trial Optional)	the Missio	on of the NIDDK (R01	Natio Digest Disea	nal Institute of Diabetes and tive and Kidney ses/NIH/DHHS	PAS-21- 031 0	7-May-2021	Not Specified
	Contact Name	Peter J. P	errin, Ph.D.					
	Contact Telephone	301-451-3	3759					
	Contact Email	Peter.Per	rin@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2024	021 , 07-Sep-2021 , 07-J	an-2022	2 , 07-May-2022 , 07-Sep-2022 , 07-	Jan-2023 , 07-	May-2023 , 07-Sep-2	.023 , 07-Jan-
	Synopsis	This Fund Institute o the NIH C HIV/AIDS	ing Opportunity Announ of Diabetes and Digestive office of AIDS Research (C Research Priorities and C	cement e and Ki DAR). Th Guidelir	t (FOA) seeks to stimulate HIV/AIDS idney Diseases (NIDDK) that align w hese priorities were most recently d hes for Determining HIV/AIDS Fundi	research with ith the HIV/AI lescribed in No ing.	in the mission of the DS research priorities DT-OD-20-018 UPDA	National outlined by TE: NIH

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
087569	Limited Competition: NIDDK Prog Optional)	ram Projects (P01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20- 075	07-May-2021	6,250,000 USD
	Contact Name	Bonnie Burgess-Beusse, Ph.D.				
	Contact Telephone	301-594-4726				
	Contact Email	Bonnie.Burgess-Beusse@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2 2022 , 25-Sep-2022 , 05-Oct-2022 , 07	021 , 25-Sep-2021 , 07-Jan-2022 , 25 Jan-2023	-Jan-2022 ,	07-May-2022 , 25-May-20	22 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Fund (P01) rend including and hema descriptic	ing Opportunity Announcemer ewal (Type 2) applications. The diabetes, selected endocrine a atologic diseases, as well as new on of NIDDK scientific program	nt (FOA) invites submission of invest proposed programs should addres nd metabolic diseases, obesity, digo v approaches to prevent, treat and areas can be found at https://www	tigator-initiated R s scientific areas r estive diseases an cure these diseas niddk.nih.gov/ab	esearch Program F elevant to the NID d nutrition, and ki es, including clinic out-niddk/researc	Project Grant DK mission dney, urologic al research. A h-areas.
080703	Small Grants for New Investigator Related Research (R21 Clinical Tri	<u>s to Prom</u> al Optiona	ote Diversity in Health-	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 222 07-N	1ay-2021	375,000 USD
	Contact Name	Lawrence	Agodoa, M.D.				
	Contact Telephone	301-594-1	1932				
	Contact Email	<u>SmallGrar</u>	nt4Diversity@niddk.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-202	21			
	Synopsis	The purped diverse based small reset (NIDDK) a have/have awards). and seeks supports of contained	ose of this Funding Opportunity ackgrounds, including from gro earch projects in the scientific r nd the National Human Genon e had less than \$125,000 direct This R21 will support small resu to facilitate the transition to re different types of projects inclu	Announcement (FOA) is to provide ups nationally underrepresented in nission areas of the National Institu- ne Research Institute (NHGRI) and (cost of combined research funding earch projects that can be carried o esearch independence of diverse N ading pilot and feasibility studies; se nt of research methodology; and d	e support for New biomedical and b ite of Diabetes an 2) who at the tim g (excluding NIH t out in a short perio ew Investigators. econdary analysis evelopment of ne	P Investigators: (1) behavioral research d Digestive and Kid e of award under t raining and NIH ca od of time with lim The R21 grant me of existing data; sr w research techno	from to conduct dney Diseases this FOA will reer ited resources chanism nall, self- plogy.
076246	Diet and Physical Activity Assessm Not Allowed)	nent Metho	odology (R21 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 857 07-N	1ay-2021	275,000 USD
	Contact Name	Mary Eva	ns, Ph.D.				
	Contact Telephone	301-594-4	1578				
	Contact Email	<u>evansmar</u>	y@niddk.nih.gov				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	.021 , 16-Jun-2021 , 07-Sep-202	1				
	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may incl development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA use the NIH R21 Exploratory/Developmental Research Grant award mechanism.							
091518	Small R01s for Clinical Trials Targe NIDDK (R01 Clinical Trial Required	eting Disea I <u>)</u>	ises within the Mission of	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20- 160 07-N	1ay-2021	600,000 USD	
	Contact Name	Susan Me	endley, M.D.					
	Contact Telephone	301- 827-	1861					
	Contact Email	<u>susan.me</u>	ndley@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 05·	021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-2022 , 05- b-2023 , 07-May-2023	Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-	
	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trialsto improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.							

100633Limited Competition: Lasker Clinical Research Scholars Transition AwardNational Institute of Diabetes andPAR-20-31-May-20212,495,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(R00 Clinical Trial Optional)			Digestive and Kidney Diseases/NIH/DHHS	315		USD
	Contact Name	Charles R	. Dearolf, Ph.D.				
	Contact Telephone	301-402-2	1225				
	Contact Email	dearolfc@	od.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	31-May-2	.021 , 30-Sep-2021 , 31-Jan-202	22 , 31-May-2022 , 30-Sep-2022 , 31	-Jan-2023 , 31-Ma	y-2023 , 30-Sep-2	023
	Synopsis	The Laske clinical re of the pro extramura	er Clinical Research Scholars Presearchers. This FOA offers the ogram. In the R00 phase, succeral research facility.	ogram supports research activities o opportunity for current Lasker awa essful Si2 scholars will receive up to	during the early sta rdees (Si2) to app 5 years of NIH sup	age careers of inde ly for the transitio port for their rese	ependent n phase (R00) earch at an
076238	Diet and Physical Activity Assessm Not Allowed)	<u>nent Meth</u>	odology (R01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-856 07-M	lay-2021	Not Specified
	Contact Name	Mary Eva	ns, Ph.D.				
	Contact Telephone	301-594-4	4578				
	Contact Email	<u>evansmar</u>	<u>y@niddk.nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-May-2	.021 , 05-Jun-2021 , 07-Sep-202	21			
Synopsis Syn				ts participating Institutes and Cente f dietary intake and physical activity oaches; better methods to evaluate ps, including children and older adu /modeling to improve assessment a idimensionality of diet and physical ysical activity along with the enviror rd mechanism.	rs invite application Applications sub instruments; asse Its; improved tech nd/or to correct for activity behavior to mental context of	ons for innovative f mitted to this FOA essment tools for o nology or applicat or measurement e hrough pattern ar f such behaviors. T	research to A may include culturally frons of rrors or nalysis; or Fhis FOA will

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101372	NIDDK High Risk Multi-Center Clin (U01 Clinical Trial Required)	nical Study Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 0 102 0	7-May-2021	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4748				
	Contact Email	rankint@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-	.021 , 05-Oct-2021 , 07-Jan-2022 , 05- Feb-2023 , 07-May-2023 , 05-Jun-202	Feb-2022 , 07- 23 , 07-Sep-202	May-2022 , 05-Jun-20 23 , 05-Oct-2023 , 07-	022 , 07-Sep- Jan-2024
	Synopsis	center. Proposed trials should be hyper focus on a disease relevant to the miss permitted under this FOA. Applicants cooperative agreement (U34; see PAR to the submission of either a U34 or U	othesis-driven, have the potential to c sion of NIDDK. Planning activities mus who require a planning phase may fir -21-101).Consultation with NIDDK Sci 101 application.	change clinical the complete st apply for an entific/Resear	practice and/or publi d prior to submission implementation plar ch staff is strongly en	c health, and and are not ning couraged prior
101373	NIDDK High Risk Multi-Center Clin (U01 Clinical Trial Not Allowed)	nical Study Cooperative Agreement	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21- 0 103 0	7-May-2021	Not Specified
	Contact Name	Tracy Rankin, Ph.D., M.P.H.				
	Contact Telephone	301-594-4748				
	Contact Email	rankint@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-	021 , 05-Oct-2021 , 07-Jan-2022 , 05- Feb-2023 , 07-May-2023 , 05-Jun-202	Feb-2022 , 07- 23 , 07-Sep-202	May-2022 , 05-Jun-20 23 , 05-Oct-2023 , 07-	022 , 07-Sep- Jan-2024
	Synopsis	This FOA invites applications for invest clinical center. Proposed studies shoul Planning activities must be completed	tigator-initiated, high-risk multi-cente Id be hypothesis-driven and focus on prior to submission and are not perm	er observationa a disease relev nitted under th	al studies involving m vant to the mission of his FOA. Applicants w	ore than one NIDDK. ho require a

SPIN ID	Program Title	Sr	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	pla wit	nning pha h NIDDK	ase may first apply for an imp Scientific/Research staff is st	plementation planning cooperative rongly encouraged prior to the sub	agreement (U34; mission of either	see PAR-21-101). a U34 or U01 appl	Consultation ication.
078518 <u>(</u>	Medical Simulators for Practicing Pat Dutcomes Assessment and Technolog Not Allowed)	<u>ent Care</u> gy Develo	Providers Skill Acquisition, N opment (R01 Clinical Trial D D	lational Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-19-065 07-N	lay-2021	Not Specified
	Contact Name Jos Contact Telephone 30 Contact Email <u>ser</u> Sponsor Website	e Serranc L-594-887 <u>ranoj@m</u>	o, M.D., Ph.D. 71 <u>nail.nih.gov</u>				
	Program URL <u>Lin</u> Deadline Dates (ALL) 07-	<u>k to prog</u> May-202	r <u>am URL</u> 21 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022			
The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient cap providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of researce Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenar experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify sti to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop "virtual coaches" by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to experienced practitioners in retaining, retraining and improving performance levels in the context of the user environic (and physiological cystem as appropriate)							opment of itient care research: 1) intenance by skills ntify strategies virtual ance to coach environment
090534	Catalytic Tool and Technology Develo Hematologic Diseases (R21 Clinical Tr	<u>pment in</u> ial Not Al	n <u>Kidney, Urologic, and</u> D <u>Ilowed)</u> D	lational Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20- 140 07-N	1ay-2021	275,000 USD
	Contact Name Da Contact Telephone 30 Contact Email <u>da</u> Sponsor Website Program URL <u>Lin</u>	niel Gosse 1-594-772 niel.gosse k to prog	ett, Ph.D. 23 <u>ett@nih.gov</u> g <u>ram URL</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL) 2 Synopsis	7-May-2021 , 16-Jun-2021 , 07-Sep-20 022 , 16-Oct-2022 , 07-Jan-2023 , 16-F he purpose of this Funding Opportunit	21 , 16-Oct-2021 , 07-Jan-2022 , 16- eb-2023 , 07-May-2023 y Announcement is to promote dev	Feb-2022 , 07-Mar elopment of innov	y-2022 , 16-Jun-20 vative, enabling to	22 , 07-Sep- ols and		
073411	Secondary Analyses in Obesity, Diab Diseases (R21 Clinical Trial Not Allow	echnologies in the areas of kidney, uro petes and Digestive and Kidney wed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-741 07-W	1ay-2021	275,000 USD		
	Contact Name A Contact Telephone 3 Contact Email <u>a</u>	ynur Unalp-Arida, MD, MSc, PhD 01-594-8879 ynur.unalp-arida@nih.gov						
	Program URL <u>Li</u> Deadline Dates (ALL) 0	<u>ink to program URL</u> 7-May-2021						
	Synopsis Synopsis Autor parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focu on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypothese through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentati data. This program will use the NIH Exploratory/Developmental (P21) grant mechanism							
085472	Limited Competition: Small Grant Pr Recipients (R03 Clinical Trial Option	rogram for NIDDK K01/K08/K23/K25 al)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19- 365 07-N	1ay-2021	150,000 USD		
	Contact Name Li Contact Telephone 3 Contact Email <u>S</u> Sponsor Website Program URL Li	isa M. Spain, Ph.D. 01-451-9871 painL@niddk.nih.gov ink to program URL						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2022	021 , 16-Jun-2021 , 07-Sep-20	21 , 16-Oct-2021 , 07-Jan-2022 , 16-	Feb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-
K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point du years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability K23, and K25 award recipients to conduct research as they complete their transition to fully independent. Synopsis The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secon existing data; small, self-contained research projects; development of research methodology; and develop research technology. The R03 is, therefore, intended to support research projects that can be carried out time with limited resources and that may provide preliminary data to support a subsequent R01, or equivare This program will use the NIH Small Research Grant (R03) award mechanism.							
076166	Time-Sensitive Obesity Policy and Not Allowed)	Program I	Evaluation (R01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18- 854 09-A	pr-2021	Not Specified
	Contact Name	Mary Eva	ns, Ph.D.				
	Contact Telephone	301-594-4	4578				
	Contact Email	<u>evansmar</u>	<u>y@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	09-Apr-20	021 , 10-May-2021 , 11-Jun-20	21,09-Jul-2021,10-Aug-2021,10-	Sep-2021		
	Synopsis	National I evaluate a sedentary research o funding. A program o initiated v submissio due date. timeline.	Institutes of Health (NIH) and i a new policy or program that i y behavior) and/or weight out where opportunities for empire All applications submitted to the offers an uncommon and scien with minimum delay. For these on. It is intended that eligible a However, administrative requ This FOA will utilize the NIH R	its participating Institutes and Centers s likely to influence obesity related comes in an effort to prevent or red rical study are, by their very nature, his FOA must demonstrate that the ntifically compelling research opport e reasons, applications submitted to applications selected for funding will uirements and other unforeseen circ D1 Research Project Grant award me	ers invite application behaviors (e.g., di uce obesity. This I only available thre evaluation of an o tunity that will on this time-sensitive be awarded with cumstances may de echanism.	ons for time-sensit etary intake, physi FOA is intended to ough expedited re besity related poli ly be available if th e FOA are not elig in 4 months of the elay issuance date	ive research to cal activity, or support view and cy and /or ne research is ible for re- application es beyond that

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
073342	<u>New Directions in Hematology Re</u> <u>Optional)</u>	search (SF	IINE-II) (R01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18- 730 07-	-May-2021	600,000 USD
	Contact Name	Terry Rog	ers Bishop, Ph.D.				
	Contact Telephone	301-594-	7726				
	Contact Email	terry.bish	op@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.021				
	Synopsis	research. Institute nonmalig invited. E validating submitted grant app	The National Institute of Diak (NHLBI), and the National Insti nant hematology. Innovative each project will propose proof novel concepts and approach d under this FOA should be mo dications. This FOA will use the	betes and Digestive and Kidney Disea tute on Aging (NIA) have joined toge research project applications that w f of principle research that is tightly hes that promise to open up new pat ore limited in scope (a single central e NIH Research Project (R01) award n	ases (NIDDK), the other to build an ill steer the field focused into on hways for disco aim) and duration mechanism.	e National Heart, Lu d promote research l in new directions a e specific aim and is very. Research app on (1-3 years) than	ing, and Blood n activities in are directed at lications typical R01
080739	Transition to Independent Enviror Career Award (K01 Independent E Humans Required)	<u>nmental H</u> Basic Expe	ealth Research (TIEHR) rimental Studies with	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19- 225 07-	May-2021	375,000 USD
	Contact Name	Carol Shr	effler, PhD				
	Contact Telephone	984-287-3	3322				
	Contact Email	shreffl1@	niehs.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	.021 , 12-Jun-2021 , 07-Sep-20	21 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The Trans for newly the caree	sition to Independent Environr independent faculty who inte r development period the can	nental Health (TIEHR) Career Award nd to pursue research careers in en didates are expected to demonstrat	is a 3-year brid vironmental hea e they can succe	ge scholar developn Ith sciences. At the essfully compete for	nent program conclusion of r research

SPIN ID	N ID Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		funding ir experime participar Types of s (i.e., expe purpose c products companic	n the environmental health sci ntal studies involving humans, nts." These studies fall within t studies that should submit und rimentally manipulate indepe of understanding the fundame in mind. Studies conducted wi on 'Independent Clinical Trial R	ences. Note: This Parent Funding Op referred to inNOT-OD-18-212 as "p he NIH definition of a clinical trial ar ler this FOA include studies that pro- ndent variables) and that assess bio ntal aspects of phenomena without th specific applications toward proce equired' PAR 18-261.	portunity Annour rospective basic so nd also meet the d spectively assign h medical or behavio specific applicatio esses or products	icement is for basi cience studies invo lefinition of basic r numan participants oral outcomes in h on towards process in mind should sul	c science olving human research. s to conditions numans for the ses or omit under the
084593	RFA-ES-19-011 Mechanism for T in Environmental Health Sciences	<u>Fime-Sensi</u> (R21 Clinio	tive Research Opportunities cal Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES- 19-011 01-A	pr-2021	275,000 USD
	Contact Name	Martha I.	Barnes, MS				
	Contact Telephone	919-541-3	3335				
	Contact Email	barnes@r	niehs.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-Apr-20 2021,03 Sep-2022)21 , 03-May-2021 , 01-Jun-20 ·Jan-2022 , 01-Feb-2022 , 01-N , 03-Oct-2022	21 , 01-Jul-2021 , 02-Aug-2021 , 01-5 /ar-2022 , 01-Apr-2022 , 02-May-20	Sep-2021 , 01-Oct- 22 , 01-Jun-2022 ,	2021 , 01-Nov-202 01-Jul-2022 , 01-A	21 , 01-Dec- Nug-2022 , 01-
	Synopsis	This fundi unpredict environm made disa feature of review/av achieved entire cyc	ing opportunity announcement able event or policy change pre- ental exposure data. The prime asters, emerging environment f an appropriate study is the n vard cycle, for the research qu by more frequent application the, from submission to award,	t (FOA) is intended to support novel ovides a limited window of opportu ary motivation of the FOA is to under al public health threats, and policy c eed for rapid review and funding, su sestion to be addressed and swiftly i due dates and expediting peer revie is expected to be within 3-4 months	environmental he nity to collect hun erstand the consec hanges in the U.S. bstantially shorte mplemented. The w, council concurr S.	ealth research in w nan biological sam quences of natural and abroad. A dis r than the typical I shortened timefra rence and award is	which an ples or and human- tinguishing NIH grant ame will be ssuance. The
100252	Notice of Special Interest (NOSI): Impact of Environmental Exposur (COVID-19)	NIEHS Sup es on Coro	port for Understanding the navirus Disease 2019	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES- 20-020 01-A	pr-2021	Not Specified

Contact Name Anika Dzierlenga, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	984-287-3	3125					
	Contact Email	anika.dzie	erlenga@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	01-Apr-20)21 , 03-May-2021					
NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to unders the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acut Synopsis respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervent strategies.								
100259	Notice of Special Interest (NOSI): Impact of Environmental Exposur (COVID-19)	NIEHS Sup es on Coro	port for Understanding the mavirus Disease 2019	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES- 20-015 01-A	pr-2021	Not Specified	
	Contact Name	Anika Dzie	erlenga, Ph.D.					
	Contact Telephone	984-287-3	3125					
	Contact Email	anika.dzie	erlenga@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	01-Apr-20	021 , 03-May-2021					
NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to und the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe a Synopsis respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide ins the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and interv strategies.							o understand vere acute de insight into intervention	
089481	Limited Competition: Centers of E (COBRE) Phase 3 - Transitional Ce	Biomedical nters (P30	Research ExcellenceNClinical Trial Optional)N	National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 115 28-N	1ay-2021	3,750,000 USD	
	Contact Name Contact Telephone	Hongwei	Gao, M.D., Ph.D.					

SPIN ID	Program Title	9	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	hongwei g	ao@nih goy				
	Sponsor Website	nongwei.go					
	Program B	Link to pro	gram LIRI				
		28-May-20	121 27-May-2022				
	Synopsis	The purpos activities o	se of this Funding Opportunit f Centers of Biomedical Resea	y Announcement (FOA) is to transi arch Excellence (COBRE) into indep	tion the core resou endence and susta	urces and biomedio ainability.	al research
000500	IDeA Networks of Biomedical Rese	arch Excell	lence (INBRE) (P20 Clinical	National Institute of General	PAR-20-	4 2024	13,750,000
088588	<u>Trial Optional)</u>			Medical Sciences/NIH/DHHS	102	viay-2021	USD
	Contact Name	Krishan K. /	Arora, Ph.D.				
	Contact Telephone						
	Contact Email	arorak@ni	gms.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	gram URL				
	Deadline Dates (ALL)	20-May-20	021 , 20-May-2022				
	Synopsis 	The Nation Networks of Institutiona independe agencies. The primarily u Only one a established lead and pa postdoctor from PUIs, careers wit	nal Institute of General Medic of Biomedical Research Excell al Development Award (IDeA ent biomedical research institu The purpose of the INBRE pro e INBRE program represents a undergraduate institutions (Pu ward will be made per IDeA- d multi-disciplinary research r artner institutions; 2) build ar ral fellows, and graduate stud community colleges, and TCC thin IDeA states; and 4) enha	al Sciences (NIGMS) invites applica ence (INBRE) awards from investig)-eligible states that award doctora utes with ongoing biomedical resea gram is to augment and strengther collaborative effort to sponsor res JIs), community colleges, and Triba eligible state. The primary goals of network to strengthen the biomedi ind increase the research base and o lents at the participating institution CUs, and serve as a "pipeline" for the net science and technology knowled	tions for Institutio ators at biomedica I degrees in health inch programs fund the biomedical re- earch between re- illy Controlled Coll the INBRE program cal research exper capacity by providi rs; 3) provide resea nese students to co dge of the state's	nal Development A al research institution- related sciences of ded by the NIH or of search capacity of search intensive in eges and Universit in are to: 1) build on tise and infrastruct ing support to facu arch opportunities ontinue in biomedi workforce.	ward (IDeA) ons within or at other federal IDeA-eligible stitutions and ies (TCCUs). n the ture of the lty, for students cal research
095405	National Institute of General Medi Research Training Grant (T32 - Clin	cal Science	es Predoctoral Institutional Iot Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 213 25-N	May-2021	Not Specified



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount		
Contact NameDr. Alison GammieContact Telephone301-594-3900Contact Emailalison.gammie@nih.govSponsor WebsiteProgram URLDeadline Dates (ALL)25-May-2021, 25-Sep-2021, 25-Jan-2022, 25-May-2022, 25-Sep-2022, 25-Jan-2023, 25-May-202The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool available to address the Nation's biomedical research agenda. Specifically, this funding opportunity provides support to eligible, domestic institutions to develop and implement effective, evidence-ind biomedical graduate training and mentoring that will keep pace with the rapid evolution of the bior enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, i development elements to prepare trainees for careers that will have a significant impact on the her 							ervice Award ined scientists nent (FOA) roaches to earch nd career research		
078176 1	Medical Scientist Training Program	independent clinical trial but	does allow	them to obtain research experie National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 036	-May-2021	n co-mentor. Not Specified		
	Contact Name	Joseph Gindhart, Ph.D.							
	Contact Telephone	301-594-0943							
	Contact Email	gindhartjg@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-May-2021							
	Deadline Dates (ALL) 25-May-2021 The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scient leaders available to meet the Nation's biomedical research needs. Specifically, this funding opportunity announcement provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., M.D., D.O., D.V.M., D.D.S., and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research adva								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		to the un research. fostering workforce career de research them to c	derstanding, detection, treatm Areas of particular importanc the persistence of MSTP alum e. NIGMS expects that the pro velopment elements to prepa needs of the Nation. This FOA obtain research experience in	nent and prevention of human dise e to NIGMS are the iterative optim ni in research careers, and enhanc posed research training programs re trainees for careers that will hav does not allow appointed trainees a clinical trial led by a mentor or co	ease, and to lead ization of MSTP ing the diversity will incorporate ve a significant ir to lead an indep -mentor.	the advancement of training efficacy and of the physician-scie didactic, research, m npact on the health- pendent clinical trial	biomedical efficiency, ntist entoring and related out does allow
088685	Biomedical Technology Developm Clinical Trial Not Allowed)	ent and D	issemination Center (RM1 -	National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 20 104	5-May-2021	4,250,000 USD
	Contact Name	Haluk Res	sat, Ph.D.				
	Contact Telephone						
	Contact Email	haluk.res	at@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	26-May-2	021 , 26-Jan-2022 , 26-May-2	022 , 26-Jan-2023			
This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Techn Development and Dissemination (BTDD) Centers. The BTDD program supports the development of technolo feasibility has been established and the dissemination of these technologies to the wider biomedical research The program encourages investigators to propose projects that address any of the biomedical research area Synopsis the mission of NIGMS. The Centers are required to make their technologies available to the research commi sustainable manner, to provide user training, and to disseminate the Center's technologies and results. Cen the leading edge of their field with respect to both technology development and engagement of the relevar community. Potential applicants are strongly encouraged to contact NIGMS staff at least 10 weeks priorto t date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center.							ogy community. vithin ty in a s should be at esearch application due
088591	Collaborative Program Grant for N Trial Optional)	<u>Aultidiscip</u>	linary Teams (RM1 - Clinical	National Institute of General Medical Sciences/NIH/DHHS	PAR-20- 103 2 ⁻	7-May-2021	7,500,000 USD
	Contact Name	Peter Pre	usch, Ph.D.				
	Contact Telephone	301-594-8	3494				
	Contact Email	RM1maill	oox@nigms.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-May-2021 , 27-Jan-2022 , 27-May-20	22 , 27-Jan-2023			
	Synopsis	This funding opportunity announcement to address ambitious and challenging re- scope of one or two investigators. Collal synergy and managed team interactions projects. Teams are encouraged to cons Applications that are mainly focused on new technologies, or infrastructure deve	t (FOA) is designed to support high search questions that are importan porative program teams are expect a. Project goals should not be achie ider far-reaching objectives that w the creation, expansion, and/or m elopment are not appropriate for t	ly integrated reseant for the mission of ted to accomplish vable with a collect ill produce major a aintenance of com his FOA.	arch teams of three of NIGMS and are I goals that require ction of individual e advances in their fi nmunity resources,	e to six PDs/PIs beyond the considerable efforts or elds. creation of
085464	Maximizing Investigators' Researc	ch Award (R35 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-19- 367 17-N	May-2021	3,750,000 USD
	Contact Name	Zhongzhen Nie, Ph.D.				
	Contact Telephone					
	Contact Email	MIRA2019RESEARCH@NIGMS.NIH.GOV				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-May-2021 , 18-Jan-2022 , 17-May-20	22			
	Synopsis	The Maximizing Investigators' Research laboratory that is within the mission of I It is anticipated that this program will: Ir enhance their ability to take on ambition investigators to follow important new re bound to specific aims proposed in adva and promising investigators to increase the time spent by researchers writing ar research; Enable investigators to devote This FOA allows both new applications f established and early-stage MIRA grante	Award (MIRA) provides support fo NIGMS. The goal of MIRA is to incre- ncrease the stability of funding for us scientific projects and approach esearch directions within the NIGM once of the studies; More widely di overall scientific productivity and t and reviewing grant applications, all e more time and energy to mentori rom eligible NIGMS-funded investi- tes.	r the program of re ease the efficiency NIGMS-supported problems more cr IS mission as oppo stribute funding an the chances for impowing them to spe ng trainees in a mo gators and renewa	esearch in an invest and efficacy of Nic investigators, whi reatively; Increase rtunities arise, rath mong the nation's portant breakthrou end more time con ore stable research al applications from	stigator's GMS funding. ch could flexibility for ner than being highly talented ughs; Reduce ducting n environment. n current
072936	Academic Research Enhancement	t Award for Undergraduate-Focused	National Institute of General	PAR-18- 07-N	May-2021	300,000

072936 Academic Research Enhancement Award for Undergraduate-Focused National Institute of General PAR-18-07-May-2021

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Institutions (R15 - Clinical Trial Nc	t Allowed)	2	Medical Sciences/NIH/DHHS	714		USD
	Contact Name	Alexandra	a M. Ainsztein, PhD.				
	Contact Telephone	301-594-0	0943				
	Contact Email	<u>Alexandra</u>	a. Ainsztein@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National (AREA) fo institutior experienc Eligible in support (1 (AREA) m	Institute of General Medical S r Undergraduate-Focused Inst ns that do not receive substant ces primarily for undergraduate stitutions must award baccala total costs) in 4 of the last 7 fis echanism.	cciences (NIGMS) invites application itutions. The purpose of the award tial funding from the NIH, with an e e students, and enhancing the rese ureate science degrees, and have r cal years. This FOA will use the NIH	ns for the Academi is to support small emphasis on provid arch environment eceived less than 6 R15 Academic Res	c Research Enhand scale research gra ing biomedical res at these applicant million dollars pe search Enhanceme	cement Award ants at search institutions. r year of NIH ent Award
102287	<u>Undergraduate Research Training</u> <u>RISE) (T34)</u>	Initiative	for Student Enhancement (U-	National Institute of General Medical Sciences/NIH/DHHS	PAR-21- 26-№ 146	1ay-2021	Not Specified
	Contact Name	Edgardo F	alcón-Morales, Ph.D.				
	Contact Telephone						
	Contact Email	<u>edgardo.f</u>	alcon@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	26-May-2	.021 , 26-May-2022 , 26-May-2	.023			
The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse properties of the Undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		applicatio of NIH Re Announce research e	ns from training programs at b search Project Grant funding le ement (FOA) does not allow app experience in a clinical trial led	accalaureate degree-granting resea ss than \$7.5 million total costs ove pointed trainees to lead an indeper by a mentor or co-mentor.	arch-active instit r the last 3 fiscal ndent clinical tria	utions (i.e., those wit years). This Funding Il but does allow ther	h an average Opportunity n to obtain
076702	RFA-MH-19-135 BRAIN Initiativ Probe Cell-Specific and Circuit-Sp Human Primate Brain (UG3/UH3	e: Develop ecific Proce Clinical Tria	ment of Novel Tools to esses in Human and Non- al Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH- 27- 19-135 [Op	Apr-2021 otional][LOI/Pre-App]	Not Specified
	Contact Name	Michelle I	Freund, Ph.D				
	Contact Telephone	301-443-1	1815				
	Contact Email	BRAIN-inf	o-NIMH@mail.nih.gov				
	Sponsor Website						
	Program URL Deadline Dates (ALL)	27 Apr 20	<u>ogram URL</u> 121 [Ontional][LOL/Bro App] 27	' May 2021			
	Synopsis	National I validate n the treatr in safe, m research o need to sp influx of e majority o cutting-eo more imp tools for u initiative v other man Explorato	nstitutes of Health (NIH) and it ovel tools to facilitate the deta nent of brain disorders in huma inimally-invasive ways. Clinical designed to remove barriers to becifically target dysfunctional exciting new research tools in the of these cutting-edge tools have dge tools, such as viral delivery ortantly are emerging as poten use in large brains or those that will support initial proof of prin mmalian species (non-human p ry/Developmental Phased Awa	s participating Institutes and Cente iled analysis and manipulation of co an populations are hindered by our intervention with novel cell and cir delivery of gene therapies. In addit circuitry poses additional challenge he past decade, especially since the been developed for use in model of genetic constructs, are increasin tial human therapeutic strategies f are more directly relevant to the h ciple studies aimed at demonstrati rimate [NHP]/sheep/pigs). This FO/ rd Cooperative Agreement award r	rs invite applicat omplex circuits i lack of ability to cuit specific too cion to identifica s. Neuroscience launch of the Bl organisms, prim gly adaptable to or brain disorde numan brain is th ng the feasibility A will use the NII mechanism.	tions for that will dev n large brains. Critica monitor and manipu s will require extensi tion and removal of k has experienced an i RAIN Initiative. Howe arily rodents, fish and larger mammalian b rs. A pressing need to be focus of this initiat of this approach in h H UG3/UH3	elop and I advances in Ilate circuitry ve focused parriers, the mpressive ver, the d flies. These rains and o develop ive. The humans and
081342	RFA-MH-20-135 - BRAIN Initiative	: Tools to I linical Tria	Facilitate High-Throughput	National Institute of Mental Health/NIH/DHHS	RFA-MH- 27- 20-135 [Or	Apr-2021 htional][[OI/Pre-App]	Not Specified
			· · · · · · · · · · · · · · · · · · ·	,,	[0]		- 1

Contact Name Fred Friedman, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-443-	4058					
	Contact Email	ffriedma	<u>@mail.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	27-Apr-20	021 [Optional][LOI/Pre-App], 27	-May-2021				
applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathot tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscop and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-print demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches and analysis strategies of neuronal structures in EM images.								
099787	Advanced Laboratories for Accele Treatments for Youth and Adults Research Centers (P50 Clinical Tri	erating the with Ment al Optiona	Reach and Impact of N tal Illness (ALACRITY) H	lational Institute of Mental lealth/NIH/DHHS	PAR-20- 293 17-N	lay-2021	7,500,000 USD	
	Contact Name	Joel Sher	rill. Ph.D.					
	Contact Telephone	301-443-	2477					
	Contact Email	jsherril@	mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	17-May-2	2021 , 17-May-2022 , 17-May-20	23				
This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinica and mental health services researchers, behavioral scientists, social scientists, health information and communications Synopsis technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating								

	Inte	sponsor runne		sponsor Number		Deadline Date	Amount
		the Reach and Impact of Tre rapid development, testing, therapeutic or preventive in delivering optimized menta impact, and durability of op program is intended to supp ecosystem, including new d science, and new federal an transdisciplinary projects th Centers program is also exp accelerate clinical research early-career investigators to submitting applications to s treatment of suicide risk, sp (P50)").	eatments for and refinem aterventions I health servitimized inter cort research iscoveries in d state mech at could not ected to faci and practice participate upport trans ecifically, are	Youth and Adults with Mental Illn ent of novel and integrative appro- for mental disorders within well-d ces within real world treatment se ventions and service delivery with that maximizes synergies across clinical research, transformative h anisms for organizing mental hea be achieved using standard resear litate widespread sharing of releva and to provide opportunities for g in transdisciplinary, T2 translation disciplinary programs of research e directed to PAR-20-286 ("Practic	ess (ALACRITY) F baches for (1) op efined target po ettings; and (3) c in diverse care s various compone ealth care techn Ith care. The Cer rch project grant ant data, methoc graduate student al mental health focused on ident re-Based Suicide	Research Centers will so otimizing the effective pulations; (2) organizi continuously improving systems. The ALACRITY ents of the mental hea hologies, advances in in nters are intended for t mechanisms. The AL/ ds, and resources that ts, postdoctoral resear research. Applicants tification, prevention, Prevention Research	support the ness of ng and g the quality, Y Centers alth research nformation ACRITY will rchers, and interested in and Centers
092121	RFA-MH-20-525 NIMH Biobeha New Scientists (NIMH BRAINS) (R	vioral Research Awards for Ir 01 Clinical Trial Optional)	novative	National Institute of Mental Health/NIH/DHHS	RFA-MH- 21 20-525 [C	1-May-2021 Optional][LOI/Pre-App]	2,500,000] USD
	Contact Name	Eric R. Murphy, Ph.D.					
	Contact Telephone	301-443-9230 ?					
	Contact Email	eric.murphy@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	21-May-2021 [Optional][LO	I/Pre-App], 2	0-Jun-2021 , 21-May-2022 [Option	nal][LOI/Pre-App	o], 20-Jun-2022	
	Synopsis	The NIMH Biobehavioral Re and research career advanc their careers and who plan award seeks to assist these that holds the potential to p The NIMH BRAINS program	search Awar ement of ou to make a lou individuals ir profoundly tr will focus on	ds for Innovative New Scientists (E istanding, exceptionally productiv ng-term career commitment to res a launching an innovative clinical, f ansform the understanding, diagn the research priorities and gap ar	RAINS) award is e scientists who search in specific translational, bas osis, treatment, eas identified in	are in the early, formation of the early, formation of the sic, or services researce or prevention of men the NIMH Strategic P	the research ative stages of NIMH. This ch program tal disorders. lan.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Health Research (P50 Clinical Tria	l Optional)	Health/NIH/DHHS	093		USD
	Contact Name	Susan Koester, Ph.D.				
	Contact Telephone	301-443-3563				
	Contact Email	koesters@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	26-May-2021 , 24-May-2022				
	Synopsis	Translational Mental Health Research. employing integrative, novel, and creat primary objectives of: (a) advancing the the underlying mechanisms that will ult the integration and translation of basic our understanding of the neurobehavio childhood and adolescence. The Conte translational research that demonstrate of the field. This program is intended of mechanisms.	The NIMH seeks teams of research ive experimental approaches to a e state of the science in basic brai timately provide the foundation f and clinical neuroscience research oral developmental mechanisms a Centers program is intended to s es an extraordinary level of syner nly for projects that could not be	hers working at diff address high-risk, hig n and behavior rese or understanding m ch on severe mental and trajectories of p upport interdisciplir gy, integration, and achieved using othe	erent levels of anal gh-impact question arch that will unco ental disorders; (b) illnesses; and/or (d sychopathology that ary basic neuroscie potential for advanter, more standard g	ysis and s with the ver and dissect supporting a dvancing at begin in ence or noting the state grant
088290	NIMH Mentoring Networks for M Clinical Trial Not Allowed)	ental Health Research Education (R25	National Institute of Mental Health/NIH/DHHS	PAR-20- 080 25-	May-2021	1,000,000 USD
	Contact Name	Nick Gaiano, Ph.D.				
	Contact Telephone	301-827-3420				
	Contact Email	nick.gaiano@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022				
	Synopsis	The NIH Research Education Program arching goal of this R25 program is to s workforce to meet the nation's biomed	(R25) supports research educatio upport educational activities that lical, behavioral and clinical resea	n activities in the m complement and/o rch needs. To accon	ission areas of the r enhance the train nplish the stated or	NIH. The over- ning of a ver-arching

SPIN ID	D Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		goal, this mentoring opportun within acc Participar scholars, a and to fos contribute objectives	FOA will support creative educa g networks. Networks may be n ities, and should comprise effor ademic programs, institutions, c nts in proposed mentoring netw and/or early-career faculty. Pro ster their career trajectory towa e to the development of a skille s of the NIMH Strategic Plan.	ational activities with a primary for ational or regional. All proposed n ts substantially beyond any ongoin or pre-existing networks; or educa- orks are limited to graduate/medi posed networks are expected to e ords independent mental health re d cadre of investigators in requisit	cus on: Mentoring networks should p ng mentoring, ne tional collaboratio ical students, meo nhance the partio search. Proposed re scientific resea	g Activities and in p rovide significant n working, or resear ons among instituti lical residents, post ipants' professiona programs are thus rch areas to advanc	articular, ew ch education ons. :doctoral Il development expected to se the
088348	NIMH Short Courses for Mental He Independent Clinical Trial Not Allo	ealth Rela wed)	<u>ted Research (R25 -</u> N H	lational Institute of Mental lealth/NIH/DHHS	PAR-20- 096 25-1	May-2021	1,000,000 USD
	Contact Name	Nick Gaia	no, Ph.D.				
	Contact Telephone	301-827-3	3420				
	Contact Email	nick.gaiar	no@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	25-May-2	021 , 25-May-2022				
	Synopsis	The NIH I arching go workforce goal, this short cou research o early-care	Research Education Program (R bal of this R25 program is to sup to meet the nation's biomedic FOA will support creative educa rses are expected to facilitate the skills to advance the mission of experiences. Participants are lin eer faculty.	25) supports research education a oport educational activities that co al, behavioral and clinical research ational activities with a primary for the development of a sophisticated the NIMH. Each short course is exp nited to graduate/medical student	ctivities in the mi implement and/o n needs. To accon cus on: Courses f l cadre of investig pected to include is, medical reside	ssion areas of the N r enhance the train plish the stated ov for Skills Developme ators with the requ both didactics and hts, postdoctoral sc	IIH. The over- ing of a er-arching ent Proposed isite scientific hands-on cholars, and/or
088301	NIMH Research Education Program Independent Clinical Trial Not Allo	ms for Psy wed)	<u>chiatry Residents (R25-</u> N H	lational Institute of Mental lealth/NIH/DHHS	PAR-20- 094 25-	May-2021	1,000,000 USD
	Contact Name Contact Telephone	Mark Cha 301-443-8	vez, Ph.D. 3942				

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Email	mchavez1@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022	<u>)</u>				
	Synopsis	The NIH Research Education arching goal of this R25 prog disciplinary backgrounds to arching goal, this FOA will su Skills Development Specifica maintain, and expand the sc	Program (R2 gram is to sup research care upport creativ Ily, this FOA ientific abilit	25) supports research education ac oport educational activities that he eers in biomedical, behavioral and we educational activities with a prin will support research-oriented exp ies of psychiatry residents in areas	tivities in the mis precruit individu clinical sciences. mary focus on: Re periences and act relevant to the n	sion areas of the NIH uals with specific spe To accomplish the st esearch Experiences wities designed to de nission of NIMH.	H. The over- ecialty or rated over- Courses for evelop,
092681	RFA-MH-20-500 Post-Acute Inte Anorexia Nervosa (R34 Clinical Tria	rventions for the Treatment al Required)	of N H	lational Institute of Mental lealth/NIH/DHHS	RFA-MH- 15- 20-500 [Op	May-2021 tional][LOI/Pre-App]	450,000 USD
	Contact Name	Mary Rooney, Ph.D., ABPP					
	Contact Telephone	301-827-1325					
	Contact Email	<u>mary.rooney@nih.gov</u>					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI	/Pre-App], 1	5-Jun-2021			
	Synopsis	NIMH seeks applications for enhanced treatment respon beyond seeking incremental and testing interventions tha with AN. Consistent with an development and testing, ac unaffiliated with specialty ea	pilot project se following gains in inte at will have a effectivenes knowledging ating disorde	s to evaluate the preliminary effect acute treatment for anorexia nerv rvention effects, and instead take significant impact on weight restors framework, studies should take a that many patients will receive por r centers.	tiveness of intervosa (AN). An emp a theory-driven, a pration and psych deployment-foc pst-acute treatme	ventions targeting su whasis is placed on tri empirical approach t ological symptoms a used approach to int ent from community	stained and als that go o developing ssociated ervention providers
090889	Innovations in HIV Prevention, Tes Optimize HIV Prevention and Care Trial Optional)	ting, Adherence and Retenti Continuum Outcomes (R21	i <u>on to</u> N <u>Clinical</u> H	lational Institute of Mental lealth/NIH/DHHS	PA-20-145 07-	May-2021	275,000 USD
	Contact Name	Christopher Gordon, Ph.D.					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone 24	10.627.2867						
		vordon 1 @mail nih gov						
	Program LIBI Lir	ak to program LIRI						
	Deadline Dates (ALL) 07	7-May-2021 , 07-Sep-2021 , 07-Jan-2022	2.07-May-2022.07-Sep-2022.07	7-lan-2023				
	This Funding Opportunity Announcement (FOA) seeks innovative research to optimize HIV prevention and care which i aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development a pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Intere (NOSIs) from NIMH DAR for further information about the Division's research priorities. PA-20-144 uses the R01 grant mechanism while this PA-20-145 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or u existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data and/or including longitudinal analysis may apply using the R01 mechanism.							
090786	Formative and Pilot Intervention Res of HIV/AIDS (R34 Clinical Trial Option	search for Prevention and Treatment N nal) H	lational Institute of Mental lealth/NIH/DHHS	PA-20-141 07-M	ay-2021	450,000 USD		
	Contact Name Ch	nristopher Gordon						
	Contact Telephone 24	10 -627-3867						
	Contact Email cg	ordon1@mail.nih.gov						
	Sponsor Website							
	Program URL <u>Lir</u>	nk to program URL						
	Deadline Dates (ALL) 07	7-May-2021 , 07-Sep-2021 , 07-Jan-2022	2 , 07-May-2022 , 07-Sep-2022 , 07	7-Jan-2023				
	This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-tes of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, "intervention" is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structur- approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are infected, or both.							
090888	Innovations in HIV Testing, Adherence Care Continuum Outcomes (R01 Clin	ce, and Retention to Optimize HIV N ical Trial Optional) H	lational Institute of Mental lealth/NIH/DHHS	PA-20-144 07-M	ay-2021	Not Specified		

SPIN ID	Program Title	Sr	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Nama	Christenher	Cardan Dh D				
	Contact Name		Gordon, Ph.D.				
	Contact Telephone	240-027-580	mail nih gay				
	Contact Emain		man.mm.gov				
		Link to prog					
		LINK to prog	<u>ram UKL</u>	2 07 May 2022 07 Car 2022 0	7 100 2022		
	Deadline Dates (ALL)	U7-IVIAy-202	21,07-Sep-2021,07-Jan-202	2,07-101ay-2022,07-Sep-2022,0	/-Jan-2023		
(DAR) priorities. Applications may include formative basic behavioral and social science to better understand a ster in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative interventi approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices o Interests (NOSIs) from NIMH DAR for further information about the Division's research priorities. PA-20-145 uses grant mechanism while this PA-20-144uses the R01 mechanism. High risk/high payoff projects that lack preliminar utilize existing data may be most appropriate for the R21 mechanism, while applications with preliminary data an including longitudinal analysis may be more appropriate for the R01 mechanism.							step or steps ntion of Special es the R21 nary data or and/or
076836	Mental Health Research Dissertat	ion Grant to	Enhance Workforce N	lational Institute of Mental	PAR-18- 07-N	lav-2021	Not
	Diversity (R36 Independent Clinica	<u>al Trial Not A</u>	<u>llowed)</u> H	lealth/NIH/DHHS	894	,	Specified
	Contact Name	Christopher	Sarampote, Ph.D.				
	Contact Telephone	301-443-195	59				
	Contact Email	<u>csarampo@</u>	mail.nih.gov				
	Sponsor Website						
	Program URL	Link to prog	ram URL				
	Deadline Dates (ALL)	07-May-202	21				
	Synopsis	National Ins strategic pri sciences res Dissertation	stitute of Mental Health (NIM iorities of the NIMH to individ search. This award supports the Award award mechanism.	H) invites applications for disserta luals from groups underrepresentene completion of the doctoral rese	tion awards in all r ed in biomedical, b earch project. This	esearch areas with ehavioral, clinical FOA will utilize the	nin the and social 9 NIH R36
068701	NIMH Exploratory/Developmenta Allowed)	I Research G	rant (R21 Clinical Trial Not F	lational Institute of Mental lealth/NIH/DHHS	PA-18-350 07-N	lay-2021	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Norma					
	Contact Name	Pim Brouwers, Ph.D.				
	Contact Telephone	240-027-3803				
	Sponsor Website	ebrouwer@mail.mil.gov				
	Brogram LIRI	Link to program LIRI				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	National Institute of Mental Health (N the NIMH mission by providing suppor considerable risk but may lead to a bre models, or strategies, or to the genera major impact on biomedical, behavior program will use the NIH Exploratory/	IIMH) invites applications for exploit t for the early and conceptual stag eakthrough or to the development tion of pilot or feasibility data. The al, or clinical mental health researc Developmental (R21) grant mechar	ratory and high-risk es of these projects. of novel techniques preliminary work fr h, or on the delivery nism.	research projects These studies ma , agents, methods, om these studies c y of mental health	that fall within y involve measures, could lead to a care. This
083168	<u>Clinical Studies of Mental Illness (</u> <u>Optional)</u>	Collaborative R01 Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-19- 297 07-N	/lay-2021	Not Specified
	Contact Name	Anjené Addington				
	Contact Telephone	301-443-6653				
	Contact Email	anjene.addington@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2 2022	021 , 05-Oct-2021 , 07-Jan-2022 , 0	5-Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
	Synopsis	This Funding Opportunity Announcem development, efficacy, or effectivenes studies of mental illnesses (e.g., psych associated with HIV/AIDS. Applicants s Accordingly, the collaborating studies sample size, accelerate recruitment, o it is expected that one site will be subr administration. For a linked set of colla	ent (FOA) seeks to support collabor s trials. Primary areas of focus inclu opathology, neurodevelopmental t hould apply to this FOA when two share a specific protocol across the r increase sample diversity and rep nitted as a coordinating R01 for da aborative R01s, each application ha	rative clinical studies ude mental health ge rajectories of psyche or more sites are ne sites and are organ resentation. In stud ta management anc as its own Program [s, not involving tre enetics, biomarker opathology) also w eded to complete ized as such in ord ies with a large nu l/or other centraliz Director/Principal I	atment studies, and /hen the study. er to increase mber of sites, zed nvestigator

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		(PD/PI). T managem	he collaborative R01 program ient, statistical analysis, and r	provides a mechanism for cross-RC eporting.	11 coordination, qu	ality control, data	base
077196	New Computational Methods for DNA Variants that are Associated Clinical Trial Not Allowed)	Understar with Ment	nding the Functional Role of tal Disorders (R01 (Collab)	National Institute of Mental Health/NIH/DHHS	PA-18-907 07-N	lay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Alexande 301-827-3 <u>alexander</u> Link to pr 07-May-2 National I bioinform of comple initiative functiona brain dise when two Program I quality co	r Arguello, PhD 3547 <u>c.arguello@nih.gov</u> <u>ogram URL</u> 021 , 05-Jun-2021 , 07-Sep-20 nstitute of Mental Health (NII natic and statistical tools to de ex etiologies identified throug is to support the developmen lity of genetic variants associa eases, and to ultimately inform o or more sites are needed to Director/Principal Investigator ntrol, database management	221, 05-Oct-2021, 07-Jan-2022 MH) invites applications for the dev termine the functional relevance of h genome-wide association or sequ t of innovative computational meth ited with mental illness, taking into n novel treatment development bas complete the study. For a linked set and the set of linked applications p statistical analysis, and reporting.	elopment of advan genetic variants as encing studies. The ods that facilitate t account the added ed on human biolo of collaborative Re provide a mechanis This FOA will use th	ced computationa ssociated with me overarching goal che elucidation of complexities and gy. This FOA shou 01s, each site mus m for cross-site co he NIH Research Pi	al, ntal disorders of this the nuances of ld be used it have its own pordination, roject (R01)
077195	New Computational Methods for DNA Variants that are Associated Trial Not Allowed)	Understar with Ment	nding the Functional Role of tal Disorders (R01 Clinical	National Institute of Mental Health/NIH/DHHS	PA-18-908 07-M	1ay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Alexande 301-827-3 alexander Link to pr	r Arguello, PhD 3547 <u>c.arguello@nih.gov</u> ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL) Synopsis	07-May-2 National I bioinform of comple initiative i functiona brain dise Research	021, 05-Jun-2021, 07-Sep-20 nstitute of Mental Health (NIM natic and statistical tools to de ex etiologies identified through is to support the development lity of genetic variants associa eases, and to ultimately inform Project (R01) award mechanis	21, 05-Oct-2021, 07-Jan-2022 AH) invites applications for the devermine the functional relevance of genome-wide association or sequer of innovative computational methed with mental illness, taking into novel treatment development bam.	velopment of advar If genetic variants a vencing studies. The nods that facilitate account the addee sed on human biole	nced computationa ssociated with me e overarching goal the elucidation of d complexities and ogy. This FOA will u	al, ntal disorders of this the nuances of use the NIH	
079331	Drug Discovery For Nervous Syste (llowed)	<u>m Disorde</u>	rs (R21 Clinical Trials Not	National Institute of Mental Health/NIH/DHHS	PAR-19- 146 07-N	1ay-2021	275,000 USD	
	Contact Name	Enrique N	1ichelotti, PhD					
	Contact Telephone	301-443-5	5415					
	Contact Email	<u>michelott</u>	iel@mail.nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-20	21 , 16-Oct-2021 , 07-Jan-2022				
	Synopsis	This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147)						
079325	Drug Discovery For Nervous Syste	m Disorde	rs (R01 Clinical Trials Not	National Institute of Mental Health/NIH/DHHS	PAR-19- 147 07-N	1ay-2021	Not Specified	
	Contact Name	Enrique M	1ichelotti, PhD					
	Contact Telephone	301-443-5	5415					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	<u>michelott</u>	iel@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	s (ALL) 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.						
	Synopsis							
080855	Institutional Translational Researc	ch Training	Program (T32)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19- 228 26-	May-2021	Not Specified	
	Contact Name	Letitia We	eigand, Ph.D.					
	Contact Telephone	301-496-4	188					
	Contact Email	letitia.wei	gand@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	26-May-2	021					
	Synopsis	SynopsisThe purpose of the Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic scientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS and NIA missions, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the						
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
---------	--	--------------------------------------	--	--	---------------------------------------	---------------------------------------	------------------------------	--
		requirem allow app trial led b	ents for translating discoveries ointed Trainees to lead an ind y a mentor or co-mentor.	s into viable therapies. This Fundin ependent clinical trial, but does allo	g Opportunity An ow them to obtain	nouncement (FOA) research experien	does not ce in a clinical	
078105	RFA-NS-19-006 BRAIN Initiative Technology Integration and Disse Allowed)	: Research mination (<u>Resource Grants for</u> U24 Clinical Trial Not	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 28-N 19-006 [Opt	/lay-2021 ional][LOI/Pre-App	Not] Specified	
	Contact Name	Stephanie	e Fertig					
	Contact Telephone	301-469-2	1779					
	Contact Email	BRAIN-FO	As@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	28-May-2	021 [Optional][LOI/Pre-App],	27-Jun-2021				
	 This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that ar described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the follow activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing ac to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resour production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowe Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 rep that are otherwise unavailable or impractical in their current form. 							
072851	RFA-NS-18-019 BRAIN Initiative Technologies for Large Scale Reco System (U01 Clinical Trials Not All	: Optimiza ording and owed)	tion of Transformative Modulation in the Nervous	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 04-N 18-019	/lay-2021	Not Specified	
	Contact Name	Edmund 1	Talley, PhD					
	Contact Telephone	301-496-2	1917					
	Contact Email	BRAIN-FO	As@nih.gov					
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to program URL						
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the optimization existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in a region and throughout the entire depth of the brain. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of- testing, and are appropriate for accelerated development of hardware and software while scaling manufacturing tec towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience practice. Propos technologies should be compatible with experiments in behaving animals, and should include advancements that en reduce major barriers to hypothesis-driven experiments. Technologies may engage diverse types of signaling beyom neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. Applications expected to integrate appropriate domains of expertise, including where appropriate biological, chemical and physic sciences, engineering, computational modeling and statistical analysis. This program will use the NIH U01 Research F Cooperative Agreements award mechanism.								
072848	RFA-NS-18-020 BRAIN Initiative Approaches for Large-Scale Recor System (R01 Clinical Trial Not Allo	:: New Technologies and Novel rding and Modulation in the Nervous owed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 04-N 18-020	1ay-2021	Not Specified		
	Contact Name	Edmund Talley, PhD						
	Contact Telephone	301-496-1917						
		BRAIN-FOAs@nih.gov						
	Sponsor website	Link to program LIDI						
	Program OKL							
Deadline Dates (ALL) 04-May-2021 National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for proof-of-concept testir and development of new technologies and novel approaches for largescale recording and manipulation of neural activity to enable transformative understanding of dynamic signaling in the nervous system. In particular, we seek exceptionally creative approaches to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain.								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		expected research. advancen types of s electrical, encourag biological the NIH R	that the proposed research ma Proposed technologies should nents that enable or reduce ma signaling beyond neuronal elect , magnetic, acoustic or genetic ed. Where appropriate, applic , chemical and physical science 01 Research Project Grant awa	ay be high-risk, but if successful cou be compatible with experiments in ajor barriers to hypothesis-driven e crical activity for large-scale analysi recording/manipulation. Application ations are expected to integrate ap es, engineering, computational mod ard mechanism.	uld profoundly chan behaving animals xperiments. Tech s, and may utilize ons that seek to in ppropriate domain deling and statistic	inge the course of s, and should inclu nologies may enga any modality such tegrate multiple a s of expertise, incl al analysis. This pr	neuroscience de ge diverse as optical, pproaches are uding ogram will use
083919	Discovery of Biomarkers and Bion Neuromuscular Disorders (R61/R	narker Sigr 33 Clinical	natures for Neurological and Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19- 315 07-N	1ay-2021	Not Specified
	Contact Name	Mary Anr	n Pelleymounter, PhD				
	Contact Telephone	301-496-3	1779				
	Contact Email	mary.pell	eymounter@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2021 , 22-Jun-2021 , 07-Sep-202	21 , 22-Feb-2022 , 07-May-2022			
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identif and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also i preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.							
100817	Analytical Validation of a Candida Neuromuscular Disorders (U44 Cl	<u>te Biomar</u> inical Trial	ker for Neurological or Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 057 04-N	1ay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Mary Anr 301-496-: <u>mary.pell</u>	n Pelleymounter, PhD 1779 <u>eymounter@nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	04-May-20 2023 <i>,</i> 22	021 , 22-Jun-2021 , 07-Sep-202 Jun-2023 , 07-Sep-2023	1 , 22-Feb-2022 , 07-May-2022 , 22	2-Jun-2022 , 07-Se	ep-2022 , 22-Feb-20	023 , 07-May-		
	Synopsis	The purpo neurologic of analytic performar guidelines already be	e purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for urological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validat analytical methods for biomarker measurements, which should include evaluation of the detection method, its formance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FD delines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology h eady been developed, and 3) the research and/or clinical need and potential context of use has been identified.						
100818	Clinical Validation of a Candidate Neuromuscular Disorders (U01 Cl	Biomarker inical Trial (f <u>or Neurological or</u> N Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 058 04-1	Лау-2021	Not Specified		
	Contact Name	Mary Ann	Pelleymounter, PhD						
	Contact Telephone	301-496-1	779						
	Contact Email	mary.pelle	eymounter@nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	04-May-20 2023 , 22	021 , 22-Jun-2021 , 07-Sep-202 Jun-2023 , 07-Sep-2023	1 , 22-Feb-2022 , 07-May-2022 , 22	2-Jun-2022 , 07-Se	ep-2022 , 22-Feb-20	023 <i>,</i> 07-May-		
	Synopsis	The purpo neurologic validation specificity identified, clinical nee	The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already beer identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/o clinical need and potential context of use has been identified.						
100816	Analytical Validation of a Candida Neuromuscular Disorders (U01 Cl	<u>te Biomark</u> inical Trial (er for Neurological or Notes Note Notes Notes No	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 056 04-N	Лау-2021	Not Specified		
	Contact Name	Mary Ann	Pelleymounter, PhD						
	Contact Telephone	301-496-1	779						
	Contact Email	mary.pelle	eymounter@nih.gov						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website	Link to program LIRI						
	Deadline Dates (ALL)	04-May-2021 , 22-Jun-2021 , 07-Sep-20 2023 , 22-Jun-2023 , 07-Sep-2023	021 , 22-Feb-2022 , 07-May-2022 , 2	2-Jun-2022 , 07-Se	ep-2022 , 22-Feb-2	023 , 07-May-		
The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous va of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technolo already been developed, and 3) the research and/or clinical need and potential context of use has been identified.								
065643	CREATE Bio Optimization Track for	r Biologics (SBIR-U44)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17- 457 07-N	Лау-2021	Not Specified		
	Contact Name	Chris Boshoff, Ph.D.						
	Contact Telephone	301-496-1779						
	Contact Email	chris.boshoff@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021						
National Institute of Neurological Disorders and Stroke (NINDS) invites SBIR applications for the optimization of potenti therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therap and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, com in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therap candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligi entry into the CREATE Bio Development track. This program will use the NIH U44 Small Business Innovation Research (S Cooperative Agreements - Phase II, and Fast-Track award mechanism.								
102396	NINDS Institutional Research Train	ning Program (T32 Clinical Trial Not	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 149 25-N	Лау-2021	Not Specified		
	Contact Name	Stephen Korn, Ph.D.						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	korns@ninds.nih.gov Link to program URL 25-May-2021 , 25-May-2022 , 25-M The purpose of this FOA is to provi- mission. These institutional researc with the research skills and scientif should be designed to enhance the and career development compone and/or translational research. Critic thorough understanding of experin both orally and in writing, to a wide activities that will foster the develo- trainees' research. NINDS institutio or more of the following groups: di postdoctoral fellows and fellowship this PAR). This Funding Opportuni trial, but does allow them to obtain	May-2023 de support for institutional research trai ch training programs should produce we fic knowledge to make a significant contr breadth and depth of training in NINDS nts in the context of a defined scientific cal components of programs supported nental design, strong statistics and analy e variety of audiences. Regardless of the opment of quantitative literacy and the a unal training programs are intended to b ssertation stage predoctoral students in p-stage clinicians. (NINDS does not support ty Announcement (FOA) does not allow on research experience in a clinical trial le	ining programs in a Il-trained neurosci- ribution to neurosci mission areas by i theme. Programs r by this FOA include rtical skills, and skil me, programs sho application of quan e 1-2 years in dura their 3rd and/or 4 ort first or second appointed Trainee d by a mentor or c	areas relevant to the entists who leave cience research. Plancorporating dida may support basic e mechanisms to e lls for communicate uld provide oppor titative approache tion and support the th year of graduate year graduate studes to lead an indep o-mentor.	he NINDS the program rograms ctic, research , clinical ensure a ting science, tunities and es to the training of one te school, dents under endent clinical		
086929	NINDS Postdoctoral Mentored Ca Independent Clinical Trial Allowed	reer Development Award (K01 - No <u>I)</u>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 049 07-N	1ay-2021	Not Specified		
	Contact Name Contact Telephone Contact Email	Stephen Korn, PhD korns@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep- 2022 , 12-Oct-2022 , 07-Jan-2023						
	Synopsis	The purpose of the NINDS Postdoc mentored postdoctoral researcher	toral Mentored Career Development Aw s to develop a potentially impactful rese	vard is to support t arch project with a	he ability of outsta a comprehensive c	anding, areer		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		developm support fir research experience developm postdocto independ leader in that does experience investigat	nent plan that will enable them rom this NINDS K01 any time be experience, and may be suppor ce. Because the completion of a nent of an impactful research pr oral eligibility window. By the er ent research career with a well- the field. This Funding Opportun not involve leading an indepen ce in a clinical trial led by a ment cor, should apply to the compan	to launch an independent research etween the second through fourth ted by this NINDS K01 within the fi strong, well-planned, thorough ca oject, is a critical aspect of this K02 nd of the proposed K01 award peri developed, impactful research pro nity Announcement (FOA) is design dent small clinical trial. Applicants tor or co-mentor. Applicants propo- tion FOA (PAR-20-050).	h program. Candid year of cumulative irst 6 years of cum meer development 1, applications are iod, the candidate oject and the expe ned specifically for to this FOA are pe osing an independe	ates are encourag e mentored postde ulative postdoctor plan, in addition t strongly encourag should be poised rtise required to b applicants propos ermitted to propos ent small clinical to	ed to apply for octoral ral research to ged early in the to begin an become a sing research se research rial as lead
070582	CREATE Bio Development Track: Development for Biologics (U01 C	Nonclinical Clinical Tria	and Early-Phase Clinical N I Optional) C	lational Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 542 07-N	1ay-2021	7,500,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Hao Wan 301-496-2 <u>CREATEin</u> Link to pr 07-May-2	g, Ph.D. 1779 <u>quiries@mail.nih.gov</u> ogram URL 2021				
Deadline Dates (ALL) 07-May-2021 National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeu Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and no emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Developme Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and t inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a suc project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This progra							
069923	NINDS Exploratory Clinical Trials ((U01 Clinica	al Trial Required)	Iational Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 420 07-N	1ay-2021	Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contract Norma	Deter D. C	Silbort Co M					
	Contact Name	Peter R. G	allbert, SC.IVI.					
		301-496-0						
		pglibert@	<u>inin.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	National I clinical tri the missic and rehat website (I	nstitute of Neurological Disord als to the National Institute of on and research interests of the pilitation therapies. Informatior https://www.ninds.nih.gov/). T	ers and Stroke (NINDS) invites app Neurological Disorders and Stroke NINDS and may evaluate drugs, b a about the mission and research ir his FOA will use the NIH Research I	Incations for invest (NINDS). The trials iologics, and devic interests of the NIN Project (R01) awar	igator-initiated ex must address que es, as well as surg IDS can be found a d mechanism.	ploratory estions within ical, behavioral It the NINDS	
071756	Disease Mechanisms of Prenatal a Clinical Trial Not Allowed)	and Pediat	ric Hydrocephalus (RO1	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-622 07-N	1ay-2021	Not Specified	
	Contact Name	Jill A. Mor	rris, Ph.D.					
	Contact Telephone	301-496-5	5745					
	Contact Email	jill.morris	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-202	1				
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use th NIH Research Project (R01) award mechanism.						
069928	NINDS Efficacy Clinical Trials (U01	Clinical Tr	ial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 422 07-№	1ay-2021	Not Specified	
	Contact Name	Peter R. G	ilbert, ScM					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Talanhana	201 406 (2020				
		501-490-0					
	Contact Email	pgintertæ	<u>mm.gov</u>				
	Sponsor website	Link to pr	ogrom LIDI				
		LINK to pr					
	Synopsis	National I trials to tl mission a and rehat website (l	nstitute of Neurological Disorden ne National Institute of Neurolo nd research interests of the NIN pilitation therapies. Information nttps://www.ninds.nih.gov/).Th	ers and Stroke (NINDS) invites appl gical Disorders and Stroke (NINDS) NDS and may evaluate drugs, biolog about the mission and research ir his FOA will utilize the Cooperative	lications for invest). The trials must a gics, and devices, a nterests of the NIN Agreement (U01)	igator-initiated eff ddress questions v as well as surgical, IDS can be found a grant mechanism.	icacy clinical vithin the behavioral t the NINDS
070148	Promoting Research in Basic Neur Allowed)	oscience (R <u>01 Clinical Trial Not</u> N C	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-18- 483 07-N	1ay-2021	Not Specified
	Contact Name	Robert Ri	ddle, PhD				
	Contact Telephone	301-496-5	5745				
	Contact Email	<u>rr260c@r</u>	<u>iih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National I fundamen the partic normal ne system, th Project (R	nstitutes of Health (NIH) and its ntal questions in basic neuroscie ipating institutes and should fo ervous system. While fundamer nis FOA is not intended to stimu 01) award mechanism.	s participating Institutes and Cente ence. Proposed projects can addre cus on understanding the develop ntal basic research often generates late research that is explicitly dise	ers invite applications ss any area of neu ment, the structur insights relevant ase-related. This F	ons for research ad roscience within th e and/or the funct to disorders of the OA will use the NII	dressing ne missions of ion of the nervous H Research
086932	NINDS Postdoctoral Mentored Ca Trial Required)	reer Devel	opment Award (K01 - Clinical N	Vational Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 050 07-№	1ay-2021	Not Specified
	Contact Name Contact Telephone	Stephen H	Korn, PhD				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL)	korns@m Link to pr 07-May-2 2022 , 12-	<u>ail.nih.gov</u> ogram URL 021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 12-Oct-2021 , 07-Jan-2022 , 12-	Feb-2022 , 07-May	y-2022 , 12-Jun-20	22 , 07-Sep-
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstandir mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive caree development plan that will enable them to launch an independent research program. Candidates are encouraged to support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral re search experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral re experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to Synopsis development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged e postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to be independent research career with a well-developed, impactful research project and the expertise required to becon leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing t the lead investigator of an independent small clinical trial, or proposing to gain research experience in a clinical trial led by anothe investigator must apply to company to company to gain research experience in a clinical trial led by anothe investigator must apply to company to company to gain research experience in a clinical trial led by anothe							anding, areer ed to apply for octoral ral research to ged early in the to begin an ecome a sing to serve as plicants not other
071757	Tools to Enhance the Study of Pre R21 Clinical Trial Not Allowed)	enatal and	Pediatric Hydrocephalus C	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-623 07-N	lay-2021	275,000 USD
	Contact Name	Jill A. Moi	rris, Ph.D.				
	Contact Telephone	301-496-5	5745				
	Contact Email	jill.morris	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
Synopsis Synopsis Context and Stroke (NINDS) invites applications that propose to develop Synopsis Synopsis and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transfor							r substantially mary objective the disease the field of

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		prenatal a innovativ and/or de mechanis	and/or pediatric hydrocephalus e technologies that will be wide eveloping therapeutics. This FO. m.	research by generating tools inclu ely used throughout the neuroscier A will use the NIH R21 Exploratory/	ding animal and concerning animal and concerning to And the community to Developmental References (Developmental References (Developmentat References (Developmental Referen	ell models, novel n understand diseas esearch Grant awa	nethods and se mechanisms ird
079593	Comparative Effectiveness Resea Clinical Trial Not Allowed)	r <mark>ch in Clini</mark>	cal Neurosciences (UG3/UH3 [National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19- 171 07-N	1ay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Adam L. F 301-496-9 adam.har Link to pr 07-May-2 The purpe prospecti Stroke (N the missio intervent interested importan	Hartman, MD 9135 tman@nih.gov ogram URL 021 , 18-Jun-2021 , 07-Sep-202 ose of this Funding Opportunity ve observational comparative e INDS) (note: only prospective o on and research interests of the ions including drugs, biologics, d in pragmatic study designs the t to current clinical practice.	1, 14-Oct-2021, 07-Jan-2022 Announcement (FOA) is to encour effectiveness research (CER) to the bservational studies will be conside NINDS and may evaluate preventi and devices, or surgical, behavioral at utilize a cost-effective means of	rage grant applica National Institute ered)). The study r ive strategies, diag I, and rehabilitatio prospectively colle	tions for investigat of Neurological Di nust address ques nostic approaches n therapies. NIND ecting observation	tor-initiated sorders and tions within 5, or S is particularly al data
073884	Innovation Grants to Nurture Init Neurotherapeutic Agent Characte (R61/R33 Clinical Trial Not Allowe	al Translat erization ar ed)	tional Efforts (IGNITE): nd In vivo Efficacy Studies	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 761 07-N	1ay-2021	750,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Mary Anr 301-496-: <u>mary.pell</u> Link to pr 07-May-2	n Pelleymounter, PhD 1779 <u>eymounter@nih.gov</u> ogram URL 021				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	National pharmaco activity to may inclu Innovatio entry crito (CREATE I other tran	Institute of Neurological Disord okinetic, and in vivo efficacy stu o warrant further development de but are not limited to small n Grants to Nurture Initial Tran eria for the NINDS Cooperative Bio) program for biologics, bioto nslational programs. This FOA w	lers and Stroke (NINDS) invites app dies to demonstrate that proposed to treat neurological disorders tha molecules, biologics or biotechnolo slational Efforts (IGNITE) to advance Research to Enable and Advance T echnology products, Blueprint Neu vill utilize the R61/R33 Phased Inno	olications to condu d therapeutic ager t fall under the NII ogy-derived produ ce projects to the p ranslational Enter rotherapeutics Ne ovation Award med	ct pharmacodyna at(s) have sufficier NDS mission. Ther cts. This FOA is pa point where they o prises for Biologic twork for small m chanism.	mic, at biological apeutic agents art of a suite of can meet the s program olecules, or
073885	Innovation Grants to Nurture Initi Development and Neurotherapeu Clinical Trial Not Allowed)	ial Translat utic Agent	ional Efforts (IGNITE): Assay Identification (R61/R33	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 07-N 762	1ay-2021	750,000 USD
	Contact Name	Mary Anr	Pelleymounter, PhD				
	Contact Telephone	301-496-2	1779				
	Contact Email	mary.pell	<u>eymounter@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological diso This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translation Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutic Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Inn Award mechanism.							ex vivo assays al disorders. ects to the elational opeutics ed Innovation
070119	NINDS Advanced Postdoctoral Ca Diversity in Neuroscience Researc	reer Trans ch (K22-Cli	ition Award to Promote Nical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 07-N 468	1ay-2021	Not Specified
	Contact Name Contact Telephone Contact Email	Michelle . 301-451-7 jonesmich	Jones-London, Ph.D. 7966 <u>ne@ninds.nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website	Link to pr	ogram LIRI				
	Deadline Dates (ALL)	07-Mav-2	021				
National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Career Transition Award to Promote Diversity. This opportunity provides postdoctoral fellows from underrep with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stal productive independent research position. Individuals are eligible for support under this award if they have research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants pro as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary existing trial that also meets the definition of a clinical trial, as part of their research and career developmen accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS Scientific contact prior to submitting an application with human subjects to determine the appropriate funding opport will utilize the NIH K22 Career Transition Award mechanism.						INDS Advanced Po s from underrepre ansition to a stable ard if they have do al prior research t or applicants prop parate ancillary st eer development. I 's definition of a c NINDS Scientific/F e funding opportur	ostdoctoral esented groups e and octoral raining at the osing to serve udy to an NINDS will only linical trial and Research nity. This FOA
070137	NINDS Faculty Development Awa Neuroscience Research (K01 Clinio	rd to Prom cal Trial Re	ote Diversity in Normal States	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 486 07-N	1ay-2021	975,000 USD
	Contact Name	Michelle J	ones-London, Ph.D.				
	Contact Telephone	301-451-7	7966				
	Contact Email	jonesmich	ne@ninds.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National I Promote I Neuroscie faculty wi mentorsh support u tenure tra	nstitute of Neurological Disord Diversity in Neuroscience Resea ence Research (K01) is to divers th research cost support, prote ip in neuroscience research. In nder this award if they have do ack or equivalent position at the	ers and Stroke (NINDS) invites app arch. The purpose of the NINDS Fac ify the pool of independent neuros octed research time and career stag dividuals from backgrounds under octoral research degrees (Ph.D. or e e time of application. This Funding	lications for the Fa culty Development science research in ge appropriate pro represented in bio equivalent) and and Opportunity Anno	aculty Development t Award to Promo nvestigators by pro- ofessional develop medical research e in the first 3 yea puncement (FOA)	nt Award to te Diversity in oviding junior ment are eligible for rs of a faculty is designed

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		specificall study, or accept ap that fall w submittin Announce	y for applicants proposing to s a separate ancillary study to ar plications to this FOA that prop vithin the NINDS research prior g an application with human su ement (FOA) will utilize the NIF	erve as the lead investigator of an i existing trial, as part of their resea pose human mechanistic trials/stuc ities. Applicants are strongly advise ubjects to determine the appropria I KO1 Research Scientist Developme	ndependent clinic arch and career de lies that meet NIH ed to consult with te funding opport ent Award - Resea	cal trial, a clinical tr evelopment. NINDS 's definition of a c NINDS program st unity. This Funding rch & Training me	rial feasibility 5 will only linical trial and aff prior to g Opportunity chanism.
070123	NINDS Advanced Postdoctoral Car Diversity in Neuroscience Researc	reer Transi h (K22-No	tion Award to Promote Independent Clinical Trials)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 469 07-N	/lay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URI	Michelle J 301-451-7 jonesmich	lones-London, Ph.D. 7966 ne@ninds.nih.gov ogram URI				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National I Career Tra Diversity i neuroscie research I Ph.D./M.I Funding C leading ar FOA are p NIH K22 C	nstitute of Neurological Disord ansition Award to Promote Div is designed to enhance the par ence research. This opportunity ence with the resources and too position. Individuals are eligibl D. or equivalent) and between Opportunity Announcement (FC n independent clinical trial, a cl career Transition Award mecha	ers and Stroke (NINDS) invites app ersity. The NINDS Advanced Postdo ticipation of highly trained early ca provides postdoctoral fellows from ols that will help facilitate a transitive for support under this award if th 2 and 5 years of postdoctoral prior DA) is designed specifically for appli- inical trial feasibility study, or an ar- experience in a clinical trial led by a nism.	lications for the N octoral Career Tra reer investigators m underrepresent on to a stable and ney have doctoral research training icants proposing r ncillary study to a a mentor or co-me	INDS Advanced Po nsition Award to P from underrepres red groupswith stru- productive indepo research degrees (at the time of app esearch that does clinical trial. Applic entor. This FOA wil	estdoctoral romote ented groupsin ong training in endent Ph.D., lication. This not involve cants to this I utilize the
070586	CREATE Bio Development Track: N Development for Biologics (U44 C	lonclinical linical Tria	and Early-Phase Clinical I Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 543 07-N	Nay-2021	Not Specified
	Contact Name Contact Telephone	Chris Bosl 301-496-1	noff, Ph.D. 1779				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email d	aris bosh	off@nih.gov				
	Sponsor Website	1113.0031	lon enningov				
	Program LIBI Li	nk to pr	ogram LIRI				
	Deadline Dates (ALL) 0	7-May-2	021				
National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeu Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and n emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorabl Synopsis properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Developm Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a su project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This progr use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-track only.							rapeutic and novel icient orable lopment e and the l, a successful program will
070144	NINDS Faculty Development Award Neuroscience Research (K01 Indepe	to Prom ndent Cl	ote Diversity in linical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18- 490 07-N	1ay-2021	975,000 USD
	Contact Name N	lichelle J	ones-London, Ph.D.				
	Contact Telephone 30	01-451-7	7966				
	Contact Email jo	nesmich	ne@ninds.nih.gov				
	Sponsor Website						
	Program URL <u>Li</u>	<u>nk to pro</u>	ogram URL				
	Deadline Dates (ALL) 0	7-May-2	021				
	N Pr Synopsis su te sp fe	ational I romote I euroscie aculty wi lentorsh upport u enure tra becificall easibility	nstitute of Neurological Disord Diversity in Neuroscience Resea ence Research (K01) is to divers th research cost support, prote ip in neuroscience research. In nder this award if they have do ack or equivalent position at the y for applicants proposing rese study, or an ancillary study to	ers and Stroke (NINDS) invites appl arch. The purpose of the NINDS Fac ify the pool of independent neuros ected research time and career stag dividuals from backgrounds underr octoral research degrees (Ph.D. or e e time of application. This Funding arch that does not involve leading a clinical trial. Applicants to this FO	ications for the Fa culty Development cience research in e appropriate pro epresented in bio quivalent) and are Opportunity Anno an independent cl A are permitted to	culty Developmen Award to Promot vestigators by pro fessional developr medical research a in the first 3 year uncement (FOA) is inical trial, a clinica p propose research	t Award to e Diversity in viding junior nent ire eligible for s of a faculty designed al trial n experience ir

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		a clinical Scientist	trial led by a mentor or co-men Development Award - Research	tor. This Funding Opportunity Ann & Training mechanism.	ouncement (FOA)	will utilize the NII	⊣ K01 Research
100306	NINDS Ruth L. Kirschstein Nationa Training of Postdoctoral Fellows (al Research F32 Clinica	n Service Award (NRSA) for al Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 032 07-N	lay-2021	Not Specified
	Contact Name	Stephen I	Korn, Ph.D.				
	Contact Telephone	301-496-4	4188				
	Contact Email	<u>korns@ni</u>	inds.nih.gov				
	Sponsor Website	h					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 11	2021 , 09-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 09-Fe	1,14-Oct-2021 , 07-Jan-2022 , 09- b-2023 , 07-May-2023 , 08-Jun-202	Feb-2022 , 07-Mav 23 , 07-Sep-2023 ,	y-2022 , 08-Jun-20 10-Oct-2023 , 07-)22 , 07-Sep- Jan-2024
	Synopsis	The purpe outstandi proposed seeks to f candidate seeks inn postdocto reasoning years of a planning Announco to propos (FOA) doo research	ose of this award is to support of ing mentors. Candidates are eli postdoctoral position to within oster early, goal-directed plann to that have the potential for sig ovative research ideas and thou oral fellow into an outstanding g and the quantitative principle a candidate's activity in a specifi and timely completion of "men ement (FOA) does not allow ap se research experience in a clinic es not allow applicants to propo- experience in a clinical trial led	butstanding scientific training of hi gible to apply for support from this in 12 months after starting in the pr ning and to encourage applications nificant impact. Inclusion of prelim ughtful plans for training and ment scientist. Applications are expected s of experimental design and analy ic laboratory or research environm tored training" within a particular plicants to propose to lead an inde ical trial led by a sponsor or co-spo ose to lead an independent clinical by a sponsor or co-sponsor.	ghly promising pos program from ~12 oposed postdocto for bold and/or in inary data is stron orship that will fac d to incorporate str sis. Support by this ent, so as to furthe lab or environmen pendent clinical tri nsor. This Funding trial, but does allo	tdoctoral candida 2 months prior to ral position. This novative projects gly discouraged; r ilitate the develop rong training in qu s program is limite er encourage early t. This Funding Op al, but does allow Opportunity Anno w applicants to pr	tes with the start of the NINDS F32 by the ather, this F32 oment of the uantitative ed to the first 4 γ , thoughtful oportunity γ applicants ouncement ropose
086471	NINDS Ruth L. Kirschstein Nationa Training of Postdoctoral Fellows (al Research F32 Clinica	n Service Award (NRSA) for al Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20- 021 07-N	lay-2021	Not Specified
	Contact Name Contact Telephone	Stephen I 301-496-4	Korn, Ph.D. 4188				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	<u>korns@ni</u>	inds.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	<u>ik to program URL</u>							
	Deadline Dates (ALL)	07-May-2 2022 , 11	021 , 09-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 14-Oct-2021 , 07-Jan-2022 , 09-	Feb-2022 , 07-Ma	ıy-2022 , 08-Jun-20)22 , 07-Sep-			
	Synopsis	outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS Fis seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, th seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, though planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunit Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicant to propose research experience in a clinical trial led by a spensor or so encourage								
065641	CREATE Bio Optimization Track fo	r Biologics	(U01)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17- 456 07-N	/lay-2021	2,500,000 USD			
	Contact Name	Chris Bos	hoff, Ph.D.							
	Contact Telephone	301-496-3	1779							
	Contact Email	chris.bosl	noff@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	021							
	Synopsis	National therapeu disorders therapeu concept s	Institute of Neurological Disord tic Biotechnology Products and identified under the NINDS mis tic lead(s) that showed promise tudies. Therefore, at the end or	ers and Stroke (NINDS) invites app Biologics (e.g., peptides, proteins, ssion. This track supports the furth as a potential therapeutic agent a f this funding period, successful pro	lications for the o oligonucleotides, er characterizatio s evidenced by co ojects will have de	ptimization of pote gene and cell ther n and optimizatior nvincing animal pr elivered and optim	ential apies) for of roof-of- ized			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		therapeut be eligible focused o and subm Project Co	ic candidate with demonstrate for entry into the CREATE Bio n the development of optimize ission of an IND package to the opperative Agreements award	ed bioactivity, stability, manufactur Development track. The CREATE B ed therapeutic candidates through e Food and Drug Administration (FE mechanism.	ability, bioavaila io Development Investigational I DA). This program	bility, in vivo efficac track is a later stage New Drug (IND)-enal n will use the NIH U	y and should e program bling studies D1 Research
100819	Clinical Validation of a Candidate I Neuromuscular Disorders (U44 Cli	Biomarker inical Trial	for Neurological or Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 059	-Mar-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Mary Ann 301-496-1 mary.pelle Link to pro 15-Mar-20 2023 , 07- The purpo neurologic validation	Pelleymounter, PhD 779 eymounter@nih.gov Ogram URL 021, 04-May-2021, 22-Jun-202 May-2023, 22-Jun-2023, 07-S ose of this Program Announcen cal and neuromuscular disorde of biomarker measurements v	21 , 07-Sep-2021 , 22-Feb-2022 , 07 ep-2023 nent (PAR) is to enable clinical valic rrs and conditions. Specifically, the vithin the clinical population of inte	7-May-2022 , 22 lation of strong goal of this PAR erest to establis	-Jun-2022 , 07-Sep-2 candidate biomarke is to enable the rigo n the clinical sensitiv	022 , 22-Feb- rs for rous clinical ity and
	Synopsis	specificity identified, clinical ne	of the biomarker consistent w , 2) detection method technolo ed and potential context of use	vith FDA guidelines. This PAR assum ogy has already been developed an e has been identified.	nes that 1) a can d analytically va	didate biomarker ha lidated, and 3) the re	s already been esearch and/or
078414	Strategies to Provide Culturally Ta for Seriously III American Indian ar Clinical Trial Optional)	ilored Palli nd Alaska I	iative and End-of-Life Care Native Individuals (R21	National Institute of Nursing Research/NIH/DHHS	PAR-19- 058 07	-May-2021	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Lynn S. Ac 301-594-8 adamsls@ Link to pro 07-May-20	lams, Ph.D. 1911 <u>Inih.gov</u> Dgram URL 021 , 16-Jun-2021 , 07-Sep-202	21 , 16-Oct-2021 , 07-Jan-2022			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Synopsis	The purpo use of evi individual	ose of this funding opportunity dence-based interventions in e s with advanced illness and the	announcement (FOA) is to encou end-of-life and palliative care (EOL eir families and communities.	rage research that v .PC) for American In	will improve and in dian/Alaska Nativ	ncrease the e (AI/AN)	
068622	Mechanisms, Models, Measureme (R21 Clinical Trial Optional)	ent, & Mar	nagement in Pain Research	National Institute of Nursing Research/NIH/DHHS	PA-18-159 07-N	1ay-2021	275,000 USD	
	Contact Name	Martha M	latocha, PhD					
	Contact Telephone	301-594-2	2775					
	Contact Email	<u>matochar</u>	n@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and for wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advance needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective behavioral and social sciences. Although great strides have been made in some areas, such as the identification of pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and ur Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly er as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.								
078636	Telomeres in Wellness and Diseas Clinical Trial Optional)	e: A Biobe	havioral Approach (R21	National Institute of Nursing Research/NIH/DHHS	PA-19-073 07-N	1ay-2021	Not Specified	
	Contact Name	Lois A. Tu	lly, PhD					
	Contact Telephone	301-594-5	5968					
	Contact Email	<u>tullyla@n</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-202	21 , 16-Oct-2021 , 07-Jan-2022				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Synopsis	The purpo telomeres research. additiona wellness,	ose of this funding opportunity s in wellness and disease, and t A body of research has demon I studies are needed to achieve reducing the risk and burden o	announcement (FOA) is to stimula o advance the incorporation of te strated the contribution of telome the full potential for incorporatin f disease, and for advancing symp	ate clinical research lomere studies into eres to health-relato g telomere-guided tom and self-mana	a that examines th biobehavioral pro ed outcomes; how approaches for m gement strategies	e role of ograms of ever, aintaining		
077974	Addressing Caregiver Symptoms through Clinical Trial Optional)		chnological Tools (R21	National Institute of Nursing Research/NIH/DHHS	PA-19-024 07-N	1ay-2021	275,000 USD		
	Contact Name Contact Telephone Contact Email Sponsor Website	Augie Dia 301-402-6 <u>dianaa@r</u>	na, Ph.D. 5423 <u>mail.nih.gov</u>						
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-202	1 , 16-Oct-2021 , 07-Jan-2022					
	Synopsis	Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.							
078635	Telomeres in Wellness and Diseas Clinical Trial Optional)	se: A Biobe	havioral Approach (RO1 F	National Institute of Nursing Research/NIH/DHHS	PA-19-074 07-N	1ay-2021	Not Specified		
	Contact Name	Lois A. Tu	lly, PhD						
	Contact Telephone	301-594-5	5968						
	Contact Email	<u>tullyla@n</u>	nail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021, 05-Jun-2021, 07-Sep-202	1,05-Oct-2021,07-Jan-2022					
	Synopsis	The purpe	ose of this funding opportunity	announcement (FOA) is to stimula	ate clinical research	that examines th	e role of		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		telomeres research. additiona wellness,	s in wellness and disease, and A body of research has demo I studies are needed to achiev reducing the risk and burden	to advance the incorporation of tele nstrated the contribution of telome e the full potential for incorporating of disease, and for advancing sympt	omere studies res to health-r g telomere-gui com and self-m	into biobehavioral pr elated outcomes; hov ded approaches for m nanagement strategies	ograms of vever, naintaining s.
079184	Research Enhancement Award Pro Schools and Graduate Schools (R15	gram (RE. 5 Clinical ⁻	AP) for Health Professional Trial Required)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 135)7-May-2021	300,000 USD
	Contact Name	Michelle I	R.J. Hamlet, PhD				
	Contact Telephone	301-496-9	9623				
	Contact Email	hamletm(@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 25-Jun-2021 , 07-Sep-20	21 , 25-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpo to stimula significant create op research p support si undergrac and to str college wi NIH-relev NIH-relev Schools ar (meaning schools, g the institutior unique ide NIH IPF no	be of the Research Enhancem ite basic and clinical research t number of the Nation's research portunities for scientists and h programs to contribute to the mall-scale research projects p duate and/or graduate studer engthen the research environ ith a unique identifier number ant baccalaureate or advance ort (in both direct and F&A/inc and colleges, the \$6 million fun all schools and colleges within raduate schools, and colleges ution are considered together as with multiple campuses, eli entifier number or NIH IPF nu- umber for all campuses, eligib ity appouncement (EOA) suppo-	in educational institutions that prov arch scientists, but that have not be health professional institutions othe Nation's biomedical and behavioral roposed by faculty members of eligints at health professional schools or ment of the applicant institution. Lige (such as DUNS) and a unique NIH In d degrees in health professions and direct costs) in 4 of the last 7 fiscal y ding limit is based on the amount of n an institution). In other words, the and all the institution's non-health and summed as total NIH funding w gibility can be considered for each im mber is established for each campus ility is determined for all campuses	Ith Professional ride baccalaure en major recip rwise unlikely research effo ble, domestic graduate scho gible institutional Pr have received rears. For institution f NIH funding r f funding for a professional s when determin ndividual camp s. For institutio (e.g. main, sat	al Schools and Gradua eate or advanced degr pients of NIH support. to participate extensi rt. REAP grants are int institutions, to expose pols to meritorious res ns (e.g., the university ofile File (IPF) number I no more than \$6 mill tutions composed of r received by the institu If the institution's hea chools and colleges the ing institutional eligib pous (e.g. main, satellit pous that use one ident ellite, etc.) together. The imal risk clinical trials	te Schools is rees for a REAP grants vely in NIH rended to e search projects, for)) must award ion per year of nultiple tion as a whole lth professional nat are part of ility. For e, etc.) only if a ifier number or This funding addressing the

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		mission a require FI psycholog	nd research interests of the p DA oversight, do not intend to rical harm.	articipating NIH institutes. Minima formally establish efficacy, and ha	risk clinical tria ve low risks to p	ls are defined as thos potentially cause phys	e that do not ical or
079185	End-of-Life and Palliative Needs of with Serious Illnesses (R01 Clinica	of Adolesce Il Trial Opti	nts and Young Adults (AYA) onal)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 136)7-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Lynn S. Ad 301-594-8 <u>lynn.adan</u> Link to pr 07-May-2 The purpo wishes, an the Cente research f	dams, Ph.D. 3911 <u>ns@nih.gov</u> 021 , 05-Jun-2021 , 07-Sep-20 ose of this funding opportunit nd decision-making processes rs for Disease Control and Pre focused on specific end-of-life	021 , 05-Oct-2021 , 07-Jan-2022 y announcement (FOA) is to foster of adolescents and young adults (evention as youth between 12–24 y c/palliative care (EOLPC) models the	research on the AYA; defined by years of age) wit at support the p	e unique perspectives, the World Health Org th serious, advanced i hysical, psychological	needs, anization and llnesses; and , spiritual, and
076049	Prevention Research in Mid-Life A	Adults (R01	<u>Clinical Trial Optional</u>	National Institute of Nursing Research/NIH/DHHS	PA-18-849 C)7-May-2021	Not Specified
	Contact Name	Mary C. R	oary, Ph.D.				
	Contact Telephone	301-594-2	2154				
	Contact Email	mary.roa	<u>y@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-20	021			
	Synopsis	National I adults (th illness and	nstitute of Nursing Research ose 50 to 64 years of age) tha d disability in later years. This	(NINR) and National Institute on Ag t can inform efforts to optimize he FOA will use the NIH Research Pro	ing (NIA) invite alth and wellne ject (R01) award	applications for resea ss as individuals age, a d mechanism.	rch on mid-life and prevent
084549	Palliative Care in Home and Com	nunity Set	ings (R01 Clinical Trial	National Institute of Nursing	PAR-19- C)7-May-2021	Not

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Optional)		R	lesearch/NIH/DHHS	321		Specified
	Contact Name	Karen A. I	(ehl. PhD. RN. FPCN				
	Contact Telephone	301-594-8	3010				
	Contact Email	karen.keh	nl@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022	021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-2022 , 05-	Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
	Synopsis	The purpo integratio an individ illness wh palliative	ose of this funding opportunity on of palliative care into home a lual resides or lives. Home- and to do not require hospitalization care.	is to stimulate research aimed at d nd community settings. Home and community-based palliative care p n but are not appropriate for hospic	etermining needs community in this programs ensure th ce have access to	and best practices s FOA refer to the nose with serious, high quality end-o	for the place where advanced f-life and
085700	Omics-guided Biobehavioral Inter Outcomes: A Step Forward in Tra	<u>ventions fo</u> nslation (R	or Improved Health N 01 Clinical Trial Optional) R	lational Institute of Nursing Research/NIH/DHHS	PAR-19- 377 07-N	1ay-2021	Not Specified
	Contact Name	Lois A. Tu	lly, PhD				
	Contact Telephone	301-594-5	5968				
	Contact Email	<u>tullyla@n</u>	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05·	021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 05-Oct-2021 , 07-Jan-2022 , 05-	Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-
	Synopsis	The purp advances epigenom health ou	oose of this funding opportunity in the fields of genomics and of nics, etc.) to incorporate these a tcomes.	v announcement (FOA) is to stimula ther omics (e.g., metabolomics, mi dvances into translatable, persona	ate clinical researc crobiomics, protec Ilized biobehaviora	th that harnesses t omics, transcriptor al interventions fo	he wealth of nics, r improved
078345	End-of-Life and Palliative Care Ap Symptoms (R01 Clinical Trial Option	proaches t onal)	o Advanced Signs and R	lational Institute of Nursing Research/NIH/DHHS	PAR-19- 045 07-N	1ay-2021	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Karen A. K	Keni, Ph.D.				
	Contact Telephone	301-594-8					
		<u>kenika@n</u>	<u>iin.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021,05-Jun-2021,07-Sep-202	21,05-Oct-2021,07-Jan-2022			
	Synopsis	The purpo foundatio	ose of this funding opportunity ns, experiences and managem	announcement (FOA) is to stimula ent of complex, advanced signs and	te research to exa d symptoms at the	amine the multi-din e end of life.	nensional
078411	Strategies to Provide Culturally Ta for Seriously III American Indian a Clinical Trial Optional)	ilored Pall nd Alaska I	iative and End-of-Life Care Native Individuals (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 057 07-N	May-2021	Not Specified
	Contact Name	Lynn S. Ac	dams, Ph.D.				
	Contact Telephone	301-594-8	3911				
	Contact Email	adamsls@	<u>)nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-202	21 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpo use of evic individual	ose of this funding opportunity dence-based interventions in e s with advanced illness and the	announcement (FOA) is to encoura end-of-life and palliative care (EOLP eir families and communities.	age research that C) for American Ir	will improve and ir ndian/Alaska Native	crease the e (AI/AN)
077788	Applying a Biopsychosocial Persperence Pain (R01 Clinical Trial Optional)	ective to Se	elf-Management of Chronic	National Institute of Nursing Research/NIH/DHHS	PA-18-945 07-N	May-2021	Not Specified
	Contact Name	Martha M	latocha, PhD				
	Contact Telephone	301-594-2	2775				
	Contact Email	matochan	n@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Dat	e Funding Amount		
	Deadline Dates (ALL) Synopsis	07-May-2021 , 05-Jun-2021 , 07-Sep The purpose of the Funding Opportu applying a biopsychosocial perspecti	-2021 , 05-Oct-2021 , 07-Jan-2022 inity announcement is to encourage ive to self-management of chronic pa	grant applications from the scienti ain.	fic community on		
077972	Addressing Caregiver Symptoms t Clinical Trial Optional)	through Technological Tools (R01	National Institute of Nursing Research/NIH/DHHS	PA-19-023 07-May-2021	Not Specified		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Augie Diana, Ph.D. 301-402-6423 <u>dianaa@mail.nih.gov</u> <u>Link to program URL</u> 07-May-2021 , 05-Jun-2021 , 07-Sep	-2021 , 05-Oct-2021 , 07-Jan-2022				
The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific communi that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregi regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needer advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, a viable tools to address the symptoms experienced by caregivers.							
074459	Maternal Nutrition and Pre-pregn Infants and Children (R01 Clinical	nancy Obesity: Effects on Mothers, Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-776 07-May-2021	Not Specified		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sung Sug (Sarah) Yoon, PhD, RN 301-402-6959 <u>sungsug.yoon@nih.gov</u> <u>Link to program URL</u> 07-May-2021, 05-Jun-2021, 07-Sep National Institute of Nursing Researc outcomes for women, infants and ch pregnancy obesity. Maternal health	-2021 ch (NINR) and Office of Dietary Supp hildren, by stimulating interdisciplina significantly impacts not only the mo	lements (ODS) invite applications to iry research focused on maternal n other but also the intrauterine envi	o improve health utrition and pre- ronment, and		

SPIN ID	Program Title	Spo	nsor Name	Sponsor Number		Deadline Date	Funding Amount	
		subsequently mechanism.	fetal development and the	e health of the newborn. This FOA	will use the NIH Re	search Project (RC	1) award	
070260	End-of-Life and Palliative Care He Serious, Advanced Illness (R01 Cli	ealth Literacy: Ir inical Trial Optic	nproving Outcomes in onal)	National Institute of Nursing Research/NIH/DHHS	PA-18-498 07-N	1ay-2021	Not Specified	
	Contact Name	Lynn S. Adams	s, Ph.D.					
	Contact Telephone	301-594-8911						
	Contact Email	l <u>adamsls@nih</u> .	gov					
	Sponsor Website	2						
	Program URL	Link to progra	<u>m URL</u>					
	Deadline Dates (ALL)	07-May-2021						
	Synopsis	strategies, inte individuals wit award mechar	erventions, and models of h serious, advanced illnes hism.	care to improve EOLPC health lite s and their families and caregiver	eracy, with the goal s. This FOA will use t	of improving outc the NIH Research	omes for Project (R01)	
077785	Biobehavioral Basis of Chronic Pa	in (R01 Clinical	Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-944 07-N	1ay-2021	Not Specified	
	Contact Name	Lois A. Tully, P	hD					
	Contact Telephone	301-594-5968						
	Contact Email	l <u>tullyla@mail.r</u>	<u>iih.gov</u>					
	Sponsor Website	2						
	Program URL	Link to progra	m URL					
	Deadline Dates (ALL)	07-May-2021	, 05-Jun-2021 , 07-Sep-202	21 , 05-Oct-2021 , 07-Jan-2022				
Deadline Dates (ALL) 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022 The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community of the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to bett understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic								

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		illness.					
078362	End-of-Life and Palliative Care Ap Symptoms (R21 Clinical Trial Optic	proaches t onal)	o Advanced Signs and	National Institute of Nursing Research/NIH/DHHS	PAR-19- 044 07-1	Мау-2021	275,000 USD
	Contact Name	Karen A. k	Kehl, Ph.D.				
	Contact Telephone	301-594-8	3010				
	Contact Email	<u>kehlka@n</u>	<u>iih.gov</u>				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-20	21 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpo foundatio	ose of this funding opportunity ns, experiences and managem	announcement (FOA) is to stimulat nent of complex, advanced signs and	te research to exa I symptoms at the	amine the multi-dir e end of life.	nensional
077787	Biobehavioral Basis of Chronic Pai	in (R21 Clir	nical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-943 07-1	Лау-2021	275,000 USD
	Contact Name	Lois A. Tu	lly, PhD				
	Contact Telephone	301-594-5	5968				
	Contact Email	tullyla@m	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-20	21 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpo the biobe assessme Research understar illness.	ose of the Funding Opportunity havioral basis of chronic pain. nts and the associated sensory relating biology and behavior nd the mechanisms underlying	y Announcement is to encourage gra The focus encompasses the individ and emotional components that un is needed to better define the indivi differences in pain experiences amo	ant applications f ual phenotype, g nderpin the indiv dual-specific bur ong individuals af	rom the scientific o enotype, and other dual's chronic pair den of chronic pair flicted with the sar	community on r omic-type a experience. a and to better me chronic
077789	Applying a Biopsychosocial Perspe Pain (R21 Clinical Trial Optional)	ective to Se	elf-Management of Chronic	National Institute of Nursing Research/NIH/DHHS	PA-18-946 07-N	Мау-2021	275,000 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	Martha M	latocha, PhD						
	Contact Telephone	301-594-2	2775						
	Contact Email	matochan	n@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-2	021 , 16-Jun-2021 , 07-Sep-20	021 , 16-Oct-2021 , 07-Jan-2022					
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community applying a biopsychosocial perspective to self-management of chronic pain.							
084550 Pa	alliative Care in Home and Comm ptional)	<u>nunity Sett</u>	ings (R21 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19- 320	7-May-2021	275,000 USD		
	Contact Name	Karen A. k	ehl, PhD, RN, FPCN						
	Contact Telephone	301-594-8	8010						
	Contact Email	karen.kehl@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2 2022	021 , 16-Jun-2021 , 07-Sep-20	021 , 16-Oct-2021 , 07-Jan-2022 , 16	-Feb-2022 , 07-	May-2022 , 16-Jun-20	022 , 07-Sep-		
	Synopsis	The purpo integratio an individ illness wh palliative	ose of this funding opportunit n of palliative care into home ual resides or lives. Home- an o do not require hospitalizati care.	y is to stimulate research aimed at o and community settings. Home and d community-based palliative care on but are not appropriate for hosp	determining ne d community in programs ensu ice have access	eds and best practices this FOA refer to the re those with serious, to high quality end-o	s for the place where advanced f-life and		
079344 <u>Er</u> <u>w</u>	nd-of-Life and Palliative Needs of ith Serious Illnesses (R21 Clinical	f Adolesce Trial Opti	nts and Young Adults (AYA) onal)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 153	7-May-2021	275,000 USD		
	Contact Name	Lynn S. Ac	lams, Ph.D.						
	Contact Telephone	301-594-8	3911						
	Contact Email	lynn.adam	ns@nih.gov						
	Sponsor Website								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20	021 , 16-Oct-2021 , 07-Jan-2022						
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.							
070262	End-of-Life and Palliative Care He Serious, Advanced Illness (R21 Cli	alth Literacy: Improving Outcomes in nical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499 07-N	1ay-2021	275,000 USD			
	Contact Name	Lynn S. Adams, Ph.D.							
	Contact Telephone	301-594-8911							
	Contact Email	adamsls@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021							
	Synopsis	National Institute of Nursing Research effective end-of-life and palliative care strategies, interventions, and models o individuals with serious, advanced illne Exploratory/Developmental Research (n (NINR) invites applications for res (EOLPC) health literacy in diverse of care to improve EOLPC health lite ass and their families and caregiver Grant award mechanism.	search focused on id settings and populat eracy, with the goal rs. This FOA will use t	entification of the ions, and to creat of improving outc he NIH R21	key barriers to e novel omes for			
068621	Mechanisms, Models, Measurem (R01 Clinical Trial Optional)	ent, & Management in Pain Research	National Institute of Nursing Research/NIH/DHHS	PA-18-141 07-№	1ay-2021	Not Specified			
	Contact Name	Martha Matocha, PhD							
	Contact Telephone	301-594-2775							
	Contact Email	matocham@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021							

SPIN ID Program Title Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
National Institutes of Health wide range of basic, clinical, a needed in every area of pain behavioral and social science Synopsis pathways of pain, the experie Furthermore, our understand Research to address these is: as is research from underrep (R01) award mechanism.	(NIH) and its participating Institutes a and translational studies on pain as the research, from the micro perspective s. Although great strides have been to ence of pain and the challenge of treat ding of how and why individuals trans sues conducted by interdisciplinary at resented, minority, disabled, or wom	and Centers invite appl ney relate to the missic e of molecular sciences made in some areas, su atment have remained sition to a chronic pain nd multidisciplinary res en investigators. This F	ications to stimulate ons of these ICs. New to the macro persp uch as the identificat uniquely individual state after an acute search teams is stror OA will use the NIH	e and foster a w advances are ective of tion of neural and unsolved. injury is limited. ngly encouraged, Research Project
SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077789 Applying a Biopsychosocial Perspective to Self-Management of Pain (R21 Clinical Trial Optional)	<u>Chronic</u> National Institute of Nursin Research/NIH/DHHS	PA-18-946	07-May-2021	275,000 USD
Contact Name Martha Matocha, PhD				
Contact Telephone 301-594-2775				
Contact Email <u>matocham@mail.nih.gov</u>				
Sponsor Website				
Program URL Link to program URL				
Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 ,	07-Sep-2021 , 16-Oct-2021 , 07-Jan-2	2022		
Synopsis The purpose of the Funding C applying a biopsychosocial p	Dpportunity announcement is to enco erspective to self-management of chr	ourage grant applicatio onic pain.	ns from the scientif	c community on
084550 Palliative Care in Home and Community Settings (R21 Clinical T Optional)	rial National Institute of Nursin Research/NIH/DHHS	ng PAR-19- 320	07-May-2021	275,000 USD
Contact Name Karen A. Kehl, PhD, RN, FPCN	l			
Contact Name Karen A. Kehl, PhD, RN, FPCN Contact Telephone 301-594-8010	l			
Contact Name Karen A. Kehl, PhD, RN, FPCN Contact Telephone 301-594-8010 Contact Email <u>karen.kehl@mail.nih.gov</u>	J			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2 2022	021 , 16-Oct-2021 , 07-Jan-2022 , 16	5-Feb-2022 , 07-Ma	y-2022 , 16-Jun-20)22 , 07-Sep-	
	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place whe an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.						
079344	End-of-Life and Palliative Needs o with Serious Illnesses (R21 Clinica	f Adolescents and Young Adults (AYA) I Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19- 153 07-N	/lay-2021	275,000 USD	
	Contact Name	Lynn S. Adams, Ph.D.					
	Contact Telephone	301-594-8911					
	Contact Email	lynn.adams@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021 , 16-Oct-2021 , 07-Jan-2022				
	Synopsis	research on the un YA; defined by the ears of age) with so at support the phys	ique perspectives, World Health Org erious, advanced i ical, psychological	needs, anization and Ilnesses; and , spiritual, and			
070262	End-of-Life and Palliative Care He Serious, Advanced Illness (R21 Cli	alth Literacy: Improving Outcomes in nical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499 07-N	May-2021	275,000 USD	
	Contact Name	Lynn S. Adams, Ph.D.					
	Contact Telephone	301-594-8911					
	Contact Email	adamsls@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	07-May-2 National effective e strategies individual Explorato	021 Institute of Nursing Research end-of-life and palliative care , interventions, and models of s with serious, advanced illno ry/Developmental Research	h (NINR) invites applications for rese e (EOLPC) health literacy in diverse s of care to improve EOLPC health lite ess and their families and caregivers Grant award mechanism.	earch focused on ide settings and populat eracy, with the goal s. This FOA will use t	entification of the ions, and to creat of improving outc he NIH R21	key barriers to e novel omes for
068621	Mechanisms, Models, Measureme (R01 Clinical Trial Optional)	ent, & Mar	nagement in Pain Research	National Institute of Nursing Research/NIH/DHHS	PA-18-141 07-N	1ay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Martha M 301-594-2 matochan Link to pro 07-May-2 National I wide rang needed in behaviora pathways Furthermo Research as is resea (R01) awa	latocha, PhD 2775 <u>m@mail.nih.gov</u> ogram URL 021 nstitutes of Health (NIH) and ge of basic, clinical, and trans n every area of pain research, al and social sciences. Althou of pain, the experience of pa ore, our understanding of ho to address these issues cond arch from underrepresented, ard mechanism.	l its participating Institutes and Cent lational studies on pain as they relat , from the micro perspective of mol- igh great strides have been made in ain and the challenge of treatment I w and why individuals transition to lucted by interdisciplinary and multi minority, disabled, or women invest	ters invite applicatic te to the missions o ecular sciences to th some areas, such a have remained uniq a chronic pain state idisciplinary researc stigators. This FOA v	ons to stimulate and f these ICs. New a ne macro perspect s the identificatio uely individual an e after an acute in h teams is strongl will use the NIH Re	nd foster a advances are tive of n of neural d unsolved. jury is limited. y encouraged, esearch Project
076050	Prevention Research in Mid-Life A	dults (R21	Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-850 07-N	1ay-2021	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Mary C. R 301-594-2 mary.roar	oary, Ph.D. 2154 y@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL Deadline Dates (ALL)	Link to program URL 07-May-2021 , 16-Jun-2021 , 07-Se	p-2021	aing (NIA) invite and	lications for resea	arch on mid-life			
	Synopsis	adults (those 50 to 64 years of age illness and disability in later years. mechanism.	ts (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent as and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award hanism.						
085882	Patient Activation for Self-Manage Clinical Trial Optional)	ement of Chronic Conditions (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 381 07-1	May-2021	Not Specified			
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FA	AN, FAAAAI						
	Contact Telephone	301-594-5970							
	Contact Email	hussk@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 05-Ju 2022 , 07-Sep-2022 , 05-Feb-2023 ,	l-2021 , 07-Sep-2021 , 05-Feb-2022 , (. 05-Mar-2023 , 07-May-2023)5-Mar-2022 , 07-Ma	y-2022 , 05-Jun-20)22 , 05-Jul-			
	Synopsis	The purpose of this Funding Oppo patient activation on self-managen	ortunity Announcement is to encoura nent of chronic conditions.	ge grant applications	that address the i	nfluence of			
102700	Notice of Special Interest (NOSI): Career Development Awards	NINR Priority Areas for Training and	National Institute of Nursing Research/NIH/DHHS	NOT-NR- 21-001 25-N	Лау-2021	Not Specified			
	Contact Name								
	Contact Telephone								
	Contact Email								
	Sponsor Website								
	Program URL	Link to program URL							
Program URL Link to program URL 25-May-2021 , 12-Jun-2021 , 08-Aug-2021 , 07-Sep-2021 , 25-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 25-Jan-202 2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 12-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-20 2023 , 07-Sep-2023									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The Nation of educati	nal Institute of Nursing Rese on and encouraging training	arch (NINR) is committed to training to in important new areas of nursing re	the next generat esearch.	ion of nurse scienti	sts at all levels
085884	Patient Activation for Self-Manage Clinical Trial Optional)	ement of C	hronic Conditions (R21	National Institute of Nursing Research/NIH/DHHS	PAR-19- 382	-May-2021	400,000 USD
	Contact Name	Karen Hus	s, PhD, RN, APRN-BC, FAAN,	FAAAAI			
	Contact Telephone	301-594-5	970				
	Contact Email	<u>hussk@ma</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20 2022 , 07-	021 , 16-Jun-2021 , 16-Jul-20 Sep-2022 , 16-Feb-2023 , 16	021 , 07-Sep-2021 , 16-Feb-2022 , 16-I -Mar-2023 , 07-May-2023	Mar-2022 , 07-M	lay-2022 , 16-Jun-20)22 , 16-Jul-
Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.							
099971	Notice of Special Interest (NOSI): A VA Mentored Physician-Scientist A Related Dementias (AD/ADRD)	Administra Award in Al	tive Supplements for NIA- Izheimer's Disease and its	National Institute on Aging/NIH/DHHS	NOT-AG- 20-043 07	-May-2021	Not Specified
	Contact Name	Lisa A. Opa	anashuk, Ph.D.				
	Contact Telephone	301-827-5	422				
	Contact Email	<u>Lisa.Opana</u>	ashuk@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-20	021				
	Synopsis	The purpo Alzheimer NIA and th scientists sustainabl resources,	ose of this initiative is to incr 's disease-related dementian ne U.S. Department of Veter to pair with both VA- and NI e process for collaboration , and increased coordination	ease the number of early stage physi s (AD/ADRD) research and improve pa ans Affairs (VA) have created a two-p A-funded mentors in the AD/ADRD fig and address key barriers or challenges between the VA and NIA.	cian-scientists in atient care for ve art opportunity eld. This will also s that often hind	Alzheimer's diseas eterans. To accomp for early career VA facilitate the devel er communication,	e and lish this goal, physician- opment of a sharing of

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
101126	RFA-AG-22-002 Aging Effects on Not Allowed)	Osteoimmunology (R01 Clinical Trial	s National Institute on Aging/NIH/DHHS	RFA-AG- 15- 22-002 [Op	May-2021 otional][LOI/Pre-App	1,500,000] USD
	Contact Name Contact Telephone Contact Email Sponsor Website	John P. Williams, Ph.D. 301-496-6403 williamsj6@nih.nih.gov				
	Program URL Deadline Dates (ALL) Synopsis	Link to program URL 15-May-2021 [Optional][LOI/Pre-App This Funding Opportunity Announcer Health, solicits grant applications tha skeletal systems in animal models. Re bone marrow niche and immunosene homeostasis, are the focus of this FO	b], 15-Jun-2021 ment (FOA), issued by the National Ins it will examine the role of aging in the esearch projects that will determine th escence impact these interactions, lead MA.	titute on Aging (N interactions betw le mechanisms in ding to pathologi	NIA) of the National l veen the immune sy volved in how both cal conditions in bor	nstitutes of stems and aging of the ie
101456	RFA-AG-22-006 New Approache its Dynamics in Brain Aging and AD Allowed)	es to Identify Neurogenesis and Study D/ADRD (R01 Clinical Trial Not	National Institute on Aging/NIH/DHHS	RFA-AG- 17- 22-006 [Op	May-2021 ptional][LOI/Pre-App	2,500,000] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Amanda DiBattista, Ph.D. 301-827-3342 <u>amanda.dibattista@nih.gov</u> <u>Link to program URL</u> 17-May-2021 [Optional][LOI/Pre-App The goal of this Funding Opportunity of existing approaches to identify the	b], 17-Jun-2021 Announcement is to support research e presence of neurogenesis and study i	on novel approa ts dynamics in br	iches and/or innovat rain aging and AD/AI	ive expansion DRD.
088437	Harmonization of Alzheimer's Dise (AD/ADRD) Genetic, Epidemiologic Therapeutic Target Discovery (U24	ease and Related Dementias c, and Clinical Data to Enhance 4 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20- 25- 099	May-2021	13,855,000 USD

Contact Name Marilyn Miller, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Talanhana	201 406 0	250						
	Contact Telephone	301-490-5							
		milerin@	<u>ma.mn.gov</u>						
	Sponsor website	Link to pr	ogram LIDI						
		LINK LO PR	<u>Ografii UKL</u>	22 25 May 2022 25 San 2022 25	lan 2022				
	Synopsis	The Natio cooperati (ADSP) ge FOA will f will work targeted t	nal Institute on Aging (NIA) in ve agreement (U24), phenoty netic and genomic data. Thes und a single vanguard networ with the ADSP and with study cherapeutic approaches for Al	vites applications specific to infrastrupic data harmonization on subjects we data will become a long-lived "legate of researchers with expertise in get cohort leads on data harmonization zheimer's disease and related demention data data data data data data data dat	ucture that will s with Alzheimer's acy" data set that netics, epidemio efforts to optim ntias (AD/ADRD).	upport, under a sin Disease Sequencing will be perpetually logy, and clinical sp ize the ability to ide	gle ; Project · curated. The ecialties who entify well-		
088306	Development of Research Educati Translational and Clinical Scientist Allowed)	ion Resour ts (R25 Ind	ces for Geriatrics-Related ependent Clinical Trial Not	National Institute on Aging/NIH/DHHS	PAR-20- 095 25-	May-2021	900,000 USD		
	Contact Name	Basil Elda	dah, MD, Ph.D.						
	Contact Telephone	301-496-6	5761						
	Contact Email	basil.elda	dah@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	25-May-2	021 , 25-Sep-2021 , 25-Jan-20	22 , 25-May-2022 , 25-Sep-2022 , 25	-Jan-2023				
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The arching goal of this R25 program is to support educational activities that complement and/or enhance the training of workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arc goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development Research Experiences							IH. The over- ing of a er-arching lopment		
101782	Institutional Training Programs to Alzheimer's Disease (AD) and AD-I	Advance 1 Related De	Translational Research on ementias (T32)	National Institute on Aging/NIH/DHHS	PAR-21- 112 25-	May-2021	Not Specified		
	Contact Name	Yuan Luo,	Ph.D.						
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
---------	--	--------------------------------------	--	---------------------	---------------	-------------------	--	--	--
	Contact Telephone 3	01-496-9350							
	Contact Email y	uan.luo@mail.nih.gov							
	Sponsor Website								
	Program URL <u>Li</u>	ink to program URL							
	Deadline Dates (ALL) 25	5-May-2021 , 27-Sep-2021 , 25-May-2	y-2021 , 27-Sep-2021 , 25-May-2022 , 26-Sep-2022 , 25-May-2023 , 25-Sep-2023						
	This Funding Opportunity Announcement (FOA) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing the development for Alzheimer's disease (AD) and AD-related dementias (ADRD). This FOA will support institutional train programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology translational and clinical research, data science and behavioral research). The program invites eligible institutions to interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease bi and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, transla and clinical research for AD and AD-related dementias. This Funding Opportunity Announcement (FOA) does not allo appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clini- led by a mentor or co-mentor.								
088853	National Institute on Aging Genetics Storage Site (U24 Clinical Trial Not A	s of Alzheimer's Disease Data	National Institute on Aging/NIH/DHHS	PAR-20- 110 25-1	May-2021	Not Specified			
	Contact Name M	Iarilyn M. Miller. Ph.D.							
	Contact Telephone 30	01-496-9350							
	Contact Email <u>m</u>	nillerm@nia.nih.gov							
	Sponsor Website								
	Program URL <u>Li</u>	ink to program URL							
	Deadline Dates (ALL) 25	5-May-2021 , 25-Sep-2021 , 25-Jan-20	22 , 25-May-2022 , 25-Sep-2022 , 25	-Jan-2023					
	This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure that will support the storage, Synopsis analysis, and sharing of primary and secondary data for the genetics and genomics of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).								
082792	Limited Competition: NIA Genome C (GCAD) (U54 Clinical Trial Not Allow	Center for Alzheimer's Disease	National Institute on Aging/NIH/DHHS	PAR-19- 288 25-1	May-2021	Not Specified			
	Contact Name	Aarilyn Miller, Ph.D.							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Talanhana	201 406 0250								
		<u>milerin@ma.nin.gov</u>								
	Sponsor website									
		LINK to program ORL	022 25 May 2022 25 Can 2022							
	Synopsis	This Funding Opportunity Announcem Alzheimer's Disease (GCAD) to facilitar serve as the focal point for all phases intended to support a major compone comprises a multidisciplinary attack of programmatic needs. The Center will	unding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for mer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is ded to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities rises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's ammatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for peutic approaches and prevention of the disease.							
		therapeutic approaches and prevention	on of the disease.							
083966	NIA Program Project Applications	(P01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19- 314 07-	-May-2021	Not Specified				
	Contact Name	Robin A. Barr, D.Phil								
	Contact Telephone	301-496-9322								
	Contact Email	BarrR@mail.nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-	2021, 21-Sep-2021, 07-Jan-2022,	25-Jan-2022 , 07-N	/lay-2022 , 25-May-	2022				
	Synopsis	The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.								
085643	Complex Integrated Multi-Compo Clinical Trial Optional)	onent Projects in Aging Research (U19	National Institute on Aging/NIH/DHHS	PAR-19- 374 25-	-May-2021	Not Specified				
	Contact Namo	Canai Sunaia DhD								

Contact Name Sanoj Suneja, PhD

SPIN ID	Program Title	Spon	sor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-402-7710						
	Contact Email	<u>sunejas@mail.r</u>	<u>nih.gov</u>					
	Sponsor Website							
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	25-May-2021 , 2	25-Sep-2021 , 25-Jan-20	22 , 25-May-2022 , 25-Sep-2022				
	Synopsis	National Institu integrated com integrated mult the NIH U19 Re	te on Aging (NIA) invites ponents focused on a co idisciplinary team of inv search Program – Coope	applications that propose large-sca ommon research question relevant to restigators within a single institution reative Agreements award mechanis	le, complex resea o aging. Such proj or a consortium o m.	rch projects with mu ects will likely involv of institutions. This F	ultiple highly ve an OA will use	
101820	NIA MSTEM: Advancing Diversity in Undergraduate Education (R25 - In	n Aging Researc ndependent Clin	<u>h through</u> iical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20- 317 25-1	May-2021	1,875,000 USD	
	Contact Name	NIA Training Of	fice					
	Contact Telephone							
	Contact Email	NIAtraining@ni	<u>h.gov</u>					
	Sponsor Website							
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	25-May-2021 , 2	25-May-2022 , 25-May-2	2023				
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue furthe studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational act with a primary focus on: Research Experiences Curriculum or Methods Development							
101921	RFA-AG-22-008 The Cellular Scal Alzheimer's Disease (U01 Clinical T	e Connectome i Frial Not Allowe	in Aging and d)	National Institute on Aging/NIH/DHHS	RFA-AG- 15-1 22-008 [Op	/lay-2021 tional][LOI/Pre-App]	Not Specified	
	Contact Name	Miroslaw 'Mack	d' Mackiewicz, Ph.D.					
	Contact Telephone	301-594-7636						
	Contact Email	<u>miroslaw.macki</u>	iewicz@nih.gov					
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Program URL	Link to program URL							
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App]], 15-Jun-2021						
	Synopsis	This Funding Opportunity Announcem comprehensive characterization of br neurodegeneration in mouse models brain in a common reference brain ce and extend research on vulnerable ce and provide a greater understanding o	s Funding Opportunity Announcement (FOA) invites applications that will: (1) promote the development of a nprehensive characterization of brain circuits susceptible to Alzheimer's disease type pathology and/or urodegeneration in mouse models of Alzheimer's disease (AD), (2) share data on the cell connectome in the aging and AE in in a common reference brain cell atlas that integrates both molecular and anatomical annotations, and (3) compleme d extend research on vulnerable cell types to include the mapping of connectivity changes between cells in aging and AD d provide a greater understanding of the mechanisms underlying resilience and vulnerability in AD.						
070904 <u>(</u>	<u> Jnderactive Bladder and Detruso</u> <u>Optional)</u>	r Activity in Aging (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PA-18-570 07-N	/lay-2021	Not Specified			
	Contact Name	Marcel E. Salive, MD							
	Contact Telephone	301-496-6761							
	Contact Email	saliveme@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021							
National Institute on Aging (NIA) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underact (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinic synopsis practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adult and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by t initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based gui the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH Research Project (R01 mechanism.									
075498 /	Alzheimer's Drug-Development Pr	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18- 820	/lay-2021	5,000,000 USD			
	Contact Name	Lorenzo M. Refolo, Ph.D.							
	Contact Telephone	301-594-7576							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	refolol@r	nia.nih.gov						
	Sponsor Website		<u>0</u>						
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-2	2021					
	Synopsis	National I small-mo cognitive as medici in animal New Drug mechanis (e.g., exen throughp award me	lational Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development mall-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat ognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activ is medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET n animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Invest New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic nechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological inte e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such a hroughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreen award mechanism.						
070906 <u>(</u>	<u> Jnderactive Bladder and Detruso</u> Dptional)	<u>r Activity i</u>	n Aging (R03 Clinical Trial	National Institute on Aging/NIH/DHHS	PA-18-571 07-N	/lay-2021	100,000 USD		
	Contact Name	Marcel E.	Salive, MD						
	Contact Telephone	301-496-6	6761						
	Contact Email	saliveme(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021						
	Synopsis	National I underacti should fo translatio and clinic advancing conseque older pers	, ational Institute on Aging (NIA) invites pilot/feasibility projects that propose basic, clinical, or translational research on nderactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Application ould focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) anslation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, managem nd clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB wild dvancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its onsequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/U/A lder persons. This FOA will use the NIH RO3 Small Grant Program award mechanism.						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
070905	Underactive Bladder and Detrusor Optional)	Activity in Aging (R21 Clinical Trial	National Institute on Aging/NIH/DHHS	PA-18-572 07-I	May-2021	275,000 USD
	Contact Name	Marcel E. Salive, MD				
	Contact Telephone	301-496-6761				
	Contact Email	<u>saliveme@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	clinical, or translatic aging and in older pe models and/or older 3) diagnosis, prevent s for the developme elopmental research y this initiative shou ed guidance in the di ploratory/Developm	nai research on un rsons. Application adults; 2) translat ion, management nt of DU/UAB with projects by provid d enhance knowle agnosis, evaluatio ental Research Gra	s should focus ion of and clinical advancing ing support for edge of n, and ant award		
097636	Notice of Special Interest (NOSI): E Affective, Motivational, and Social Alzheimer's Disease and Related D	Basic and Translational Research on Function in Normative Aging and/or Pementias (AD/ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG- 20-040 07-I	May-2021	Not Specified
	Contact Name	Janine Simmons, M.D., Ph.D.				
	Contact Telephone	301-480-8959				
	Contact Email	janine.simmons@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-20	21 , 07-Sep-2021 , 05-Oct-2021 ,	16-Oct-2021 , 07-Jan	-2022	
	Synopsis	This Notice of Special Interest (NOSI) is neuroscientific research on affective, m	intended to underscore NIA's co otivational, and social functions	ntinued commitmen in midlife and aging.	t to psychological NIA supports rese	and arch to further

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		clarify the cognitive changes i motivatio fold: (1) t role in be dysfunctio observed social, em and/or st AD/ADRD	e changes in and trajectories of impairment (MCI), Alzheimer n the structure and function of onal, and social behaviors and o advance understanding of n havior and cognition, and the on in these processes might n on in these processes might a in AD/ADRD. Such studies man notional, and cognitive well-be rengthen social or emotional	of these processes in adults who are 's disease (AD), and AD-related demo of neurobiological and neuromodulat interact with other psychological fur formative maturational changes in af ir underlying integrative neural-beha nanifest in MCI and the early stages of ccount for any of the Behavioral and ay identify novel targets for preventa eing; facilitate adaptive function in a resilience at different stages of the li	aging normally an entias (ADRD). NI/ tory systems medi nctions, including ffective, motivatio avioral mechanism of AD/ADRD; and/ Psychological Syr Itive or therapeut ging; normalize so ife course and at c	d/or in individuals A also seeks to und ate or moderate a cognition. NIA's go nal, and social pro ns; (2) to elucidate or (3) to determine nptoms of Dement ic interventions to ocial or emotional o lifferent disease st	with mild erstand how ffective, als are three- cesses, their how e how tia (BPSD) promote dysregulation; ages in
100297	Notice of Special Interest (NOSI): Mechanisms Underlying Fundame	Integrative ental Affec	<u>e Studies of Neural</u> tive Processes in Aging	National Institute on Aging/NIH/DHHS	NOT-AG- 21-012 07-1	May-2021	Not Specified
	Contact Name	Luci Robe	erts, Ph.D.				
	Contact Telephone	2					
	Contact Email	l <u>roberlu@</u>	mail.nih.gov				
	Sponsor Website	2					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023	2021 , 05-Jun-2021 , 16-Jun-20 -May-2022 , 05-Jun-2022 , 16 , 07-May-2023 , 05-Jun-2023)21 , 07-Sep-2021 , 05-Oct-2021 , 16- -Jun-2022 , 07-Sep-2022 , 05-Oct-202 , 16-Jun-2023 , 07-Sep-2023 , 05-Oc	Oct-2021 , 07-Jan 22 , 16-Oct-2022 , t-2023 , 16-Oct-20	-2022 , 05-Feb-202 07-Jan-2023 , 05-F)23 , 07-Jan-2024	22 , 16-Feb- eb-2023 , 16-
The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA's interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to "reverse translate" clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigatc working at different levels of neurobiological and behavioral analysis.							
086469	Aging Research Dissertation Awai	rds to Incre	ease Diversity (R36 Clinical	National Institute on Aging/NIH/DHHS	PAR-19- 394 07-1	May-2021	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Shahrooz Vahedi, Ph.D. 301-496-9322 <u>shahrooz.vahedi@nih.gov</u> Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-20 2022 , 16-Oct-2022 , 07-Jan-2023)21 , 16-Oct-2021 , 07-Jan-2022 , 16-F	eb-2022 , 07-Ma	y-2022 , 16-Jun-202	2 , 07-Sep-		
The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of res Synopsis within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research o aging-related health conditions.								
102562	AD/ADRD Clinical Trials Short Cou Not Allowed)	rse (R25 Independent Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-21- 141 25-N	May-2021	400,000 USD		
	Contact Name	Laurie Ryan						
	Contact Telephone	301-496-9350						
	Contact Email	ryanl@mail.nih.go						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022 , 25-May-	2023					
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development It is essential to expand and diversify the skilled AD/ADRD clinical trial workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of AD/ADRD clinical trialists in state-of-the-art clinical research skills.						
102870	RFA-AG-22-012 High-Priority Be Networks in Alzheimer's Disease a Dementias (R24 Clinical Trial Optio	havioral and Social Research and Alzheimer's Disease-Related onal)	National Institute on Aging/NIH/DHHS	RFA-AG- 23-N 22-012 [Opt	Vlay-2021 tional][LOI/Pre-App	1,250,000] USD		

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount	
	Contact Name	John W. R. Phillips, PhD						
	Contact Telephone	301- 827-4137						
	Contact Email	John.Phillips@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	!3-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021						
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infinite networks for behavioral and social research on Alzheimer's disease and Alzheimer's disease-related dementias attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities in research; and address ongoing needs for harmonization and biomarker collection in large population panel study AD/ADRD research as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities are not limited to: meetings to develop novel research areas and interact on the development of infrastructure pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing needs as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; meas dementia care in home and community-based services (HCBS); the dementia care workforce; and education a						
102872	RFA-AG-22-013 High-Priority Be	havioral and Social Research	N	ational Institute on	RFA-AG- 23	-May-2021	1,250,000	
102872	Networks (R24 Clinical Trial Optio	nal)	A	ging/NIH/DHHS	22-013 [O	ptional][LOI/Pre-Ap	p] USD	
	Contact Name	John W. R. Phillips, Ph.D.						
	Contact Telephone	301- 827-4137						
	Contact Email	<u>John.Phillips@nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	23-May-2021 [Optional][LOI/	Pre-App], 2	3-Jun-2021				
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		limited to harmoniz and innov	the following priority areas: ation of Health and Retireme vation in longitudinal aging st	midlife reversibility of biobehavioral nt Study (HRS) international aging stu udies.	risk associated wi udies; biomarker	th early life adversit collection in populat	y; ion studies;
100265	RFA-AA-20-011 Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional) Contact Name Mark Egli, Ph.D.			National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA- 26-/ 20-011 [Op	Apr-2021 tional][LOI/Pre-App]	Not Specified
	Contact Name	Mark Egli	, Ph.D.				
	Contact Telephone	301-594-6	5382				
	Contact Email	<u>megli@m</u>	<u>ail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	26-Apr-20	021 [Optional][LOI/Pre-App],	26-May-2021			
	Synopsis	This Fund Integrativ applicatic 20-012, a	ing Opportunity Announceme e Neuroscience Initiative on A ons. Please see companion FO nd for submission of collabor	ent (FOA) solicits cooperative agreem Alcoholism (INIA). This FOA solicits su As for submission of resource-related ative research projects (U01) applica	nents to participa Ibmission of admi d and support cor tions, RFA-AA-20-	te in two consortia unistrative resource of the second content of	inder the cores (U24) is, RFA-AA-
100267	RFA-AA-20-013 Integrative Neu	roscience	Initiative on Alcoholism	National Institute on Alcohol Abuse	RFA-AA- 26-/	Apr-2021	Not
100207	(INIA) Consortia (U01 Clinical Tria	l Optional)		and Alcoholism/NIH/DHHS	20-013 [Op	tional][LOI/Pre-App]	Specified
	Contact Name	Mark Egli	, Ph.D.				
	Contact Telephone	301-594-6	5382				
	Contact Email	<u>megli@m</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	26-Apr-20	021 [Optional][LOI/Pre-App],	26-May-2021			
	Synopsis	This Fund Integrativ companic 20-012 fo	ing Opportunity Announceme e Neuroscience Initiative on A on FOA, RFA-AA-20-011 for su r submission of resource-rela	ent (FOA) solicits cooperative agreem Alcoholism (INIA). This FOA solicits re bmission of administrative resource ted and support cores applications.	nents to participat search projects (l cores applications	te in two consortia u J01) applications. Pl s, and companion FC	inder the ease see the DA, RFA-AA-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
100266	<u>RFA-AA-20-012 Integrative Neur</u> (INIA) Consortia Research Resource	<u>oscience</u> e (U24) ((Initiative on Alcoholism Tinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA- 2 20-012 [26-Apr-2021 Optional][[OI/Pre-Ap	Not ol Specified	
	Contact Name	Mark Egli					e] opeoee	
	Contact Telenhone	301-594-6	5382					
	Contact Email	megli@m	ail nih gov					
	Sponsor Website	megneen						
	Program UBI	Link to pr	ogram URI					
	Deadline Dates (ALL)	26-Apr-20)21 [Optional][LOI/Pre-App].	26-Mav-2021				
	Synopsis	This Fund under the applicatic Resource	ing Opportunity Announcem Integrative Neuroscience In ons (U24) to support the cons core (U24) application, and	eent (FOA) solicits research cooperativ itiative on Alcoholism (INIA). This FOA sortium. Please see companion RFA-AA companion RFA-AA-20-013 for submis	e agreements solicits subm A-20-011 for s sion of Resear	to participate in two ission of Research Res ubmission of an Admi rch Project application	consortia source core nistrative ns (U01).	
100731	NIAAA Resource-Related Research Allowed)	<u>Projects</u>	(R24 Clinical Trial Not	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21- 072	25-May-2021	Not Specified	
	Contact Name	Gary J Mu	ırray, Ph.D.					
	Contact Telephone	301-443-9	9940					
	Contact Email	gary.muri	ray@nih.gov					
	Sponsor Website							
	Program URL	<u>Link to pr</u>	ogram URL					
	Deadline Dates (ALL)	25-May-2	021 , 25-Sep-2021 , 25-Jan-2	022 , 25-May-2022 , 25-Sep-2022 , 25	-Jan-2023 , 25	-May-2023 , 25-Sep-2	023	
Synopsis Synopsis Synopsis								
071738	Understanding Processes of Recov	erv in the	Treatment of Alcohol Use	National Institute on Alcohol Abuse	PA-18-619 C)7-Mav-2021	Not	

071738 <u>Understanding Processes of Recovery in the Treatment of Alcohol Use</u> National Institute on Alcohol Abuse PA-18-619 07-May-2021

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Disorder (R01 Clinical Trial Option	al <u>)</u>	ā	and Alcoholism/NIH/DHHS			Specified		
	Contact Name	Brett T. H	agman						
	Contact Telephone	301-443-0	0638						
	Contact Email	brett.hag	man@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	021						
	Synopsis	National and relap that addr precipitar and 5) Exa mechanis	I Institute on Alcohol Abuse an se in the treatment of Alcohol ess the following potential top nts of relapse; 3) Understandir amining processes of extended m.	d Alcoholism (NIAAA) invites applica Use Disorders. Applications high in vics: 1) defining recovery; 2) Examini og mechanisms of mutual help and r d treatment for AUD. This FOA will u	ations that seek to innovation and signg new and innov ecovery; 4) Evalua se the NIH Resear	o examine process gnificance are hig ative methods to o ting recovery syst ch Project (R01) a	es of recovery nly encouraged examine ems of care; ward		
076319	Alcohol and Other Drug Interactio Overdoses: Epidemiology and Pre-	<u>ns: Uninte</u> vention (R	entional Injuries and 101 - Clinical Trial Optional) a	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-863 07-N	/lay-2021	Not Specified		
	Contact Name	Robert Fr	eeman, Ph.D.						
	Contact Telephone	301-443-8	8820						
	Contact Email	<u>rfreeman</u>	<u>@mail.nih.gov</u>						
	Sponsor Website								
	Program URL								
	Deadline Dates (ALL)	07-May-2	.021 , 05-Jun-2021 , 07-Sep-20	21					
	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite application that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.								
101405	RFA-AA-21-001 Improving Healt Services (R01 Clinical Trial Optiona	h Disparit al)	ies in Alcohol Health	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA- 21-001 07-N	Лау-2021	2,500,000 USD		
	Contact Name	Laura E. K	(wako, Ph.D.						

I

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-451-8	8507				
	Contact Email	laura.kwa	<u>ako@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05 May-2024	:021 , 05-Jun-2021 , 07-Sep-2(-Oct-2022 , 07-Jan-2023 , 05-I 4	021 , 05-Oct-2021 , 07-Jan-2022 , 05-F Feb-2023 , 07-May-2023 , 05-Jun-202	eb-2022 , 07-May 3 , 07-Sep-2023 ,	/-2022 , 05-Jun-20 07-Jan-2024 , 05-F	22 , 07-Sep- eb-2024 , 07-
	Synopsis	This Fund focusing All Applic	ing Opportunity Announceme on: 1.) access to treatment; 2. ations are expected to empha	ent (FOA) solicits applications on heal) making treatment more appealing; ssize health disparities in addition to t	th disparities and 3.) costs; 4.) disse the other four are	health services-re mination and imp as of focus mention	lated research lementation. oned above.
072233	Genetics of Alcohol Sensitivity and Allowed)	d Toleranc	e (R01 Clinical Trial Not	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-660 07-N	1ay-2021	Not Specified
	Contact Name	Hemin R.	Chin, Ph.D.				
	Contact Telephone	301-443-3	1282				
	Contact Email	<u>chinh@m</u>	ail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National the devel and influe identifyin alcohol. T	I Institute on Alcohol Abuse an opment of tolerance and the enced both by genetic and en- g genetic, genomic and epige his FOA will use the NIH Rese	nd Alcoholism (NIAAA) invites applica progression to alcohol use disorder. A vironmental factors. The purpose of t netic factors contributing to the deve arch Project (R01) award mechanism	tions for novel ge Alcohol use disord his FOA is to stim lopment of sensit	netic mechanisms lers is complex, m ulate and support ivity and toleranc	underlying ultifactorial, efforts on e to
076324	Alcohol and Other Drug Interactio Overdoses: Epidemiology and Pre	ons: Uninte vention (R	entional Injuries and 21 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-862 07-N	1ay-2021	275,000 USD
	Contact Name	Robert Fr	eeman, Ph.D.				
	Contact Telephone	301-443-	8820				
	Contact Email	<u>rfreeman</u>	@mail.nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021			
	Synopsis	National Institute on Alcohol Abuse a that explore whether and how alcohol unintentional injuries and poisonings a combination. This FOA will use the NIP	nd Alcoholism (NIAAA) and National I and other illicit drugs or illicitly used and how to prevent and/or reduce sin I R21 Exploratory/Developmental Gra	nstitute on Drug / prescription drug nultaneous use of int award mechar	Abuse (NIDA) invit s interact to contr alcohol or drugs s ism.	e applications ibute to ingly or in
076327	Alcohol and Other Drug Interactic Overdoses: Epidemiology and Pre	ons: Unintentional Injuries and evention (R03 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-861 07-N	Лау-2021	100,000 USD
	Contact Name	Robert Freeman, Ph.D.				
	Contact Telephone	301-443-8820				
	Contact Email	rfreeman@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute on Alcohol Abuse a that explore whether and how alcohol unintentional injuries and poisonings a combination. This FOA will use the NIF	nd Alcoholism (NIAAA) and National I and other illicit drugs or illicitly used and how to prevent and/or reduce sin I R03 Small Grant Program award me	nstitute on Drug / prescription drug nultaneous use of chanism.	Abuse (NIDA) invit s interact to contr alcohol or drugs s	e applications ibute to ingly or in
083915	Mechanisms of Tolerance (R21/R	<u> 33 - Clinical Trial Required)</u>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19- 311 07-N	/lay-2021	1,775,000 USD
	Contact Name	Elizabeth M Powell, PhD				
	Contact Telephone	301-443-0786				
	Contact Email	elizabeth.powell3@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This funding opportunity announceme	ent (FOA) focuses on sensitivity and to	lerance mechanis	ms underlying the	development

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		of alcoho that regu tolerance (R21/R33 and resea by NIAAA interested tolerance	l use disorder. The intent of t late sensitivity and tolerance and the progression to alcoh) mechanism, clinical trial rec arch testing the hypotheses c program staff after evaluation d in animal studies on the me may consider FOA (PA-18-66	his FOA is to: (1) develop hypotheses to alcohol, and (2) develop quantitati nol use disorder. These objectives will quired, in which secondary data analys an be expanded in the R33 phase. The on of the achievement of specific mile echanisms of tolerance may consider R 50).	about cellular, m ve models to pre be accomplished sis or pilot studies transition to the stones set for the OA (PAR-18-659	olecular or networ dict the developm with a Phased Inn s can occur during R33 phase will be R21 phase. Applic or in the genetic	rk mechanisms ent of ovation the R21 phase, determined cants basis of
072235 <u>N</u>	Aechanisms of Alcohol Tolerance	e (R21/R33	Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	/PAR-18- 659 07-1	May-2021	Not Specified
	Contact Name	Elizabeth	M Powell, PhD				
	Contact Telephone	Elizabeth	M Powell, PhD				
	Contact Emai	<u>elizabeth</u>	.powell3@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National underlyin molecula predict th a Phased and resea by NIAAA the NIH R	I Institute on Alcohol Abuse a g the development of alcoho r or network mechanisms tha ne development of tolerance Innovation (R21/R33) mecha arch testing the hypotheses c program staff after evaluatio 21/R33 Phased Innovation A	nd Alcoholism (NIAAA) invites applica I use disorders. The intent of this FOA It regulate sensitivity and tolerance to and the progression to alcohol depen nism, in which secondary data analys an be expanded in the R33 phase. The on of the achievement of specific mile ward mechanism.	tions on sensitivi is to: (1) develop alcohol, and (2) dence. These obj is or pilot studies transition to the stones set for the	ty and tolerance m o hypotheses abou develop quantitati ectives will be acco can occur during t R33 phase will be R21 phase. This F	nechanisms t cellular, ve models to omplished with he R21 phase, determined OA will use
097916 <u>R</u>	lotice of Special Interest (NOSI): esearch Data	<u>Secondary</u>	Analyses of Existing Alcohol	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-018 07-1	May-2021	Not Specified
	Contact Name	Wenxing	Zha, Ph.D.				
	Contact Telephone	301-443-0	0633				
	Contact Emai	zhaw@m	ail.nih.gov				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 <i>,</i> 07- Feb-2023	021 , 05-Jun-2021 , 16-Jun-202 -May-2022 , 05-Jun-2022 , 05-Ju , 16-Feb-2023 , 07-May-2023 ,	1 , 07-Sep-2021 , 05-Oct-2021 , 16-0 un-2022 , 16-Jun-2022 , 07-Sep-2022 16-Jun-2023	Dct-2021 , 07-Jan- 2 , 05-Oct-2022 , 1	2022 , 05-Feb-202 16-Oct-2022 , 07-J	22 , 16-Feb- an-2023 , 05-
The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of exist data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) a Synopsis related health services and health systems, including access, quality, and efficiency. This Notice encourages application proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, a developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral ar genetics research.							
098270 <u></u>	Notice of Special Interest (NOSI):	Alcohol an	d Aging a	ational Institute on Alcohol Abuse nd Alcoholism/NIH/DHHS	NOT-AA- 20-019 07-N	1ay-2021	Not Specified
	Contact Name	Andras O	rosz, Ph.D.				
	Contact Telephone	301-443-2	2193				
	Contact Email	orosza@r	nail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07- Feb-2023	021 , 05-Jun-2021 , 16-Jun-202 -May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 ,	1 , 07-Sep-2021 , 05-Oct-2021 , 16-0 un-2022 , 07-Sep-2022 , 05-Oct-202 16-Jun-2023 , 07-Sep-2023	Dct-2021 , 07-Jan- 2 , 16-Oct-2022 , (·2022 , 05-Feb-202 07-Jan-2023 , 05-F	22 , 16-Feb- eb-2023 , 16-
	Synopsis	The purpe alcohol cc organism, the effect consumpt for alcoho and 3) Re diseases a	ose of this Notice of Special Inter- onsumption on aging across diff , and societal levels. The follow as of alcohol consumption on lif- tion, drinking pattern, and dura of use disorder (AUD) among of search to extend the health spa- associated with alcohol use.	erest (NOSI) is to promote research ferent levels of biological organization ing broad research areas will be end respan, health span, and age-related ation of drinking; 2) Research to info der adults as well as prevention, dia an of older adults who drink and dec	to improve our un on including the r couraged: 1) Basic I diseases depend rm evidence-base gnosis, and treat crease the health	nderstanding of th nolecular, cellular, and clinical resea ling on level of alco ed guidance for ido ment of AUD in th care burden of ag	e effects of , tissue, organ, rch defining ohol entifying risk is population; e-related

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
100945	Notice of Special Interest (NOSI): Treatment, Services, and Recover	Advances y of Alcoh	in Research for the ol Use Disorder	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-022 07-N	Nay-2021	Not Specified
	Contact Name	Brett T. H	lagman, Ph.D.				
	Contact Telephone	301-443-0	0638				
	Contact Email	brett.hag	<u>man@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023	2021 , 05-Jun-2021 , 16-Jun-2 -May-2022 , 05-Jun-2022 , 16 , 07-May-2023 , 05-Jun-2023	021 , 07-Sep-2021 , 05-Oct-2021 , 16- 5-Jun-2022 , 07-Sep-2022 , 05-Oct-202 3 , 16-Jun-2023 , 07-Sep-2023	Oct-2021 , 07-Jan 2 , 16-Oct-2022 ,	-2022 , 05-Feb-20 07-Jan-2023 , 05-	22 , 16-Feb- ⁻ eb-2023 , 16-
	Synopsis	The purpo of Treatm such as h and innov interest in disparity at all leve large.	ose of this Notice of Special I nent and Recovery Research (ealth services, behavioral the vative methods and technolo nclude topics focusing on spe populations, as well as those els from FASD to elderly, effor	nterest (NOSI) is to advance research (DTRR). DTRR's research interests are erapies and mechanisms of behavioral gies for alcohol use disorder (AUD) tre ecial-emphasis and underserved popul with co-occurring disorders; and feta rts will be made to include participant	on various topics wide-ranging and change (MOBC), eatment and susta ations, including I alcohol spectrun s that reflect the	that fall within NI encompass broad recovery, translat aining recovery. O NIH-designated U n disorders (FASD diversity of the po	AAA's Division I categories ional research, ther areas of .S. health). In all studies, opulation at
101458	Notice of Special Interest (NOSI): Organ System Diseases (R01/R21,	<u>Alcohol-in</u> /R03)	duced Tissue-specific and	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 20-024 07-N	/lay-2021	Not Specified
	Contact Name	Li Lin					
	Contact Telephone	301-827-	7749				
	Contact Email	linli@mai	il.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023 16-Feb-20	2021 , 05-Jun-2021 , 16-Jun-2 -May-2022 , 05-Jun-2022 , 16 , 07-May-2023 , 05-Jun-2023 024 , 07-May-2024	021 , 07-Sep-2021 , 05-Oct-2021 , 16- 5-Jun-2022 , 07-Sep-2022 , 05-Oct-202 3 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct	Oct-2021 , 07-Jan 2 , 16-Oct-2022 , -2023 , 16-Oct-20	-2022 , 05-Feb-20 07-Jan-2023 , 05- 23 , 07-Jan-2024 ,	22 , 16-Feb- ⁻ eb-2023 , 16- 05-Feb-2024 ,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice is to inform studying the harmful effects of alcoho	n potential applicants of the NIAAA's s ol on the body's tissues, organs, and sy	pecial interest in stems in diverse	n research project a e populations acros	applications s the lifespan.
080217	Summer Research Education Expension Allowed)	rience Program (R25 Clinical Trial Not	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19- 197 07-	-May-2021	500,000 USD
	Contact Name	L Lynn Morin				
	Contact Telephone	301-402-0176				
	Contact Email	Lynn.Morin@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	The NIH Research Education Program arching goal of this R25 program is to workforce to meet the nation's biome	(R25) supports research education ac support educational activities that co edical, behavioral and clinical research	tivities in the min mplement and/ needs.	ssion areas of the N or enhance the trai	NH. The over- ning of a
101187	NIDCD Research Dissertation Fello	owship for Au.D. Audiologists (F32)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello	owship for Au.D. Audiologists (F32) Alberto L. Rivera-Rentas, Ph.D.	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello Contact Name Contact Telephone	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 08· 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello Contact Name Contact Telephone Contact Email	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 riverara@nidcd.nih.gov	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello Contact Name Contact Telephone Contact Email Sponsor Website	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 riverara@nidcd.nih.gov	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 08- 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 <u>riverara@nidcd.nih.gov</u>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 093	-Apr-2021	Not Specified
101187	NIDCD Research Dissertation Fello Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 <u>riverara@nidcd.nih.gov</u> <u>Link to program URL</u> 08-Apr-2021 , 07-May-2021 , 08-Aug- 2022 , 07-Sep-2022 , 08-Dec-2022 , 07 Jan-2024	National Institute on Deafness and Other Communication Disorders/NIH/DHHS 2021 , 07-Sep-2021 , 08-Dec-2021 , 07 7-Jan-2023 , 08-Apr-2023 , 07-May-202	PAR-21- 08- 093 -Jan-2022 , 08-A 23 , 08-Aug-2023	-Apr-2021 Apr-2022 , 07-May-2 3 , 07-Sep-2023 , 08	Not Specified 2022 , 08-Aug- -Dec-2023 , 07-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		by a spons	sor or co-sponsor.				
090099	Advancing HIV/AIDS Research wit Clinical Trial Optional)	hin the Mis	ssion of the NIDCD (R01	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20- 127 0	7-May-2021	2,499,995 USD
	Contact Name	Trinh T. Ly	ı, MD				
	Contact Telephone	301-435-4	085				
	Contact Email	trinh.ly@r	nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021,07-Sep-2021,07-Jan-2	2022 , 07-May-2022 , 07-Sep-2022 , 07	-Jan-2023		
	Synopsis	areas of th priority HI research/ a clinical t	ne National Institute on Dea IV/AIDS research outlined by research-priorities] in the ar rial, only low risk clinical tria	thess and Other Communications Disc y the NIH Office of AIDS Research (OAI eas of hearing, balance, taste, smell, v als will be supported.	orders (NIDCD) R) [https://ww voice, speech, a	. Applications should w.oar.nih.gov/hiv-pol and language. For app	address high icy-and- llications with
090106	Advancing HIV/AIDS Research wit Clinical Trial Optional)	hin the Mis	ssion of the NIDCD (R21	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20- 123 0	7-May-2021	275,000 USD
	Contact Name	Trinh T. Ly	ı, MD				
	Contact Telephone	301-435-4	085				
	Contact Email	trinh.ly@r	nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2	021,07-Sep-2021,07-Jan-2	2022 , 07-May-2022 , 07-Sep-2022 , 07	-Jan-2023		
	Synopsis	The purpc areas of th priority HI research/i	ose of this Funding Opportune National Institute on Dea W/AIDS research outlined by research-priorities] in the ar	nity Announcement (FOA) is to stimula fness and Other Communications Disc y the NIH Office of AIDS Research (OAI reas of hearing, balance, taste, smell, v	nte HIV/AIDS re orders (NIDCD) R) [https://ww voice, speech, a	esearch within the scie . Applications should w.oar.nih.gov/hiv-pol and language. For app	entific mission address high icy-and- lications with

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		a clinical t	rial, only low risk clinical tria	als will be supported.				
078368	Advancing Research in Augmenta (AAC) (R21 Clinical Trial Optional)	tive and Al	ternative Communication	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-046 07-N	Nay-2021	275,000 USD	
	Contact Name	Lana Shek	im, Ph.D.					
	Contact Telephone	301-496-5	061					
	Contact Email	<u>shekiml@</u>	nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-20	021 , 16-Jun-2021 , 07-Sep-2	2021 , 16-Oct-2021 , 07-Jan-2022				
	alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals Synopsis complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools an strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encoura range of research inclusive of basic, clinical, and translational.							
078310	Advancing Research in Augmenta (AAC) (R01 Clinical Trial Optional)	tive and Al	ternative Communication	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-047 07-N	Лау-2021	Not Specified	
	Contact Name	Lana Shek	im, Ph.D.					
	Contact Telephone	301-496-5	061					
	Contact Email	shekiml@	nidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-20	021 , 05-Jun-2021 , 07-Sep-2	2021 , 05-Oct-2021 , 07-Jan-2022				
	Synopsis	This fundi Alternativ severe spe communic	ng opportunity announceme e Communication (AAC) to a eech and physical impairme cative challenges. This FOA i	ent (FOA) seeks Research Project Grar advance our scientific knowledge in th nts (SSPI). AAC is a set of tools and str s for R01s only and encourages a rang	nts (R01) application e evaluation and t rategies that an in- re of research inclu	ons on Augmentat treatment of indiv dividual uses to so usive of basic, clini	ive and iduals with plve everyday ical, and	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		translatio	nal.				
101155 <u>1</u>	NIDCD Low Risk Clinical Trials in Co Trial Required)	ommunica	ation Disorders (R01 Clinical	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 063	-May-2021	2,499,995 USD
	Contact Name	Trinh T. L	y, M.D.				
	Contact Telephone	301-435-	4085				
	Contact Email	<u>trinh.ly@</u>	<u>nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05	2021 , 05-Jun-2021 , 07-Sep-20 -Oct-2022 , 07-Jan-2023 , 05-	021 , 05-Oct-2021 , 07-Jan-2022 , 05- Feb-2023 , 07-May-2023 , 05-Jun-202	Feb-2022 , 07-M 3 , 07-Sep-2023	ay-2022 , 05-Jun-20 , 05-Oct-2023 , 07)22 , 07-Sep- Jan-2024
	Synopsis	The NIDC disorders supports must mee formally or risk trials definition in each N above are Disorders	D is committed to identifying by supporting well-designed investigator initiated low risk et ALL the following criteria: r establish efficacy and have low determined to be Basic Scien of a clinical trial and also me IDCD Clinical Trials in Commu e referred companion U01 FO 5.	effective interventions for the diagno and well-executed clinical trials. This clinical trials addressing the mission neet the budget limits of this FOA, no w risks to potentially cause physical o ce Experimental Studies involving Hu set the definition of basic research. It inication Disorders R01 application. H A PAR-21-064, NIDCD Cooperative Ag	osis, prevention, funding opportu and research int it require FDA ov r psychological I mans (BESH). Th is advisable that igh risk clinical t greement for Cli	or treatment of co unity announcemen erests of NIDCD. Cli versight, are not int narm. This FOA also uese studies fall with only one clinical tri rials not meeting al nical Trials in Comm	mmunication t (FOA) nical trials ended to supports low nin the NIH fal be proposed I the criteria nunication
101736 <u> </u> 	NDCD Research Career Enhancem nvestigators (K18 Independent Ba Aumans Required)	<u>nent Awar</u> asic Exper	<u>d for Established</u> imental Studies with	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 096	-May-2021	Not Specified
	Contact Name	Alberto L	. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-	1804				
	Contact Email	riverara@	nidcd.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2022 , 07	2021 , 08-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 06-Fe	21 , 08-Oct-2021 , 07-Jan-2022 , 08- 26-2023 , 07-May-2023 , 08-Jun-202	Feb-2022 , 07-Ma 23 , 07-Sep-2023 ,	y-2022 , 07-Jun-20 10-Oct-2023 , 07-J)22 , 07-Sep- Jan-2024
	Synopsis	establishe skills to a Opportur "prospecti biomedic without s processes Establishe experime humans li for Establ	ed, proven investigators to aug nswer questions relevant to the nity Announcement is for basic tive basic science studies involve meet the definition of basic rest vely assign human participants al or behavioral outcomes in he pecific application towards pro- s or products in mind should su ed Investigators (K18 Clinical Tr intal study with humans, or pro- ed by another investigator, mu- lished Investigators (K18Indepe	ment or redirect their research pro- e hearing, balance, smell, taste, voi science experimental studies involv- ving human participants." These stu- earch. Types of studies that should to conditions (i.e., experimentally in umans for the purpose of understar ocesses or products in mind. Studies abmit under PAR-21-094 "NIDCD Re- rial Required)"' Applicants not plann posing to gain research experience st apply to companion FOA PAR-21- endent Clinical Trial Not Allowed)".	grams through the ce, speech and lar ving humans, refer dies fall within the submit under thi manipulate independing the fundame conducted with s esearch Career Enh ning an independe in a clinical trial o -095 "NIDCD Rese	e acquisition of ne aguage sciences. The red to in NOT-OD- e NIH definition of s FOA include stuce endent variables) a ental aspects of phe specific application nancement Award int clinical trial or he r basic experiment arch Career Enhar	w research his Funding -18-212 as a clinical trial lies that and that assess nenomena is toward for pasic tal study with neement Award
101734	NIDCD Research Career Enhancen Investigators (K18 Independent C	nent Awar linical Tria	rd for Established C I Not Allowed) C	lational Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 095	Лау-2021	Not Specified
	Contact Name	Alberto L	. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-3	1804				
	Contact Email	riverara@	nidcd.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07	2021 , 08-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 06-Fe	21 , 08-Oct-2021 , 07-Jan-2022 , 08- 2b-2023 , 07-May-2023 , 08-Jun-202	Feb-2022 , 07-Ma 23 , 07-Sep-2023 ,	y-2022 , 07-Jun-20 10-Oct-2023 , 07-J	122 , 07-Sep- Jan-2024
	Synopsis	The purpe establishe skills to a Opportur independ	ose of the NIDCD Research Car ed, proven investigators to aug nswer questions relevant to the nity Announcement (FOA) is de lent clinical trial, a clinical trial	eer Enhancement Award for Establi ment or redirect their research pro- e hearing, balance, smell, taste, voi- signed specifically for applicants pro- feasibility study or an ancillary study	shed Investigators grams through the ce, speech and lar oposing research t y to a clinical trial.	s (K18) program is e acquisition of ne nguage sciences. T hat does not invo proposing to serv	to enable w research his Funding lve leading an re as the lead

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		investigat independ companic	or of an independent clinical t ent clinical trial, or proposing t on FOA PAR-21-094 or for PAR-	rial, as part of their research and car o gain research experience in a clini 21-096 for Independent Basic Exper	reer developmen cal trial led by an imental Studies v	t. Those planning a other investigator, vith Humans Requi	n must apply to red.
101733	NIDCD Research Career Enhancen Investigators (K18 Clinical Trial Re	<u>nent Awar</u> quired)	d for Established C C	lational Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 094 07-1	Лау-2021	Not Specified
	Contact Name	Alberto L	Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-2	1804				
	Contact Email	<u>riverara@</u>	nidcd.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022,07	021 , 08-Jun-2021 , 07-Sep-202 ·Oct-2022 , 07-Jan-2023 , 06-Fe	21 , 08-Oct-2021 , 07-Jan-2022 , 08-l 2b-2023 , 07-May-2023 , 08-Jun-202	Feb-2022 , 07-Ma 3 , 07-Sep-2023 ,	y-2022 , 07-Jun-20 10-Oct-2023 , 07-J	22 , 07-Sep- an-2024
	Synopsis	The purpe establishe skills to a Opportur independ career de trial led b trial, but Career En Required	ose of the NIDCD Research Car ed, proven investigators to aug nswer questions relevant to th ity Announcement (FOA) is de ent clinical trial, a clinical trial velopment. Those not planning y another investigator, must a planning a basic experimental hancement Award for Establis	eer Enhancement Award for Establis ment or redirect their research prog e hearing, balance, smell, taste, void signed specifically for candidates pro feasibility study, or a separate ancill g an independent clinical trial, or pro oply to companion FOA (PAR-21-095 study with humans, must apply to con hed Investigators (K18 Independent	shed Investigator grams through th ce, speech and lar oposing to serve ary clinical trial, a oposing to gain re 5). Applicants not ompanion FOA PA Basic Experimen	s (K18) program is e acquisition of new nguage sciences. Th as the lead investig s part of their rese esearch experience planning an indep AR-21-096 - NIDCD tal Studies with Hu	to enable w research his Funding ator of an arch and in a clinical endent clinical Research mans
101085	NIDCD Mentored Career Developm Au.D./Ph.D. Audiologists (K01 Indevited Mith Humans Required)	<u>ment Awa</u> ependent	rd for Postdoctorate N Basic Experimental Studies C C	lational Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 087 07-1	May-2021	315,000 USD
	Contact Name Contact Telephone Contact Email	Alberto L. 301-496-: <u>riverara@</u>	Rivera-Rentas, Ph.D. 1804 Pnidcd.nih.gov				



SPIN ID	Program Title	S	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website								
	Program URL	Link to prog	gram URL						
	Deadline Dates (ALL)	07-May-202 2022 , 13-0	21 , 17-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 14-Fe	21 , 13-Oct-2021 , 07-Jan-2022 , 17- b-2023 , 07-May-2023 , 13-Jun-202	Feb-2022 , 07-Ma 3 , 07-Sep-2023 ,	y-2022 , 14-Jun-20 13-Oct-2023 , 07-	022 , 07-Sep- Jan-2024		
The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. support comprehensive and rigorous postdoctoral research and career development experience behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to independent investigators in scientific health-related research fields relevant to NIDCD's mission Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announce experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic scien participants." These studies fall within the NIH definition of a clinical trial and also meet the der research. Types of studies that should submit under this FOA include studies that prospectively conditions (i.e., experimentally manipulate independent variables) and that assess biomedical of humans for the purpose of understanding the fundamental aspects of phenomena without spec processes or products in mind. Studies conducted with specific applications toward processes or submit under the appropriate 'Independent Clinical Trial Required' (PAR-21-085). Applicants no clinical trial, or proposing to gain research in a clinical trial led by another investigator must app 'Independent Clinical Trial Not Allowed' (PAR-21-086) FOA.							K01) is to dical, ctive, ed Career sic science volving human participants to atcomes in towards ind should ndependent anion		
101080	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 No	ment Award Independen	l <u>for Postdoctorate</u> C <u>ot Clinical Trials)</u> D	lational Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 086 07-N	/lay-2021	315,000 USD		
	Contact Name	Alberto L. R	Rivera-Rentas, Ph.D.						
	Contact Telephone	301-496-18	304						
	Contact Email	<u>riverara@n</u>	<u>iidcd.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to prog	gram URL						
	Deadline Dates (ALL)	07-May-202 2022 , 13-0	07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep- 2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024						
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical,							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
		behaviora independ Announce clinical tri propose a study to a Required	al, or clinical sciences of promi ent investigators in scientific h ement (FOA) is designed specif al, a clinical trial feasibility stu a research experience in a clini an ongoing clinical trial as lead or for PAR-21-087 for Indeper	sing Au.D./Ph.D. audiologists who have lealth-related research fields relevan fically for candidates proposing rese dy, or an ancillary study to a clinical cal trial led by a mentor or co-mentor investigator, should apply to the co indent Basic Experimental Studies wit	ave the potential t nt to NIDCD's miss arch that does no trial. Under this F or. Those proposir mpanion FOA PAF ch Humans Requir	to become products sion. This Funding t involve leading a OA candidates are ng a clinical trial or R-21-085 for Clinica ed	tive, Opportunity n independent e permitted to r an ancillary al Trial	
101078	NIDCD Mentored Career Develop Au.D./Ph.D. Audiologists (K01 Clin	ment Awa iical Trial R	rd for Postdoctorate Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21- 085 07-N	Лау-2021	315,000 USD	
	Contact Name	Alberto L	. Rivera-Rentas, Ph.D.					
	Contact Telephone	301-496-2	1804					
	Contact Email	<u>riverara@</u>	onidcd.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 13	021 , 17-Jun-2021 , 07-Sep-20 -Oct-2022 , 07-Jan-2023 , 14-F	21 , 13-Oct-2021 , 07-Jan-2022 , 17- eb-2023 , 07-May-2023 , 13-Jun-202	Feb-2022 , 07-Ma 3 , 07-Sep-2023 ,	y-2022 , 14-Jun-20 13-Oct-2023 , 07)22 , 07-Sep- lan-2024	
	Synopsis	Synopsis Synopsis Synopsis Synopsis						

077346 <u>HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)</u> Abuse/NIH/DHHS 915 07-May-2021 Specified

Contact Name Richard A. Jenkins, Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		201 442 1022				
		301-443-1923				
		Jenkinsri@mail.nin.gov				
	Sponsor website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021, 07-Sep-2021	A 1			
	Synopsis	This FOA will use the NIH Research Pr	A invites applications for high prior oject (R01) award mechanism.	rity research relevant	t to drug misuse ai	nd HIV/AIDS.
077319	AIDS-Science Track Award for Res Optional)	earch Transition (R03 Clinical Trial	National Institute on Drug Abuse/NIH/DHHS	PA-18-916 07-N	/lay-2021	200,000 USD
	Contact Name	Richard A. Jenkins, Ph.D.				
	Contact Telephone	301-443-1923				
	Contact Email	jenkinsri@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021				
	Synopsis	National Institute on Drug Abuse (NID investigators to the area of drug use a Research Transition (A-START), encou misuse and/or use disorder and HIV/A welcomes applications integrating dru NIDA. This program will use the NIH S	A) provides support to facilitate the and use disorder research and HIV/ rages Small Research Grant (RO3) a NDS that can be carried out in a sho g misuse and/or use disorder and b mall Research Grant (RO3) award m	e entry of both newly AIDS. This FOA, AIDS pplications to suppo ort period of time wit HIV/AIDS across all a nechanism.	y independent and S-Science Track Aw rt research projec th limited resource reas of research so	l early career ard for ts on drug es. This FOA upported by
084960	NIDA Program Project Grant Appli	ications (P01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 345 07-N	/lay-2021	Not Specified
	Contact Name	Kevin Walton, Ph.D.				
	Contact Telephone	301-827-5980				
	Contact Email	waltonkm@nida.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	07-May-2 2022	021 , 25-May-2021 , 07-Sep-	2021 , 25-Sep-2021 , 07-Jan-2022 , 2	25-Jan-2022 , 07-Ma	ay-2022 , 25-May-2	2022 , 07-Sep-	
	Synopsis	This Fund disciplina research more high significan duration advance t	ing Opportunity Announcem ry teams which is of high prio approaches. The NIDA Progra hly meritorious projects as a t scientific advantages over s of the award, each Program is the mission and goals of NIDA	ent (FOA) announces the availability prity to NIDA and leads to synergistic am Projects funding opportunity will group enriches both the component upporting the same projects as indi- must consist of a minimum of three A.	y of support for colla c outcomes based o l support research in t projects and the ov vidual research grar research projects fo	aborative research n the synthesis of n which the fundir verall program to nts (i.e., synergy). ocused on issues c	n by multi- multiple ng of three or offer For the ritical to	
094123	Substance Use/Substance Use Dis (R36 - Clinical Trials Optional)	order Diss	ertation Research Award	National Institute on Drug Abuse/NIH/DHHS	PA-20-208 07-N	1ay-2021	100,000 USD	
	Contact Name	Aria Crum	ıp, Sc.D.					
	Contact Telephone	301-435-0	0881					
	Contact Email	acrump@	nida.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16	021 , 16-Jun-2021 , 07-Sep-2 -Oct-2022 , 07-Jan-2023 , 16-	021 , 16-Oct-2021 , 07-Jan-2022 , 16 Feb-2023 , 07-May-2023	5-Feb-2022 , 07-May	y-2022 , 16-Jun-20	22 , 07-Sep-	
	The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detail here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan Synopsis (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).							
100294	Notice of Special Interest (NOSI): in Substance Use Disorders	Neuroimm	nune Signaling and Function	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 20-046 07-N	1ay-2021	Not Specified	
	Contact Name	Roger G S	orensen, Ph.D., MPA					
	Contact Telephone	301-443-3	3205					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Contact Email	rsorense@nida.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-20 2022 , 05-Feb-2022 , 16-Feb-2022 , 25- Oct-2022 , 16-Oct-2022 , 25-Oct-2022 16-Jun-2023 , 25-Jun-2023 , 07-Sep-20	021 , 25-Jun-2021 , 07-Sep-2021 , 05- -Feb-2022 , 07-May-2022 , 05-Jun-20 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb 23	-Oct-2021 , 16-Oct 22 , 16-Jun-2022 , -2023 , 25-Feb-202	-2021 , 25-Oct-202 25-Jun-2022 , 01-3 23 , 07-May-2023 ,	21 , 07-Jan- Sep-2022 , 05- , 05-Jun-2023 ,			
	The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.								
084606	Grand Opportunity in Medications Disorders (U01 - Clinical Trial Optic	<u>s Development for Substance-Use</u> onal)	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 327 01-N	/lay-2021	15,000,000 USD			
	Contact Name	Ivan D. Montoya, M.D., M.P.H.							
	Contact Telephone	301-827-5936							
	Contact Email	<u>imontoya@mail.nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-May-2021, 01-Sep-2021, 01-Jan-2	022 , 01-May-2022 , 01-Sep-2022						
	The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to \$5 million per year) cooperative agreements with close monitoring and significant scienti involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.								
071556	Women & Sex/Gender Differences Abuse/Dependence (R01 Clinical T	s in Drug and Alcohol Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-603 07-N	/lay-2021	Not Specified			
	Contact Name	Cora Lee Wetherington, Ph.D.							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telenhone	301-435-1	1319				
	Contact Email	cwetheri	ອmail nih gov				
	Sponsor Website	eweenene					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021				
	Synopsis	National I applicatio mechanis specific to alcohol re	nstitute on Drug Abuse (NIDA ons to (1) advance identificatio ms of those differences, and t o women or highly relevant to esearch. This FOA will use the l) and National Institute on Alcohol A n of male-female differences in drug o conduct translational research on women. Both preclinical and clinica NIH Research Project (R01) award me	buse and Alcoho g and alcohol reso those differences l studies are soup echanism.	lism (NIAAA) invite earch outcomes, to s, and (2) to advanc ght across all areas	uncover the e research of drug and
085474	Accelerating the Pace of Drug Abu Clinical Trial Optional)	<u>ise Resear</u>	ch Using Existing Data (R01	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 368 07-	May-2021	2,499,995 USD
	Contact Name	Marsha F	. Lopez, Ph.D., M.H.S.				
	Contact Telephone	301-443-6	5504				
	Contact Email	<u>marsha.lc</u>	opez@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-20	21			
	Synopsis Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, preventio of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective an efficient services for the prevention and treatment of substance use disorder and HIV.						
101989	Notice of Special Interest (NOSI): Consequences of COVID-19 in Ind Use Disorders	Long-Term ividuals Liv	Neurocognitive ving with HIV and Substance	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-018 07-	May-2021	Not Specified

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Raul Mandler, MD					
	Contact Telephone	301-480-2541					
	Contact Email	mandlerr@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07 2022 , 05-Oct-2022 , 07-Jan-202 Feb-2024 , 07-May-2024 , 05-Ju	-Sep-202 3 , 05-Fe n-2024 ,	21 , 05-Oct-2021 , 07-Jan-2022 , 05-I 2b-2023 , 07-May-2023 , 05-Jun-202 07-Sep-2024	eb-2022 , 07-May 3 , 07-Sep-2023 ,	y-2022 , 05-Jun-20 05-Oct-2023 , 07-J	22 , 07-Sep- an-2024 , 05-
	Synopsis	NIDA is interested in receiving r COVID-19/HIV/SUDs syndemic.	esearch	applications focusing on studying th	e long-term neur	ocognitive conseq	uences of the
074442	International Research Collaboration Research (R01 Clinical Trial Option	on on Drug Abuse and Addictior al)	<u>n</u> N A	lational Institute on Drug buse/NIH/DHHS	PA-18-773 07-N	/lay-2021	Not Specified
	Contact Name	Steven Gust, Ph.D., Director					
	Contact Telephone	301-443-6480					
	Contact Email	ipdirector@nida.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2021					
National Institute on Drug Abuse (NIDA) solicits collaborative research applications on drug abuse and addiction that: Tak advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery; Describe how the research will significant advance U.S. health sciences; Demonstrate specific relevance to the NIDA mission and objectives. To determine whether research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NI international scientific priority areas (https://www.drugabuse.gov/international/research-priorities); and Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. This FOA will use NIH Research Project (R01) award mechanism.							n that: Take s, or significantly e whether your address NIDA's de an A will use the
079379	Accelerating the Pace of Child Hea the Adolescent Brain Cognitive Dev	Ith Research Using Existing Data velopment (ABCD) Study (R01-C	<u>from</u> N linical A	lational Institute on Drug buse/NIH/DHHS	PAR-19- 162 07-N	/lay-2021	1,250,000 USD

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
1	rial Not Allowed)	1							
	Contact Name	Karen Siro	оссо						
	Contact Telephone	301-451-8	8661						
	Contact Email	siroccok@	Dnida.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 05-Jun-2021 , 07-Sep-20	021					
	Synopsis Synopsis								
077321 <u>f</u>	Developing the Therapeutic Poter or Pain Treatment (R01 - Clinical	ntial of the Trial Optic	<u>e Endocannabinoid System</u> onal <u>)</u>	National Institute on Drug Abuse/NIH/DHHS	PA-18-917 07-N	/lay-2021	Not Specified		
	Contact Name	David Tho	omas, PhD						
	Contact Telephone	301-435-1	1313						
	Contact Email	dthomas1	<u>1@nida.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 05-Jun-2021 , 07-Sep-20	021					
	Synopsis	National I elucidate based the	Institutes of Health (NIH) and the therapeutic potential of t erapies for pain. This FOA will	its participating Institutes and Cent he cannabinoids and endocannabir use the NIH Research Project (R01)	ers invite application noid system in the d award mechanism.	ons for projects th development of m	at will echanism-		
102016	Notice of Special Interest (NOSI): and Vaping Drugs of Abuse in Indi	Medical Co	onsequences of Smoking th HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-017 07-N	May-2021	Not Specified		
	Contact Name	Raul Man	dler, MD						
	Contact Telephone	301-480-2	2541						
			NUL Funding Onne	thuridian Duar May 2024					

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	mandlerr	<u>@nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023 16-Feb-20	2021 , 05-Jun-2021 , 16-Jun-20 -May-2022 , 05-Jun-2022 , 16- , 07-May-2023 , 05-Jun-2023 024 , 07-May-2024 , 05-Jun-20	21 , 07-Sep-2021 , 05-Oct-2021 , 16- Jun-2022 , 07-Sep-2022 , 05-Oct-202 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct 24 , 16-Jun-2024 , 07-Sep-2024	Oct-2021 , 07-Jan- 22 , 16-Oct-2022 , (-2023 , 16-Oct-20	-2022 , 05-Feb-202 07-Jan-2023 , 05-F 23 , 07-Jan-2024 ,	22 , 16-Feb- eb-2023 , 16- 05-Feb-2024 ,	
	Synopsis	NIDA is in cocaine a	terested in receiving research nd/or methamphetamine to c	applications focusing on individuals letermine the long-term effects of th	with HIV who smo neir use among inc	oke or vape mariju dividuals with HIV	Jana, tobacco, and COVID-19.	
090993 <u> </u>	NIDA Small Research Grant Progra	am (RO3 Cl	linical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20-146 07-N	/lay-2021	100,000 USD	
	Contact Name	Katrina L	Foster, PhD					
	Contact Telephone	301-827-5	5815					
	Contact Email	fosterkl@	nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16	2021 , 16-Jun-2021 , 07-Sep-20 -Oct-2022 , 07-Jan-2023 , 16-F	21 , 16-Oct-2021 , 07-Jan-2022 , 16- eb-2023 , 07-May-2023	Feb-2022 , 07-May	y-2022 , 16-Jun-20	22 , 07-Sep-	
	Synopsis	The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.						
102120	Notice of Special Interest (NOSI): vith HIV and Substance Use Disor	<u>Telehealth</u> : <u>ders</u>	Strategies for Individuals	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-019 07-N	Nay-2021	Not Specified	
	Contact Name Contact Telephone	Raul Man 301-480-2	dler, MD 2541					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	mandlerr@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-20 2022 , 07-May-2022 , 05-Jun-2022 , 16 Feb-2023 , 07-May-2023 , 05-Jun-2023 16-Feb-2024 , 07-May-2024 , 05-Jun-2	021 , 07-Sep-2021 , 05-Oct-2021 , 16 -Jun-2022 , 07-Sep-2022 , 05-Oct-20 , 16-Jun-2023 , 07-Sep-2023 , 05-Oc 024 , 16-Jun-2024 , 07-Sep-2024	-Oct-2021 , 07-Jan 22 , 16-Oct-2022 , t-2023 , 16-Oct-20	-2022 , 05-Feb-202 07-Jan-2023 , 05-F)23 , 07-Jan-2024 ,	!2 , 16-Feb- eb-2023 , 16- 05-Feb-2024 ,		
The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to Synopsis explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).								
077343	Imaging - Science Track Award for Clinical Trial Optional)	Research Transition (I/START) (R03	National Institute on Drug Abuse/NIH/DHHS	PAR-18- 918 07-1	May-2021	150,000 USD		
	Contact Name	Steven Grant, Ph.D.						
	Contact Telephone	301-443-4877						
	Contact Email	sgrant@nida.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2	021					
	Synopsis	National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.						
083682	Behavioral Science Track Award fo Clinical Trial Optional)	or Rapid Transition (B/Start)(RO3	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 310 07-1	May-2021	75,000 USD		
	Contact Name	Holly Moore, Ph.D.						
	Contact Telephone	301-827-7376						
	Contact Email	holly.moore@nih.gov						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep	o-2021, 16-Oct-2021, 07-Jan-2022					
Synopsis Synopsis								
071560	Women & Sex/Gender Difference Abuse/Dependence (R21 Clinical	es in Drug and Alcohol Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-602 07-N	1ay-2021	275,000 USD		
	Contact Name	Cora Lee Wetherington, Ph.D.						
	Contact Telephone	301-435-1319						
	Contact Email	<u>cwetheri@mail.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021						
	National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the Synopsis mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.							
071562	Women & Sex/Gender Difference Abuse/Dependence (R03 Clinical	es in Drug and Alcohol Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-601 07-N	1ay-2021	100,000 USD		
	Contact Name	Cora Lee Wetherington, Ph.D.						
	Contact Telephone	301-435-1319						
	Contact Email	cwetheri@mail.nih.gov						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021						
	Synopsis	National application mechanis specific to alcohol re	Institute on Drug Abuse (NIDA) ons to (1) advance identification sms of those differences, and to o women or highly relevant to v esearch. This FOA will use the N	and National Institute on Alcohol A o of male-female differences in drug conduct translational research on women. Both preclinical and clinica IH RO3 Small Grant Program award	buse and Alcoholi g and alcohol rese those differences, al studies are soug mechanism.	ism (NIAAA) invite arch outcomes, to , and (2) to advanc ht across all areas	uncover the e research of drug and		
079380 <u>t</u>	Accelerating the Pace of Child Hea he Adolescent Brain Cognitive De Frial Not Allowed)	alth Resea evelopmer	rch Using Existing Data from N nt (ABCD) Study (R21-Clinical A	ational Institute on Drug buse/NIH/DHHS	PAR-19- 163 07-N	Лау-2021	275,000 USD		
	Contact Name	Karen Sir	оссо						
	Contact Telephone	301-451-	8661						
	Contact Email	<u>siroccok(</u>	<u>စာnida.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	rogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 16-Jun-2021 , 07-Sep-202	21					
	Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).							
101618	Pilot and Feasibility Studies in Pre Prevention Trials (R34 Clinical Tria	paration f Il Optiona	or Substance Use N	ational Institute on Drug buse/NIH/DHHS	PA-21-110 07-N	/lay-2021	450,000 USD		
	Contact Name	Amy B. G	oldstein, PhD						
	Contact Telephone	301-827-	4124						
	Contact Email	amy.gold	<u>stein@nih.gov</u>						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Sponsor Website								
	Program URL	ink to program URL							
	Deadline Dates (ALL))7-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-F€	21 , 16-Oct-2021 , 07-Jan-2022 , 16- eb-2023 , 07-May-2023 , 16-Jun-202	Feb-2022 , 07-May 23 , 07-Sep-2023 , 1	y-2022 , 16-Jun-20 16-Oct-2023 , 07-J	22 , 07-Sep- lan-2024			
	ר י Synopsis י י י י י י י י י י י י י י י י י י	esearch in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the nitiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining uestions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to ntervention, and/or other service system-based research to address areas such as economics, funding, service quality and ngagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the esearch supported through this FOA include a reduction in negative sequalae such as deaths related to impaired driving, uicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and iral hepatitis among diverse populations and settings.							
074542	Development and Testing of Novel Prevention, Care, and Program Imp Optional)	Interventions to Improve HIVNIlementation (R34-Clinical TrialA	lational Institute on Drug buse/NIH/DHHS	PA-18-780 07-N	1ay-2021	450,000 USD			
	Contact Name F	Richard A. Jenkins, PhD							
	Contact Telephone	301-443-1923							
	Contact Email j	<u>enkinsri@mail.nih.gov</u>							
	Sponsor Website								
	Program URL <u>L</u>	<u>ink to program URL</u>							
	Deadline Dates (ALL) ()7-May-2021							
	Synopsis National Institute on Drug Abuse (NIDA) invites applications for formative research, intervention development, and pilot- testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of nove or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who ar HIV infected. This FOA will use the NIH R34 Planning Grant award mechanism.								
074449	Pilot Health Services and Economic Alcohol, and Tobacco Use Disorder	Research on the Treatment of Drug, s (R34 Clinical Trial Optional)N	lational Institute on Drug buse/NIH/DHHS	PA-18-774 07-№	Nay-2021	450,000 USD			
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
---------	--	--	--	---	--	--	--		
		1							
	Contact Name	Sarah Q. D	Duffy, Ph.D.						
	Contact Telephone	301-451-4	4998						
	Contact Email	<u>duffys@ni</u>	<u>ida.nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-2	021						
	Synopsis	for pilot a a wide rar effectiven services fo and those feasibility, NIH R34 P	nd preliminary research in pro- nge of approaches, including i bess, affordability and utilization or comorbid medical and men that are commonly used in p , acceptability, and utility of the Planning Grant grant mechanis	eparation for larger-scale services re nterventions, practices, and policies on of drug, tobacco, or alcohol use d tal disorder conditions. Relevant app ractice but lack an evidence base. Th nese approaches, in addition to usua sm.	search effectivene designed to optin isorder treatment proaches may incl his FOA provides r I trial preparation	ess trials. Relevant nize access to, and is and related serv ude both those the esources for assess activities. This FO	trials may test the quality, ices, as well as at are novel, sing the A will use the		
082413	Exploratory Clinical Neuroscience (R61/R33 Clinical Trial Optional)	Research o	on Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	PAR-19- 282 07-N	Лау-2021	Not Specified		
	Contact Name	Vani Pariy	vadath, Ph.D.						
	Contact Telephone	301-443-3	3209						
	Contact Email	vani.pariy	adath@nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-2	021 , 13-Oct-2021 , 07-Jan-20	22 , 11-Jul-2022 , 07-Sep-2022 , 10-N	/lar-2023 , 07-Ma	y-2023			
	Synopsis	This Fundi research a mechanisi projects n (e.g., Neu	ing Opportunity Announceme applications that are explorate ms underlying Substance Use ot requiring a phased researc roscience Research on Drug A	nt (FOA) uses a R61/R33 Phased Inn ory and developmental in nature and Disorders (SUD), including fundame h approach, applicants are encourag buse (R01 Clinical Trial Optional).	ovation Award mo l focus on underst ntal brain function ed to apply unde	echanism to suppo tanding the neurol n relevant to subst r a different fundir	rt clinical biological ance use. For ng mechanism		
102446	Notice of Special Interest (NOSI): Knowledge and Program Planning	<u>Using Data</u> [to Advance HIV Epidemic	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 21-007 07-N	May-2021	Not Specified		
**									

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Richard A	lenkins PhD				
	Contact Telephone	301-443-2	1923				
	Contact Email	jenkinsri@	Dmail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07- Feb-2023 16-Feb-20	021 , 05-Jun-2021 , 16-Jun-202 -May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 ,)24 , 07-May-2024 , 05-Jun-202	1 , 07-Sep-2021 , 05-Oct-2021 , 16- un-2022 , 07-Sep-2022 , 05-Oct-202 16-Jun-2023 , 07-Sep-2023 , 05-Oct 4 , 16-Jun-2024 , 07-Sep-2024	Oct-2021 , 07-Jan- 2 , 16-Oct-2022 , -2023 , 16-Oct-20	2022 , 05-Feb-202 07-Jan-2023 , 05-F 23 , 07-Jan-2024 ,	22 , 16-Feb- Feb-2023 , 16- 05-Feb-2024 ,
	The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of subst use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to incret the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions well as other publicly available data including those provided by government bodies, data warehouses and commercial sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public point is particularly interested in research that integrates substance use considerations into program planning and policies is provided by the guidemices and their recognises to substance using nonvelations.						
091070 <mark>E</mark>	Extracellular RNA Carrier Subclass Use Disorders or HIV infection (R2	ses in Proce 21- Clinical	esses Relevant to Substance N Trial Not Allowed) A	ational Institute on Drug buse/NIH/DHHS	PAR-20- 148 07-N	1ay-2021	275,000 USD
	Contact Name	John Satt	erlee, Ph.D				
	Contact Telephone	301-435-2	1020				
	Contact Email	<u>satterleej</u>	<u>@nida.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2023	021 , 13-Oct-2021 , 07-Jan-202	2 , 15-Mar-2022 , 07-May-2022 , 13	-Oct-2022 , 07-Ja	n-2023 , 15-Mar-2	.023 , 07-May-
	Synopsis	The purpo	ose of this FOA is to encourage	research investigating the roles of e	extracellular RNA	(exRNA) carrier su	bclasses in

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		biological Applicant improved	processes relevant to substa s may propose to investigate technologies to investigate e	nce use disorders (SUDs) and/or HIV biological mechanisms involving exR extracellular vesicles or other exRNA o	infection, late NA carrier sul carriers.	ency, or pathogenesis bclasses, or propose to	in the CNS. develop
091068	Extracellular RNA Carrier Subclass Use Disorders or HIV infection (RC	<u>es in Proce</u>)1- Clinical	esses Relevant to Substance Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20- 147	07-May-2021	Not Specified
	Contact Name Contact Telephone	John Satto 301-435-2	erlee, Ph.D 1020				
	Contact Email Sponsor Website	<u>satterleej</u>	<u>@nida.nih.gov</u>				
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2023	<u>ogram URL</u> 021 , 13-Oct-2021 , 07-Jan-20	022 , 15-Mar-2022 , 07-May-2022 , 13	3-Oct-2022 , ()7-Jan-2023 , 15-Mar-2	2023 , 07-May-
	Synopsis	The purpo biological Applicant improved	ose of this FOA is to encourag processes relevant to substa s may propose to investigate technologies to investigate e	e research investigating the roles of nce use disorders (SUDs) and/or HIV biological mechanisms involving exR extracellular vesicles or other exRNA	extracellular infection, late NA carrier su carriers.	RNA (exRNA) carrier su ency, or pathogenesis bclasses, or propose to	ibclasses in in the CNS. develop
097934	Notice of Special Interest (NOSI): Type 2 Diabetes Mellitus from He	Comprehe alth Dispai	nsive Care for Adults with rity Populations	National Institute on Minority Health and Health Disparities/NIH/DHHS	NOT-MD- 20-026	07-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Larissa Av 301-827-6 avilessant Link to pr 07-May-2 The purpo on develo	viles-Santa, MD, MPH 5924 <u>cal@nih.gov</u> 0g <u>ram URL</u> 021 ose of this Notice of Special Ir oping and testing multi-level s	nterest is to support multidisciplinary trategies to effectively implement re	, investigative commended	e and collaborative res guidelines of compreh	earch focused ensive clinical
091370	NIMHD Exploratory/Development	care for ir	ndividuals with Type 2 diabete <u>h Grant Program (R21 -</u>	es from health disparity populations. National Institute on Minority Health	1 PAR-20-	07-May-2021	275,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Clinical Trial Optional)		ar	nd Health Disparities/NIH/DHHS	150		USD
	Contact Name						
	Contact Telephone	301-402-1	366				
	Contact Email	<u>GrantsInfo</u>	@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	gram URL				
	Deadline Dates (ALL)	07-May-20 2022 , 16-0	021 , 16-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 16-Fe	1 , 16-Oct-2021 , 07-Jan-2022 , 16-F b-2023 , 07-May-2023	eb-2022 , 07-Ma	y-2022 , 16-Jun-202	22 , 07-Sep-
	Synopsis	NIMHD inv break new directions U.S.	vites applications to support sh ground in the fields of minorit or applications that can direct	ort-term exploratory or developme ty health and/or health disparities o ly contribute to improving minority	ntal research pro r extend previou: health and/or reo	jects that have the s discoveries towar ducing health dispa	e potential to rd new prities in the
102732	RFA-MD-21-005 Technologies for Eliminating Health Disparities (R4:	or Improvin 1/R42- Clini	g Minority Health and Ni ical Trial Optional) ar	ational Institute on Minority Health nd Health Disparities/NIH/DHHS	RFA-MD- 05-A 21-005 [Opt	pr-2021 ional][LOI/Pre-App	Not] Specified
	Contact Name	Rick Berzo	n, DrPH				
	Contact Telephone	301-594-8	949				
	Contact Email	rick.berzor	n@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	05-Apr-202	21 [Optional][LOI/Pre-App], 03	-May-2021			
	Synopsis	This Fundi Business T commercia one or mo culturally a	ng Opportunity Announcemen echnology Transfer (STTR) grau alization with the aim of impro re NIH-defined health disparity acceptable.	t (FOA) invites eligible United States nt applications that propose to deve ving minority health and/or reducin y population groups. Appropriate te	s small business c lop a product, pr g and ultimately chnologies should	oncerns (SBCs) to s rocess or service for eliminating health d be effective, affor	submit Small r disparities in rdable, and
102734	RFA-MD-21-006 Innovations for Health and Eliminating Health Dis Optional)	⁻ Healthy Liv parities (R4	ving - Improving Minority 3/R44 - Clinical Trial ar	ational Institute on Minority Health nd Health Disparities/NIH/DHHS	RFA-MD- 05-A 21-006 [Opt	.pr-2021 ional][LOI/Pre-App	Not] Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Rick Berzo	on, DrPH				
	Contact Telephone	301-594-8	3949				
	Contact Email	rick.berzo	on@nih.gov				
	Sponsor Website		<u> </u>				
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	05-Apr-20		03-May-2021			
	Synopsis	This Fund Business I commerc one or mo affordable	ing Opportunity Announceme Innovation Research (SBIR) gr ialization with the aim of imp ore NIH-defined population gr e, and culturally acceptable.	ent (FOA) invites eligible United State ant applications that propose to deve roving minority health and/or reduci roups who experience health disparit	es small business c elop a product, pro ng and ultimately ies. Appropriate t	oncerns (SBCs) to ocess or service fo eliminating health echnologies shoul	submit Small r disparities in d be effective,
088439 🤇	Genomic Expert Curation Panels (U24 Clinica	al Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20- 101 27-N	1ay-2021	660,000 USD
	Contact Name	Melissa A	. Parisi, MD, PhD				
	Contact Telephone	301-435-6	5880				
	Contact Email	parisima@	@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	27-May-2	.021 , 27-May-2022				
	Synopsis	The purpe condition significan this FOA a tools and genes and	ose of this FOA is to establish s of high priority to participat ce for diagnosis and treatmer are required to utilize the NHG informatics infrastructure to d variants that will support de	expert panels that will select genes a ing NIH Institutes and Centers (ICs) a at of these diseases or conditions. The GRI Clinical Genomics Resource (Clino determine the strength of evidence s velopment of clinical practice guideli	nd genomic varian nd systematically e Genomic Expert Gen) and the NCBI supporting the clir nes.	nts associated wit determine their cl Curation Panels fu ClinVar procedure nical significance o	n diseases or inical unded through es, interfaces, f the selected
080328	Centers of Excellence in Genomic	Science (R	M1 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-19- 204 20-N	1ay-2021	8,750,000 USD

Contact Name Adam Felsenfeld, Ph.D.

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telenhone	301-480-	2269				
	Contact Email	adam fel	senfeld@nih.gov				
	Snonsor Website		<u>semenaemingov</u>				
	Program URI	Link to pr	ogram URI				
	Deadline Dates (ALL)	20-May-2	2021				
	Synopsis Syn						
100256	Notice of Special Interest (NOSI): Supplements for the Impact of CC and Health Disparities	Competiti OVID-19 Ou	ve and Administrative utbreak on Minority Health	National Institutes of Health/DHHS	NOT-MD- 20-019 01-N	Nay-2021	Not Specified
	Contact Name	Rada K Da	agher, Ph.D., M.P.H.				
	Contact Telephone	301-451-	2187				
	Contact Email	rada.dag	ner@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-May-2	2021				
Synopsis The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOS highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health out for NIH-designated health disparity populations.							st (NOSI) to COVID-19 Ith outcomes
100877	Multidisciplinary Studies of HIV/A	JDS and A	ging (R01 Clinical Trial	National Institutes of Health/DHHS	PAR-21- 07-N	/lav-2021	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Optional)			068		Specified		
	Contact Name	Basil A. Eldadah, MD, PhD						
	Contact Telephone	301-496-6761						
	Contact Email	<u>eldadahb@nia.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-: 2024	2022 , 07-May-2022 , 07-Sep-2022 , 07	-Jan-2023 , 07-Ma	ay-2023 , 07-Sep-2	023 , 07-Jan-		
	This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and i treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIN related comorbidities, co-infections, and complications in different populations and cultural settings by applying our curre understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.							
100879	Multidisciplinary Studies of HIV/A Optional)	IDS and Aging (R01 Clinical Trial	National Institutes of Health/DHHS	PAR-21- 07-N 069	/lay-2021	275,000 USD		
	Contact Name	Basil A. Eldadah, MD, PhD						
	Contact Telephone	301-496-6761						
	Contact Email	<u>eldadahb@nia.nih.gov</u>						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan- 2024	2022 , 07-May-2022 , 07-Sep-2022 , 07	-Jan-2023 , 07-Ma	ay-2023 , 07-Sep-2	.023 , 07-Jan-		
	Synopsis Synopsis Synopsis							

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		scientific	priorities outlined by the N	NIH Office of AIDS Research (OAR) as de	scribed in NC	DT-OD-20-018.	
101106	Mentored Research Experiences	for Genetic	Counselors (R25)	National Institutes of Health/DHHS	PAR-21- 074	25-May-2021	1,250,000 USD
	Contact Name	Ebony B. I	Madden, Ph.D.				
	Contact Telephone	301-503-5	5620				
	Contact Email	l <u>ebony.ma</u>	idden@nih.gov				
	Sponsor Website	2					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	25-May-2	021 , 25-May-2022 , 25-M	ay-2023			
	Synopsis	overarchin research o opportun Experienc	ng goal of this NHGRI R25 careers in biomedical, beh ity announcement (FOA) v es.	program is to help recruit individuals w avioral and clinical sciences. To acco vill support innovative educational activ	ith specific sp mplish the st ities with a p	pecialty or disciplinary ated over-arching goa rimary focus on Resea	backgrounds to I, this funding rch
101111	Research Experience in Genomic	Research fo	or Data Scientists (R25)	National Institutes of Health/DHHS	PAR-21- 075	25-May-2021	1,250,000 USD
	Contact Name	Ebony B. I	Madden, Ph.D.				
	Contact Telephone	301-503-5	5620				
	Contact Email	l <u>ebony.ma</u>	idden@nih.gov				
	Sponsor Website	2					
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	25-May-2	021 , 25-May-2022 , 25-M	ay-2023			
	Synopsis	The NIH R overarchin backgroun studies or support co	esearch Education Progra ng goal of this NHGRI R25 nds, including those from p careers in research. To ac reative educational activit	m (R25) supports research education ac program is to support educational activ groups underrepresented in the biomec complish the stated over-arching goal, ies with a primary focus on Research Ex	tivities in the ities that end lical and beha this funding of periences.	e mission areas of the I courage individuals fro avioral sciences, to pur opportunity announce	NIH. The m diverse rsue further ment (FOA) will
100302	Notice of Special Interest (NOSI):		hility of Administrative	National Institutes of Health/DHHS	NOT-AG-	01-May-2021	Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Supplements and Revision Supplet (COVID-19)	ments on Coronavirus Disease 2019		20-022		Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Rebecca Fuldner, Ph.D. 301-402-7748 <u>fuldnerr@nia.nih.gov</u> <u>Link to program URL</u> 01-May-2021				
	Synopsis	NIA is issuing this Notice of Special Int (COVID-19). The mission of NIA is to su research on aging. This NOSI supports	erest (NOSI) to highlight the urgent ne upport and conduct genetic, biologica mission critical areas of research for I	eed for research o l, clinical, behavio NIA as they relate	on Coronavirus Dis ral, social, and eco to the COVID-19	ease 2019 onomic pandemic.
087570	Jointly Sponsored Ruth L. Kirschste Institutional Predoctoral Training I Clinical Trial Not Allowed)	ein National Research Service Award Program in the Neurosciences (T32	National Institutes of Health/DHHS	PAR-20- 076 25-N	Иау-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Nick Gaiano, Ph. D. 301-827-3420 <u>nick.gaiano@nih.gov</u> <u>Link to program URL</u> 25-May-2021 , 25-May-2022 The Jointly Sponsored NIH Predoctora supports broad and fundamental rese neurosciences, a key component will k methodology and quantitative reason appointed to this training grant during students to be outstanding scientists e	I Training Program in the Neuroscienc arch training in the neurosciences. In be a curriculum that provides a strong ing. JSPTPN programs are intended to g the first 2 years of their graduate res equipped to pursue careers in neurosc	es (JSPTPN) is an addition to a broa foundation in exp be 2 years in dura earch training. Th cience.	institutional progr ad education in the perimental design ation and student he primary objectiv	am that e , statistical s may only be ve is to prepare

SPIN ID Program Title	Sponsor Name Spons	sor Number Deadline Date Funding Amount
Icahn School of Medicine at	NIH Funding Opportunities Due: May 2021	225

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount	
094281	HIV Infection of the Central Nervo	ous System	(R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-149 07	-May-2021	Not Specified	
	Contact Name	Jeymohan	Joseph, Ph.D.						
	Contact Telephone	240-627-3	869						
	Contact Email	jjeymoha(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-20	021,07-Sep-2021,07-Jan-202	2,07-N	1ay-2022 , 07-Sep-20	22 , 07-Jan-2023 , 07-N	1ay-2023		
	pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also Synopsis encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required.								
094284	Eradication of HIV-1 from Central Not Allowed)	Nervous sy	ystem Reservoirs (R01 Clinical 1	<u>Trial</u>	National Institutes of Health/DHHS	PA-20-151 07	-May-2021	Not Specified	
	Contact Name	Jeymohan	Joseph, Ph.D.						
	Contact Telephone	240-627-3	869						
	Contact Email	jjeymoha(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pro	ogram URL						
	Deadline Dates (ALL)	07-May-20	021,07-Sep-2021,07-Jan-202	2,07-N	1ay-2022 , 07-Sep-20	22 , 07-Jan-2023 , 07-N	1ay-2023		
	Synopsis	This Fundi and eradic and transl collaborat treatment	ng Opportunity Announcemen cation strategies specifically foc ational research in domestic ar ive alliances are encouraged bu should apply to the companio	it (FOA) cused or nd interr ut not re on FOA P	invites research gram the central nervous national settings are equired. Applications A-20-149.	nt applications studying s system (CNS) in the co of interest. Multidiscip s focused on HIV-associ	mechanisms of HIN ontext of viral support linary research tea ated CNS comorbic	V-1 persistence ression. Basic ms and lities and	
096506	Ruth L. Kirschstein National Resea for Students at Institutions Witho Degree Training Programs (Paren	arch Service out NIH-Fun t F30)	e Award (NRSA) Individual Fellc ded Institutional Predoctoral D	<u>owship</u> Dual-	National Institutes of Health/DHHS	PA-20-245 08	-Apr-2021	Not Specified	
Icahi Mou	n School of Medicine at nt Sinai		NIH Funding Opport	unities D	Due: May 2021			226	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) 08-A 2022 This prece fello mati DVN clinie	to program URL Apr-2021 , 07-May-2021 , 08-Aug-202 2 , 07-Sep-2022 , 08-Dec-2022 , 07-Ja 3 Funding Opportunity Announcemen doctoral dual-degree training program wship (F30) is to enhance the integra riculated in a combined MD/PhD or o 1/PhD), and who intend careers as ph cal training plan and a dissertation re	1, 07-Sep-2021, 08-Dec-2021, 07-Jan-2022, 08-Ap n-2023, 08-Apr-2023, 07-May-2023 at (FOA) will support students at institutions without ns. The purpose of the Kirschstein-NRSA, dual-docto ated research and clinical training of promising predo other dual-doctoral degree training program (e.g. DC nysician/clinician-scientists. Candidates must propos esearch project in scientific health-related fields relev	r-2022 , 07-May-2 NIH-funded instit ral degree, predoc octoral students, v /PhD, DDS/PhD, A e an integrated re /ant to the mission	.022 , 08-Aug- utional ctoral vho are AuD/PhD, search and ns of the
	Synopsis Synopsis itrial led b scien cons addi care requ (http cons	icipating NIH Institutes and Centers. elop into a productive, independent p gned specifically for candidates proper feasibility study, or an ancillary clinic by a sponsor or co-sponsor. NOTE: Per ntific workforce engaged in research sequences by providing support for re- ction science. Special Note: Not all N fully note which ICs participate in this irrements at the Table of IC-Specific In ps://grants.nih.gov/grants/guide/con sider applications for funding. Consul-	The fellowship experience is expected to clearly enh obysician/clinician-scientist. This Funding Opportunit osing research that does not involve leading an inde cal trial, but does allow candidates to propose resear er NOT-DA-20-037 NIDA announces a special interes to develop treatments for substance use disorders a esearch training and career development for talente IIH Institutes and Centers participate in Parent Anno s announcement and view their respective areas of information, Requirements, and Staff Contacts websi tacts/parent_F30b.html) ICs that do not participate tation with NIH staff before submitting an applicatio	ance the individua by Announcement pendent clinical tr ch experience in a t in the development nd the associated d investigators int uncements. Applie research interest a te in this announcer n is strongly encou	I's potential to (FOA) is ial, a clinical clinical trial ent of a medical erested in cants should and ment will not uraged.
096508	Ruth L. Kirschstein National Research S Fellowship (Parent F31) (Defunct)	Service Award (NRSA) Individual Pred	octoral National Institutes of Health/DHHS PA-20-246 08-A	pr-2021	Not Specified
	Contact Name Contact Telephone Contact Email <u>Grar</u>	ntsInfo@nih.gov			

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	<u>Link to pr</u> 08-Apr-20 2022 , 07	-ogram URL 021 , 07-May-2021 , 08-Aug-202 -Sep-2022 , 08-Dec-2022 , 07-Ja	21 , 07-S an-2023	ep-2021 , 08-Dec-20 . 08-Apr-2023 . 07-N)21 , 07-Jan-2022 , 08-Ap /av-2023	r-2022 , 07-May-2	2022 , 08-Aug-
The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship award is to enable promising predoctoral students to obtain individualized, mentored research training from out faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate's of research project and is expected to clearly enhance the individual's potential to develop into a productive, indep research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates propose that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical t allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NO NIDA announces a special interest in the development of a scientific workforce engaged in research to develop t for substance use disorders and the associated medical consequences by providing support for research training development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and C participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirement Contacts website (https://grants.nih.gov/grants/guide/contacts/parent_F30b.html) ICs that do not participate i announcement will not consider applications for funding. Consultation with NIH staff before submitting an appli							iip (Parent F31) utstanding ns of the dissertation ependent bring research trial, but does OT-DA-20-037 treatments ng and career I Centers nent and view ents, and Staff in this blication is	
096596 <mark>-</mark>	Ruth L. Kirschstein National Resea Fellowship (Parent F33) (Defunct)	<u>rch Servic</u>	e Award (NRSA) Individual Senio	<u>or</u>	National Institutes of Health/DHHS	PA-20-247 08-A	vpr-2021	Not Specified
	Contact Name							
	Contact Telephone	Constant (
	Contact Email	Grantsinf	<u>oænin.gov</u>					
	Program LIRI	Link to pr	ogram URI					
	Deadline Dates (ALL)	08-Apr-20 2022 , 07	D21,07-May-2021,08-Aug-202 -Sep-2022,08-Dec-2022,07-Ja	21 , 07-S an-2023	ep-2021 , 08-Dec-20 , 08-Apr-2023 , 07-N)21 , 07-Jan-2022 , 08-Ар Лау-2023	r-2022 , 07-May-2	:022 , 08-Aug-
	Synopsis	The Natio	onal institutes of Health (NIH) av	wards se	enior individual resea	arch training fellowships	to experienced sc	ientists who

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		wish to m acquiring NIH Instit research t but does a	ake major changes in the direct new research capabilities as inc utes and Centers. This Funding that does not involve leading an allow candidates to propose res	tion of their research career dependent investigators in r Opportunity Announcemen i independent clinical trial, a search experience in a clinic	s or who wish to broader research fields relevant to t (FOA) is designed specif a clinical trial feasibility st al trial led by a sponsor o	n their scientific b o the missions of p ically for applican udy, or an ancillan r co-sponsor.	ackground by participating ts proposing ry clinical trial,
100374	Ruth L. Kirschstein National Resea Fellowship (Parent F31)	arch Servic	e Award (NRSA) Individual Pred	octoral National Institutes of Health/DHHS	PA-21-051 08-A	pr-2021	Not Specified
	Contact Name Contact Telephone Contact Email	GrantsInf	o@nih gov				
	Sponsor Website	Granconn					
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	08-Apr-20 2022 , 07-) 21 , 07-May-2021 , 08-Aug-202 Sep-2022 , 08-Dec-2022 , 07-Ja	1 , 07-Sep-2021 , 08-Dec-20 n-2023 , 08-Apr-2023 , 07-N)21 , 07-Jan-2022 , 08-Ap /lay-2023 , 08-Aug-2023 ,	r-2022 , 07-May-2 07-Sep-2023	.022 , 08-Aug-
	Synopsis	The purpe award is t faculty sp participat research y research y that does allow can NIDA ann for substa developm participat their resp Contacts y announce strongly e	ose of the Ruth L. Kirschstein Na o enable promising predoctoral onsors while conducting dissert ing NIH Institutes and Centers. oroject and is expected to clear scientist. This Funding Opportur not involve leading an indepen didates to propose research exp ounces a special interest in the ince use disorders and the asso- tent for talented investigators in e in Parent Announcements. Ap ective areas of research interes website (https://grants.nih.gov/ ement will not consider applicat incouraged.	ational Research Service Awa I students to obtain individu cation research in scientific I The proposed mentored res by enhance the individual's p nity Announcement (FOA) is dent clinical trial, a clinical t berience in a clinical trial lec development of a scientific ciated medical consequence nterested in addiction science pplicants should carefully no t and requirements at the T /grants/guide/contacts/pare ions for funding. Consultation	ard (NRSA) Individual Pre- nalized, mentored research nealth-related fields relev search training must refle- potential to develop into designed specifically for trial feasibility study, or a by a sponsor or co-spon workforce engaged in re- es by providing support for ce. Special Note: Not all ote which ICs participate i fable of IC-Specific Inform ent_F30b.html) ICs that of on with NIH staff before s	doctoral Fellowsh ch training from o vant to the missio ect the candidate's a productive, inde candidates propo n ancillary clinical sor. NOTE: Per N search to develop or research trainir NIH Institutes and in this announcem nation, Requirement do not participate submitting an app	ip (Parent F31) utstanding ns of the dissertation pendent sing research trial, but does OT-DA-20-037 treatments ng and career I Centers nent and view ents, and Staff in this lication is

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
100542	Ruth L. Kirschstein National Resear Fellowship to Promote Diversity in	rch Service Award (NRSA) Individual Pred Health-Related Research (Parent F31-Div	octoral National Institutes versity) of Health/DHHS	PA-21-052 08-A	Apr-2021	Not Specified		
	Contact Name Contact Telephone							
	Contact Email	<u>GrantsInfo@nih.gov</u>						
	Sponsor Website							
Program URL Link to program URL 08-Apr-2021, 07-May-2021, 08-Aug-2021, 07-Sep-2021, 08-Dec-2021, 07-Jan-2022, 08-Apr-2022, 07-May-2022, 08-A Deadline Dates (ALL)								
	- Synopsis I I	The purpose of this Ruth L. Kirschstein Na Diversity in Health-Related Research awa the research training of predoctoral stude underrepresented in the biomedical, beh predoctoral students will obtain individua conducting well-defined research project Institutes and Centers. The proposed me develop into a productive, independent r candidates to propose to lead an indeper does allow candidates to propose researc	ational Research Service Aw rd is to enhance the diversi- ents from diverse backgroun avioral, or clinical research alized, mentored research to s in scientific health-related ntored research training is e research scientist. This Fund ndent clinical trial, a clinical tri ch experience in a clinical tri	ard (NRSA) Individual Pro ty of the health-related r nds including those from workforce. Through this raining from outstanding fields relevant to the m expected to clearly enhar ing Opportunity Announ trial feasibility study, or al led by a sponsor or co	edoctoral Fellows esearch workforc groups that are award program, p faculty sponsors issions of the part nee the individual cement (FOA) doe an ancillary clinica -sponsor.	nip to Promote e by supporting promising while icipating NIH 's potential to es not allow al trial, but		
100399	Ruth L. Kirschstein National Resear Fellowship (Parent F33)	rch Service Award (NRSA) Individual Senio	or National Institutes of Health/DHHS	PA-21-047 08-A	Apr-2021	Not Specified		
	Contact Name							
	Contact Telephone							
	Contact Email	GrantsInfo@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-202 2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Ja	1 , 07-Sep-2021 , 08-Dec-20 n-2023 , 08-Apr-2023 , 07-N	21 , 07-Jan-2022 , 08-Ap 1ay-2023 , 08-Aug-2023 ,	r-2022 , 07-May-2 07-Sep-2023	2022 , 08-Aug-		
	Synopsis [–]	The National Institutes of Health (NIH) av	vards senior individual resea	arch training fellowships	to experienced so	ientists who		

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount
		wish to m acquiring NIH Instit research but does	take major changes in the direct new research capabilities as inc utes and Centers. This Funding (that does not involve leading an allow candidates to propose res	ion of t lepend Opport indepo earch o	their research career ent investigators in r unity Announcement endent clinical trial, a experience in a clinica	s or who wish to b esearch fields rele t (FOA) is designed a clinical trial feasib al trial led by a spo	roaden vant to specifi pility stu nsor or	their scientific b the missions of p cally for applican udy, or an ancillan co-sponsor.	ackground by participating ts proposing ry clinical trial,
100436	Ruth L. Kirschstein National Resea for Students at Institutions with N Degree Training Programs (Parent	<u>rch Servic</u> IH-Fundeo F30)	e Award (NRSA) Individual Fello d Institutional Predoctoral Dual-	<u>wship</u>	National Institutes of Health/DHHS	PA-21-049	08-Aj	or-2021	Not Specified
	Contact Name								
	Contact Telephone								
	Contact Email	<u>GrantsInf</u>	o@nih.gov						
	Sponsor Website								
	Program URL Link to program URL								
	Deadline Dates (ALL)	08-Apr-20 2022 . 07	J21 , 07-May-2021 , 08-Aug-202 -Sep-2022 , 08-Dec-2022 , 07-Ja	1,07-S n-2023	ep-2021,08-Dec-20 .08-Apr-2023.07-N	121,07-Jan-2022, 1av-2023.08-Aug-	08-Apr 2023 .	-2022 , 07-May-2 07-Sep-2023	022 , 08-Aug-
	Synopsis	This Fund predoctor fellowship matricula DVM/PhE clinical tra participat develop in designed trial feasi led by a s	ding Opportunity Announcement ral dual-degree training program to (F30) is to enhance the integra ted in a combined MD/PhD or o D), and who intend careers as pha aining plan and a dissertation re- ing NIH Institutes and Centers. Into a productive, independent pro- specifically for candidates propro- bility study, or an ancillary clinic ponsor or co-sponsor.	t (FOA) ns. The ted res ther du search The fell ohysicia osing re al trial,	will support student purpose of the Kirsc earch and clinical tra- ual-doctoral degree t /clinician-scientists. project in scientific h owship experience is n/clinician-scientist. esearch that does no but does allow cand	ts at institutions w hstein-NRSA, dual- aining of promising raining program (e Candidates must p health-related field s expected to clear This Funding Oppo t involve leading a lidates to propose	ith NIH doctors g predo e.g. DO/ propose ls releva ly enha prtunity n indep researc	-funded institution al degree, predoc ctoral students, w 'PhD, DDS/PhD, A an integrated re ant to the mission nce the individua Announcement endent clinical tr ch experience in a	nal toral vho are uD/PhD, search and ns of the Il's potential to (FOA) is ial, a clinical clinical trial
100434	Ruth L. Kirschstein National Resea Postdoctoral Fellowship (Parent F	<u>rch Servic</u> 32)	e Award (NRSA) Individual		National Institutes of Health/DHHS	PA-21-048	08-AJ	or-2021	Not Specified
	Contact Name								
	Contact Telephone	301-945-7	7573						
			NIH Funding Opport	nities l)ue: May 2021				221

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Email	GrantsInf	o@nih.gov								
	Contact Emain	<u>Urantsiin</u>									
	Sponsor website	California and									
	Program URL		<u>- In to program one</u>								
	Deadline Dates (ALL)	08-Apr-20 2022 , 07	J21 , 07-May-2021 , 08-Aug-202 -Sep-2022 , 08-Dec-2022 , 07-Ja	1 , 07-Sep-2021 , 08-Dec-20 n-2023 , 08-Apr-2023 , 07-N	021 , 07-Jan-2022 , 08-Ap May-2023 , 08-Aug-2023 ,	or-2022 , 07-May-2 , 07-Sep-2023	2022 , 08-Aug-				
The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the part Synopsis NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Oppor Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an in clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose resea experience in a clinical trial led by a sponsor or co-sponsor.											
090436	Investigator Initiated Extended Cl	inical Trial	(R01 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-139 13-N	May-2021	Not Specified				
	Contact Name	Sergei Ro	mashkan, M.D., Ph.D.								
	Contact Telephone	301-435-3	3047								
	Contact Email	romashks	@mail.nih.gov								
	Sponsor Website										
	Program URL	Link to pr	ogram URL								
	Deadline Dates (ALL)	13-May-2	.021 , 13-Sep-2021 , 13-Jan-2022	2, 13-May-2022, 13-Sep-20	022,13-Jan-2023						
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-init requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-drive Synopsis the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do extended project period of 6 or 7 years.							d clinical trials nd related to ne submission t require an				
100438	Ruth L. Kirschstein National Resea for Students at Institutions Witho Degree Training Programs (Parent	arch Servic ut NIH-Fur t F30)	e Award (NRSA) Individual Fello nded Institutional Predoctoral D	wship ual- of Health/DHHS	PA-21-050 08-A	Apr-2021	Not Specified				
	Contact Name										

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Contact Telephone										
	Contact Email	GrantsInfo@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL	ink to program URL								
	Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-202 2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Ja	1 , 07-Sep-2021 , 08-Dec-202 n-2023 , 08-Apr-2023 , 07-Ma	1 , 07-Jan-2022 , 08-Ap iy-2023 , 08-Aug-2023 ,	r-2022 <i>,</i> 07-May-2 , 07-Sep-2023	.022 , 08-Aug-					
This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded instituti predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctor fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, wh matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, Au DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated rese Synopsis clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual! develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (F designed specifically for candidates proposing research that does not involve leading an independent clinical tria trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a c											
086663	Getting To Zero: Understanding H United States (R01 Clinical Trial O	IV Viral Suppression and Transmission in t	the National Institutes of Health/DHHS	PAR-20-036 07-N	May-2021	Not Specified					
	Contact Name	Robin E. Huebner, Ph.D., M.P.H.									
	Contact Telephone	240-627-3216									
	Contact Email	rhuebner@niaid.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-202	2 , 07-May-2022 , 07-Sep-2022	2							
	Synopsis	The purpose of this Funding Opportunity suppression and HIV transmission in the science approaches and m/eHealth, and to inform and evaluate context-specific H	Announcement (FOA) is to su United States (U.S.) using pop implementation science resea IIV control strategies towards	upport grants to improvoulation-level epidemio arch. Data generated the the goal of ending the	ve understanding o logy, novel tools f nrough this researd HIV epidemic in th	of viral rom data ch will be used he U.S.					

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
086667	Support of Competitive Research Not Allowed)	(SCORE) Pi	lot Project Award (SC2 Clinical	<u>Trial</u>	National Institutes of Health/DHHS	PAR-20-040	07-May-2021	300,000 USD
	Contact Name Contact Telephone	Irina N. Kr	asnova, Ph.D.					
	Contact Email	<u>irina.krasr</u>	nova@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	research k previous 1 institutior received l	base at institutions with an expl LO years of training and graduat Is must award science degrees ess than 6 million dollars per ye	icitly stu ing stu to unde ear of N	ated historical mission dents from backgrou ergraduate (B.S. or B. IIH R01 support (tota	on and/or a demons inds underrepresent .A.) and/or graduate l costs) in each of th	trated track record wil ed in biomedical resea students (M.S. or Ph.I e last 2 fiscal years.	chin the arch. Eligible D.) and have
086672	Support of Competitive Research Clinical Trial Not Allowed)	(SCORE) R	esearch Continuance Award (SC	<u>3</u>	National Institutes of Health/DHHS	PAR-20-041	07-May-2021	300,000 USD
	Contact Name	lrina N. Kr	asnova, Ph.D.					
	Contact Telephone							
	Contact Email	irina.krasr	nova@nih.gov					
	Sponsor Website							
	Program URL	Link to pro	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	The SCOR research b previous 1 institutior received l	E Program is a developmental p base at institutions with an expl LO years of training and graduat hs must award science degrees ess than 6 million dollars per ye	orograr icitly st ing stu to und ear of N	n designed to increas tated historical missio dents from backgrou ergraduate (B.S. or B. IIH R01 support (tota	e the research comp on and/or a demons inds underrepresent .A.) and/or graduate I costs) in each of th	petitiveness of faculty trated track record wit ed in biomedical resea students (M.S. or Ph.I e last 2 fiscal years.	and the hin the arch. Eligible D.) and have
088347	Biomedical Knowledgebase (U24 -	Clinical Tr	ials Not Allowed)		National Institutes of Health/DHHS	PAR-20-097	07-May-2021	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Contact Name	Veerasamy Ravichandran, Ph.D.								
	Contact Telephone	<u>.</u>								
	Contact Email	l veerasamy.ravichandra@nih.gov								
	Sponsor Website	2								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 24-Sep-2021 , 07-Jan-2022 2023)7-May-2021 , 24-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 06-May-2022 , 26-Sep-2022 , 06-Jan-2023 , 25-Jan-2023 , 08-May- 2023							
Synopsis curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operat of the knowledgebase. Applications that have a significant focus on software or tool development are not appropriate fo activity.										
088346	Biomedical Data Repository (U24	- Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-089 07-N	May-2021	Not Specified				
	Contact Name	Veerasamy Ravichandran, Ph.D.								
	Contact Telephone	2								
	Contact Email	l veerasamy.ravichandra@nih.gov								
	Sponsor Website	2								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 24-Sep-2021 , 07-Jan-2022 2023	2 , 25-Jan-2022 , 06-May-20	22 , 26-Sep-2022 , 06-Jar	-2023 , 25-Jan-20	23 , 08-May-				
	Synopsis	This funding opportunity announcement under this announcement should have th accessible the data related to a particular improves the efficiency and accessibility Support for software and tool developme	is designed to support bion ne primary function to inges r system or systems. Suppor of data ingestion, managem ent must be limited to that v	nedical data repositories. t, archive, preserve, man rt for data curation must nent, and use and reuse k which provides essential	Biomedical data in age, distribute, ar be limited to that by the user commu functions or signif	epositories Id make which unities. icantly				

increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool

SPIN ID	Program Title	Sponsor	Name	Sponso	or Number			Deadline Date	Funding Amount
		development are n	ot appropriate for this	activity	у.				
100652	Stephen I. Katz Early Stage Investig Experimental Studies with Humans	ator Research Proj Required)	ect Grant (R01 Basic		National Institutes of Health/DHHS	PAR-21-039	26-Aj	pr-2021	Not Specified
	Contact Name								
	Contact Telephone	301-945-7573							
	Contact Email	<u>GrantsInfo@nih.go</u>	<u>v</u>						
	Sponsor Website								
	Program URL	<u>ink to program UF</u>	<u>RL</u>						
	Deadline Dates (ALL)	1ay-2021 , 26-Aug-2023 2 , 28-Dec-2022 , 26-Jar 2 Early Stage Investigate	1 , 28-S n-2023 or Rese	ep-2021 , 28-Dec-20 , 26-Apr-2023 , 26-N earch Project Grant se	21 , 26-Jan-2022 , 1ay-2023 , 26-Aug upports an innova	, 26-Apr -2023 , ative pro	-2022 , 26-May-2 26-Sep-2023 , 28 bject that represe	2022 , 26-Aug- -Dec-2023 ents a change in	
	Synopsis	esearch direction Funding Opportuni attachment describ of one or more of t Opportunity Annou (prospective basic and also meet the prospectively assig biomedical or beha without specific ap coward processes of appropriate 'Clinica	for an early stage invest ty Announcement (FO) bing the change in rese the participating NIH In uncement is for basic so science studies involvin definition of basic rese n human participants t avioral outcomes in hur plication towards proc or products in mind and al Trial Not Allowed' FC	stigator A) must arch di stitute cience ing hum arch. T o cond mans fo esses o d which DA .	r (ESI) and for which is t not include prelimin rection. The propose s and Centers (ICs) be experimental studies han participants." The ypes of studies that s itions (i.e., experime or the purpose of unco or products in mind. S h also do not meet th	no preliminary da nary data. Applica ed project must be ased on their scie involving human ese studies fall wit should submit und ntally manipulate derstanding the fu studies that are N e clinical trial def	ta exist. tions m e related ntific mi s, referr thin the der this indepe undame OT cond inition s	Applications sub ust include a sep to the programmissions. This Fund red to in NOT-OD NIH definition of FOA include stud ndent variables) ntal aspects of ph ducted with speci hould submit und	omitted to this arate matic interests ling -18-212 as a clinical trial ies that and that assess nenomena fic applications der the
100648	<u>Stephen I. Katz Early Stage Investig</u> <u>Not Allowed</u>)	ator Research Proj	ect Grant (R01 Clinical	<u>Trial</u>	National Institutes of Health/DHHS	PAR-21-038	26-Aj	pr-2021	Not Specified
	Contact Name								
	Contact Telephone	301-945-7573							
	Contact Email	GrantsInfo@nih.go	<u>v</u>						
	Sponsor Website								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Drogram LIDI	ink to program LIPI							
			21 20 Car 2021 20 Day 202		- 2022 - 26 Mars 2	022 26 4			
	Deadline Dates (ALL)	26-Apr-2021 , 26-May-2021 , 26-Aug-20. 2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Ja	-Apr-2021 , 26-May-2021 , 26-Aug-2021 , 28-Sep-2021 , 28-Dec-2021 , 26-Jan-2022 , 26-Apr-2022 , 26-May-2022 , 26-Aug- 22 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023						
_	The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a chang research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to th Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic intere of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.								
091820	Ruth L. Kirschstein National Resear Institutional Research Training Gra	<u>ch Service Award (NRSA) Short-Term</u> nt (Parent T35)	National Institutes of Health/DHHS	PA-20-162 07-N	May-2021	Not Specified			
	Contact Name								
	Contact Telephone								
	Contact Email 🤇	<u>GrantsInfo@nih.gov</u>							
	Sponsor Website								
	Program URL <u>I</u>	<u>ink to program URL</u>							
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-20 2022 , 25-Sep-2022 , 05-Jan-2023 , 07-Ja	21 , 25-Sep-2021 , 07-Jan-202 n-2023 , 07-May-2023	22 , 25-Jan-2022 , 07-Ma	ay-2022 , 25-May-2	2022 , 07-Sep-			
	٦ ١ ١ Synopsis ٢ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩ ٩	The National Institutes of Health (NIH) we nstitutional Research Training Grants (T opportunities for predoctoral students in nstitutes and Centers (ICs) use this NRS/ for health professional students (medical programs) during the summer. This prog quantitative sciences to pursue research The training should be of sufficient dept exposure to the principles underlying the does not allow appointed Trainees to lead a clinical trial led by a mentor or co-men	vill award Ruth L. Kirschstein M 35) to eligible, domestic insti- nterested in careers in biome A program exclusively to supp Il students, veterinary studen gram is also intended to encou careers by short-term expos h to enable the trainees, upon e conduct of biomedical resea ad an independent clinical tria tor.	National Research Servic tutions to develop and/ dical, behavioral, or clin port intensive, short-terr ts, and/or students in or urage training of gradua ure to, and involvement n completion of the pro arch. This Funding Opp al, but does allow them	ce Award (NRSA) S or enhance researd ical research. Man m research training ther health-profes ite students in the t in, the health-rela gram, to have a th portunity Announc to obtain research	hort-Term ch training y NIH g experiences sional physical or ated sciences. orough ement (FOA) experience in			

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	Trials Optional)		of Health/DHHS			Specified					
	Contact Name	Behrouz Shabestari, PhD									
	Contact Telephone	301-451-6771									
	Contact Email	shabestb@mail.nih.gov									
	Sponsor Website										
	Program URL	Link to program URL	nk to program URL								
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-202 2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jar	21 , 25-Sep-2021 , 07-Jan-2022 , 2 1-2023 , 07-May-2023	5-Jan-2022 , 07-Ma	y-2022 , 25-May-	2022 , 07-Sep-					
This Funding Opportunity Announcement (FOA) encourages grant applications for National Centers for Biomedical Imaging and Bioengineering (NCBIB). NCBIB are national resource centers for conducting research and development on new Synopsis technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly.											
101706	RFA-EY-21-001 BRAIN Initiative Recording and Modulation in the Allowed)	: New Concepts and Early-Stage Research Nervous System (R21) (Clinical Trial Not	for National Institutes of Health/DHHS RFA-	EY-21-001 03-M	lay-2021	400,000 USD					
	Contact Name	Martha Flanders, PhD									
	Contact Telephone	301-451-2020									
	Contact Email	BRAIN-FOAs@nih.gov									
	Sponsor Website										
	Program URL	Link to program URL									
	Deadline Dates (ALL)	03-May-2021 , 29-Oct-2021 , 02-May-202	22 , 28-Oct-2022 , 01-May-2023 , 2	27-Oct-2023							
This FOA seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the pre and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range modalities are appropriate including acoustic, chemical, electrical, magnetic, optical and chemical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving anim											

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Application especially	ons are encouraged from any qu those not typically involved wit	ialified individuals, including th neuroscience research.	g physicists, engineers, th	neoreticians, and s	cientists,
101780	Notice of Special Interest (NOSI): Impact on Health and Disease	Promoting	Research on Interoception and	Its National Institutes of Health/DHHS	NOT-AT-21-002 07-N	May-2021	Not Specified
	Contact Name	Wen G. C	hen, M.MSc, Ph.D.				
	Contact Telephone	301-451-3	3989				
	Contact Email	<u>chenw@r</u>	<u>nail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023 16-Feb-20	021 , 05-Jun-2021 , 16-Jun-2022 -May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 , 2)24 , 07-May-2024	L , 07-Sep-2021 , 05-Oct-202 in-2022 , 07-Sep-2022 , 05-0 L6-Jun-2023 , 07-Sep-2023 ,	21 , 16-Oct-2021 , 07-Jan Oct-2022 , 16-Oct-2022 , 05-Oct-2023 , 16-Oct-20	-2022 , 05-Feb-20 07-Jan-2023 , 05-F 123 , 07-Jan-2024 ,	22 , 16-Feb- ⁻ eb-2023 , 16- 05-Feb-2024 ,
	Synopsis	The purpe disease. T interocep from with diverse ex molecular context o processes intelligen	ose of this NOSI is to promote in This initiative is broadly support tion includes the processes by w in itself and represents its inter opertise; 2) develop and use inn r, cellular, circuit, functional, an f diseases and disorders; 4) deter on health and/or disease; and ce models relevant to interocep	novative and rigorous resea ed by many participating NII which an organism senses, in nal states. This NOSI encour ovative technologies and ap d/or behavioral levels; 3) as ermine the impact of interve 5) develop and validate pre- tion and its impact on healt	arch on interoception an H institutes, centers, and nterprets, integrates, and rages basic and clinical re proaches to delineate in sess pathophysiological entions and therapies to dictive biomarkers, comp ch and disease.	d its impact on he l offices (ICOs). Fo d regulates signals esearch projects th ateroceptive mech processes of intero manipulate intero putational models,	alth and r this NOSI, originating nat 1) combine anisms at the oception in the oceptive , or artificial
090787	Ruth L. Kirschstein National Resea Training Grant (Parent T32)	arch Servic	e Award (NRSA) Institutional Re	search National Institutes of Health/DHHS	PA-20-142 07-N	May-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	<u>GrantsInf</u>	o@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	'-May-20	021 , 25-May-2021 , 07-Sep-202 Sep-2022 , 07-Jan-2023 , 25-Jar	21 , 25- ו-2023	Sep-2021 , 07-Jan-20 , 07-May-2023	22 , 25-Jan-2022 , 07	-May-2022 , 25-May-	2022 , 07-Sep-	
	Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training from the search training, and help ensure that a diverse and highly trained workforce is available to meen needs of the Nation's biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Program (T35) exclusively reserved for predoctoral, short-term research training. This Funding Opportunity Announce (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.								
088438	Genomic Community Resources (U24	4 Clinica	al Trial Not Allowed)		National Institutes of Health/DHHS	PAR-20-100	25-May-2021	Not Specified	
	Contact Name Ch	ristoph	er Wellington						
	Contact Telephone 30	1-480-3	3496						
	Contact Email <u>we</u>	ellingtor	nc@mail.nih.gov						
	Sponsor Website								
	Program URL <u>Lir</u>	<u>nk to pro</u>	ogram URL						
	Deadline Dates (ALL) 25	-May-2	021 , 25-Sep-2021 , 25-Jan-2022	2,25-N	1ay-2022 , 25-Sep-20	22 , 25-Jan-2023			
	To ba the Synopsis fea str	facilita sic rese e develo search o odel org atures (s	te genomic research and the dis arch, disease studies, model or opment and distribution of gene community. Such resources incl ganism databases, ontologies, a such as functional genomic eler variants in 1000 Genomes or G	ssemina ganism omic re ude (bu nd anal ments), TEx sar	ation of its products, studies, and other b sources that use cos it are not limited to) ysis toolsets), compr and standard data to nples).	NHGRI supports gen iomedical research. A t-effective approache databases and inforr rehensive identification ypes produced using	omic resources that a wards under this FO as and will be valuable natics resources (such on and collections of central sets of sample	re crucial for A will support for the broad as human and genomic es (such as	
100037	Specialized Programs of Research Exercised Programs of Research Exercised Programs 2021, 2022, 2023 (P50 Clinical	cellence Trial Re	e (SPOREs) in Human Cancers fo equired)	<u>or</u>	National Institutes of Health/DHHS	PAR-20-305	25-May-2021	7,000,000 USD	
	Contact Name To	by T. He	echt, Ph.D, Associate Director						

SPIN ID	Program Title		Sponsor Name	Sponse	or Number			Deadline Date	Funding Amount
	N ID Program Title Contact Telephon Contact Em Sponsor Websi Program U Deadline Dates (Al Synop: 6664 Support of Competitive Resears Clinical Trial Not Allowed) 6664 Support of Competitive Resears Clinical Trial Not Allowed) Contact Nar Contact Telepho Contact Em Sponsor Websi Program U Deadline Dates (Al Synop	240-276- hechtt@r Link to pr 25-May-2 Through t and Crani Excellenc research a highly r from the programm for promo SPORE m common	5683 mail.nih.gov cogram URL 2021 , 25-Sep-2021 , 25-Jan-202 this funding opportunity annou iofacial Research (NIDCR) invite e (SPORE). The program will fur that will contribute to improved elated group of cancers. For the same organ system, such as gas natically appropriate groups of oting tumorigenesis and/or can ay focus on cancers caused by t signaling pathway. In addition,	22 , 25-N ncemen applica nd P50 S d prever e purpos strointes cancers cancers cer prog che same a SPORE	lay-2022 , 25-Sep-20 t (FOA), the Nationa tions for P50 Resear PORE grants to supp ntion, early detection se of this FOA, a grou stinal, neuroendocri may include those of gression in organ site infectious agent or E may focus on cross	022 , 25-Jan-2023 , I Cancer Institute (ch Center Grants fo port state-of-the-ar n, diagnosis, and tr up of highly related ne, head and neck, centered around a es that belong to di cancers promoted s-cutting themes su	25-Ma (NCI) ar or Spec rt inves catmen d cance , and of commo ifferent d and su uch as p	y-2023 , 25-Sep-2 nd National Institu- cialized Programs tigator-initiated t nt of an organ-sp rs are those that ther cancers. Oth on biological mec corgan systems. F ustained by dysre	Amount 2023 ute of Dental of Research cranslational ecific cancer or are derived her chanism critical For example, a egulation of a or cancer
	Support of Competitive Research	human bi must hav	ology using cellular, molecular, e the goal of reaching a translat	structu tional hu	ral, biochemical, and uman endpoint with	d/or genetic experi in the project perio	mental od of th	approaches. SPC ne grant.)RE projects
086664	Clinical Trial Not Allowed)			<u> </u>	of Health/DHHS	PAR-20-039	07-N	1ay-2021	USD
	Contact Name	lrina N. K	rasnova, Ph.D.						
	Contact Telephone								
	Contact Email	<u>irina.kras</u>	nova@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021						
	Synopsis	The SCOR research previous institution	RE Program is a developmental p base at institutions with an exp 10 years of training and gradua ns must award science degrees	program licitly st ting stud to unde	n designed to increas ated historical missi- dents from backgrou ergraduate (B.S. or B	se the research cor on and/or a demor Inds underreprese .A.) and/or gradua	npetitiv nstrateo nted in te stud	veness of faculty d track record wit biomedical resea ents (M.S. or Ph.I	and the thin the arch. Eligible D.) and have

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		received less than 6 million dollars per ye	ar of NIH R01 support (tota	l costs) in each of the la	st 2 fiscal years.	
094033	NIH Exploratory/Developmental F Not Allowed)	Research Grant Program (Parent R21 Clinic	al Trial National Institutes of Health/DHHS	PA-20-195 07-	May-2021	275,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2022 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb	1 , 16-Oct-2021 , 07-Jan-202 ɔ-2023 , 07-May-2023	22 , 16-Feb-2022 , 07-M	ay-2022 , 16-Jun-2	022 , 07-Sep-
	Synopsis	The NIH Exploratory/Developmental Gran for the early and conceptual stages of the breakthrough in a particular area, or to the that could have a major impact on a field Centers (ICs) participate in Parent Announ announcement and view their respective Contact website. ICs that do not participate	nt supports exploratory and ese projects. These studies r ne development of novel teo of biomedical, behavioral, o ncements. Applicants should areas of research interest a ste in this announcement wit	developmental researce may involve considerable chniques, agents, metho or clinical research. Not d carefully note which I at the R21 IC-Specific Sc ill not consider application	th projects by prov e risk but may lead odologies, models, e: Not all NIH Insti Cs participate in th ientific Interests ar ions for funding.	iding support I to a or applications tutes and .is 1d
094050	NIH Small Research Grant Program	m (Parent R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-200 07-	May-2021	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2022 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb	1 , 16-Oct-2021 , 07-Jan-202 p-2023 , 07-May-2023	22 , 16-Feb-2022 , 07-M	ay-2022 , 16-Jun-2	022 , 07-Sep-
	Synopsis	The NIH Small Research Grant Program su limited resources. This program supports	upports small research proje different types of projects i	ects that can be carried including pilot and feasi	out in a short peri bility studies; seco	od of time with ndary analysis

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		of existing research Not all NI participat and Conta	g data; small, self-contained res echnology. This Funding Oppor H Institutes and Centers (ICs) pa e in this announcement and vie act website. ICs that do not part	earch projects; developmen tunity Announcement does articipate in Parent Announ w their respective areas of icipate in this announceme	nt of research methodol s not accept applications cements. Applicants sho research interest at the ent will not consider app	ogy; and developm proposing clinical puld carefully note R01 IC-Specific Scie lications for fundin	ient of new trial(s). Note: which ICs entific Interests g.
094032	NIH Exploratory/Developmental Required)	Research G	rant Program (Parent R21 Clinic	cal Trial National Institutes of Health/DHHS	PA-20-194 07-	May-2021	275,000 USD
	Contact Name Contact Telephone Contact Emai Sponsor Website	grantsinfo	o@nih.gov				
	Program URI	Link to pr	ogram URI				
	Deadline Dates (ALL)	07-May-2 2022 , 16	021 , 16-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 16-Fel	1 , 16-Oct-2021 , 07-Jan-20 b-2023 , 07-May-2023	22 , 16-Feb-2022 , 07-M	ay-2022 , 16-Jun-20)22 , 07-Sep-
	Synopsis	The NIH E for the ea breakthro that could Announce interests should no definition accept me of Arthrit Institutes this anno Required consider a	xploratory/Developmental Gran rly and conceptual stages of the bugh in a particular area, or to the have a major impact on a field ement requires that at least 1 cl of one or more of the participat the that some ICs (seeRelated No- of a clinical trial through this fu- echanistic studies that meet NIH is and Musculoskeletal and Skin and Centers (ICs) participate in uncement and view their respect IC-Specific Scientific Interests and applications for funding.	nt supports exploratory and ese projects. These studies ne development of novel te of biomedical, behavioral, inical trial be proposed. The ing NIH Institutes and Cent otices) only accept applicat inding opportunity announ I's definition of a clinical tri Diseases (NIAMS) National Parent Announcements. A ctive areas of research inter nd Contact website. ICs tha	d developmental researce may involve considerable chniques, agents, methe or clinical research. This e proposed project must ers (ICs) based on their s ions proposing mechani cement. The following Ir al. See Related Notices s Institute of Mental Hea pplicants should carefull rest at the R21 Basic Exp t do not participate in th	ch projects by provi e risk but may lead odologies, models, parent Funding Op be related to the p scientific missions. stic studies that me hstitutes/Centers o section below. Nati Ith (NIMH) Note: N y note which ICs par erimental Studies which is announcement of	ding support I to a or applications oportunity orogrammatic Applicants eet NIH's nly onal Institute lot all NIH articipate in with Humans will not



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number				Deadline Date	Funding Amount
	Contact Name	Wendy Nilser	n, PhD						
	Contact Email	nelsonw@ma	± ail.nih.gov						
	Sponsor Website								
	Program URL	Link to progra	am URL						
	Deadline Dates (ALL)	07-May-2021	L						
	Synopsis	This funding of Behavioral ar for research g outcomes. Ap Descriptive an including the in all applicat intervention within. This F	opportunity announcement nd Social Sciences Research (grant applications that addres oplications may address hea nd intervention research ma patient, caregiver/family, p cions is paramount, with emp mechanisms of action. The s OA accepts applications tha	(FOA) is being issued b OBSSR) with participates patient adherence thcare regimen initiat y address adherence of rovider and/or healthc ohasis on appropriates pecific research interes t either propose or do	y the I ion fro to trea on, im leterm are sys sample sts of not pr	NIH Adherence om multiple NIH atment and prev plementation, a ninants at one or stem, and comm e sizes, valid out participating NII opose a clinical	Network Institut ention r and/or p more la nunity le come m H Institu trial(s).	k through the Offi- ces and Centers. T regimens to prom- persistence by pati- evels of ecologic in evels. Attention to reasures, and test ites and Centers a	ce of his FOA calls ote health ients. nfluence, scientific rigor ing re detailed
094034	NIH Exploratory/Developmental F Experimental Studies with Humar	Research Gran Is Required)	t Program (Parent R21 Basic	National Instit of Health/DHF	utes IS	PA-20-196	07-N	/lay-2021	275,000 USD
	Contact Name								
	Contact Telephone	301-496-4000	0						
	Contact Email	grantsinfo@c	od.nih.gov						
	Sponsor Website								
	า-2022	2 , 16-Feb-2022 ,	, 07-May	y-2022 , 16-Jun-20)22 , 07-Sep-				
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing sup for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a Synopsis breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applic that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunit Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212as "prospectiv									ding support to a or applications oportunity ospective basic

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		science st definition human pa behaviora applicatic products project m based on Applicant interest a that do no	tudies involving human participa of basic research. Types of stud articipants to conditions (i.e., ex al outcomes in humans for the p on towards processes or produc in mind should submit under th nust be related to the programm their scientific missions. Note: I as should carefully note which IC at the R21 Basic Experimental St ot participate in this announcen	ants." These studies fall with dies that should submit unde perimentally manipulate inc purpose of understanding th ts in mind. Studies conducte te appropriate 'Clinical Trials natic interests of one or mor Not all NIH Institutes and Ce Cs participate in this annound udies with Humans Required nent will not consider applic	nin the NIH definition of a er this FOA include studie dependent variables) and e fundamental aspects o ed with specific applicatio s Required' or 'Clinical Tri re of the participating NIH enters (ICs) participate in cement and view their re d IC-Specific Scientific Int cations for funding.	a clinical trial and es that prospectiv I that assess biom f phenomena with ons toward proces al Optional' FOA. I Institutes and Ce Parent Announce espective areas of erests and Contac	also meet the ely assign edical or nout specific ses or The proposed enters (ICs) ments. research ct website. ICs
095691	Pilot Projects Increasing the Impace Botanicals and Other Natural Prode Allowed)	ct of the N ducts (PI2	IIH Centers for Advancing Resea CARBON) (R03 Clinical Trials No	nrch on National Institutes of Health/DHHS	PAR-20-228 07-N	Nay-2021	100,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website						
	Program URL Deadline Dates (ALL)	Link to pr 07-May-2 2022 , 16-	r <mark>ogram URL</mark> 2021 , 16-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 16-Oct-2021 , 07-Jan-202	22 , 16-Feb-2022 , 07-Ma	y-2022 , 16-Jun-20	022 , 07-Sep-
	Synopsis	The purper potential underlyin Centers for describing to RFA OD agreemen effects, or products vitro and	ose of this funding opportunity effects relevant to human healt g such effects. A critical elemen or Advancing Research on Botar g collaboration with one or mor D-19-001 by July, 2020, must be nt of its collaborating Center(s), r of their causal, molecular mec through use of methods develo non-human animal models to, w	announcement (FOA) is to so th of chemically complex nat at of each proposed project r nicals and Other Natural Pro- re of the U19 Botanical Dieta included at the time of sub- leverage products used in the chanisms of action, or increa- ped and used in the Centers where feasible and appropri	upport collaborative pilo tural products and/or the must be collaboration wi ducts (CARBON). More s ary Supplements Researc mission. Each proposed p hose Centers to extend u se understanding of othe s. Research approaches n ate, obtaining additional	t research project e causal, molecula th one or more of pecifically, letters h Centers awarde pilot project must, inderstanding of t er chemically com hay range from be feasibility or outc	s focused on r mechanisms the NIH of support d pursuant with heir biological plex natural ench through in come

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		information from the clinical trials being p measures or through secondary analysis o	performed by the CARBON of data or specimens	awardees, either throug	h inclusion of add	itional
088011	Engineering Next-Generation Hui (R01 Clinical Trials Not Allowed)	man Nervous System Microphysiological Sy	stems National Institutes of Health/DHHS	PAR-20-055 07-	May-2021	Not Specified
	Contact Name	David M. Panchision, Ph.D.				
	Contact Telephone	301-443-5288				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 2022 , 05-Oct-2022 , 07-Jan-2023	, 05-Oct-2021 , 07-Jan-202	22 , 05-Feb-2022 , 07-Ma	ay-2022 , 05-Jun-2	022,07-Sep-
	Synopsis	This Funding Opportunity Announcement generation human cell-derived microphys architectures and physiology with improve future studies of complex nervous system intended to provide support for the furthe line of investigation. Applicants without p	(FOA) encourages research iological systems (MPS) an ed fidelity over current cap development, function an er development of projects reliminary data may wish t	h grant applications dire d related assays that rep pabilities. Supported proj d aging in healthy and d s where preliminary data to apply to the companic	cted toward devel plicate complex ne jects will be expec isease states. This supports the feas on R21 FOA(PAR-20	oping next- rvous system ted to enable FOA is ibility of the D-082).
078546	Processing and Presentation of N Not Allowed)	on-Conventional MHC Ligands (R21 Clinical	Trial National Institutes of Health/DHHS	PA-19-066 07-	May-2021	275,000 USD
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.				
	Contact Telephone	240-627-3566				
	Contact Email	tglewis@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021	, 16-Oct-2021 , 07-Jan-202	22		
	Synopsis	This Funding Opportunity Announcement mechanisms used in the generation of nov unique antigenic ligands to protective imm	(FOA) invites applications vel peptidic and non-peption nune responses against inf	to determine antigen pr dic ligands and to detern fectious disease pathoge	ocessing and present nine the contributions and/or vaccines	entation on of these s; pathogen-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		associated facilitate t	d immune pathogenesis; and/or the development of novel tools	limit progression or inducti and reagents to advance de	ion of immune-mediated sign of immune-based tl	d diseases. These s herapeutics and va	tudies may accines.
088090	Development and Application of for Drug Discovery and for Pathor Clinical Trial Not Allowed)	PET and SP physiologic	ECT Imaging Ligands as Biomark al Studies of CNS Disorders (RO2	Kers National Institutes of Health/DHHS	PAR-20-037 07-N	May-2021	825,000 USD
	Contact Name	Enrique N	1ichelotti, Ph.D.				
	Contact Telephone	301-443-5	5415				
	Contact Email	michelott	iel@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-Sep-202: Oct-2022 , 07-Jan-2023	L , 05-Oct-2021 , 07-Jan-202	2 , 05-Feb-2022 , 07-Ma	y-2022 , 05-Jun-20)22 , 07-Sep-
	Synopsis	This Fund of novel ra imaging ir studies ar FOA PAR-	ing Opportunity Announcement adioligands for positron emissic n rodent and nonhuman primate nd appropriate model developm 20-038.	: (FOA) invites research gran on tomography (PET) or sing e brain and incorporation of ent. Projects proposing clini	nt applications that proper le photon emission comp pilot or clinical feasibilit ical assessments of nove	ose the preclinical puted tomography ty evaluation in pr el radioligands sho	developmen [*] / (SPECT) e-clinical uld respond t
102333	Notice of Special Interest (NOSI): Postdoctoral Fellowship Applicati Including Under-Represented Mir	National R ons from In norities	esearch Service Award (NRSA) F ndividuals from Diverse Backgrc	32 National Institutes of Health/DHHS	NOT-EY-21-001 08-A	Apr-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	08-Apr-20 2022 , 07-	21 , 07-May-2021 , 08-Aug-202 Sep-2022 , 08-Dec-2022 , 07-Ja	1 , 07-Sep-2021 , 08-Dec-20 n-2023 , 08-Apr-2023 , 07-N	21 , 07-Jan-2022 , 08-Ap 1ay-2023 , 08-Aug-2023 ,	r-2022 , 07-May-2 , 07-Sep-2023 , 08	022 , 08-Aug- -Dec-2023
	Synopsis	The institu	utes participating in the Notice	seek to promote diversity in	all of our training and re	esearch programs	and to



SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		increase t diversity a OD-20-03 along this Science a Institute o	the participation of underrepres among the biomedical research 1). Evidence from several repor pathway would benefit the res nd Technology Talent at the Cro of Medicine 2011;and Advancing	sented workfo ts dem earch o ssroad g the N	groups. As the US pop orce is vital to our scie constrates that an inte community (Expandin ls, National Academy lation's Health Needs	pulation becomes in ence enterprise and ervention designed g Underrepresenter of Sciences, Nationa : NIH Research Train	creasingly diverse, refle the NIH research missic to facilitate successful tr d Minority Participation: al Academy of Engineeri ning Programs).	ction of that on (See NOT- ransitions America's ng, and
102332	RFA-DK-21-005 Immune Cell En Monitoring in Type 1 Diabetes (R	gineering)1 Clinical	For Targeted Therapy And Disea Trial Not Allowed)	<u>ase</u>	National Institutes of Health/DHHS	RFA-DK-21-005	22-May-2021 [Optional][LOI/Pre-App	3,000,000] USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Olivier Blo 301-451-5 <u>blondelol</u> Link to pr 22-May-2 This initia previoush therapeu	ondel, Ph.D. 7334 <u>@niddk.nih.gov</u> 021 [Optional][LOI/Pre-App], 22 tive will support the engineerin y inaccessible information abou tic responses to restore islet hea	2-Jun-2 g of im t diabe alth an	021 mune cells to target t tes initiation and pro d prevent the progres	the human pancreat gression, and/or to ssion to T1D.	ic compartment to repo deliver environment-spe	ort on ecific
087977	RFA-NS-20-006 BRAIN Initiative and Recording Technologies (R01	: Biology a Clinical Tr	nd Biophysics of Neural Stimula ials Optional)	i <u>tion</u>	National Institutes of Health/DHHS	RFA-NS-20-006	02-May-2021 [Optional][LOI/Pre-App	Not] Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Sahana N 301-496-: <u>BRAIN-FC</u> Link to pr 02-May-2	. Kukke, PhD 1447 DAs@nih.gov Ogram URL 021 [Optional][LOI/Pre-App], 02	1-Jun-2	021 , 01-Sep-2021 [O	ptional][LOI/Pre-Ap	p], 01-Oct-2021 , 02-Jan	-2022
	Deadline Dates (ALL) Synopsis	[Optional App], 03- A central][LOI/Pre-App], 01-Feb-2022 , 0 Oct-2022 goal of the BRAIN Initiative is to	2-May	-2022 [Optional][LOI/ op new and improved	Pre-App], 01-Jun-20	22 , 03-Sep-2022 [Optic ble for recording from as	onal][LOI/Pre- s well as

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		controllin accomplis or stimula systemati neuronal bioinform technolog use of mu	g specified cell types and circuit sh these goals, further informati ating the nervous system. This R cally characterize, model, and v and non-neuronal cells to vario natic content of signals recorded gies, therapies and disease mod- ultiple recording or stimulation t	s to me fon is n FA acc alidate us type I from i els is o echnol	odulate and understand eeded to understand epts grant application the membrane, cellu so of stimulation tech neuronal and non-ne utside the scope of th ogies are allowed.	and function in the centra I the function of current Ins in two related but dist ular, circuit, and adaptive nologies. The second is t uronal cells and circuits. his FOA. Activities related	al nervous system. technologies used inct areas. The firs e-biological respon o understand the l Development of n d to enabling the s	In order to for recording st is to uses of biological and new imultaneous
102379	National Institute of Allergy and I Monitoring Center (CSMC)	nfectious [Diseases (NIAID) Clinical Site		National Institutes of Health/DHHS	75N93020R00021 24-N	Лау-2021	Not Specified
	Contact Name	Deborah	Blyveis					
	Contact Telephone	24066951	43					
	Contact Email	blyveisd@	<u>Pniaid.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	24-May-2	021					
	Synopsis	Introduct Departme immunolo and diagn has a requ Institute of Services (NIAID Div research contracts efficacy o approach clinical re functiona immune-i	ion The National Institute of Alle ent of Health and Human Service ogy leading to the development using of infectious and immune- uirement for a clinical site moni- of Allergy and Infectious Disease HHS), strives to better understa ision of Allergy, Immunology, an focusing on protective immune . This includes support for clinic f therapeutic and preventive ap es and agents. A critical compor search studies, including Phase I state of immune tolerance in t mediated rejection of transplan	ergy an es (DHI of vace mediat toring o es (NIAI nd, tre nd Tran respon al resea proach nent of 1 throu hree m ted sol	Id Infectious Diseases HS) supports research cines, therapeutics, a ed diseases. The NIA center. Description R ID), National Institute at, and ultimately pro- splantation (DAIT) su ses and immune-me arch programs and in nes and agents, and 2 DAIT's awarded grar ugh 4 clinical trials of nain clinical areas: au- id organs, tissues, an	s (NIAID), National Institu n related to the basic und nd medical diagnostics for ID Division of Allergy, Imp esearch supported and c es of Health (NIH), Depar event immunologic, infec- upports extramural basic diated diseases through dividual research project) elucidate the underlyin nts and contracts involves investigational approach toimmune diseases; asth d cells. Purpose and Obje	ites of Health (NIH derstanding of mic or the prevention, munology, and Tra- conducted by the N tment of Health ar ctious, and allergic , pre-clinical, and c a variety of resear- ts to 1) evaluate the g mechanisms of s s the design and co hes, intended to lea- ima and allergic dis- ectives The purpos), of the robiology and treatment, ansplantation lational and Human diseases. The clinical ch grants and as safety and such onduct of ad to a seases; and se of this

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

acquisition is to: Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for: the Immune Tolerance Network (ITN) Asthma and Allergic Diseases Clinical Research Programs: Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) Atopic Dermatitis Research Network (ADRN) Consortium for Food Allergy Research (CoFAR) Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN) Autoimmunity Centers of Excellence (ACE) Transplantation Clinical Research Programs: Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA) Non-network clinical research/trials on a limited, as-needed basis, and Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs. 2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance. Project requirements The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for: Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures; Training: Develop and implement training programs for clinical site personnel and site monitors; CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed; Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities; Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance; Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted; Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost,

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Da	te Funding Amount
		and moni and techr for the su provide a	toring and reporting on project nical personnel have the relevar ccessful completion of contract Il facilities, equipment and othe	status it indivi requir r resou	and progress. The PI, idual education, trair ements; Facilities, Eq irces necessary to ca	/Project Director will hing, expertise, exper juipment and Other F rry out the requireme	ensure that the c ience, and qualifi esources: The Co ents of the contra	linical, scientific, cations required ontractor shall ict.
069085	NINDS Exploratory Neuroscience	Research (Grant (R21- Clinical Trial Option	al)	National Institutes of Health/DHHS	PA-18-358 ()7-May-2021	275,000 USD
	Contact Name	Timothy L	aVaute, PHD					
	Contact Telephone	301-496-2	1447					
	Contact Emai	lavautetm	n@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2	021					
	Synopsis	National projects, projects. the poten of novel t the NIH E	Institute of Neurological Disord which fall within the mission of These studies often assess the f itial to bring about breakthroug echniques, agents, methodolog xploratory/Developmental (R21	ers and the NIN easibili hs in th ies, or .) grant	I Stroke (NINDS) invit NDS. Awards will prov ty of a novel avenue ie understanding of i models, of high value mechanism.	tes applications for exvide support for the export for the export for the export for investigation and important areas of neets to the neuroscience	ploratory and in early and concept nvolve considera uroscience, or to community. This	novative research ual stages of ble risk, but have the development program will use
088012	Engineering Next-Generation Hui (R21 Clinical Trials Not Allowed)	<u>man Nervo</u>	us System Microphysiological S	<u>ystems</u>	National Institutes of Health/DHHS	PAR-20-082 ()7-May-2021	275,000 USD
	Contact Name	David M.	Panchision, Ph.D.					
	Contact Telephone	301-443-5	5288					
	Contact Emai	panchisio	nd@mail.nih.gov					
	Sponsor Website	h						
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 16	021 , 16-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1,16-0	oct-2021 , 07-Jan-202	22 , 16-Feb-2022 , 07-	May-2022 , 16-Ju	ın-2022 , 07-Sep-
	Synopsis	This Fund	ing Opportunity Announcemen	t (FOA)	encourages research	n grant applications d	irected toward d	eveloping next-

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
	۹ ۲ ۲ ۲ ۲	generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).						
080162	Ruth L. Kirschstein National Resear for Students at Institutions Withou Degree Training Programs (Parent I	<u>ch Service</u> t NIH-Fun F30)	e Award (NRSA) Individual Fello ded Institutional Predoctoral D	<u>wship</u> ual-	National Institutes of Health/DHHS	PA-19-192 08-A	vpr-2021	Not Specified
	Contact Name Contact Telephone Contact Email <u>C</u> Sponsor Website	GrantsInfo	o@nih.gov					
	Program URL <u>L</u> Deadline Dates (ALL) (<u>ink to pro</u>	ogram URL 21 07-May-2021 08-Aug-202	1 07-5	en-2021 08-Dec-20	21 07-lan-2022		
	Synopsis a c c c c c c c c c c c c c c c c c c	This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science.						
080180	Ruth L. Kirschstein National Resear Fellowship (Parent F31)	ch Service	e Award (NRSA) Individual Pred	octoral	National Institutes of Health/DHHS	PA-19-195 08-A	pr-2021	Not Specified


SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone	rantsinfo@nih.gov			
	Sponsor Website				
	Program LIBI	nk to program LIBI			
	Deadline Dates (ALL) 08	3-Apr-2021 . 07-May-2021 . 08-Aug-202	1.07-Sep-2021.08-Dec-2021.07-Jan-2022		
	Th av fa Synopsis re in re in re	ne purpose of the Ruth L. Kirschstein Na ward is to enable promising predoctoral culty sponsors while conducting dissert articipating NIH Institutes and Centers. search project and is expected to clear search scientist. This Funding Opportur dependent clinical trial, a clinical trial fe search experience in a clinical trial led l	ational Research Service Award (NRSA) Individua I students to obtain individualized, mentored res cation research in scientific health-related fields The proposed mentored research training must ly enhance the individual's potential to develop in hity Announcement (FOA) does not allow applicate easibility study, or an ancillary clinical trial, but d by a sponsor or co-sponsor.	Predoctoral Fellowsh earch training from o elevant to the missio eflect the applicant's nto a productive, indents nts to propose to lear oes allow applicants t	nip (Parent F31) utstanding ns of the dissertation ependent d an to propose
080156	Ruth L. Kirschstein National Research for Students at Institutions with NIH Degree Training Programs (Parent F3	h Service Award (NRSA) Individual Fello -Funded Institutional Predoctoral Dual- 30)	National Institutes of Health/DHHS)8-Apr-2021	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email <mark>Gr</mark>	rantsInfo@nih.gov			
	Sponsor Website				
	Program URL <u>Li</u>	nk to program URL			
	Deadline Dates (ALL) 08	3-Apr-2021 , 07-May-2021 , 08-Aug-202	1 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022		
	Th pr Synopsis m DV cli	nis Funding Opportunity Announcement redoctoral dual-degree training program llowship (F30) is to enhance the integra atriculated in a combined MD/PhD or c VM/PhD), and who intend careers as ph inical training plan and a dissertation re	t (FOA) will support students at institutions with ns. The purpose of the Kirschstein-NRSA, dual-do ated research and clinical training of promising p other dual-doctoral degree training program (e.g nysician/clinician-scientists. Applicants must prop esearch project in scientific health-related fields	NIH-funded institutio ctoral degree, predoc redoctoral students, v , DO/PhD, DDS/PhD, pose an integrated res relevant to the missio	nal ctoral who are AuD/PhD, search and ns of the

SPIN ID	Program Title		Sponsor Name	Sponsor	Number			Deadline Date	Funding Amount
		participat develop i allow app does allov	ing NIH Institutes and Centers. nto a productive, independent p licants to propose to lead an ind w applicants to propose researc	The fellov ohysician/ depender h experie	vship experience is clinician-scientist. t clinical trial, clini nce in a clinical tria	s expected to clea This Funding Opp cal trial feasibility al led by a sponso	rly enha portunity study, r or co-s	ance the individua y Announcement or an ancillary cli sponsor.	al's potential to (FOA) does not nical trial, but
080145	Ruth L. Kirschstein National Resea Fellowship (Parent F33)	arch Servic	e Award (NRSA) Individual Senio	or N o	ational Institutes f Health/DHHS	PA-19-187	08-A	pr-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	GrantsInf	<u>o@nih.gov</u>						
	Program URL Deadline Dates (ALL)	<u>Link to pr</u> 08-Apr-20	ogram URL)21 , 07-May-2021 , 08-Aug-202	21 <i>,</i> 07-Sep	o-2021 , 08-Dec-20	21 , 07-Jan-2022			
	Synopsis	The Natio wish to m acquiring NIH Instit independ research	nal Institutes of Health (NIH) av take major changes in the direct new research capabilities as inc utes and Centers. This Funding ent clinical trial, a clinical trial fe experience in a clinical trial led l	wards sen tion of the dependen Opportun easibility s by a spons	ior individual resea ir research career t investigators in r ity Announcemen tudy, or an ancilla sor or co-sponsor.	arch training fello s or who wish to l esearch fields rele t (FOA) does not a ry clinical trial, bu	wships t proaden evant to allow ap at does a	to experienced so their scientific b the missions of p plicants to propo allow applicants t	ientists who ackground by participating se to lead an to propose
093908	NIH Research Project Grant (Pare	nt R01 Clir	ical Trial Not Allowed)	N O	ational Institutes f Health/DHHS	PA-20-185	07-N	lay-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	grantsinfo	o@nih.gov						
	Program URL Deadline Dates (ALL)	Link to pr 07-May-2 2022 , 05-	ogram URL 021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 05-Feb-2023	1 <i>,</i> 05-Oct	-2021 , 07-Jan-202	2 , 05-Feb-2022 ,	07-May	-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	The NIH F	Research Project Grant supports	a discret	e, specified, circun	nscribed project in	n areas	representing the	specific

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		interests or more c Announce participat their resp participat	and competencies of the investi of the participating NIH Institute ement does not accept applicati e in Parent Announcements. Ap ective areas of research interes e in this announcement will not	gator(s s and C ons pro plicant t at the consic	s). The proposed proj Centers (ICs) based or Oposing clinical trial(s as should carefully no PRO1 IC-Specific Scier ler applications for fu	ect must be related n their scientific mis). Note: Not all NIH te which ICs partici ntific Interests and G inding.	to the programmatic sions. This Funding Op Institutes and Centers pate in this announcer Contact website. ICs th	interests of one oportunity 5 (ICs) ment and view hat do not
097189	Assay Development and Screenin Immunomodulators (R01)	g for Disco	very of Chemical Probes, Drugs	<u>or</u>	National Institutes of Health/DHHS	PAR-20-271	05-May-2021 [Optional][LOI/Pre-A	Not pp] Specified
	Contact Name	Suzanne I	Forry, Ph.D.					
	Contact Telephone	240-276-5	5922					
	Contact Email	forryscs@)mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	05-May-2 Oct-2021 2022 , 05-	021 [Optional][LOI/Pre-App], 07 , 05-Jan-2022 [Optional][LOI/Pr -Jun-2022 , 05-Sep-2022 [Optior	'-May-: e-App] nal][LO	2021 , 05-Jun-2021 , (, 07-Jan-2022 , 05-Fe J/Pre-App], 05-Oct-20	05-Sep-2021 [Optio b-2022 , 05-May-20)22 , 07-Jan-2023	nal][LOI/Pre-App], 07- 22 [Optional][LOI/Pre	Sep-2021 , 05- -App], 07-May-
	Synopsis	Through t novel, sm Institutes validated primary s throughp set; and 4	this funding opportunity annour all molecules for their potential (NIDCD, NIMH); and to generat as important drug targets. Stag creen implementation to identif ut screens); 3) hit validation usin b) hit-to-lead optimization.	icemer use in e new es of di y initia ng a sei	It (FOA), NCI wishes t studying disease trea insight into the biolog scovery research cov I screening hits (high ries of assays and init	o stimulate researc atment relevant to t gy of relevant disea vered by this FOA in throughput target- ial medicinal chemi	h in discovery and dev he missions of the par ses and processes tha clude: 1) assay develo focused screens, or m stry inspection to prio	relopment of ticipating NIH t have yet to be pment; 2) oderate ritize the hit
097158	Notice of Special Interest (NOSI): Cardiopulmonary Impacts of Part Populations	<u>Stimulatin</u> iculate Ma	g Intervention Research to Redu tter in Air Pollution among High	<u>ice</u> -Risk	National Institutes of Health/DHHS	NOT-HL-20-788	07-May-2021	Not Specified
	Contact Name	Lawrence	J. Fine, MD, DrPH					
	Contact Telephone	301-435-0	0305					
	Contact Email	Lawrence	.Fine@NIH.gov					

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount	
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022 , 05	.021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-0 b-2023	Oct-2021 , 07-Jan-202 , 07-May-2023 , 05-J	22 , 05-Feb-2022 , 07 un-2023 , 07-Sep-20	7-May 023	-2022 , 05-Jun-20	022 , 07-Sep-	
	Synopsis	The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lu and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in a pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.								
097215	Notice of Special Interest (NOSI): Decision Making in Aging and/or A Related Dementias (AD/ADRD)	Fundamer Alzheimer'	ntal and Translational Research s Disease and Alzheimer's Disea	on ase	National Institutes of Health/DHHS	NOT-AG-20-039	07-M	ay-2021	Not Specified	
	Contact Name	Luke Stoe	ckel, Ph.D.							
	Contact Telephone	202-570-9	9388							
	Contact Email	luke.stoe	<u>ckel@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	.021 , 05-Jun-2021 , 07-Sep-202	1,05-0	Oct-2021 , 07-Jan-202	22				
	Synopsis	This Notic the affect normally, (ADRD). R decision r social fact to financi preclinica midlife ar support in assess de	ce of Special Interest (NOSI) und tive, cognitive, social, and motiv as well as in individuals with m desearch is sought that character making are differentially impact tors on decision making or othe al exploitation and other forms al and applied research on decis and older adults with and withoun therventions to leverage cognitic cisional canacities: strategies for	derscord vational ild cogr erizes th ed in no r factor of mist ion mal t MCI a ive, emo	es NIA's continued co parameters of impa nitive impairment (M e extent to which be ormal aging, MCI, an rs that render older a reatment and abuse king that may facilita nd AD/ADRD. Specifi otional, social, and m ifving choices and of	ommitment to resea ired and intact decis CI), Alzheimer's dise ehavioral, psycholog d AD/ADRD. Investig idults (with or witho are of particular int te the design of dec c opportunities inclu- notivational strength fering better default	arch th sion m ease (A ical, ar gations out cog cerest. ision-s ude th ns of th ts: and	at seeks to bette aking in adults w AD), and AD-relat nd neural process s that target the i gnitive impairmer This NOSI also er supportive interve te development o hese populations;	r characterize ho are aging ed dementias ses involved in influence of nt) vulnerable ncourages entions for if decision- ; tools to	

SPIN ID	Program Title		Sponsor Name	Sponso	or Number			Deadline Date	Funding Amount	
		adoption neural ba making is	of optimal delegation practices sis of affective, cognitive, social also invited.	s (e.g., po l, and mo	ower of attorney, live	ing wills, etc.). The ers as they relate to	use of b age-r	animal models to elated changes ir	explore the decision	
078543	Processing and Presentation of N Not Allowed)	on-Conver	itional MHC Ligands (R01 Clinica	<u>al Trial</u>	National Institutes of Health/DHHS	PA-19-067	07-M	ay-2021	Not Specified	
	Contact Name	Timothy A	A. Gondré-Lewis, Ph.D.							
	Contact Telephone	240-627-3	3566							
	Contact Email	tglewis@	niaid.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2	021 , 05-Jun-2021 , 07-Sep-202	1,05-00	ct-2021 , 07-Jan-202	2				
	Synopsis	This Fund mechanis class I and responses induction tools and	This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the nduction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.							
093638	Identifying Innovative Mechanism and Its Consequences (R01 Clinica	ns or Interv al Trial Opt	ventions that Target Multimorbi ional)	<u>idity</u>	National Institutes of Health/DHHS	PAR-20-180	07-M	ay-2021	Not Specified	
	Contact Name	David L. T	illey, MPH, MS, CPH							
	Contact Telephone	301-827-6	5014							
	Contact Email	david.tille	y@nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fel	1 , 05-00 b-2023 ,	ct-2021 , 07-Jan-202 07-May-2023 , 05-J	2 , 05-Feb-2022 , 0 un-2023 , 07-Sep-2	7-May 023	-2022 , 05-Jun-20	22 , 07-Sep-	
	Synopsis	This Fund mechanis	ling Opportunity Announcemen ms and development of innova	nt (FOA) itive inte	invites applications rventions to address	that seek to suppo s multimorbidity or	rt the i [.] multip	dentification of s ble chronic condit	hared ions (MCCs)	

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount
		and its co pathways contextua managem innovativ assessme diverse p Studies m may be h intervent address t developir to suppor signature	onsequences. Intervention resea s that prevent MCCs, including t al risk factors and interactions the nent, including self-managemen re health care partnership mode ents of interactions between risk opulations. Use of innovative te nay also include those that make elpful in understanding the imp ions that target prevention and herapeutic targets for preventir ng improved measures and mether rt basic mechanistic discovery of es, should see PAR-20-179.	arch sup he ider hat cor hat of M els for n c factor e chnolo e use o act of r treatm ng co-o hods fc f share	pported by this initiat atification of early bio atribute to the develo CCs to delay progress nanaging or treating I s and interventions t gies to assess and int f existing data and/or mechanisms in isolati nent of multiple chror ccurring MCCs. Prosp or understanding mul- d MCC pathways and	tive should be desomarkers, behavio opment of commo- sion and prevent MCCs. Studies ma hat address MCCs rervene on risk fau data linkages to on or in combinat nic health condition ective applicants timorbidity, inclu- identification and	signed to oral path on MCCs onset or y incluc s at diffe ctors an explore tion. Of ons, incl whose ding but d initial	o study: (1) mech mays, and individ ; (2) targeted the f new diseases; ar le shared mechan erent periods of th d pathways are e new research qu particular interes uding study desig research interests t not limited to m evaluation of MC	anisms or dual and rapies and nd (3) nisms, and he lifespan in ncouraged. estions that t are gns that s relate to easures/tools C shared
093636	Advancing Research to Develop Ir Understanding Multimorbidity (R	mproved N 01 Clinical	<u>Aeasures and Methods for</u> Trial Optional)		National Institutes of Health/DHHS	PAR-20-179	07-N	1ay-2021	Not Specified
	Contact Name	David L. T	Гilley, MPH, MS, CPH						
	Contact Telephone	301-827-0	6014						
	Contact Email	david.tille	<u>ey@nih.gov</u>						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2022 , 05	2021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-0 b-2023	Oct-2021 , 07-Jan-202 , 07-May-2023 , 05-J	2 , 05-Feb-2022 , un-2023 , 07-Sep	07-May -2023	y-2022 , 05-Jun-20	022 , 07-Sep-
	Synopsis	This Fund data and multimor measures measures identifica focused s approach	ling Opportunity Announcemen measures that capture multimo bidity data. Research supported s/tools that reflect the longitudi s/tools to support basic mechan tion and initial biological, analytic studies that capture patient reported the best suited for use with multiples	t (FOA) orbidity d by thi nality a istic dis tical, ar orts and timorbi	invites applications f or multiple chronic o s initiative should be and life course diversi scovery of shared MC ad clinical evaluation d related constructs s dity data and matche	that seek to impre- conditions (MCCs) designed to disco ty of multimorbic C pathways using of MCC shared si such as functional ed to target popul	ove the and the over, de dity. This g animal gnature limitati ations;	availability, qualit e methods for and velop, and/or eva s includes but is n I models of MCCs, s. Also sought are ons and quality o and approaches t	ty, and utility of alyzing luate MCC ot limited to , and e patient- f life; analytic hat fully

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		harness tl to explore studies th 180.	ne wealth of multimorbidity dat e new research questions relate at identify shared mechanisms	a available in EHR systems. d to co-occurring MCCs. Pro or development of innovati	Studies may make use o ospective applicants who ve interventions to addr	f existing data and ose research intere ess MCCs should s	data linkages sts relate to ee PAR-20-
093035	ong-Term Effects of Disasters or Populations (R01- Clinical Trial Op	<u>Health Ca</u> ptional)	re Systems Serving Health Dispa	arity National Institutes of Health/DHHS	PA-20-172 07-	May-2021	Not Specified
	Contact Name	Larissa Av	ilés-Santa, MD, MPH				
	Contact Telephone	301-827-6	5924				
	Contact Email	<u>avilessant</u>	al@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05·	021 , 05-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 05-Fel	1 , 05-Oct-2021 , 07-Jan-202 ɔ-2023 , 07-May-2023 , 05-J	22 , 05-Feb-2022 , 07-Ma lun-2023 , 07-Sep-2023	ıy-2022 , 05-Jun-20)22 , 07-Sep-
	Synopsis	The purpe on unders disparity include ra Native Ha and unde	ose of this Funding Opportunity standing the long-term effects of populations in communities in t icial and ethnic minorities (Black waiians and other Pacific Island rserved rural populations.	Announcement (FOA) is to of natural and/or human-ma he U.S., including the U.S. to (ss/African Americans, Hispa ers), sexual and gender min	support investigative an ade disasters on health c erritories. NIH-designate nics/Latinos, American I norities, socioeconomica	d collaborative res are systems servin d health disparity ndians/Alaska Nat lly disadvantaged p	earch focused g health populations ives, Asians, populations,
097755	RFA-OD-20-016 Emergency Aw Surveillance Methods for High Ris Optional)	ards: RADx ik Clustere	-RAD Multimodal COVID-19 d Populations (R01 Clinical Trial	National Institutes of Health/DHHS	RFA-OD-20-016 07-1	May-2021	Not Specified
	Contact Name	Elena Kou	stova, PhD, MBA				
	Contact Telephone	301-496-8	3768				
	Contact Email	<u>elena.kou</u>	<u>stova@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 05-Fel	1 , 05-Oct-2021 , 07-Jan-202 p-2023 , 07-May-2023 , 05-J	22 , 05-Feb-2022 , 07-Ma lun-2023 , 07-Sep-2023 ,	iy-2022 , 05-Jun-20 07-Jan-2024)22 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	NIH is issu the Secre- as part of developm individual periods of these tech general a translate facilities i Projects p funding fo	uing this Funding Opportunity A tary, HHS, for 2019 Novel Coror the Rapid Acceleration of Diagr nent and validation studies of CO s, in settings and institutions, in f time. There are numerous pro hnologies are often not interope pplicability to public health or for a combination of digital surveill n making clinically meaningful co proposed may use strategies that or this initiative is provided form	nnouncement (FOA) in resp navirus (COVID-19). This em nostics-Radical (RADx-rad) in OVID-19 surveillance metho including residential, with a h mising technologies which a erable, not optimized for in- or the specific need of high- ance modalities into platfor are recommendations for p it incorporate ideas and app in the Paycheck Protection P	ponse to the declared pul ergency FOA provides an nitiative. This FOA invites ods, not based or focused high density of individual could allow for multimod tegration to increase rob trisk population surveillar rms that can assist the pr patients at risk of COVID- proaches from multiple d program and Health Care	blic health emerge expedited fundin applications to put on direct viral test s who are togethe lal surveillance inp sustness and not te nce. Applications a rofessional staff of 19 or other respirat lisciplines, as appro-	ncy issued by g mechanism ursue ting of r for prolonged outs. However, ested for are invited that high-risk atory viruses. opriate. The , 2020.
097838 🖪	<u> R01 - Clone (Defunct)</u>			National Institutes of Health/DHHS	07-1	May-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)	07-May-2 2022,05·	021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 05-Fe	1 , 05-Oct-2021 , 07-Jan-202 o-2023 , 07-May-2023 , 05-J	22 , 05-Feb-2022 , 07-Ma Jun-2023 , 07-Sep-2023 ,	y-2022 , 05-Jun-20 07-Jan-2024)22 , 07-Sep-
	Synopsis						
100289	Discovery of in vivo Chemical Pro Not Allowed)	bes for the	Nervous System (R01 Clinical T	rial National Institutes of Health/DHHS	PAR-21-029 07-1	May-2021	Not Specified
	Contact Name	Enrique L	. Michelotti, Ph.D.				
	Contact Telephone	301-443 5	5415				
	Contact Email	<u>michelott</u>	iel@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	07-May-2 2022 , 05-	021 , 05-Jun-2021 , 07-Sep-2022 Oct-2022 , 07-Jan-2023 , 05-Feb	1 , 05-00 b-2023 ,	ct-2021 , 07-Jan-202 07-May-2023 , 05-J	2 , 05-Feb-2022 , 07-Ma un-2023 , 07-Sep-2023 ,	y-2022 , 05-Jun-20 05-Oct-2023 , 07-J)22 , 07-Sep- lan-2024	
	Synopsis	join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their opsis potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).							
099859	Notice of Special Interest (NOSI): ⁻ Heterogeneity of Acute Respirator (ARDS/ALI)	The Influer ry Distress	nce of Host Resilience on Syndrome/Acute Lung Injury		National Institutes of Health/DHHS	NOT-HL-20-814 07-N	Лау-2021	Not Specified	
	Contact Name	Guofei Zh	ou, PhD						
	Contact Telephone	301-827-7	7825						
	Contact Email	guofei.zho	ou@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2022 , 05- Feb-2024	021 , 05-Jun-2021 , 07-Sep-202: Oct-2022 , 07-Jan-2023 , 05-Feb , 07-May-2024 , 05-Jun-2024	1 , 05-0 b-2023 ,	ct-2021 , 07-Jan-202 07-May-2023 , 05-J	2 , 05-Feb-2022 , 07-Ma un-2023 , 07-Sep-2023 ,	y-2022 , 05-Jun-20 05-Oct-2023 , 07-J	022 , 07-Sep- 0an-2024 , 05-	
	Synopsis	The purpo research t /acute lur	ose of this Notice of Special Inte to understand host resilience as ng injury (ALI).	erest (NC s a critica	DSI) is to inform pote al determinant of ou	ential applicants of the spitcomes in acute respirat	pecial interest of N ory distress syndro	IHLBI in ome (ARDS)	
101245	Notice of Special Interest (NOSI): I and Implementation among Popu	Research t lations tha	o Address Vaccine Hesitancy, U t Experience Health Disparities	lptake,	National Institutes of Health/DHHS	NOT-MD-21-008 07-N	Лау-2021	Not Specified	
	Contact Name	Deborah I	E. Linares, Ph.D., M.A.						
	Contact Telephone	301-402-2	2516						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	deborah.	linares@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2	2021 , 05-Jun-2021 , 07-Sep-202	1 , 05-Oct-2021 , 07-Jan-202	22		
	Synopsis	This Notic hesitancy to unders influenza, especially inequities intervent address t and likely	ce of Special Interest (NOSI) high y, uptake, and implementation a stand and address misinformatio , hepatitis B, human papilloma w y in populations at increased risk s and chronic medical conditions ion strategies (e.g., expand reac he barriers to increasing reach, to experience vaccine hesitance	nlights the need for research mong populations who exp on, distrust, and hesitancy re virus (HPV), and herpes zost for morbidity and mortalit s. The purpose of this NOSI h, access) to facilitate vacci access, and uptake of vaccir y.	n strategies and interven erience health disparities egarding vaccines (e.g., S er) among adults in the L y due to long-standing sy is to solicit community-en nation uptake in clinical a nations among health dis	tions to address va s in the US.* Resea ARS-CoV-2, pneun Jnited States and t vstemic health and ngaged research to and community co parity populations	accine arch is needed nococcal, territories, social o: 1) evaluate ontexts; and 2) s at high risk
088091	Development and Application of F for Drug Discovery and for Pathop Clinical Trial Optional)	PET and SP physiologic	PECT Imaging Ligands as Biomarl cal Studies of CNS Disorders (RO	KersNational Institutes1of Health/DHHS	PAR-20-038 07-N	Лау-2021	Not Specified
	Contact Name	Enrique N	/lichelotti, Ph.D.				
	Contact Telephone	301-443-5	5415				
	Contact Email	<u>michelott</u>	<u>tiel@mail.nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05 [.]	2021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 05-Oct-2021 , 07-Jan-202	22 , 05-Feb-2022 , 07-Ma	y-2022 , 05-Jun-20)22 , 07-Sep-
	Synopsis	This Fund evaluatio (SPECT) ir in pre-clir use in clir	ling Opportunity Announcemen n of novel radioligands for posit maging in human brain and the nical studies. These studies are e nical research. Projects proposin	t (FOA) invites research gran ron emission tomography (I incorporation of pilot or clin expected to provide the req og only preclinical animal stu	nt applications that proper PET) or single photon em nical feasibility evaluation uisite data needed to adv udies should consider the	ose the developmo ission computed t from previously o vance promising P companion FOA F	ent and omography collected data ET ligands for PAR-20-037.
096860	Countermeasures Against Chemic	al Threats	(CounterACT)	National Institutes	PAR-20-253 26-N	/ay-2021	275,000



SPIN ID	Program Title		Sponsor Name	Sponso	Number			Deadline Date	Funding Amount
	Exploratory/Developmental Proje	cts (R21 C	linical Trial Not Allowed)		of Health/DHHS				USD
	Contact Name	Shardell S	Spriggs, Ph.D.						
	Contact Telephone	301-443-	8189						
	Contact Email	shardell.s	priggs@nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	26-May-2	2021 , 31-May-2022 , 30-May-20	023					
	Synopsis	This Fund (Counter, research Chemical productic pharmace the devel programs	ling Opportunity Announcemen ACT) exploratory/developmenta that will advance development threats are toxic compounds th on, storage or shipping. They ind eutical-based agents. Projects so opment of competitive applicat sor other related initiatives.	nt (FOA) e al (R21) p of new a hat could clude trac supportec tions for	ncourages applicat rojects. The missio nd improved thera be used in a terror litional chemical w by this FOA are ex more extensive sup	ions for NIH Cour n of the NIH Cour peutics to mitigat ist attack or accio arfare agents, too pected to genera port from theNIH	ntermea nterACT te the he dentally xic indus te prelir H Counte	sures Against Che program is to fos ealth effects of ch released from ind strial chemicals, p minary data that w erACT Cooperative	Mical Threats ter and support emical threats. lustrial esticides, and would facilitate e Agreement
094932	NCCIH Natural Product Early Phas (R61/R33 Clinical Trial Required)	e Clinical	Trial Phased Innovation Award		National Institutes of Health/DHHS	PAR-20-218	07-N	/lay-2021	1,750,000 USD
	Contact Name	Wendy W	/eber, N.D., Ph.D, M.P.H.						
	Contact Telephone	301-402-	1272						
	Contact Email	weberwj(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	2021 , 01-Oct-2021 , 07-Jan-202	2 , 01-Jur	-2022 , 07-Sep-202	22 , 01-Feb-2023	, 07-Ma	y-2023	
	Synopsis	This Fund of natura further cl informati This FOA bioavaila	ling Opportunity Announcemen I products (i.e., botanicals, dieta inical testing. Under this FOA, t on of high scientific utility and v will provide up to three years (I bility, and assessment of the na	nt (FOA) e ary suppl rials mus will suppo R61 phas atural pro	ncourages applicat ements, and probic t be designed so th ort decisions about e) of support for m duct's effect (i.e., n	ions for investiga otics), which have at results, wheth further developr ilestone-driven to neasure of mecha	ator-initi a stron er positi nent or esting of anism of	ated, early phase g scientific premis ve or negative, w testing of the nat pharmacokinetic action) when use	, clinical trials se to justify ill provide ural product. s, ed by humans

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount
		on a biolo be award whether to outcomes impact of different treatmen target po milestone intended testing to trials, nor be suppo Scientific, to this FO	pgical signature(s). If milestones ed to replicate the impact of the there is an association between s in a patient population. Applic the natural product on the biol doses or formulation. In addition t approach that is known to imp pulation that is more responsive e-driven, and directly related to to accelerate the translation of determine whether continued will it support trials to test naturated the two phases of the R (Research contact for the area of the test of the test of the area of the test of the area of the test of the area of the test of the test of the area of the test of test of the test of the test of the test of the test of te	in the e natur the de ations a logical s on, appl pact the e. Clinic the res emerg clinical ural pro 61/R33 of scien	R61 phase are achie al product on the bi gree of the impact of signature by optimiz ications can be desi e same biological sig cal trials submitted u earch priorities and ing basic science fin research is warrant oducts for the treatr award. Applicants a ce for which they ar	eved, up to 3 year ological signature on the biological s lesign R33 studies ting the delivery of gned to combine mature; or study f under this FOA are mission of NCCIF dings about natur red. This FOA will nent or preventio are encouraged to re planning to dev	s of addi e(s) wher ignature to deten of the natu the impa e expecte I. This Re ral produ not supp on of can contact velop an	tional support (R n used by humans and functional or rmine how to opti- tural product by e ral product with a ct of the natural p ed to be hypothes 51/R33 funding m locts into early-stag port efficacy or efficer. A maximum of the appropriate application prior f	33 phase) may and assess r clinical imize the xamining another product in a sis based, echanism is ge clinical fectiveness of 5 years will NCCIH to submitting
094931	NCCIH Natural Product Early Phas Required)	e Clinical	Trial Award (R33 Clinical Trial		National Institutes of Health/DHHS	PAR-20-217	07-N	/lay-2021	1,050,000 USD
	Contact Name	Wendy W	/eber, N.D., Ph.D, M.P.H.						
	Contact Telephone	301-402-2	1272						
	Contact Email	weberwj(@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	.021 , 01-Oct-2021 , 07-Jan-202	2 , 01-Jı	un-2022 , 07-Sep-20	22 , 01-Feb-2023	, 07-Ma	y-2023	
	Synopsis	This Fund of natura further cl informati This FOA signature biological to determ	ing Opportunity Announcemen I products (i.e., botanicals, dieta inical testing. Under this FOA, tr on of high scientific utility and v will provide up to 3 years suppo (s) when used by humans and a signature and functional or clir nine how to optimize the impac	t (FOA) ary supp rials mu will supp ort for s assess w nical ou t of the	encourages applica plements, and probi ist be designed so th port decisions abou tudies to replicate t whether there is an a tcomes in a patient natural product on	tions for investiga otics), which have nat results, wheth t further develope he impact of the association betwe population. Appli the biological sig	ator-initi e a stron, ner positi ment or natural p en the d cations a nature b	ated, early phase, g scientific premis ve or negative, w testing of the nation product on the bio egree of the impa are encouraged to y optimizing the o	clinical trials to justify ill provide ural product. ological oct on the o design studies delivery of the

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		natural p natural p of the nat be hypoth mechanis stage clin effectiver	roduct by examining different de roduct with another treatment a tural product in a target populat nesis based, milestone-driven, a m is intended to accelerate the ical testing to determine wheth ness trials, nor will it support tria	oses or approac tion tha ind direc translat er conti als to te	formulations. In add th that is known to ir t is more responsive ctly related to the re tion of emerging bas nued clinical researc st natural products f	ition, applications can be npact the same biologic . Clinical trials submitte search priorities and m ic science findings abou ch is warranted. This FO for the treatment or pre	be designed to com cal signature; or stu d under this FOA an ission of NCCIH. Thi it natural products A will not support e evention of cancer.	bine the idy the impact re expected to is R33 funding into early efficacy or
100769	Addressing the Etiology of Health Immigrant Populations (R01 Clinic	Disparitie al Trial No	s and Health Advantages Amon ot Allowed)	g	National Institutes of Health/DHHS	PAR-21-080 07-	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Deborah 301-402- <u>deborah.</u>	Linares, Ph.D. 2516 Iinares@nih.gov					
	Program URL Deadline Dates (ALL)	Link to pr 07-May-2 2022 , 05	<mark>ogram URL</mark> .021 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1 , 05-0	ct-2021 , 07-Jan-202	2 , 05-Feb-2022 , 07-M	ay-2022 , 05-Jun-20)22 , 07-Sep-
	Synopsis	The purpe uniquely immigran	ose of this Funding Opportunity associated with the immigratior t populations.	Annoui n experi	ncement (FOA) is to a ence that contribute	support innovative rese to health disparities or	arch to understand health advantages	I factors among U.S.
100780	Addressing Health Disparities and Interventions (R01 Clinical Trial O	ong Immig otional)	rant Populations through Effect	<u>ive</u>	National Institutes of Health/DHHS	PAR-21-081 07-	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Deborah 301-402- deborah.	Linares, Ph.D. 2516 linares@nih.gov ogram URL 021 05-lup-2021 07-Sep 2021	1 05 0	ct_2021_07_lan_202	2 05-Eeb-2022 07 M	av-2022 05-lup 20	122 07-Sep-
	Deadline Dates (ALL)	2022,05	-Oct-2022 , 05-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1,05-0	ct-2021 , 07-Jan-202	2,05-Feb-2022,07-M	ay-2022 , 05-Jun-20	122 , U7-Sep-

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this initiative is to suppor advantages and reduce the health dispar	t research to design and implemen ities among US immigrant population	t effective interve ons.	entions to enhance	e health
100758	Notice of Special Interest (NOSI): of Health (NIH) Partnership Progr	Academy of Finland (AKA) – National Insti am	tutes National Institutes NOT-C of Health/DHHS	D-21-021 07-N	/lay-2021	Not Specified
	Contact Name	Sarah Scharf, MPA				
	Contact Telephone	301-496-4784				
	Contact Email	sarah.scharf@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 07-Jan-2023 , 05-Feb-2023 , 07-Ma	1 , 05-Oct-2021 , 07-Jan-2022 , 05-F ay-2023 , 05-Jun-2023 , 05-Jun-2023	eb-2022 , 07-May 3 , 07-Sep-2023 , (y-2022 , 07-Sep-20 05-Oct-2023 , 07	022 , 05-Oct- Jan-2024
	Synopsis	The purpose of this Notice of Special Inte knowledge and information on a program research collaboration.	rest (NOSI) is to alert the communi n designed to foster the expansion	ty about this oppo of U.SFinland bio	ortunity and disse omedical and beh	eminate avioral
102106	NIH Support for Conferences and Allowed)	Scientific Meetings (Parent R13 Clinical Tr	ial Not National Institutes of Health/DHHS	151 12-A	pr-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Apr-2021 , 07-May-2021 , 12-Aug-202 2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Ja Jan-2024	1 , 07-Sep-2021 , 12-Dec-2021 , 07- n-2023 , 12-Apr-2023 , 07-May-202	Jan-2022 , 12-Apı 3 , 12-Aug-2023 ,	r-2022 , 07-May-2 07-Sep-2023 , 12	022 , 12-Aug- -Dec-2023 , 07-
	Synopsis	The purpose of the NIH Research Confere public health and to the scientific mission	ence Grant (R13) is to support high n of the participating Institutes and	quality conferenc Centers.	es that are releva	nt to the
094250	Mentored Patient-Oriented Resea Independent Clinical Trial Require	arch Career Development Award (Parent K ed)	X23 National Institutes of Health/DHHS	206 07-№	Nay-2021	Not Specified

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount				
	Contact Name											
	Contact Telephone											
	Contact Email	grantinfo	@nih.gov									
	Sponsor Website											
	Program URL											
Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023)22 , 07-Sep-				
	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeav on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants properties as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not a Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in the announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Informa Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider application funding. Consultation with NIH staff before submitting an application is strongly encouraged.											
094234	Mentored Clinical Scientist Resea	rch Career	Development Award (Parent K	<u>08</u>	National Institutes	PA-20-202 0	7-May-2021	Not				
		<u>,</u>						Specified				
	Contact Telephone	301-496 9	2520									
	Contact Fmail	grantinfo	anih gov									
	Sponsor Website	grantino	<u>erini.gov</u>									
	Program URL	Link to pr	ogram URI									
Deadline Dates (ALL) 2022, 12-Oct-2022, 07-Jan-2023, 12-Feb-2023, 07-Jan-2023, 12-Feb-2023, 07-May-2022, 12-Feb-2022, 07-May-2022, 12-Jun-2022, 07-Jan-2023, 07-May-2023)22 , 07-Sep-				
The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to Synopsis prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation This program represents the continuation of a long-standing NIH program that provides support and "protected time" to												

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		individual biomedic designed feasibility planning must app Applicant interest a participat applicatic	Is with a clinical doctoral degree al and behavioral research, inclu specifically for applicants prope study, or a separate ancillary cl an independent clinical trial, or ly to companion FOA. Special Ne s should carefully note which IC nd requirements at the Table of the in this announcement will not on is strongly encouraged.	e for an intensive, supervisuding translational researd osing to serve as the lead i linical trial, as part of their proposing to gain researc ote: Not all NIH Institutes is participate in this annou f IC-Specific Information, I consider applications for	sed research career deve ch. This Funding Opportu investigator of an indepe r research and career de h experience in a clinical and Centers participate uncement and view their Requirements and Staff (funding. Consultation w	lopment experience inity Announcement ndent clinical trial, a velopment. Applicar trial led by another in Parent Announce respective areas of Contacts website. IC ith NIH staff before	in the fields of t (FOA) is clinical trial nts not investigator, ments. research s that do not submitting an
094248	Mentored Patient-Oriented Resea Independent Clinical Trial Not Allo	arch Caree wed)	r Development Award (Parent K	X23 National Institute of Health/DHHS	^{2S} PA-20-205 07	7-May-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	<u>grantinfo</u>	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 12	021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2 b-2023 , 07-May-2023	022 , 12-Feb-2022 , 07-N	1ay-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purpe developm on patien research clinical tri mentor. A FOA Spec which ICs the Table announce strongly e	ose of the NIH Mentored Patien nent of individuals with a clinica t-oriented research. This Fundir that does not involve leading ar al. Applicants to this FOA are per Applicants proposing a clinical tr ial Note: Not all NIH Institutes a participate in this announceme of IC-Specific Information, Requ ement will not consider applicat encouraged.	t-Oriented Research Care I doctoral degree who hav ng Opportunity Announce i independent clinical trial ermitted to propose resea ial or an ancillary clinical f nd Centers participate in ont and view their respect uirements and Staff Conta ions for funding. Consulta	er Development Award (ve made a commitment to ment (FOA) is designed s I, a clinical trial feasibility arch experience in a clinic trial as lead investigator, Parent Announcements. ive areas of research inter acts website. ICs that do ation with NIH staff befor	K23) is to support the ofocus their resear specifically for applice study, or a separate should apply to the Applicants should cerest and requirement participate in the submitting an apple	ne career ch endeavors cants proposing e ancillary ntor or co- companion arefully note ents at is plication is

SPIN ID	Program Title	Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
094040	Mentored Quantitative Research De Basic Experimental Studies with Hu	evelopment Award (Parent K25 Ir mans Required)	ndependent	National Institutes of Health/DHHS	PA-20-198 07-N	Лау-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL <u>L</u>	ink to program URL					
	Deadline Dates (ALL) 2	7-May-2021 , 12-Jun-2021 , 07-Se 022 , 12-Oct-2022 , 07-Jan-2023 ,	ep-2021 , 12-C , 12-Feb-2023	oct-2021 , 07-Jan-202 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-
	t q a ir r r t t Synopsis ir f p c t t t t c a a c t	hose investigators whose quantiti- uestions of health and disease. T nd research for productive profes- maging science, informatics, phys- esearch. This Parent Funding Opp eferred to in NOT-OD-18-212 as " he NIH definition of a clinical trial nder this FOA include studies than dependent variables) and that as undamental aspects of phenomer- lanning an independent clinical tri linical trial or basic experimental rial Not Allowed' companion FOA he participating NIH Institutes and enters participate in Parent Anno- nd view their respective areas of nd Staff Contacts website. ICs that consultation with NIH staff before	ative science a The K25 award ssionals with o ics, chemistry portunity Anno prospective b and also mee it prospectivel ssess biomedi na without spe rial or basic ex study with hu the propose d Centers (ICs) puncements. A research inter at do not parti submitting ar	and engineering rese will provide support juantitative (e.g., ma) and engineering ba- puncement is for basi asic science studies i t the definition of ba y assign human parti- cal or behavioral out ecific application tow perimental study with mans led by another d project must be re- based on their scient applicants should car- rest and requirement cipate in this announ application is strong	arch has thus far not been thand "protected time" for thematics, statistics, eco- ckgrounds to integrate the ic science experimental s nvolving human participa- sic research. Types of st icipants to conditions (i.e. comes in humans for the vards processes or produ- th humans, or proposing investigator, must apply lated to the programmat nuffic missions. Special No efully note which ICs par ts at the Table of IC-Spec- incement will not consider gly encouraged.	en focused primari or a period of supe nomics, compute neir expertise with tudies involving h ants." These stud udies that should a., experimentally purpose of under to gain research e to the 'Independe to the 'Independe tic interests of one ote: Not all NIH Ins ticipate in this ann ific Information, R r applications for f	ly on ervised study r science, n NIH-relevant umans, ies fall within be submitted manipulate rstanding the cants not experience in a ent Clinical e or more of stitutes and nouncement equirements funding.
094233	Mentored Clinical Scientist Researc	h Career Development Award (Pa	arent KO8	National Institutes	PA-20-201 07-N	/lav-2021	Not

Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) 2	<u>Link to program URL</u> 07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe The primary purpose of the NIH Mentore	1 , 12-Oct-2021 , 07-Jan-202 b-2023 , 07-May-2023 ed Clinical Scientist Researcl	2 , 12-Feb-2022 , 07-Ma n Career Development A	y-2022 , 12-Jun-20 wards (K08) progra	122 , 07-Sep- am is to
	۲ ۲ ۱ ۵ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲	prepare qualified individuals for careers to This program represents the continuation individuals with a clinical doctoral degree biomedical and behavioral research, inclu- pasic science experimental studies involve involving human participants." These stu- pasic research. Types of studies that sho participants to conditions (i.e., experimen- butcomes in humans for the purpose of u- cowards processes or products in mind. A numans, or proposing to gain research ex- investigator, must apply to the 'Independ related to the programmatic interests of scientific missions. Special Note: Not all N carefully note which ICs participate in thi requirements at the Table of IC-Specific I chis announcement will not consider app strongly encouraged.	that have a significant impact of a long-standing NIH pro- e for an intensive, supervised uding translational research ring humans, referred to in N udies fall within the NIH defi- ould be submitted under this ntally manipulate independen understanding the fundame Applicants not planning an in- kperience in a clinical trial of dent Clinical Trial Not Allowe one or more of the participa NIH Institutes and Centers participation is announcement and view to nformation, Requirements a lications for funding. Consul	ct on the health-related in gram that provides supp d research career develo . This Parent Funding Op NOT-OD-18-212 as "prosp nition of a clinical trial and FOA include studies that ent variables) and that as ntal aspects of phenome independent clinical trial of r basic experimental stud ed' companion FOA. The ating NIH Institutes and C articipate in Parent Anno heir respective areas of p and Staff Contacts websit Itation with NIH staff bef	research needs of ort and "protected pment experience portunity Announ- pective basic scien and also meet the d t prospectively ass assess biomedical o na without specifi or basic experiment by with humans led proposed project of Centers (ICs) based buncements. Appli research interest a te. ICs that do not fore submitting an	the Nation. d time" to in the fields of cement is for ce studies efinition of sign human r behavioral c application ntal study with d by another must be d on their cants should and participate in application is
094235	Mentored Clinical Scientist Researce Independent Clinical Trial Not Allow	ch Career Development Award (Parent Ki wed)	08 National Institutes of Health/DHHS	PA-20-203 07-N	May-2021	Not Specified
	Contact Name					

Contact Telephone 301-496-8580



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email Sponsor Website Program URL	grantinfo Link to pr	<u>@nih.gov</u> ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-20 b-2023 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-	
	Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nat This program represents the continuation of a long-standing NIH program that provides support and "protected time" individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) i designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clir trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead invest should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcem Applicants should carefully note which ICs participate in this announcement and view their respective areas of researce interest and requirements at the website. ICs that do not participate in this announcement will not consider application.						
094244	Mentored Patient-Oriented Research Independent Basic Experimental	arch Caree Studies wi	r Development Award (Parent H th Humans Required)	(23 National Institutes of Health/DHHS	PA-20-204 07-N	/lay-2021	Not Specified	
	Contact Name Contact Telephone Contact Email							
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-20 b-2023 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-	
	Synopsis Synopsis an experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These							

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
		studies fa should be experime purpose of products to gain re to the 'Ind interests Note: Not participat Specific In consider	Idies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that ould be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., perimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the rpose of understanding the fundamental aspects of phenomena without specific application towards processes or oducts in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or prop gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must a the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programma cerests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special ote: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which IC rticipate in this announcement and view their respective areas of research interest and requirements at the Table of I ecific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not nsider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.					
094044	Mentored Quantitative Research Clinical Trial Not Allowed)	Developm	ent Award (Parent K25 Indepen	<u>ident</u>	National Institutes of Health/DHHS	PA-20-199	07-May-2021	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	grantinfo	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-0 b-2023	Oct-2021 , 07-Jan-202 , 07-May-2023	2 , 12-Feb-2022 , 07	7-May-2022 , 12-Jun-2	022 , 07-Sep-
	Synopsis	The purper those inve questions and resea imaging s research. not involv FOA are p clinical tri Note: Note	ose of the Mentored Quantitativ estigators whose quantitative so s of health and disease. The K25 arch for productive professional science, informatics, physics, che This Funding Opportunity Anno ve leading an independent clinic permitted to propose research e ial or an ancillary clinical trial as t all NIH Institutes and Centers p	ve Rese cience 5 award s with o emistry buncer cal trial experie lead in barticip	earch Career Develop and engineering resea d will provide support quantitative (e.g., ma) and engineering bac nent (FOA) is designed , a clinical trial feasibi nce in a clinical trial fe westigator, should ap pate in Parent Annour	ment Award (K25) is arch has thus far no and "protected tim thematics, statistics ckgrounds to integra d specifically for app lity study, or an anc ed by a mentor or co pply to the companion cements. Applicant	s to attract to NIH-rele of been focused primar ne" for a period of supe s, economics, compute ate their expertise with plicants proposing rese cillary clinical trial. App o-mentor. Applicants p on FOA (PA-20-197). Sp ts should carefully note	evant research rily on ervised study er science, h NIH-relevant earch that does licants to this proposing a pecial e which ICs

SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount	
		participat Specific Ir consider	e in this announcement and vie nformation, Requirements and S applications for funding. Consul	w thei Staff Co tation	r respective areas of intacts website. ICs t with NIH staff before	research interest and re hat do not participate i submitting an applicat	equirements at the n this announceme ion is strongly enco	Table of IC- nt will not uraged.	
097728	Notice of Special Interest (NOSI): the NINDS IGNITE Program	Discovery	of Analgesic Natural Products th	nrough	National Institutes of Health/DHHS	NOT-AT-20-016 07	-May-2021	Not Specified	
	Contact Name	D. Craig H	lopp, Ph.D.						
	Contact Telephone	301-496-	5825						
	Contact Email	hoppdc@	nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2	.021						
	Synopsis	The purpe this NOSI suitable f products microbial and inflar	ose of this Notice of Special Inte , NCCIH is interested in supporti or medium- to high-throughput are defined as extracts, chroma , or animal sources. For this NOS nmatory pain conditions.	rest (N ng rese screer tograp SI, NCC	OSI) is to announce I earch geared toward ing of natural produc hic fractions, or isola IH is prioritizing anal	NCCIH participation in t development of robust ct libraries. For the purp ted constituents derive gesic targets relevant to	he NINDS IGNITE pi , validated analgesi poses of this NOSI, i d from herbal, bota p musculoskeletal, i	rogram. For ic assays natural anical, marine, neuropathic,	
093931	NIH Pathway to Independence Av Required)	vard (Pare	nt K99/R00 Independent Clinica	<u>l Trial</u>	National Institutes of Health/DHHS	PA-20-187 07	-May-2021	Not Specified	
	Contact Name								
	Contact Telephone								
	Contact Email	grantinfo	@nih.gov						
	Sponsor Website		-						
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	07-May-2 2022 , 12	021 , 12-Jun-2021 , 07-Sep-202 Oct-2022 , 07-Jan-2023 , 12-Fel	1 , 12-0 b-2023	0ct-2021 , 07-Jan-202 , 07-May-2023	22 , 12-Feb-2022 , 07-M	ay-2022 , 12-Jun-20	022 , 07-Sep-	
	Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to							

SPIN ID	Program Title		Sponsor Name	Sponso	or Number		Deadline Date	Funding Amount
		independ during thi Opportur independ career de clinical tri	ent, tenure-track or equivalent is transition in order to help aw hity Announcement (FOA) is des ent clinical trial, a clinical trial fo velopment. Applicants not plan ial led by another investigator, r	faculty p ardees t igned sp easibility ning an nust app	positions. The progra o launch competitiv pecifically for applica v study, or a separat independent clinica oly to companion FC	am will provide indepe e, independent resear nts proposing to serve e ancillary clinical trial trial, or proposing to A.	ndent NIH research ch careers. This Fun as the lead investig as part of their reso gain research exper	support ding ;ator of an earch and ience in a
093214	Independent Scientist Award (Par with Humans Required)	<u>ent KO2 In</u>	dependent Basic Experimental	<u>Studies</u>	National Institutes of Health/DHHS	PA-20-173 0	'-May-2021	Not Specified
	Contact Name							
	Contact Telephone							
	Contact Email	<u>grantinfo</u>	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 12	021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-00 b-2023 ,	ct-2021 , 07-Jan-202 07-May-2023	2 , 12-Feb-2022 , 07-N	1ay-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purper them to e five years period of program for basic s involving basic rese participar outcomes towards p humans, o investigat related to scientific	ose of the NIH Independent Scie expand their potential to make s of salary support and "protected intensive research focus as a m must be tailored to meet the in- science experimental studies inv human participants." These stu- earch. Types of studies that sho hts to conditions (i.e., experime is in humans for the purpose of the processes or products in mind. A or proposing to gain research ex- cor, must apply to the 'Independ of the programmatic interests of missions.	entist Aw ignificar ed time" eans of dividual volving h udies fall uld be s ntally m understa opplican operienc lent Clin one or r	vard (K02) is to foste nt contributions to t for newly independ enhancing their rese needs of the candid numans, referred to within the NIH defi ubmitted under this anipulate independe anding the fundaments not planning an ir se in a clinical trial or ical Trial Not Allowe more of the participa	er the development of heir field of research. ent scientists who car earch careers. Each ind ate. This Parent Fundi in NOT-OD-18-212 as nition of a clinical trial FOA include studies t ent variables) and that ntal aspects of phenor idependent clinical tri basic experimental st cd' companion FOA. Th ating NIH Institutes an	outstanding scientis The KO2 award prov demonstrate the n ependent scientist ng Opportunity Ann "prospective basic s and also meet the o nat prospectively as assess biomedical o nena without specified or basic experime udy with humans le e proposed project d Centers (ICs) base	its and enable ides three to eed for a career award ouncement is cience studies definition of sign human or behavioral ic application ntal study with d by another must be d on their

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
093210	Independent Scientist Award (Par	rent K02 - Independent Clinical Trial Requi	red) National Institutes P/ of Health/DHHS	A-20-171 07-№	1ay-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2022 , b-2023 , 07-May-2023	12-Feb-2022 , 07-May	/-2022 , 12-Jun-2()22 , 07-Sep-
	Synopsis	them to expand their potential to make s five years of salary support and "protecte period of intensive research focus as a m program must be tailored to meet the ind designed specifically for applicants propo feasibility study, or a separate ancillary c planning an independent clinical trial, or must apply to companion FOA.	entist Award (KO2) is to roster to significant contributions to their ed time" for newly independen eans of enhancing their resear dividual needs of the candidate osing to serve as the lead invest linical trial, as part of their rese proposing to gain research exp	ir field of research. The it scientists who can de ch careers. Each indep e. This Funding Opport tigator of an independ earch and career devel perience in a clinical tri	e KO2 award prov emonstrate the n bendent scientist cunity Announcen ent clinical trial, a opment. Applicar ial led by another	ides three to eed for a career award nent (FOA) is a clinical trial nts not investigator,
093225	Independent Scientist Award (Par Allowed)	rent K02 - Independent Clinical Trial Not	National Institutes of Health/DHHS	A-20-174 07-№	1ay-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-2022 , b-2023 , 07-May-2023	12-Feb-2022 , 07-May	/-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purpose of the NIH Independent Scie them to expand their potential to make s	entist Award (K02) is to foster t ignificant contributions to the	he development of ou ir field of research. The	tstanding scientis e KO2 award prov	ts and enable ides three to

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date	Funding Amount
		five years period of program designed trial feasi in a clinica investigat	of salary support and "protecte intensive research focus as a me must be tailored to meet the inc specifically for applicants propo bility study, or a separate ancilla al trial led by another investigate or, should apply to the compan	d time eans of lividual sing re ry clini or. App ion FOA	" for newly independ enhancing their rese needs of the candid search that does not cal trial. Applicants to licants proposing a c	lent scientists who ca earch careers. Each in ate. This Funding Opp involve leading an inc o this FOA are permit linical trial or an ancil	n demonstrate the ne dependent scientist o portunity Announcem dependent clinical tri ted to propose resea lary clinical trial as le	eed for a career award eent (FOA) is al, a clinical rch experience ad
099505	Notice of Special Interest (NOSI): Care	<u>Advancing</u>	the Science of Geriatric Palliativ	<u>/e</u>	National Institutes of Health/DHHS	NOT-AG-20-041 0	7-May-2021	Not Specified
	Contact Name	Basil Elda	dah, M.D., Ph.D.					
	Contact Telephone	301-496-6	5761					
	Contact Email	<u>eldadahb</u>	<u>@nia.nih.gov</u>					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023	021 , 05-Jun-2021 , 16-Jun-2021 ·May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 , 1	. , 07-So n-2022 .6-Jun-1	ep-2021 , 05-Oct-202 : , 07-Sep-2022 , 05-C 2023 , 07-Sep-2023	1 , 16-Oct-2021 , 07 Oct-2022 , 16-Oct-202	an-2022 , 05-Feb-202 2 , 07-Jan-2023 , 05-F	22 , 16-Feb- eb-2023 , 16-
	Synopsis	This Notic populatio specialty clinics and healthcar and medi specimen observati	e of Special Interest (NOSI) enco ns. This NOSI covers studies in a medical or surgical wards, inten d doctors' offices, patients' hom e or community settings. This N cal records, claims data, or othe repositories, and other existing onal approaches, quasi-experim	ourages variet sive can es and OSI end r sourc resear ental d	s research grant appl y of settings including re units, and emerger other residential set courages both prospe res. Leveraging ongoi ch resources and infi lesigns, and intervent	ications focused on p g hospitals (and speci ncy departments), po tings, long-term care ective studies and ana ng cohorts, intervent rastructure is encoura tional studies.	alliative care in geria fic sites within hospit st-acute care settings facilities, hospices, ar lyses of existing data on studies, networks ged. Study designs m	tric als including s, outpatient nd other sets, health , data and nay include
099392	Notice of Special Interest (NOSI): Reproductive and Obstetrical Out Associated Comorbid Conditions	Optimizing comes in A (Clinical Tr	g Precision Treatment of Gynecc Adolescents and Adults with PCC ial Optional)	<u>logic,</u>)S and	National Institutes of Health/DHHS	NOT-HD-20-026 0	7-May-2021	Not Specified
	Contact Name Contact Telephone	Esther Eis 301-496-6	enberg, MD MPH 5516					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	esther.eisenberg@nih.gov				
	Sponsor website	Link to program LIPI				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-2022 2022 , 07-May-2022 , 05-Jun-2022 , 16-Ju Feb-2023 , 07-May-2023 , 05-Jun-2023 , 2	1 , 07-Sep-2021 , 05-Oct-202 in-2022 , 07-Sep-2022 , 05-0 16-Jun-2023 , 07-Sep-2023	21 , 16-Oct-2021 , 07-Jan Oct-2022 , 16-Oct-2022 ,	-2022 , 05-Feb-202 07-Jan-2023 , 05-F	22 , 16-Feb- Feb-2023 , 16-
	Synopsis	The National Institute of Child Health and announce the opportunity for investigate adolescents and reproductive age wome are to stimulate interdisciplinary scientifi and subspecialists in diverse medical field mental health professionals, pulmonolog gynecologic, reproductive and obstetrica increase knowledge and understanding of outcomes; and 3) discover and develop r with underlying comorbid conditions. Ult adults with PCOS who have concomitant	d Human Development (NIC ors to apply for funding to o n with a diagnosis of Polycys c collaboration between gy ds, including cardiologists, e ists, among others, to: 1) ac I needs and desires; 2) pron of interaction of various ther ovel safe and more effectiv imately, this research would medical conditions.	HD) is issuing this Notice ptimize treatments of co stic Ovary Syndrome (PC necologists/reproductive ndocrinologists, gastroen dvance individualized tre- note translational and cli rapies on gynecologic, re e therapies for adolescen d advance precision thera	of Special Interes morbid conditions OS). The goals of t endocrinologists, nterologists, psych atments consisten nical research to productive and ob nts and women wi apeutics for adole	t (NOSI) to s in his initiative dobstetricians hiatrists, ht with hestetric th PCOS scents and
100292	Discovery of Cell-based Chemical Not Allowed)	Probes for Novel Brain Targets (R21 Clinic	al Trial National Institutes of Health/DHHS	PAR-21-028 07-N	May-2021	275,000 USD
	Contact Name	Enrique L. Michelotti, Ph.D.				
	Contact Telephone	301-443 5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-202 2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Fe	1 , 16-Oct-2021 , 07-Jan-202 b-2023 , 07-May-2023 , 16-J	22 , 16-Feb-2022 , 07-Ma lun-2023 , 07-Sep-2023 ,	y-2022 , 16-Jun-20 16-Oct-2023 , 07-)22 , 07-Sep- Jan-2024
	Synopsis	The purpose of this Funding Opportunity join efforts for the discovery of cell-based hand, the starting compounds ("validated Through this FOA, NIH wishes to stimulat	Announcement (FOA) is to d chemical probes for novel d hits") for chemical optimiz e research in: 1) discovery a	support investigators wh brain targets. It is expect ation and bioassays for t and development of nove	no have interest ar ted that applicant cesting new analog el, small molecules	nd capability to s will have, in g compounds. s for their

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date	Funding Amount
		potential and/or va projects t emphasis in develo	use in understanding biological lidation of novel, biological targ hat provide new insight into im of projects submitted under th ping in vivo chemical probes ma	proces ets tha portant s FOA s y wish	ses relevant to the m t will inform studies disease-related biolo should be the discove to apply using the co	hissions of NIMH, NIDA, of brain disease mechan ogical targets and biolo ery of cell-based chemic mpanion R01 mechanis	NEI and/or NIA; an nisms. Emphasis wi gical processes. The al probes. Applicar m, (PAR-21-029).	d 2) discovery Il be placed on e main nts interested
099801	Notice of Special Interest (NOSI): Immunity in HIV-Infected and/or Tuberculosis Vaccine Design Notic	Mechanisr Uninfecter ce Number	ns of Mycobacterial-Induced d Individuals to Inform Innovativ <u>r:</u>	<u>e</u>	National Institutes of Health/DHHS	NOT-AI-20-071 07-	May-2021	Not Specified
	Contact Name	Que Dang	g, PhD					
	Contact Telephone	240-292-0	5181					
	Contact Email	que.dang	@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	07-May-2 2022,07	.021 , 05-Jun-2021 , 16-Jun-2022 -May-2022 , 05-Jun-2022 , 16-Ju	. , 07-Si n-2022	ep-2021 , 05-Oct-202 ! , 07-Sep-2022 , 05-C	1 , 16-Oct-2021 , 07-Jar)ct-2022 , 16-Oct-2022 ,	1-2022 , 05-Feb-202 , 07-Jan-2023	22 , 16-Feb-
	Synopsis	The purper responses disease. S (BCG) or i NOSI show immune r character immune r understar including	ose of this Notice of Special Inte s that mediate protection from studies may focus on any stage of nvestigational TB vaccines and n uld go beyond descriptive inforr modulation by non-tuberculous ization of the timing, anatomica responses to mycobacterial infe nding of immune mechanisms ir in populations also infected wit	rest (N Aycoba of mycc nay inc nation mycob I locati ction ar Mtb ir h HIV.	OSI) is to stimulate in cterium tuberculosis bacterial infection of clude HIV-infected or currently known abo acterial (NTM) infection and contribution nd/or vaccination are offection/vaccination	inovative studies to ide (Mtb) infection or prog r following vaccination uninfected individuals. ut Mtb infection, immu ion, or by HIV/AIDS. Ap to disease outcome, of e sought. This research i and contribute to the a	ntify and understan ression to active tu with Bacillus Calme Research supporte ne responses to TB plications that inclu mucosal and/or sy s expected to adva dvancement of new	nd the immune berculosis (TB) ette-Guérin ed under this vaccines, or ude stemic nce v TB vaccines,
100050	Notice of Special Interest (NOSI): with the COVID-19	Research o	on Rehabilitation Needs Associa	ted	National Institutes of Health/DHHS	NOT-HD-20-031 07-	May-2021	Not Specified
	Contact Name Contact Telephone	Theresa C 301-496-9	Cruz, PhD. 9233					



SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount		
	Contact Email	<u>cruzth@r</u>	nail.nih.gov							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023	Way-2021, 05-Jun-2021, 16-Jun-2021, 07-Sep-2021, 05-Oct-2021, 16-Oct-2021, 07-Jan-2022, 05-Feb-2022, 16-Feb- 2, 07-May-2022, 05-Jun-2022, 16-Jun-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 07-Jan-2023, 05-Feb-2023, 16- -2023, 07-May-2023							
	Synopsis	The purp 19, the as of COVID associate the assoc considere Center fo	ose of this Notice of Special Inte ssociated mitigation actions, and -19 Understand the impact of di d mitigation actions Understand iated mitigation actions on peop ed responsive; not all topics are r Medical Rehabilitation Resear	erest is d rehat isruptic d the sc ple wit expect ch (NCI	to encourage applica bilitation: Encourage r bns to rehabilitation s bocial, behavioral, ecor h physical disabilities ed within the same a MRR) at NICHD.	tions in three areas research to address rervices caused by t nomic, and health ir Research applicatic pplication. Applicat	related to the interse the rehabilitation nee he COVID-19 pandemi mpact of the COVID-19 ons addressing these to ions will be directed to	ction of COVID- ds of survivors c and) pandemic and opics are o the National		
101300	Notice of Special Interest (NOSI): Analysis	<u>Use of Hu</u>	man Connectome Data for Seco	<u>ndary</u>	National Institutes of Health/DHHS	NOT-MH-21-075	07-May-2021	Not Specified		
	Contact Name	Yvonne B	ennett, Ph.D.							
	Contact Telephone	301-222-	7094							
	Contact Email	<u>yvonne.b</u>	<u>ennett@nih.gov</u>							
	Sponsor Website									
	Program URL	Link to pr	ogram URL							
	Deadline Dates (ALL)	07-May-2 2022 , 07 Feb-2023 16-Feb-20	2021 , 05-Jun-2021 , 16-Jun-2022 -May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 , 2 024 , 07-May-2024	1 , 07-S ın-2022 16-Jun-	ep-2021 , 05-Oct-202 2 , 07-Sep-2022 , 05-C 2023 , 07-Sep-2023 ,	21 , 16-Oct-2021 , 0 Dct-2022 , 16-Oct-20 05-Oct-2023 , 16-O	7-Jan-2022 , 05-Feb-20 022 , 07-Jan-2023 , 05- oct-2023 , 07-Jan-2024	122 , 16-Feb- Feb-2023 , 16- , 05-Feb-2024 ,		
	Synopsis	NIMH an secondar Connecto collected interrelat environm	Id participating institutes/center y analyses of data from the Hum ome projects and the Human Co the data are encouraged to app cionships among: brain structure mental factors; life event, social a	rs (ICs) nan Col nnecto oly. The e, funct and psy	listed above are issui nnectome Project (HC mes Related to Huma analyses will serve to ion and connectivity; rchosocial factors; ger	ng this Notice of Sp CP) including the mu an Disease. Applicar o generate and eval cognitive, affective nomic data, and clir	ecial Interest (NOSI) to ultiple datasets in the nts beyond the groups luate hypotheses abou e, sensory and motor p nical symptoms during	o encourage Lifespan Human that originally It the complex rocesses; development,		

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		aging, or behaviora website: l	disease. Details about the "Lifes Il assessments, can be found at https://www.humanconnectom	pan" and "Disease" Connec the Connectome Coordinati e.org/ and at the NIMH Dat	tomes, including neuroir ng Facility a Archive (NDA) www.nc	naging protocols a la.nih.gov.	ind clinical and
101367	Notice of Special Interest (NOSI): Analysis	<u>Use of Hur</u>	man Connectome Data for Seco	ndary National Institutes of Health/DHHS	NOT-MH-21-175 07-N	/lay-2021	Not Specified
	Contact Name	Yvonne B	ennett, Ph.D.				
	Contact Telephone	301-222-7	7094				
	Contact Email	<u>yvonne.b</u>	ennett@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022,07 Feb-2023 16-Feb-20	021 , 05-Jun-2021 , 16-Jun-2022 •May-2022 , 05-Jun-2022 , 16-Ju , 07-May-2023 , 05-Jun-2023 , 2)24 , 07-May-2024	L , 07-Sep-2021 , 05-Oct-202 in-2022 , 07-Sep-2022 , 05-C L6-Jun-2023 , 07-Sep-2023 ,	1 , 16-Oct-2021 , 07-Jan Oct-2022 , 16-Oct-2022 , 05-Oct-2023 , 16-Oct-20	-2022 , 05-Feb-202 07-Jan-2023 , 05-F 23 , 07-Jan-2024 ,	22 , 16-Feb- eb-2023 , 16- 05-Feb-2024 ,
	Synopsis	NIMH and secondary Connecto collected interrelat environm aging, or behaviora website: l	I participating institutes/center y analyses of data from the Hum me projects and the Human Co the data are encouraged to app ionships among: brain structure ental factors; life event, social a disease. Details about the "Lifes al assessments, can be found at https://www.humanconnectom	s (ICs) listed above are issuin nan Connectome Project (HG nnectomes Related to Huma ly. The analyses will serve to function and connectivity; and psychosocial factors; gen pan" and "Disease" Connec the Connectome Coordinati e.org/ and at the NIMH Dat	ng this Notice of Special I CP) including the multiple an Disease. Applicants be o generate and evaluate cognitive, affective, sen nomic data, and clinical s tomes, including neuroir ing Facility a Archive (NDA) www.nc	nterest (NOSI) to e datasets in the L eyond the groups t hypotheses about sory and motor pr symptoms during o naging protocols a la.nih.gov.	encourage ifespan Human that originally the complex ocesses; development, and clinical and
098640	Mentored Career Development P Nonhuman Primate Research Mo Allowed)	rogram (Ki dels (K01 I	01) for Early Stage Investigators ndependent Clinical Trial Not	Using National Institutes of Health/DHHS	PAR-20-258 07-N	/lay-2021	Not Specified
	Contact Name	Deborah	Philp, Ph.D.				
	Contact Telephone	301-761-7	7766				
	Contact Email	<u>deborah.</u>	ohilp@nih.gov				



SPIN ID	Program Title		Sponsor Name	Spons	or Number		Deadline Date	Funding Amount
	Sponsor Website							
	Program LIRI	Link to pr	ogram LIRI					
	Deadline Dates (ALL)	07-May-2 2022 , 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023	1,12-0	Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 0	7-May	y-2022 , 12-Jun-20)22 , 07-Sep-
The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage in "protected time" (up to five years) for intensive, research-focused career development pr of an experienced mentorship team with expertise in both the preclinical application of m in translation of the results from such studies to clinical application. The focus of this prog highly skilled scientists using NHP models to address complex translational biomedical res of outcomes into the clinic. The expectation is that through this sustained period of resea training, awardees will launch independent research careers and become competitive for RO1) funding. This Funding Opportunity Announcement (FOA) is designed specifically for a does not involve leading an independent clinical trial, a clinical trial feasibility study, or an Applicants to this FOA are permitted to propose research experience in a clinical trial led							tigators with supp am activities unde uman primate (NH n is to increase the ch designed to fos career developme v research project icants proposing r cillary study to a cl mentor or co-me	port and er the guidance HP) models and a number of ster translation ant and grant (e.g., research that linical trial.
100331	Notice of Special Interest (NOSI): to Apply for PA-20-222: Research Related Research (Admin Supp - C	Encourage Suppleme Clinical Tria	e Eligible NIH HEAL Initiative Awa ents to Promote Diversity in Hea al Not Allowed)	ardees Ith-	National Institutes of Health/DHHS	15-N	1ay-2021	Not Specified
	Contact Name	Eric M. H	udak, PhD					
	Contact Telephone	301-496-2	1779					
	Contact Email	eric.huda	<u>k@nih.gov</u>					
	Sponsor Website							
	Program URL							
	Deadline Dates (ALL)	15-May-2 Feb-2024	2021 , 15-Nov-2021 , 15-Feb-202 . , 15-May-2024	2,15-	May-2022 , 15-Nov-2022 , 15-Feb-2023	, 15-N	1ay-2023 , 15-Nov	-2023 , 15-
	Synopsis	The NIH h encourag identified support t interest a administr	has a strong interest in the diver tes institutions to diversify their as underrepresented in the bio hese efforts through ongoing pr and encourages eligible grant an rative supplements in response	sity of scienti medica ogram d coop to PA-2	the NIH-funded research enterprise (see fic workforce by increasing the participa al, clinical, behavioral, and social science s and supplement funding opportunities erative agreement awardees in the HEA 20-222 (or any subsequent reissuances),	NIH i tion o s. Par This L Initia Resea	notice NOT-OD-20 f individuals from ticipating institute specific notice rei ative community t arch Supplements)-031) and groups es continue to iterates this to apply for to Promote

SPIN ID	Program Title		Sponsor Name	Spons	or Number			Deadline Date	Funding Amount
		Diversity Addiction Initiative enhance	in Health-Related Research (Adu Long-term (HEAL) Initiative to s is a trans-NIH effort to (1) impro pain management. More inform	min Su speed s ove pre nation a	op - Clinical Trial Not cientific solutions to vention and treatme bout the HEAL Initia	Allowed). This n the national opi ent strategies for tive is available a	otice is p oid publi opioid m at: https:,	art of the NIH's H c health crisis. Th hisuse and addicti //heal.nih.gov/.	elping to End e NIH HEAL on and (2)
093932	NIH Pathway to Independence Av Not Allowed)	vard (Pare	nt K99/R00 Independent Clinica	<u>l Trial</u>	National Institutes of Health/DHHS	PA-20-188	07-N	1ay-2021	Not Specified
	Contact Name								
	Contact Telephone								
	Contact Email	grantinfo	<u>@nih.gov</u>						
	Sponsor Website	Link to pr	ogram LIPI						
	Deadline Dates (ALL)	07-May-2 2022 , 12	021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fel	1 , 12-0 b-2023	Oct-2021 , 07-Jan-202 , 07-May-2023	22 , 12-Feb-2022	, 07-Мау	/-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purper postdoctor independ during the Opportur independ propose r clinical tri participat their resp Contacts with NIH	ose of the NIH Pathway to Indep oral researchers with a research ent, tenure-track or equivalent is transition in order to help awa hity Announcement (FOA) is des ent clinical trial, a clinical trial fe research experience in a clinical fal as lead investigator, should a re in Parent Announcements. Ap pective areas of research interes website. ICs that do not particip staff before submitting an appli	penden and/o faculty ardees igned s easibilit trial le pply to pplican t and r bate in cation	ce Award (K99/R00) r clinical doctorate de positions. The progr to launch competitiv pecifically for applica ty study, or an ancilla d by a mentor or co- the companion FOA ts should carefully no equirements at the T this announcement v is strongly encourage	program is to fa egree from men am will provide re, independent ants proposing re ary clinical trial. A mentor. Applican Special Note: N ote which ICs par Table of IC-Special will not consider ed.	cilitate a tored, po independ research esearch t Applicant nts propo lot all NIH ticipate i fic Inform applicatio	timely transition stdoctoral resear lent NIH research careers. This Fun hat does not invo s to this FOA are sing a clinical tria H Institutes and C n this announcen ation, Requireme ons for funding. C	of outstanding ch positions to support ding lve leading an permitted to l or an ancillary enters nent and view ents and Staff Consultation
093935	NIH Pathway to Independence Av Experimental Studies with Humar	vard (Pare	nt K99/R00 Independent Basic d)		National Institutes of Health/DHHS	PA-20-189	07-N	1ay-2021	Not Specified
	Contact Name Contact Telephone								

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL)	k to program URL May-2021 , 12-Jun-2021 , 07-Sep-2021 22 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb e purpose of the NIH Pathway to Indep stdoctoral researchers with a research ependent, tenure-track or equivalent f ring this transition in order to help awa portunity Announcement is for basic se rospective basic science studies involvin d also meet the definition of basic rese pospectively assign human participants to medical or behavioral outcomes in hum shout specific application towards proc sic experimental study with humans, on the humans led by another investigator, posed project must be related to the p inters (ICs) based on their scientific miss nouncements. Applicants should careful research interest and requirements at at do not participate in this announcem- pomitting an application is strongly enco	1, 12-Oct-2021, 07-Jan-202 bendence Award (K99/R00) p and/or clinical doctorate de faculty positions. The progra ardees to launch competitive cience experimental studies ng human participants." The earch. Types of studies that s to conditions (i.e., experiment mans for the purpose of unc resses or products in mind. A r proposing to gain research must apply to the 'Independ programmatic interests of or sions. Special Note: Not all N ully note which ICs participa the Table of IC-Specific Infor- nent will not consider applica- puraged.	2 , 12-Feb-2022 , 07-Ma program is to facilitate a gree from mentored, po am will provide independ e, independent research involving humans, refer ese studies fall within th should be submitted un ntally manipulate independ derstanding the fundame Applicants not planning a experience in a clinical dent Clinical Trial Not Al ne or more of the partic NIH Institutes and Cente te in this announcemen rmation, Requirements a ations for funding. Cons	y-2022 , 12-Jun-20 timely transition o ostdoctoral research dent NIH research careers. This Pare rred to in NOT-OD- te NIH definition o der this FOA includ endent variables) a ental aspects of ph an independent cli trial or basic expen lowed' companior ipating NIH Institu rs participate in Pa t and view their re and Staff Contacts ultation with NIH s	122 , 07-Sep- of outstanding ch positions to support ent Funding -18-212 as f a clinical trial de studies that and that assess nenomena nical trial or rimental study n FOA. The tes and arent espective areas website. ICs staff before
094015	Mentored Research Scientist Develop Clinical Trial Required)	oment Award (Parent K01 - Independer	nt National Institutes of Health/DHHS	PA-20-176 07-N	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email gra Sponsor Website Program URL Linl	ntsinfo@nih.gov k to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2 2022 , 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fel	1 , 12-Oct-2021 , 07-Jan-202 b-2023 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purper (three to sciences I mechanis individua illness or candidate separate trial, or p (PA-20-19 carefully requirem this anno strongly e	ose of the NIH Mentored Reseau five years) for an intensive, supe leading to research independent is who propose to train in a new pressing family circumstances es proposing to serve as the lead ancillary clinical trial, as part of roposing to gain research exper 90). Special Note: Not all NIH In note which ICs participate in thi ents at the Table of IC-Specific I uncement will not consider app encouraged.	rch Scientist Development A ervised career development ce. Although all of the parti ent experiences that lead to a field or for individuals who This Funding Opportunity A d investigator of an indepent their research and career d ience in a clinical trial led by nstitutes and Centers partic s announcement and view to nformation, Requirements lications for funding. Consu	Award (K01) is to provide t experience in the biome cipating NIH Institutes an research independence, b have had a hiatus in the announcement (FOA) is de ident clinical trial, a clinic evelopment. Those not p y another investigator, m cipate in Parent Announce their respective areas of r and Staff Contacts websit Itation with NIH staff bef	support and "pro- edical, behavioral, of Centers (ICs) use some ICs use the ir research career esigned specificall al trial feasibility s lanning an indepe ust apply to comp ements. Applicant research interest a te. ICs that do not ore submitting an	tected time" or clinical e this support KO1 award for because of y for study, or a indent clinical anion FOA is should and participate in application is
094038	Mentored Quantitative Research Clinical Trial Required)	<u>Developm</u>	ent Award (Parent K25 Indepen	dent National Institutes of Health/DHHS	PA-20-197 07-N	/lay-2021	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	grantinfo	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 <i>,</i> 12	2021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-202 b-2023 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purper those inver- questions and reseat imaging s research.	ose of the Mentored Quantitative estigators whose quantitative so s of health and disease. The K25 arch for productive professionals cience, informatics, physics, che This Funding Opportunity Anno	ve Research Career Develop cience and engineering rese award will provide suppor s with quantitative (e.g., ma emistry) and engineering ba puncement (FOA) is designe	oment Award (K25) is to a earch has thus far not bee t and "protected time" fo athematics, statistics, eco ckgrounds to integrate th d specifically for applican	attract to NIH-releven focused primari or a period of supe nomics, computer neir expertise with ts proposing to se	vant research ly on rvised study r science, n NIH-relevant erve as the lead

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date	Funding Amount
	i ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	investigat research a experienc and Cente announce Requirem funding. C	for of an independent clinical tri and career development. Applic te in a clinical trial led by anothe ers participate in Parent Annour ement and view their respective tents and Staff Contacts website Consultation with NIH staff befo	al, a cli cants no er inves ncemen areas o e. ICs th re subr	nical trial feasibility s ot planning an indepe- tigator, must apply to ts. Applicants should of research interest a at do not participate nitting an applicatior	etudy, or a separate anci endent clinical trial, or p o companion FOA. Spec I carefully note which IC and requirements at the in this announcement w n is strongly encouraged	llary clinical trial, a roposing to gain re ial Note: Not all NI 's participate in thi Table of IC-Specifi will not consider ap	as part of their esearch H Institutes s c Information, oplications for
094020	Mentored Research Scientist Deve Clinical Trial Not Allowed)	lopment	Award (Parent K01 - Independe	<u>nt</u>	National Institutes of Health/DHHS	PA-20-190 07-	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email ی Sponsor Website	grantsinfo	o@nih.gov					
	Program URL I Deadline Dates (ALL)	<u>Link to pr</u> 07-May-2 2022 , 12∙	<mark>ogram URL</mark> 021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fel	1,12-C b-2023)ct-2021 , 07-Jan-202 , 07-May-2023	2 , 12-Feb-2022 , 07-Ma	ay-2022 , 12-Jun-20	022 , 07-Sep-
	Synopsis	The purpo (three to sciences l mechanis individual illness or applicants separate mentor o the comp carefully n requirement this annot strongly e	ose of the NIH Mentored Resear five years) for an intensive, supe eading to research independent m to support career development s who propose to train in a new pressing family circumstances s proposing research that does not ancillary clinical trial. Applicants r co-mentor. Applicants proposi anion FOA. Special Note: Not al note which ICs participate in this ents at the Table of IC-Specific In uncement will not consider app encouraged.	rch Scie ervised ce. Alth ent expe / field o This Fu not invo to this ng a cli l NIH In s annou nforma lication	entist Development A career development ough all of the partic eriences that lead to r for individuals who nding Opportunity A olve leading an indep FOA are permitted t nical trial or an ancill stitutes and Centers uncement and view t tion, Requirements a s for funding. Consul	ward (K01) is to provide experience in the biom cipating NIH Institutes and research independence have had a hiatus in the nnouncement (FOA) is co pendent clinical trial, a cl o propose research exp ary clinical trial as lead participate in Parent Arr heir respective areas of and Staff Contacts webs tation with NIH staff be	e support and "pro edical, behavioral, nd Centers (ICs) us , some ICs use the eir research career designed specifical inical trial feasibili erience in a clinica investigator, shoul nouncements. App research interest a ite. ICs that do not fore submitting an	tected time" or clinical e this support KO1 award for because of ly for ty study, or a l trial led by a d apply to plicants should and participate in application is

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
093955	Midcareer Investigator Award in Pat Independent Clinical Trial Required)	tient-Oriented Research (Parent K24	National Institutes of Health/DHHS	PA-20-193 07-N	Лау-2021	Not Specified
	Contact Name Contact Telephone					
	Contact Email gr	rantinfo@nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL)	7-May-2021 , 12-Jun-2021 , 07-Sep-2021 022 , 12-Oct-2022 , 07-Jan-2023 , 12-Fet	L , 12-Oct-2021 , 07-Jan-202)-2023 , 07-May-2023	2 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-
	l he Al Cl Synopsis de le Pa re Ca w	he purpose of the NIH Middareer invest ealth-professional doctorates for protec nentors for junior clinical investigators pu nnouncement (FOA) is designed specific inical trial, a clinical trial feasibility study evelopment. Applicants not planning an ed by another investigator, must apply to arent Announcements. Applicants shoul espective areas of research interest and ontacts website. ICs that do not particip with NIH staff before submitting an applicants	Igator Award in Patient-Orie ted time to devote to patien ursuing POR research, such ally for applicants proposing , or a separate ancillary clir independent clinical trial, o o companion FOA. Special N d carefully note which ICs p requirements at the Table c ate in this announcement w cation is strongly encourage	ented Research (K24) is t int-oriented research (PO as clinical residents Thi g to serve as the lead inv ical trial, as part of their r proposing to gain resea ote: Not all NIH Institute articipate in this announ of IC-Specific Informatior vill not consider applicati d.	to provide support (R) and to act as re- s Funding Opport restigator of an ind research and care arch experience in s and Centers par cement and view n, Requirements a ons for funding. C	to mid-career esearch unity dependent eer a clinical trial ticipate in their nd Staff consultation
094026	Mentored Research Scientist Develo Experimental Studies with Humans I	opment Award (Parent K01 Independent Required)	<u>Basic</u> National Institutes of Health/DHHS	PA-20-191 07-N	/lay-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL)	7-May-2021 , 12-Jun-2021 , 07-Sep-2021 022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb	l , 12-Oct-2021 , 07-Jan-202 o-2023 , 07-May-2023	2 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2()22 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purper (three to sciences I mechanis individual illness or studies in participar research. participar outcomes towards p humans, o investigat related to scientific carefully requirem this anno strongly e	ose of the NIH Mentored Resear five years) for an intensive, supe eading to research independent of the support career development is who propose to train in a new pressing family circumstances. Nolving humans, referred to in M ints." These studies fall within the Types of studies that should be not to conditions (i.e., experiment is in humans for the purpose of the processes or products in mind. A or proposing to gain research ex- tor, must apply to the 'Independ of the programmatic interests of missions. Special Note: Not all M note which ICs participate in thi ents at the Table of IC-Specific I uncement will not consider app encouraged.	rch Scientist Development a ervised career development ce. Although all of the parti- ent experiences that lead to a field or for individuals who This Parent Funding Opport NOT-OD-18-212 as "prospe- te NIH definition of a clinical e submitted under this FOA thally manipulate independ understanding the fundame applicants not planning an i aperience in a clinical trial of lent Clinical Trial Not Allow one or more of the particip IIH Institutes and Centers p is announcement and view information, Requirements lications for funding. Consu	Award (K01) is to provide at experience in the biome icipating NIH Institutes ar o research independence, o have had a hiatus in the tunity Announcement is fi- ective basic science studie al trial and also meet the a include studies that pros- dent variables) and that as ental aspects of phenome independent clinical trial or basic experimental stud- yed' companion FOA. The participate in Parent Anno- their respective areas of and Staff Contacts websi- ultation with NIH staff bef	support and "pro- edical, behavioral, ad Centers (ICs) us some ICs use the eir research career or basic science ex s involving human definition of basic spectively assign h ssess biomedical of ma without specifi or basic experiment dy with humans lea proposed project Centers (ICs) based buncements. Appli research interest a te. ICs that do not fore submitting an	tected time" or clinical e this support K01 award for because of sperimental uman r behavioral c application ntal study with d by another must be d on their cants should and participate in application is
093953	Midcareer Investigator Award in F Independent Clinical Trial Not Allo	Patient-Ori owed)	iented Research (Parent K24	National Institutes of Health/DHHS	PA-20-186 07-N	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email	grantinfo	@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 12 ⁻	021 , 12-Jun-2021 , 07-Sep-202 -Oct-2022 , 07-Jan-2023 , 12-Fe	1 , 12-Oct-2021 , 07-Jan-20 p-2023 , 07-May-2023	22 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-20)22 , 07-Sep-
	Synopsis	The purpo health-pr	ose of the NIH Midcareer Invest ofessional doctorates for protec	igator Award in Patient-Ori ted time to devote to pation	iented Research (K24) is t ent-oriented research (PC	o provide support DR) and to act as re	to mid-career esearch

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	mente Fundi leadir permi an an Cente and v and S Consu	rs for junior clinical investigators p og Opportunity Announcement (FC g an independent clinical trial, a cli ted to propose research experience illary clinical trial as lead investigat rs participate in Parent Announcen ew their respective areas of resear aff Contacts website. ICs that do n tation with NIH staff before subm	bursuing POR research, such a DA) is designed specifically fo nical trial feasibility study, or the in a clinical trial led by and tor, should apply to the comp nents. Applicants should care ch interest and requirements ot participate in this announ- itting an application is strong	as clinical residents and/ or applicants proposing ro r an ancillary clinical tria other investigator. Applic panion FOA. Special Not efully note which ICs par s at the Table of IC-Spec cement will not consider gly encouraged.	for junior clinical f esearch that does I. Applicants to th cants proposing a e: Not all NIH Inst ticipate in this and ific Information, R r applications for f	aculty. This not involve is FOA are clinical trial or itutes and nouncement equirements funding.	
093954	Midcareer Investigator Award in Patient Independent Basic Experimental Studies	Oriented Research (Parent K24 with Humans Required)	National Institutes of Health/DHHS	PA-20-192 07-N	May-2021	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	program URL y-2021 , 12-Jun-2021 , 07-Sep-202	1, 12-Oct-2021, 07-Jan-202	2 , 12-Feb-2022 , 07-Ma	y-2022 , 12-Jun-2(022 , 07-Sep-	
	The p health mento Paren OD-18 a clini Synopsis incluc variab aspec indep or bas Allow the pa	Professional doctorates for prote- professional doctorates for prote- rs for junior clinical investigators p Funding Opportunity Announcem -212 as "prospective basic science cal trial and also meet the definition e studies that prospectively assign (es) and that assess biomedical or s of phenomena without specific a endent clinical trial or basic experi- ic experimental study with humans ed' companion FOA. The proposed rticipating NIH Institutes and Cent	igator Award in Patient-Orie cted time to devote to patier oursuing POR research, such a ent is for basic science expen- studies involving human par n of basic research. Types of human participants to condi behavioral outcomes in hum opplication towards processe nental study with humans, o s led by another investigator, project must be related to th ers (ICs) based on their scien	ented Research (K24) is to nt-oriented research (PC as clinical residents and rimental studies involvin rticipants." These studie f studies that should be itions (i.e., experimental ans for the purpose of u as or products in mind. A or proposing to gain rese , must apply to the 'Inde he programmatic interes tific missions. Special No	o provide support OR) and to act as re junior clinical fact og humans, referre ts fall within the N submitted under ly manipulate inde inderstanding the pplicants not plan arch experience in spendent Clinical T sts of one or more ote: Not all NIH Ins	to mid-career esearch alty. This ed to in NOT- IH definition of this FOA ependent fundamental ning an a clinical trial frial Not of stitutes and	
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
---------	--	--	--	--	--	---	---
		Centers p and view and Staff Consultat	articipate in Parent Announcem their respective areas of resear Contacts website. ICs that do no ion with NIH staff before submi	nents. Applicants should car ch interest and requiremen ot participate in this annour tting an application is stron	efully note which ICs ts at the Table of IC-S ncement will not con gly encouraged.	s participate in this ann Specific Information, Re sider applications for f	ouncement equirements unding.
102271	RFA-OD-21-002 Tobacco Regula	atory Scien	ce (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-OD-21-002	15-May-2021 [Optional][LOI/Pre-App	2,500,000 o] USD
	Contact Name	Rachel Gr	ana Mayne, PhD				
	Contact Telephone	240-276-5	5899				
	Contact Email	granar@r	<u>nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL) [15-May-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 17-Dec-2021 [Optional][LOI/Pre-App], 15-Feb-2022 , 15-May-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 17-Dec-2022 [Optional][LOI/Pre-App], 14-Feb-2023						
	Synopsis	The purpe behaviora Research Administr that have Research regulation	ose of this Funding Opportunity al research that will provide scie Projects must address the resea ration (FDA) Center for Tobacco been made available through F results from this FOA are expect n of the manufacture, distribution	Announcement (FOA) is to ntific data to inform regular arch priorities related to the Products (CTP). The awards DA CTP and the Family Smo ted to generate findings an on, and marketing of tobacc	invite R01 applicatio tion of tobacco produ- e regulatory authority s under this FOA will oking Prevention and d data that are direct co products to protect	ns to support biomedia ucts to protect public h y of the Food and Drug be administered by NII Tobacco Control Act (F tly relevant in informin ct public health.	cal and lealth. H using funds P.L. 111-31). g the FDA's
102735	RFA-NS-21-015 HEAL Initiative: Non-addictive Analgesic Theraper Allowed)	Team Reso utics Devel	earch for Initial Translational Eff opment (U19 Clinical Trial Not	orts in National Institutes of Health/DHHS	RFA-NS-21-015	28-Mar-2021 [Optional][LOI/Pre-App	7,500,000 o] USD
	Contact Name	Michael L	. Oshinsky, PhD				
	Contact Telephone	301-496-9	9964				
	Contact Email	michael.c	<u>shinsky@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	28-Mar-2	021 [Optional][LOI/Pre-App], 27	7-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-Ap	op], 22-Jun-2021 , 13-S	ep-2021

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synops	[Optiona App], 11- This fund non-addi screening pharmac of the pro Initiative Trial Opt a plan the data doe target(s) outcome for acute neuropat stroke pa develop a will also older adu the thera	I][LOI/Pre-App], 13-Oct-2021, 1 Oct-2022, 10-May-2023 [Optio ling opportunity announcement ctive therapeutics to treat pain. g and early optimization work to odynamic markers efficacy and oject should be to advance a hit : Non-addictive Analgesic Thera ional) within the 5 years of the a at will lead to the development s not currently exist, the applica to the proposed pain indication s for the disease. This FOA is no pain, chronic pain, painful neur chy, chemotherapy-induced neu in, myofascial pain, painful diso analgesics for a combination of be considered. Projects that see ults, and other underrepresente opeutic goals of the project is en tic(s) that will be ready to be su	0-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022, nal][LOI/Pre-App], 09-Jun-2023, 10-Sep-2023 [Option (FOA) is part of a suite of FOAs to support the develor The goal of this FOA is to support team-based resea develop a non-addictive therapeutic to treat pain. If pharmacokinetic/pharmacodynamic (PK/PD) studies or lead to the point where they can meet the entry of peutics Development [Small Molecules and Biologics award, there is no opportunity for renewal of this aw of analgesics with a rigorous biological rationale and ation must include a strong plan for developing data I and supporting the hypothesis that altering the targ t specific for any one or group of pain conditions. Pro- ropathy, musculoskeletal pain, headache disorders, o ropathy, eye pain, sickle-cell pain, post-surgical pain, orders of the orofacial region and other conditions wi chronic overlapping pain conditions or for specific dis- k to identify pain treatment targets in specific popula d groups will also be responsive to this FOA. Input fro- couraged. The goal of each 5-year U19 application ship biblicted to RFA-NS-21-010 for further optimization.	11-Sep-2022 [Opti nal][LOI/Pre-App], opment of safe, ef rch projects to dev Discovery and valid are also responsiv criteria for RFA-NS] to Treat Pain (UG ard. Applications s scientifically soun inking the putative et activity will pro ojects to develop t steoarthritis, diab cancer pain, visce Il be considered. P sease or pathologi ations such as wor om patients and ca hould be to identif	onal][LOI/Pre- 10-Oct-2023 fective, and velop assays, ation of re. The result -21-010 HEAL 3/UH3 Clinical should propose d assays. If the e therapeutic duce desirable herapeutics etic eral pain, post rojects to cal conditions nen, children, aregivers on y candidate

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102738	RFA-NS-21-016 HEAL Initiative: Development Initial Translational Biologics] (R34 Clinical Trial Not A	Planning Studies for Initial Analgesic Efforts [Small Molecules and Illowed]	National Institutes of Health/DHHS	RFA-NS-21-016	28-Mar-2021 [Optional][LOI/Pre-App]	1,000,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Michael L. Oshinsky, PhD 301-496-9964 <u>michael.oshinsky@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Program URL L	ink to program URL						
	2 Deadline Dates (ALL) [(A	28-Mar-2021 [Optional][LOI/Pre-App], 2 Optional][LOI/Pre-App], 13-Oct-2021 , 1 App], 11-Oct-2022 , 10-May-2023 [Optio	7-Apr-2021 , 28-May-2021 [C .0-May-2022 [Optional][LOI/I nal][LOI/Pre-App], 09-Jun-20)ptional][LOI/Pre-App], Pre-App], 09-Jun-2022 , 23 , 10-Sep-2023 [Optic	22-Jun-2021 , 13-S 11-Sep-2022 [Opti onal][LOI/Pre-App]	ep-2021 onal][LOI/Pre- , 10-Oct-2023		
	T p Ir B Synopsis t t t r r ir	ropose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL hitiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and iologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to stablish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay ne groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research eam to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong esearch team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.						
084924	Maximizing Opportunities for Scien Careers (MOSAIC) Postdoctoral Car Diversity (K99/R00 - Independent C	ntific and Academic Independent reer Transition Award to Promote Clinical Trial Not Allowed)	tional Institutes of alth/DHHS	PAR-19-343 07-Ma	ay-2021	Not Specified		
	Contact Name K	cenneth D. Gibbs, Jr., Ph.D.						
	Contact Telephone							
	Contact Email <u>K</u>	<u>ennetn.glbbs@nin.gov</u>						
	Program URL	ink to program URI						
	Deadline Dates (ALL)	17-May-2021 , 12-Jun-2021 , 07-Sep-202 2022 , 12-Oct-2022	1 , 12-Oct-2021 , 07-Jan-202	2 , 12-Feb-2022 , 07-Ma	ıy-2022 , 12-Jun-20)22 , 07-Sep-		
	T c la Synopsis l I p b	The purpose of the MOSAIC Postdoctora ohort of early career, independent inve ong-term goal of this program is to enha lesigned to facilitate a timely transition interest in Diversity) from their mentore positions at research-intensive institutio pefore and after this transition to help a	l Career Transition Award to stigators from diverse backgr ance diversity in the biomedia of promising postdoctoral re- d, postdoctoral research pos ns. The MOSAIC K99/R00 pro wardees launch successful, in	Promote Diversity (K99 rounds conducting rese cal research workforce. searchers from diverse itions to independent, t ogram will provide indep ndependent research ca	/R00) program is to arch in NIH missior The MOSAIC K99/I backgrounds (e.g., enure-track or equ pendent NIH resear reers. Additionally	o support a n areas. The R00 program is see NIH's livalent faculty rch support n, MOSAIC		

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	K9 pr Di re cli m	9/R00 scholars will be part of organ ofessional development activities c versity (UE5) grantees. This Funding search that does not involve leadin nical trial. Applicants to this FOA ar entor.	nized scientific cohorts and will I oordinated by MOSAIC Institutio g Opportunity Announcement (F g an independent clinical trial, a e permitted to propose research	be expected to partic onally-Focused Resea OA) is designed spec clinical trial feasibilit n experience in a clin	ipate in mentoring, r rch Education Awarc ifically for applicants y study, or an ancilla cal trial led by a mer	networking, and I to Promote proposing ry study to a ntor or co-
102741	Notice of Special Interest (NOSI): Un Impact of Structural Racism and Disc Progression and the Biomedical Res	derstanding and Addressing the rimination on Biomedical Career earch Enterprise	National Institutes of Health/DHHS	NOT-GM-21- 033	May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Th Synopsis of bid	<u>k to program URL</u> -May-2021 , 04-Oct-2021 , 13-Oct- e purpose of this Notice of Special General Medical Sciences (NIGMS) omedical career progression and th	2021 , 18-Jan-2022 , 17-May-202 Interest (NOSI) is to inform appl to study and/or address the im e biomedical research enterpris	22 , 03-Oct-2022 icants of topic areas pacts of structural rac e.	of interest to the Nat	tional Institute
102020	Notice of Special Interest (NOSI): Ur Administrative Supplements for Res in Minority Institutions (RCMI U54s) Uptake, and Implementation	gent Competitive Revisions and earch at NIMHD Research Centers on SARS-CoV-2 Vaccine Hesitancy,	National Institutes of Health/DHHS	NOT-MD-21- 012	May-2021	Not Specified
	Contact Name De Contact Telephone 30 Contact Email de Sponsor Website Program URL Lin Deadline Dates (ALL) 03	borah E. Linares, Ph.D., M.A. 1-402-2516 <u>borah.linares@nih.gov</u> <u>k to program URL</u> -May-2021				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	This N CoV-2 States SARS- Synopsis increa condit uptak amon (RCMI	otice of Special Interest (NOSI) hig vaccine hesitancy, uptake, and im (U.S.). Research is urgently neede oV-2 (COVID-19) vaccine among ed risk for morbidity and mortali ons. ThisNOSI solicits community in clinical and community contex health disparity populations. App currently active U54 awards, wh	shlights the urgent need for r pplementation among popula ed to understand and address adults in the U.S. and its terr ty due to long-standing syste -engaged research to: 1) eva (ts; and 2) address the barrie polications for this NOSI are lin ich are not in an extension at	research strategies and in ations who experience he s misinformation, distrus itories, especially among mic health and social ine luate innovative interven rs to increasing reach, ac mited to NIH Research Ce t the time of application s	aterventions to add alth disparities in a t, and hesitancy re populations who a quities and chroni ations to facilitate v excess, and uptake o enters in Minority I submission.	dress SARS- the United garding the are at c medical vaccination of vaccinations nstitution's
102531	RFA-AG-22-020 Triadic Interactions in People with Alzheimer's Disease and Alz Dementias (AD/ADRD), Clinicians, and C Optional)	Clinical Encounters Involving neimer's Disease-Related Na re Partners (R01 Clinical Trial He	ational Institutes of ealth/DHHS	RFA-AG-22-020 23-Ma [Optio	ıy-2021 nal][LOI/Pre-App]	2,500,000 USD
	Contact Name Meliss	a S. Gerald, Ph.D.				
	Contact Telephone 301-4	6-3136				
	Contact Email meliss	i.gerald@nih.gov				
	Sponsor Website					
	Program URL Link to	program URL				
	Deadline Dates (ALL) 23-Ma	/-2021 [Optional][LOI/Pre-App], 2	23-Jun-2021			
	This F proce care p outco Synopsis intera stages interv betwe betwe	nding Opportunity Announcements ses between individuals with Alzh artners. NIA seeks to increase our nes. The goal of this initiative is to tions in clinical settings and help of AD/ADRD and across the conti ntion development clinical trials en patients, clinicians, and care patients and care patients in t	nt (FOA) invites applications neimer's disease or Alzheime understanding of the impace identify targets for the deve build and preserve strong an nuum of care. To these ends in two high-priority areas: (1 artners; and (2) the clinical si he context of patient-caregiv	focused on triadic interact r's disease-related demen t of such interactions on elopment of behavioral in a supportive caregiving r , this FOA solicits basic re) triadic communication a gnificance of dyadic proc ver-clinician encounters.	ctions and interper ntias (AD/ADRD), c patient health and nterventions to op relationships throu esearch and Stage and interpersonal resses in caregiving	sonal linicians, and well-being timize ghout all behavioral relationships relationships
093907	Research Project Grant (Parent R01 Bas Humans Required)	Experimental Studies with National Hereit	ational Institutes of ealth/DHHS	PA-20-184 07-Ma	y-2021	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-4000 grantsinfo@od.nih.gov Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe The NIH Research Project Grant support interests and competencies of the inves experimental studies involving humans, participants." These studies fall within the Types of studies that should submit und (i.e., experimentally manipulate indepen- purpose of understanding the fundamen- products in mind. Studies conducted with appropriate 'Clinical Trials Required' or the programmatic interests of one or more	21, 05-Oct-2021, 07-Jan-202 eb-2023, 07-May-2023 is a discrete, specified, circur tigator(s). This Parent Fundir referred to in NOT-OD-18-22 he NIH definition of a clinical er this FOA include studies th ndent variables) and that ass ntal aspects of phenomena v th specific applications towar (Clinical Trial Optional' FOA.)	22 , 05-Feb-2022 , 07-Mainscribed project in areasing Opportunity Announce 12 as "prospective basic so I trial and also meet the control of the prospectively assign for the prospectively assign for the proposed project mutures and Centers (ICs) basis	y-2022 , 05-Jun-20 representing the s ement is for basic science studies inv definition of basic numan participant oral outcomes in h on towards proces in mind should su ist be related to th ased on their scier	122, 07-Sep- specific science folving human research. s to conditions humans for the ses or bmit under the netific missions.
		participate in this announcement and vi and Contact website. ICs that do not par	ew their respective areas of rticipate in this announceme	research interest at the F nt will not consider appli	R01 IC-Specific Scie cations for funding	entific Interests
093897	Research Project Grant (Parent R	01 Clinical Trial Required) He	ational Institutes of ealth/DHHS	PA-20-183 07-Ma	ay-2021	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	grantsinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-202 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Fe	21 , 05-Oct-2021 , 07-Jan-202 eb-2023 , 07-May-2023	22 , 05-Feb-2022 , 07-Ma	y-2022 , 05-Jun-20	22 , 07-Sep-

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Dat	e Funding Amount
	Synopsis	The NIH F interests clinical tri participat accept me National I Stroke (N (NIMH)	Research Project Grant support and competencies of the inve al be proposed. The propose ing NIH Institutes and Center echanistic studies that meet Institute of Arthritis and Mus INDS) National Center for Co	rts a discrete, specified, circ estigator(s). This Parent Fun d project must be related to rs (ICs) based on their scient NIH's definition of a clinical culoskeletal and Skin Diseas mplementary and Integrativ	cumscribed project oding Opportunity A o the programmatic tific missions. NOTE trial. National Hear ses (NIAMS) Nationa ve Health (NCCIH) N	in areas representing nnouncement require interests of one or m The following Institut Lung, and Blood Inst Institute of Neurolog ational Institute of Me	the specific s that at least 1 pre of the ces/Centers only itute (NHLBI) gical Disorders and ental Health
102906	Support for Research Excellence (Allowed)	(SuRE) Awa	ard (R16 Clinical Trial Not	National Institutes of Health/DHHS	PAR-21-169	26-May-2021	400,000 USD
	Contact Name	lrina N. K	rasnova, Ph.D.				
	Contact Telephone						
	Contact Email	<u>irina.kras</u>	nova@nih.gov				
	Sponsor Website						
	Program URL	<u>Link to pr</u>	ogram URL				
	Deadline Dates (ALL)	26-May-2	.021 , 07-Sep-2021 , 26-May-	2022 , 07-Sep-2022 , 26-Ma	y-2023 , 07-Sep-202	23	
	Synopsis	SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher educat institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the resear environment at the applicant institutions. The purpose of SuRE awards is to provide research grant support for faculty investigators who have prior experience in leading externally-funded, independent research but are not currently fund any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.					
102794	RFA-OD-21-005 Short Courses of Approaches in the Behavioral and Clinical Trial Not Allowed)	on Innovat I Social Sci	<u>ive Methodologies and</u> ences (R25 - Independent	National Institutes of Health/DHHS	RFA-OD-21- 005	04-May-2021 [Optional][LOI/Pre-/	800,000 USD
	Contact Name	Erica L. Sp	ootts, Ph.D.				
	Contact Telephone	301-594-2	2105				
	Contact Email	<u>spottse@</u>	od.nih.gov				
	Sponsor Website						

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL Link to Deadline Dates (ALL) 04-Ma The N Synopsis workf goal, t	program URL y-2021 [Optional][LOI/Pre-App H Research Education Program ching goal of this R25 program prce to meet the nation's biome his FOA will support creative ec	, 04-Jun-2021 , 07-Sep-2021 (R25) supports research educat is to support educational activit edical, behavioral and clinical re lucational activities with a prima	tion activities in the miss ties that complement an search needs. To accom ary focus on: Courses for	ion areas of the N d/or enhance the t olish the stated ov Skills Developmer	H. The training of a er-arching nt
102922	Notice of Special Interest (NOSI): Admin INCLUDE (INvestigation of Co-occurring to Understand Down syndromE) Project	strative Supplements for the conditions across the Lifespan	National Institutes of Health/DHHS	NOT-OD-20- 024 12-Ma	y-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The O active for fun conditi supple mecha	program URL y-2021 , 23-Jul-2021 , 23-Nov-2 fice of the Director of the Natio NIH-supported grants from the ided projects to meet new NIH ions across the Lifespan to Und ments for the following nisms ONLY: R01,R03,R21,R24,	021 , 23-Mar-2022 , 23-Jul-2023 onal Institutes of Health (NIH) ar participating Institutes listed al Down syndrome research object erstand Down syndromE (INCLU P01,P20, P30,P40,P50,P51,U01,	2 nnounces the opportunit bove to submit administr ctives related to the NIH JDE) Project. This Notice ,U10,U19,U24,U42,U54,I	y for investigators rative supplement INvestigation of Co is soliciting admin JG1,UG3,UL1,U2C	with relevant applications o-occurring istrative ,K12, and T32.
102357	RFA-HL-22-007 Early Intervention to P of Mothers and Children (ENRICH) Mult (Collaborative UG3/UH3 Clinical Trial Re	romote Cardiovascular Health site Clinical Centers quired)	National Institutes of Health/DHHS	RFA-HL-22-007 [Optio	y-2021 nal][LOI/Pre-App]	Not Specified
	Contact Name Charle Contact Telephone 301-4 Contact Email <u>charle</u> Sponsor Website	tte A. Pratt, MS, PhD 5-0382 <u>tte.pratt@mail.nih.gov</u>				

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	11-May-2	021 [Optional][LOI/Pre-App]	, 11-Jun-2021				
	Synopsis	group- or cluster-randomized trial under the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program. ENRICH will aim to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years old) who are of low socio- economic status (SES), live in low-resource rural or urban communities, or who are in diverse geographic regions of the U.S. with high burden of cardiovascular disease (CVD) risk factors. Specifically, this initiative will support multi-site interventions designed to determine if a CVH module delivered within the context of a home visiting program can enhance maternal and early childhood CVH. This FOA uses the bi-phasic, milestone-driven cooperative agreement mechanism (UG3/UH3) and runs in parallel with a companion FOA (RFA-HL-22-008) that encourages applications for a collaborating Resource Coordinating Center (RCC). Awards made under this FOA will support a milestone driven planning phase including feasibility studies and pilot activities for up to 2 years (UG3), with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 may transition to the UH3 phase. Applications submitted to this FOA must address both the UG3 and UH3 phases. Applications must also include plans for project management, subject recruitment and retention, scientific conduct of the trial including study design, intervention, measurement and data analysis, and performance milestones for each phase.						
	RFA-HL-22-008 Early Intervention	<u>on to Pron</u>	note Cardiovascular Health	National Institutes of	11.	May-2021	Not	
102358	of Mothers and Children (ENRICH	<u>I) Multisite</u>	e Resource and	Health/DHHS	RFA-HL-22-008	tional][I OI/Pre-App]	Specified	
	Coordinating Center (U24 Clinical	l Trial Requ	<u>uired)</u>		[0]		opeenieu	
	Contact Name	Charlotte	A. Pratt, MS, PhD					
	Contact Telephone	301-435-0	0382					
	Contact Email	charlotte.	.pratt@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	11-May-2	021 [Optional][LOI/Pre-App]	, 11-Jun-2021				
	Synopsis	This Fund Early Inte group- or The RCC v	ling Opportunity Announcem rvention to Promote Cardiov cluster- randomized trial wit will coordinate and provide s	ent (FOA) invites applications for ascular Health of Mothers and th clinical or community sites to upport for the clinical or comm	or a Resource and Co Children (ENRICH) pr be supported under unity sites that propo	ordinating Center (RC ogram, a new NIH mu the companion RFA-H ose to test the effectiv	C) for the Iti-center 1L-22-007. reness of an	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years of age) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or are in diverse geographic regions of the U.S. with a high burden of cardiovascular disease (CVD) risk factors. Applicants should propose activities that include the following: Plan and support study coordinating structure and functions, including efforts to promote communication and collaborations among study investigators, training of staff on study protocols, convening of meetings, evaluating the data collected from the ENRICH clinical/community sites, and coordinating ancillary studies that leverage the ENRICH research platform Facilitate the development of a common intervention protocol for the UH3 phase, including the study design, analytic plan, sample size, and use of common elements and measures across studies, to be reviewed by the NHLBI-appointed DSMB and approved by the NHLBI prior to UH3 phase for the clinical or community sites Develop and implement data collection procedures, facilitate the collection of biomedical data, establish a central database, provide additional biostatistical expertise, conduct data analysis of data across study sites, and facilitate reporting of trial results, including process, impact, and outcomes measures. Involve and develop the skills of Early Stage Investigators (ESIs) and home-visiting staff professionals in early CVH promotion and implementation strategies to foster the next generation of researchers in promoting maternal and child CVH. Coordinate the development of public access data files to be made available in a data repository as designated by the NHLBI. This U24 cooperative agreement initiative is administered by the NHLBI but includes extensive participation and funding contributions from a coalition of Institutes, Centers, and Offices (ICOs) at the National Institutes of Health (NIH) as well as the Health Resources and Services Administration (HRSA) and the Administration for Children and Families (ACF). HRSA and ACF will provide the infrastructure and in-kind support to awardee investigators to gain access to evidence-based home visiting programs already being supported by HHS. HRSA and ACF staff, along with NIH staff will provide staff-level scientific and technical input for ENRICH. HRSA and ACF staff along with NIH staff may serve as project scientists on the Steering Committee and various subcommittees (e.g., intervention, measurement, publications, ancillary studies subcommittees). .

RFA-DK-21-004 The Autoantige Etiology and Pathophysiology of] Optional)	National Institutes of Health/DHHS	RFA-DK-21-004	22-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD	
Contact Name	Salvatore Sechi, Ph.D.				
Contact Telephone					
Contact Email					
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	22-May-2021 [Optional][LOI/Pre-App	o], 22-Jun-2021 , 09-Feb-2022 [Op	otional][LOI/Pre-	App], 09-Mar-2022	
	RFA-DK-21-004 The Autoantige Etiology and Pathophysiology of T Optional) Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	RFA-DK-21-004 The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) Contact Name Salvatore Sechi, Ph.D. Contact Telephone 301-594-8814 Contact Email sechi@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL)	RFA-DK-21-004 The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) National Institutes of Health/DHHS National Institutes of Contact Name Contact Telephone Contact Email Salvatore Sechi, Ph.D. Sponsor Website Program URL Sechi@nih.gov Link to program URL Link to program URL Deadline Dates (ALL) 22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021, 09-Feb-2022 [Optional]	RFA-DK-21-004 The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) National Institutes of Health/DHHS RFA-DK-21-004 Optional) Contact Name Contact Telephone Solvatore Sechi, Ph.D. 301-594-8814 Sechi@nih.gov Sponsor Website Program URL Link to program URL Link to program URL Deadline Dates (ALL) 22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021, 09-Feb-2022 [Optional][LOI/Pre-	RFA-DK-21-004 The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) National Institutes of Health/DHHS RFA-DK-21-004 22-May-2021 [Optional][LOI/Pre-App] Optional) Contact Name Salvatore Sechi, Ph.D. 301-594-8814 Value

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis Synopsis	nding Opportunity Announceme I research aimed at the character is the function that post-translati ses and overall in the etiology an igens or neoepitopes are within eries with the present knowledge T8). In the long-term the goals of ssion and treatment, and potent	nt (FOA) encourages application rization of the function of neod onal modifications might have d pathophysiology of type 1 d the scope of this solicitation, b on established epitopes and a this initiative are to facilitate ally to facilitate the developm	ons from institutions an epitopes and neoantige e in the humoral and cel iabetes. Applications th put should propose a pla antigens (e.g. autoantib the development of bet ent of personalized the	d organizations pro ns in type 1 diabet I mediated autoim at include the disc in for integrating t odies for insulin, G tter tools to monit rapeutics.	oposing es. This imune overy of hese GAD65, IA-2, or disease
102925	Notice of Special Interest (NOSI): NIH Re Down Syndrome (R01) for the INCLUDE conditions across the Lifespan to Unders	search Project Grants on INvestigation of Co-occurring tand Down syndromE) Project	ational Institutes of ealth/DHHS	NOT-OD-20- 024 07-Ma	y-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The pu on Do Synopsis Applic innova	program URL y-2021 , 05-Jun-2021 , 07-Sep-20 rpose of this Notice of Special Int vn syndrome and that meet prog unication of outputs of appropria ints responding to this NOSI are s tive data analytics approaches (s	21 , 05-Oct-2021 , 07-Jan-2022 erest (NOSI) is to support rese rammatic objectives for the IN te interest to broader commu strongly encouraged to describ ee Goal 3, NIH Strategic Plan F	2 earch project grant (R01 ICLUDE Project. Sharing nities are a high priority pe plans for rapid sharin or Data Science).) applications that of resources and of the INCLUDE P g of data and resu	are focused effective roject. Its as well as
102380	AMENDMENT Development of Medica Biothreat Agents, Antimicrobial-Resistar Infectious Diseases	I Countermeasures for N t Infections an Emerging H	ational Institutes of ealth/DHHS	HHS-NIH- NIAID- 24-Ma BAA2021-1	y-2021	Not Specified
	Contact Name Alexar Contact Telephone 24066 Contact Email <u>alexar</u> Sponsor Website	dra Buck 95174 dra.buck@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
SPIN ID	Program Ink to Deadline Dates (ALL) 24-May 2021 N Allergy (DHHS) vaccine mediat (R&D) e (R&D) f Microb AGENC discuss 001: A Researd sagents these p future f include Infectio Researd gents these p future f include include infectio Researd Emergi combin complete propos Biodefe is the d pathog	Sponsor Name program URL 2-2021 IAID DMID Omnibus Broad Agence and Infectious Diseases (NIAID), N supports research related to the s, therapeutics, and medical diage ed diseases. This Broad Agency A expertise necessary for successfull iology and Infectious Diseases (DM Y ANNOUNCEMENT No. HHS-NIH- ed below. Description: DIVISION dvanced Development of Vaccine ch Area 001 is to advance vaccine support vaccine development the The goal of Research Area 001 is to important for biodefense and/or latforms and technologies to rapid development of these technologies : Vaccines for Anti-Microbial Resion bus Diseases. NIAID estimates that ch Area entitled "Development of ng Infectious Diseases" for a total ed) across all contracts. The totation xity of the offeror's proposed rese ed by an Offeror shall not exceed ense, Anti-Microbial Resistant (AM evelopment of promising new the ens and select bacterial and fungation of the offeror shall not exceed ense, Anti-Microbial Resistant (AM evelopment of promising new the ens and select bacterial and fungation support and select bacterial and fungation and and and and and and and and and and	y Announcement HHS-NIH-NIAID-BAA2021-1 Introduces Vational Institutes of Health (NIH), of the Department basic understanding of microbiology and immunology nostics for the prevention, treatment, and diagnosis nnouncement is soliciting proposals that possess the ly carrying out research toward meeting the program MID), NIAID, NIH. The Research Areas included in this NIAID-BAA2021-1, as well as the projected amounts OF MICROBIOLOGY AND INFECTIOUS DISEAES (DMID Candidates for Biodefense and Emerging Infectious I technologies and platforms that have sufficient proc rough manufacturing, toxicology testing, and testing o advance vaccine technologies and platforms which emerging pathogens to protect human health and w dly progress into Phase 1 clinical trials will provide cr es into approved therapies and vaccines. Solicited pr istant (AMR) Organisms and Vaccines for Pandemic P t three (3) or more awards may be issued across this Therapeutic Products for Biodefense, Anti-Microbial cost of up to \$11 million for the non-severable base al duration of a proposed contract should be consister earch. The total performance period comprised of th five (5) years. Research Area 002 Development of TI MR) Infections and Emerging Infectious Diseases. The erapeutics to address infections caused by NIAID Cate al infections identified in the 2019 CDC Antibiotic Res	Deadline Date Iction: The Nation t of Health and Hu y leading to the d of infectious and i research and dev o objectives of the NIAID DMID OM of available fundi D), NIAID, NIH Res Diseases. The object of of concept data in phase 1 or 2 cli could be deployed ell-being. The dev itical data to redu oducts are anticip reparedness and Research Area ar Resistant (AMR) work (direct and ent with the natur ne base and any o nerapeutic Product objective of Rese egory A, B, and C istance Threats R	Funding Amount al Institute of uman Services evelopment of immune- relopment Division of NIBUS BROAD ing, are earch Area ective of and/or clinica incal ed against elopment of ice the risk for bated to Emerging nd the next Infections and indirect costs e and ptions cts for arch Area 002 priority eport
	Emergi combir comple propos Biodefe is the d pathog https:// therapo evident produc	ng Infectious Diseases" for a total ed) across all contracts. The tota xity of the offeror's proposed rese ed by an Offeror shall not exceed ense, Anti-Microbial Resistant (AN evelopment of promising new the ens and select bacterial and funga www.cdc.gov/drugresistance/pd eutic activity is defined as the cure to the purposes of this solicitat t candidate, and is either a small r	cost of up to \$11 million for the non-severable base al duration of a proposed contract should be consiste earch. The total performance period comprised of th five (5) years. Research Area 002 Development of Th AR) Infections and Emerging Infectious Diseases. The erapeutics to address infections caused by NIAID Cate al infections identified in the 2019 CDC Antibiotic Res f/threats-report/2019-ar-threats-report-508.pdf. For e or mitigation of disease, preferably, once signs and tion, a therapeutic candidate refers to an advanced le molecule (synthetic or natural product) or a biologica	work (direct and nt with the nature ne base and any o nerapeutic Product objective of Rese egory A, B, and C p istance Threats Rese the purposes of the symptoms of infe- ead series, optimi of product (e.g. mo	ind e an ptic cts f arc pric epc this ecti- zec

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Therapeutics; and Anti-toxin Therapeutics. NIAID estimates that three (3) or more awards may be issued across this Research Area and the preceding Research Area entitled "Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases" for a total cost of up to \$11 million for the non-severable base work (direct and indirect costs combined) across all contracts. The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror shall not exceed five (5) years Research Area 003: Advanced Development of Sequencing-Based Diagnostics for Biothreats and Emerging Infectious Diseases The objective of Research Area 003 is to advance the research and development of nucleic acid and protein sequencing solutions on established commercial platforms for the targeted and agnostic detection of bio-threat and naturally emerging infectious pathogens. Solicited products are anticipated to include: Early through late-stage development for a sequencing-based diagnostic test that supports biodefense and naturally emerging and re-emerging infectious pathogen preparedness. Diagnostic must detect one of the following agents: Bacillus anthracis, including genotypic resistance markers Yersinia pestis, including genotypic resistance markers Francisella tularemia, including genotypic resistance markers Burkholderia sp., including genotypic resistance markers Botulinum toxin, including identifying and distinguishing relevant serotypes ESKAPE pathogens (Enterococcus faecium, Staph. aureus, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterobacter species), including genotypic resistance markers Lassa virus Nipah virus Rift Valley Fever virus Enterovirus D68 virus Candida auris Coccidioides sp. Novel coronaviruses NIAID estimates that one (1) or more awards may be issued across this Research Area for a total cost of up to \$4 million for the non-severable base work (direct and indirect costs combined) across all contracts. The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror shall not exceed five (5) years The Omnibus BAA is governed by Federal Acquisition Regulation (FAR) 6.102(d)(2) and FAR 35.016, as well as the NIH Policy Manual, Manual Chapter 6035, Broad Agency Announcements. A BAA may be used as a solicitation mechanism for basic and applied research directed toward advancing the state-of-the-art or increasing knowledge or understanding and that part of development not related to the development of a specific system or hardware procurement. BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government. Proposals received in response to this BAA are NOT evaluated against each other since they are not submitted in accordance with a common SOW issued by the Government. Instead, Research and Technical Objectives will be provided in the BAA that describe individual Research Areas in which the Government is interested. Proposals received in response to the BAA will be evaluated in accordance with the Evaluation Factors for Award specified in the announcement. The Government reserves the right to conduct discussions with all, some,

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline	Date Funding Amount
		one, or ne right to su product. the right anticipate programs Agency. T https://bu No facsim NIAID ele acceptab	one of the proposals receive uggest modifying, adding or The Government also reserv to accept proposals in their ed. Selection for award unde s, and the availability of fund This BAA will be available ele eta.sam.gov/. This notice do hile transmissions will be acc ctronic Contract Proposal Su le. For directions on using e	d in response to this BAA. If di deleting milestones, decision es the right to make awards w entirety or to select only portion r this BAA will be based upon s. Any responsible offeror man ctronically on or about Februa es not commit the Governmen epted. For this solicitation, the bmission (eCPS) website. Sub CPS, go to the website: https:/	iscussions are con points, research p vithout discussions ons of proposals f the evaluation fac y submit a propos ary 23, 2021 and m nt to award a cont e NIAID requires p mission of propos V/ecps.nih.gov and	ducted, the Goverr lans, processes, sch s. Additionally, the or award. Multiple ctors, importance to al which shall be co hay be accessed the rract. No collect cal roposals to be sub- als by facsimile or e I then click on "How	ament reserves the nedules, budget or Government reserves awards are o the agency onsidered by the rough Beta Sam: Is will be accepted. mitted online via the e-mail is not v to Submit."
099844	Computational Approaches to Cu Research Assets (R01 Clinical Tria	ration at S I Not Allov	icale for Biomedical ved)	National Library of Medicine/NIH/DHHS	PAR-20-304	07-May-2021	1,000,000 USD
	Contact Name	Alan Vanl	Biervliet, PhD				
	Contact Telephone	301-594-4	4882				
	Contact Email	<u>vanbiervl</u>	ietaq@mail.nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	07-May-2 2022 , 05	2021 , 05-Jun-2021 , 07-Sep-2 -Oct-2022 , 07-Jan-2023 , 05	2021 , 05-Oct-2021 , 07-Jan-20 -Feb-2023 , 07-May-2023)22 , 05-Feb-2022	, 07-May-2022 , 05	-Jun-2022 , 07-Sep-
	Synopsis	National computat of the cur	Library of Medicine (NLM) v tional models that can serve ration processes.	vishes to accelerate the availa as the basis of transformative	bility of and acces biomedical disco	ss to secure, compl veries by improving	ete data sets and g the speed and scope
076848	NLM Research Grants in Biomedia Clinical Trial Optional)	<u>cal Inform</u>	atics and Data Science (R01	National Library of Medicine/NIH/DHHS	PAR-18-896	07-May-2021	1,000,000 USD
	Contact Name	Dr. Hua-C	Chuan Sim				
	Contact Telephone	301-594-4	4882				
	Contact Email	<u>simh@ma</u>	ail.nih.gov				
	Sponsor Website						

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	07-Mav-2	021.05-Jun-2021.07-Sep-20	021							
	Synopsis	National L data scien approache reusable a Biomedica computer biomedica managem organizati data scien are develo use the N	ata science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and pproaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, eusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. iomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, omputer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic iomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health informatic nanagement in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, rganization, management, integration and presentation of information relevant to human health and biology. NIH defines ata science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems re developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.								
073256	Improving Patient Adherence to T to Promote Health (R01 Clinical T	<u>Freatment</u> rial Option	and Prevention Regimens (aal)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-722 07-Ma	ay-2021	Not Specified				
	Contact Name	Wendy Ni	ilsen, PhD								
	Contact Telephone	240-276-6	5971								
	Contact Email	nelsonw@	<u>@mail.nih.gov</u>								
	Sponsor Website										
	Program URL	Link to pro	ogram URL								
	Deadline Dates (ALL)	07-May-2	021								
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address pat adherence to treatment and prevention regimens to promote health outcomes. Applications may address health regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may ad adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, prov healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emph appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific re interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either do not propose a clinical trial(s). This FOA will use the NIH Research Project (R01) award mechanism.											

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
073264	Improving Patient Adherence to T to Promote Health (R01 Clinical T	Treatment and Prevention Regimens rial Optional)	Office of Behavioral and Soc Sciences Research/NIH/DH	cial PA-18-723 07-Ma IS	ay-2021	275,000 USD			
Contact Telephone 240-276-6971 Contact Email nelsonw@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address adherence to treatment and prevention regimens to promote health outcomes. Applications may address hear regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research mar adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, p healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with en appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specifi interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that eitld do not propose a clinical trial(s). This FOA will use the NIH R21 Exploratory/Developmental Research Grant aw mechanism.									
101526	Limited Competition: Specific Pat Clinical Trial Not Allowed)	hogen Free Macaque Colonies (U42	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-089 07-Ma	ay-2021	Not Specified			
	Contact Name	Sheri Hild, Ph.D.							
	Contact Telephone	301-594-8937							
	Contact Email	<u>sheri.hild@nih.gov</u>							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan- 2024	2022 , 07-May-2022 , 07-Sep	-2022 , 07-Jan-2023 , 07-M	ay-2023 , 07-Sep-2	2023 , 07-Jan-			
	Synopsis	The purpose of this Funding Opportunity Announcement is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-18-669 and PAR-14-066. Breeding colonies are essential to							

SPIN ID	Program Title		Sponsor Name	Sponsor Number			Deadline Date	Funding Amount
		sustain ap Syndrome investigat major his responses immune r	opropriate macaques for res e (AIDS). Pedigree SPF macac tions or present a risk to the tocompatibility complex (MI s to Simian Immunodeficience responses to HIV.	earch related to Human Immun ques are free of certain viruses, personnel who care for the ani HC) class I types, because MHC o cy Virus (SIV, which can induce a	odeficiency Viru which may conf mals. The SPF m class I genotypes AIDS in nonhuma	s (HIV)// ound the acaques s have la an prima	Acquired Immunc e results of HIV/A are genetically cl rge effects on ma tes (NHP)) and or	deficiency IDS-related naracterized for icaque immune n human
095227	Limited Competition: National Pr (Clinical Trials Not Allowed)	imate Rese	earch Centers (P51)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-20-181	25-Ma	y-2021	Not Specified
	Contact Name	Sheri Ann	Hild, PhD					
	Contact Telephone	301-594-8	8937					
	Contact Email	<u>hildsa@m</u>	nail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	25-May-2	.021 , 25-Sep-2021 , 25-Jan-2	2022 , 25-May-2022 , 25-Sep-20	22,25-Jan-2023	3 , 25-Ma	ay-2023	
This FOA encourages grant applications that support the activities of the National Primate Research Centers (N Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore critical animal models for basic and translational research aimed at understanding human biology, both in nor Synopsis diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual reso are most effectively and economically provided in centralized primate centers, the resources of which are man investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NH research and thereby complement and help enable the missions of the NIH Institutes and Centers.								IPRCs). re, NHPs are mal and urces, which le available to Ps in biomedical
088104	104 Animal and Biological Material Resource Center Not-Allowed)		enters (P40) (Clinical Trials	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD-20- 002	07-Ma	y-2021	Not Specified
	Contact Name Oleg Mirochnitchenko, Ph.D.							
	Contact Telephone	301-435-0	0748					
	Contact Email	oleg.miro	chnitchenko@mail.nih.gov					
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount				
	Program URL	Link to program URL								
	Deadline Dates (ALL)	07-May-2021 , 26-May-2021 , 07-Sep-2 2022 , 27-Sep-2022 , 07-Jan-2023	2021 , 28-Sep-2021 , 07-Jan-2	022 , 26-Jan-2022 , 07	-May-2022 , 26-May-	2022 , 07-Sep-				
	Synopsis	This FOA encourages grant application support for special colonies of laborate (cells, tissues, and organs) and genetic a local, regional, and national basis. The resources, which are facilitating the op- reproducibility of biomedical research application to multiple NIH Institutes of orip). This funding opportunity is desi- appropriate. Prior to preparing an app- to be advised on appropriateness of the and ORIP's program priorities.	upport for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on local, regional, and national basis. The important mission of the projects described by this FOA is to provide research esources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental eproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad pplication to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission (https://orip.nih.gov/about-rip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones wher ppropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, nd ORIP's program priorities.							
085529	RFA-OD-19-027Resource-Relate of Animal Models and Related Ma Allowed)	d Research Projects for Development of aterials (R24 Clinical Trials Not-	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD-19- 027 10-	-May-2021	Not Specified				
	Contact Name	Stephanie Murphy, VMD, PhD								
	Contact Telephone	301-451-7818								
	Contact Email	stephanie.murphy@nih.gov								
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	10-May-2021 , 26-May-2021 , 08-Sep-2 2022	2021 , 28-Sep-2021 , 10-Jan-2	022 , 26-Jan-2022 , 10	-May-2022 , 26-May-	-2022 , 08-Sep-				
Synopsis Synopsis and at developing, characterizing synopsis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORI trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad resear areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select a										

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount					
	research only per	search will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are Ily peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.									
079634	Methods Development for Cryogenic or O and Revival of Drosophila and Zebrafish G Trial Not Allowed)	ther Long-term Preservation O enetic Stocks (R21 Clinical Ir P	ffice of Research nfrastructure rograms/NIH/DHHS	PAR-19-176 07-Ma	y-2021	275,000 USD					
	Contact Name Sige Zou Contact Telephone 301-435 Contact Email <u>zous@m</u>	, Ph.D. -0749 Jail.nih.gov									
Sponsor Website Program URL <u>Link to program URL</u> Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022											
	This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential Iaboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long- term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.										



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
102421	Dear Colleague Letter: Request f	or Expression of Interest Regarding Pro	vision of a Drilling	National Science	NSF 21-	01-Ma	ay-2021	Not Specified
	Vessel to Support Future Interna	tional Scientific Ocean Discovery		Foundation	043	[LOI/P	re-App]	
	Contact Name	James F. Allan						
	Contact Telephone	703-292-8144						
	Contact Email	jallan@nsf.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-May-2021 [LOI/Pre-App]						
	Synopsis	the National Science Foundation (NSF) Guide, to support the science needs ar by Scientific Ocean Drilling 2050 Science the American scientific community and India. All totaled, over 800 participants to address critical global geoscience pr sampling or observation.	Major Multi-User ad enable new scie ce Framework. The d international wor defined the need oblems in the ocea	Research Facilities pro nce discovery as defin 2050 Science Framew kshops held in Europe for a multi-decade pro ans and explore areas	ocess as des ed in the re vork is base e, Japan, Ch ogram with of the Earth	cribed cently d on we ina, Aus a globa n otherv	in the NSF Ma completed Ex orkshop-deriv stralia, South I ally ranging sci wise inaccessi	jor Facilities oloring Earth ed input from Korea, and entific drillship ble for
102018	National Robotics Initiative 3.0: I	nnovations in Integration of Robotics (N	<u>NRI-3.0)</u>	National Science Foundation	21-559	03-Ma	ay-2021	Not Specified
	Contact Name	David Miller						
	Contact Telephone	703-292-4914						
	Contact Email	damiller@nsf.gov						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	03-May-2021 , 22-Feb-2022						
Synopsis The National Robotics Initiative 3.0: Innovations in Integration of Robotics (NRI-3.0) program builds u Synopsis cience of robot integration. The program supports research that promotes integration of robots to the including human safety and human independence. Collaboration between academic, industry, non-p								receding nce the of humans other



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		science and tiple agencie ilture (USDA tional Institu	l engineering and t es of the federal go A), the National Ae utes of Health (NIH	echnology overnment ronautics and), and the			
102422	Dear Colleague Letter: Compute Fellowships (CSGrad4US)	r and Information Science and Engineeri	ng Graduate	National Science Foundation	NSF 21- 044	04-May-2021	138,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	703-292-8950 <u>csgrad4us@nsf.gov</u>					
	Program URL	Link to program URL					
	Synopsis	The computer and information science these undergraduate degree recipients small fraction of these individuals consi number of diverse, domestic graduate s computer and information science and (NSF) Directorate for Computer and Info Graduate Fellowships (CSGrad4US) as a practical experience following their bac degree. The goals of the CSGrad4US Fe with the demonstrated potential to be among groups underrepresented in CIS Natives, Native Hawaiians, Native Pacifi overall strategy by NSF's CISE directorat advancing CISE research and innovation	and engineering f have outstanding ders pursuing rela- students in these engineering resea ormation Science pilot effort. In pa helor's degree an llowships are to: high-achieving CIS E disciplines, inclu- ic Islanders, and p te to develop the n.	Fields are experiencing g job opportunities in in ated doctoral degree-g areas and thereby bols arch and innovation we and Engineering (CISE inticular, CSGrad4US is d are now interested in 1) select, recognize, an SE researchers and inne ding women, African A persons with disabilities national workforce ne	booming ur ndustry and ranting pro- ster the U.S. orkforce, the announces intended fo n pursuing a d financially ovators; and Americans, I s. CSGrad4U cessary to e	ndergraduate enro at other organizat grams. In order to population in the e National Science is intention to su or individuals who h a research-based da y support early-car d 2) to broaden par Hispanics, America JS Fellowships are insure the Nation's	llments. Many of ions, and only a increase the Nation's Foundation's pport CISE nave some octoral eer individuals rticipation n Indians, Alaska a part of an leadership in
092037	Civic Innovation Challenge			National Science Foundation	20-562	05-May-2021	1,000,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name	David Corman							
	Contact Telephone	/03-292-8754							
	Contact Email	dcorman@nsf.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	05-May-2021							
	Synopsis	domain designed to build a more cohesive research-to-innovation pipeline and foster a collaborative spirit. Building or NSF S&CC program and the extensive S&CC ecosystem, CIVIC aims to accelerate the impact of S&CC research, and dee cooperation and information sharing across sectors and regions. CIVIC will lay a foundation for a broader and more flu exchange of research interests and civic priorities that will create new instances of collaboration and introduce new and technical and social scientific discovery. CIVIC will fund projects that can produce significant community impact within months (following a four-month planning phase) — in contrast to many community-university partnerships that take provide tangible benefits to communities — and have the potential for lasting impact beyond the period of the CIVIC							
102062	Understanding the Rules of Life:	Emergent Networks (URoL:EN)		National Science Foundation	21-560 1	0-May-2021	3,000,000 USD		
	Contact Name	Betsy von Holle							
	Contact Telephone	703-292-4974							
	Contact Email	e-networks@nsf.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	10-May-2021							
The Understanding the Rules of Life: Predicting Phenotype "Big Idea" is based on developing a predictive understand how key properties of living systems emerge from interactions of factors such as genomes, phenotypes, and evolvin environments. This activity has launched a series of new research programs designed to elucidate "minimal rules" (b synthetic cell), "rules of complexity" (epigenetics), and "rules of interaction" (microbiome). This Understanding the Life: Emergent Networks (URoL:EN) solicitation adds to those previous foundational activities to now understand "ru emergence" for networks of living systems and their environments. Emergent networks describe the interactions an organismal, environmental, social, and human-engineered systems that are complex and often unexpected given th									

SPIN ID Program Title Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
--------------------------	-------------	-------------------	------------------	-------------------

behaviors of these systems when observed in isolation. The behavior of emergent networks of living systems depend on, but are not wholly predicted by, chemical and physical principles and unit-level biological properties (molecule/cell/organism/population), as well as communication and information flows among nodes in the network. Networks of living systems are reciprocally coupled with natural, built, and social environments in ways that are complex and difficult to predict. The often-unanticipated outcomes of these interactions can be both wide-ranging and enormously impactful. Prediction is further hampered by accelerating perturbations within evolving environments and the associated increase in the frequency of previously rare or extreme events. Determining the emergent properties of these networks, which arise from complex and nonlinear interactions among the different systems that in isolation do not exhibit such properties, is a critical and unsolved problem. One of many examples of this could include the emerging network of interactions across scales that arose from the arrival of the nonnative pathogen, Cryphonectria parasitica, or Chestnut blight, introduced with nursery stock. This pathogen effectively eliminated a dominant overstory tree species, American chestnut (Castanea dentata), across North America and had concomitant impacts on and feedbacks between biotic, abiotic, and social networks. For example, the economic impacts of this pathogen ranged from local agricultural and social impacts to global scale impacts on the timber industry. Successful projects of the URoL:EN program are expected to use convergent approaches that explore emergent network properties of living systems across various levels of organizational scale and, ultimately, contribute to understanding the rules of life through new theories and reliable predictions about the impact of specific environmental changes on behaviors of complex living systems, or engineerable interventions and technologies based on a rule of life to address associated outcomes for societal benefit. The convergent scope of URoL:EN projects also provides unique STEM education and outreach possibilities to train the next generation of scientists in a diversity of approaches and to engage society more generally. Hence, the URoL:EN program encourages research projects that integrate training and outreach activities in their research plan, provide convergent training opportunities for researchers and students, develop novel teaching modules, and broaden participation of under-represented groups in science. The UROL:EN Program will support projects with a total budget of up to \$3,000,000 and an award duration of up to 5 years.

102254 <u>Fu</u>	uture Manufacturing (FM) (Defunct)	National Science Foundation	21-564	14-May-2021	Not Specified
------------------	------------------------------------	--------------------------------	--------	-------------	---------------

Contact Name William Olbricht Contact Telephone 703-292-4842 Contact Email wolbrich@nsf.gov Sponsor Website Link to sponsor website Program URL Link to program URL



SPIN ID	Program Title	ogram Title		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	14-May-2021 The global manufacturing ecosystem has globalization and steered by the pursui Manufacturing states that worldwide c maturation, commoditization, and wide leveling the global technological playing [1]. The next generation of technologic the reliable translation of product desig execution of those plans will produce p systems, processes, machines, and desi research will be required in robotics, ar public policy, and workforce development enhance U.S. leadership in manufacturing entrepreneurs, improving our health ar addressing global challenges such as cli support fundamental research and edu economic and social barriers in order to will require major advances in technolo devices, components and systems of as artificial intelligence and machine learn modeling, new dynamics and control m bioprocessing, and new ways to influer requires creative convergence approac workforce development to address pre leverage highly integrated physical, dig addresses urgent social challenges such marginalized populations and commun scientists, engineers, social and behavio solutions that are equitable and inclusing	as evolved dramatically in recent decade t of greater efficiencies at scale. The Stra ompetition in manufacturing has been of espread application of computation in pa- g field and placing a premium on low wa al competition in manufacturing will be gns to manufacturing plans; process con roducts that meet specifications; invent gn and work methods; and new social si tificial intelligence, biotechnology, mate ent to lead this global competition. The ing far into the future by providing new and quality of life, reducing the impact of mate change, pandemics and smart gro cation of a future workforce to overcom o enable new manufacturing capabilities based and algorithms for the synthesis an issured quality with high yield at reasona ing, new cyber infrastructure, new appr tethodologies, new ways to integrate sys- thes in science, technology and innovation sing challenges for manufacturing. At the ital and social frameworks that underpir in as global health disparities, economic a ities, and environmental sustainability. (oral economists, and experts in arts and ve.	es, driven by ategy for An lominated in roduction en ages and incu- dictated by trols that pr tions of new tructures an erials science research sup capabilities manufactur wth. The go ne scientific, that do not ble cost. It v coaches for r stems biolog navior, and s on, empirica he same tim n society to o and social di Cross-discipl humanities	forces of technolo nerican Leadership n recent decades by quipment and logist remental technical the use of computa- rovide assurances the materials, chemical d business practice e, sustainability, edu- oported under this for established com- ring on the environn al of Future Manufa- technological, edu- technological, edu- t	gy and in Advanced the ics, effectively improvements tion to ensure nat the ls, devices, s. Fundamental ucation and solicitation will spanies and nent and acturing is to cational, Manufacturing chemicals, rances in omputational y and ufacturing ucation and turing can ng that e deficits of among provide
090120	Future Manufacturing (FM)		National Science Foundation	21-564	14-May-2021	Not Specified



SPIN ID	ogram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
SPIN ID	Program Title Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	William Olbricht 703-292-4842 wolbrich@nsf.gov Link to sponsor website Link to program URL 14-May-2021 The global manufacturing ecosystem h globalization and steered by the pursui Manufacturing states that worldwide c maturation, commoditization, and widd leveling the global technological playin [1]. The next generation of technologic the reliable translation of product desig execution of those plans will produce p systems, processes, machines, and des research will be required in robotics, ar public policy, and workforce developm enhance U.S. leadership in manufactur entrepreneurs, improving our health ar addressing global challenges such as cli-	sponsor Name as evolved dramatically in recent decade it of greater efficiencies at scale. The Stra- competition in manufacturing has been of espread application of computation in p g field and placing a premium on low wa cal competition in manufacturing will be gns to manufacturing plans; process con products that meet specifications; invent ign and work methods; and new social s rtificial intelligence, biotechnology, mate ent to lead this global competition. The ing far into the future by providing new nd quality of life, reducing the impact of imate change, pandemics and smart gro	es, driven by force ategy for America dominated in recei- roduction equipm ages and incremer dictated by the us trols that provide cions of new mate tructures and bus erials science, sust research supporte capabilities for es manufacturing or wth. The goal of I	Deadline Date Date Date Sof technolog n Leadership ir nt decades by ent and logisti tal technical ir se of computat assurances that rials, chemical iness practices ainability, edu ed under this so tablished composed tablished tablished composed tablished tablished composed tablished tablished tab	Funding Amount Amount y and n Advanced the cs, effectively mprovements tion to ensure at the s, devices, s. Fundamental cation and olicitation will panies and nent and acturing is to
	Synopsis	entrepreneurs, improving our health and addressing global challenges such as cli support fundamental research and edu economic and social barriers in order to will require major advances in technolo devices, components and systems of as artificial intelligence and machine learn modeling, new dynamics and control m bioprocessing, and new ways to influen requires creative convergence approact workforce development to address pre- leverage highly integrated physical, dig addresses urgent social challenges such	nd quality of life, reducing the impact of imate change, pandemics and smart gro ucation of a future workforce to overcom o enable new manufacturing capabilities ogies and algorithms for the synthesis an ssured quality with high yield at reasona ning, new cyber infrastructure, new appr nethodologies, new ways to integrate sys nee the economy, workforce, human beh shes in science, technology and innovation essing challenges for manufacturing. At t yital and social frameworks that underping in as global health disparities, economic a	manufacturing on wth. The goal of F ne scientific, techn that do not exist id production of n ble cost. It will rec oaches for mathe stems biology, syn navior, and society on, empirical valid he same time, Fut n society to enable and social divides,	the environm -uture Manufa iological, educa today. Future ew materials, educa matical and co ithetic biology y. Future Manufacture ation, and educ ture Manufacturir infrastructure	ent and cturing is to ational, Manufacturing chemicals, ances in omputational and ufacturing ication and uring can ng that e deficits of



SPIN ID	Program Title	gram Title			Sponsor Number		Deadline Date	Funding Amount	
		marginalized populations and commun scientists, engineers, social and behavi solutions that are equitable and inclusi	arginalized populations and communities, and environmental sustainability. Cross-disciplinary partnerships among ientists, engineers, social and behavioral economists, and experts in arts and humanities may be required to provide lutions that are equitable and inclusive.						
092508	NSF Convergence Accelerator Ph	nase I and II		National Science Foundation	20-565	17-Ma	ay-2021	Not Specified	
	Contact Name	Linda Molnar							
	Contact Telephone	703-292-8316							
	Contact Email	ImoInar@nsf.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	17-May-2021							
	Synopsis	The goals of NSF's convergence acceler of national importance within particula the Future (IotF), NSF's Big Ideas, or of the potential for significant national im described in this solicitation. Phase I av ideas and identify crucial partnerships in Phase II. This solicitation invites prop Data and Model Sharing (Track D).	rator effort are to ar topics (tracks). I ther topics, that m pact. The 2020 N wardees receive si and resources to a posals for the follo	support and accelerate NSF Convergence Accel hay not relate directly t SF Convergence Accele gnificant resources to accelerate their project wing Tracks: Quantum	e use-inspir lerator trac to an lotF or rator is a tw further dev ts, leading t Technolog	red con ks can r Big Id wo-pha relop th to deliv ty (Trac	vergence rese be related to ea, however, se program. E eir converger erable resear k C); Al-Drive	earch in areas Industries of they must have Both phases are nce research ch prototypes n Innovation via	

SPIN ID	Program Title	S	ponsor Name	Spo	onsor Number	Deadline Date	Funding Amount
102467	Conservation Innovation Grants	Louisiana_	Natural Resources Conse Service/Department of A	ervation Agriculture	USDA-NRCS-LA-CIG- 001-NOFO0001064	21- 04-May-2021	L 150,000 USD
	Contact Name	Aziza B. Clark					
	Contact Telephone						
	Contact Email	aziza.clark@usda.g	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program UF	<u> </u>				
	Deadline Dates (ALL)	04-May-2021					
	Synopsis	NRCS is announcin approaches and te Louisiana. A total c and individuals are years in duration. 1	g the availability of CIG funding chnologies. Applications are acc f up to \$300,000.00 is available invited to apply, with the sole e The maximum award amount fo	to stimulate epted from for the Louis exception of r a single aw	the development and ac eligible entities for proje siana CIG competition in federal agencies. Project vard in FY 2021 is \$150,00	doption of innovativ cts carried out in the FY 2021. All non-fee ts may be between o 00.00.	e conservation e state of deral entities (NFE) one and three
057652	Large Health Services Research D Dissemination Projects for Prever Associated Infections (R18)	emonstration and ntion of Healthcare-	Agency for Healthcare Re Quality/DHHS	esearch and	PA-17-007	25-May-2021	L 2,500,000 USD
	Contact Name	James I. Cleeman,	M.D.				
	Contact Telephone	301-427-1330					
	Contact Email	james.cleeman@al	hrq.hhs.gov				
	Sponsor Website						
	Program URL	Link to program UF	<u>{L</u>				
	Deadline Dates (ALL)	25-May-2021					
	Synopsis	Agency for Healthc Services Research I prevention and rec which funds are av utilize the AHRQ La	are Research and Quality (AHRO Demonstration and Dissemination luction of Healthcare-Associated ailable to support Health Service arge Health Services Research De	2) invites app on Projects (I Infections es Research emonstratio	plications for funding for (R18) that propose to add (HAIs). The FOA describe Demonstration and Disse n and Dissemination Gra	funding to conduct dress strategies and to the broad areas of emination Projects. ant (R18) award mec	Large Health approaches for HAI research for This FOA will hanism.
073607	Making Health Care Safer in Amb	ulatory Care Setting	s and Agency for Healthcare R	esearch and	PA-18-750	25-May-2021	1,350,000 USD



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
	Long Term Care Facilities (R18)		Quality/DHHS			
	Contact Name	Barbara A. Bartman.	MD. MPH			
	Contact Telephone	301-427-1515				
	Contact Email	barbara.bartman@al	hrg.hhs.gov			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-May-2021 , 25-Se	p-2021			
	Synopsis	Agency for Healthcar projects that pertain processes to improve settings that develop already been validate Research Demonstra	re Research and Quality (AHRQ) invites to ambulatory care settings and long t e patient safety, especially those involv o, utilize, and evaluate strategies to imp ed and have been shown to be efficacion tion and Dissemination Project award	applications for research d erm care facilities with a for ving transitions in care. AHR plement existing measures, ous in improving patient saf mechanism.	lemonstration and in cus on implementing Q is interested in st metrics, tools or pra fety sites. This FOA v	nplementation g evidence-based udies in these two actices that have will use the R18
057446	AHRQ Conference Grant Program	<u>n (R13)</u>	Agency for Healthcare Research a Quality/DHHS	and PA-16-453	01-May-2023	1 150,000 USD
	Contact Name	Linda Franklin				
	Contact Telephone	301-427-1904				
	Contact Email	linda.franklin@ahrq.	hhs.gov			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-May-2021 , 01-Au	ıg-2021 , 01-Nov-2021			
	ng conferences thro ort conferences that e, equitable and affo sed conference grant (R	ugh the AHRQ help to further its rdable, and to 13) award				
102711	Gulf War Illness Research Program	mNew Investigator	Department of the Army	W81XWH-21-GWIR	P-NIA 07-May-2022	1 Not Specified



SPIN ID	Program Title	S	ponsor Name	Spo	onsor Number	Deadline Date	Funding Amount		
	Award					[LOI/Pre-Ap	p]		
	Contact Name								
	Contact Telephone	301-682-5507							
	Contact Email	help@eBRAP.org							
	Sponsor Website	Link to sponsor we	<u>bsite</u>						
	Program URL	Link to program UF	<u> </u>						
	Deadline Dates (ALL)	07-May-2021 [LOI/	'Pre-App], 19-Aug-2021						
	Synopsis	Synopsis Synopsis Synopsis GWI research and GWI research and/or possess other relevant expertise to strengthen the application. The application of GWI research and/or possess other relevant expertise to strengthen the application. The application should describe how the collaboration(s) will augment the PI's ability to address the research question. PIs must meet spec eligibility criteria under one of the following categories. Transitioning Postdoctoral Fellow; Early-Career Investigator; New GWI Researcher.							
102719	Gulf War Illness Research Program	mIdea Award	Department of the A	rmy	W81XWH-21-GWIF	RP-IA 07-May-202 [LOI/Pre-Ap	21 Not Specified p]		
	Contact Name								
	Contact Telephone	301-682-5507							
	Contact Email	help@eBRAP.org							
	Sponsor Website								
	Program URL	Link to program UF	<u> </u>						
	Deadline Dates (ALL)	07-May-2021 [LOI/	'Pre-App], 19-Aug-2021						
	Synopsis	The FY21 GWIRP Ic will contribute to n has a special intere studies in any othe Overarching Challe	lea Award supports innovation narkers or treatments for GV est in the exploration of the t or GWI research area relevant onges. • Innovative treatmen	ve, high-risk/hig VI. FY21 GWIRP copics listed belo t to the mission its for GWI • Ide	sh-reward research in the Idea Award Areas of En ow. Applicants are not re of the GWIRP and in the contification of the cause	ne earliest stages of nphasis: The FY21 G estricted to this list e context of the FY2 s of and treatment t	development that WIRP Idea Award and may propose 11 GWIRP cargets for		

SPIN ID	Program Title		Sponsor Name	S	ponsor Number	Deadline Date	Funding Amount
		dysregulated biol mood and behavi fatigue Gastrointe gastrointestinal d (central, peripher system dysfunctio The impact of stro crosstalk (e.g., im the gastrointestin signatures (e.g., g based on commo	ogical system function. Emphasis sh for disturbances Non-restorative slee estinal effects including dietary intol lisorders (FGIDs) Sinus and respirato ral, autonomic, and/or neuromuscul on, with special attention to kidney a esses (e.g., exertion, immune challer munological dysfunction that alters nal tract) that contributes to malfunc genomic, proteomic, metabolic, and n underlying pathobiology • Investig	ould be ep or sle erances ry effec ar) Imm and live nge) on the ner ction in epigene gation o	e placed on: Cognitive diffi- eep disturbances Chronic v s, gastroesophageal reflux ets Headaches Dermatolog nune system dysfunction E r (e.g., Cytochrome P450 a the severity and duration roous system, autonomic o several physiological syste etic) underlying symptoms of comorbidities, mortality	culties to include m wide-spread pain C disease (GERD), an ical issues Neurolog indocrine, exocrine, abnormalities) Micr of the symptoms D dysfunction that imp ems • Identification s and the grouping o , sex or ethnic diffe	emory deficits, hronic debilitating d functional gical dysfunction and/or excretory obiome variants isordered system pacts functioning of of molecular of symptom sets rences
102437 <u>L</u>	ung Cancer Research ProgramI ranslational Research Award	nvestigator-Initiat	ed Department of the Army		W81XWH-21-LCRP-	IITRA 05-May-202 [LOI/Pre-Ap	21 600,000 USD p]
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
	Program URL	Link to program L	JRL				
	Deadline Dates (ALL)	05-May-2021 [LO	I/Pre-App], 28-Jul-2021				
	Synopsis	The FY21 LCRP In develop promisin basic science and population-based move a concept of translational rese ideas and informa studies, including applications with Investigational Ne completed clinica support the feasil	vestigator-Initiated Translational Re- g ideas in lung cancer into clinical ap clinical observations. Observations I studies, or a clinician's firsthand kn or observation forward into clinical a earch as a one-way continuum from ation between basic and clinical scie t, but not limited to, the following: human samples/cohorts. Late ew Drug (IND) application submissio al trial and projects that develop end bility of the research hypotheses an	search / oplicatio that dri owledg pplicati bench t nce. Th Stu e-stage n points f d resear	Award mechanism suppor ons. Translational research ve a research idea may or ge of patient care. The ultir ion. However, Principal Inv o bedside. The research p his mechanism is intended udies advancing/translatin preclinical work leading to Correlative studies that a for clinical trials. Prelimina rch approaches are require	ts translational rese in may be defined as iginate from a labournate goal of transla vestigators (PIs) sho lan must involve a r to fund a broad ran g in vitro and/or an p/preparing for a cli are associated with ary lung cancer releved.	earch that will an integration of ratory discovery, tional research is to ould not view reciprocal flow of nge of translational imal studies to nical trial, e.g., an open/ongoing or vant data to



SPIN ID	Program Title	Spor	nsor Name	Sponsor Number	Deadline Date Fu	unding Amount
102721	Gulf War Illness Research Program Advancement Award	nResearch	Department of the Army	W81XWH-21-GWIF	07-May-2021 [LOI/Pre-App]	Not Specified
	Contact Name					
	Contact Telephone	301-682-5507				
	Contact Email	help@eBRAP.org				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 [LOI/Pre	-App], 19-Aug-2021			
	Synopsis	The FY21 GWIRP Resear validation of markers a	arch Advancement Award supports and treatments that are supported	applied research in GWI that by evidence in the GWI field.	t is aimed at continued	expansion and
102416	Capacity Building for Sustainable	HIV Services	Health Resources and Services Administration/DHHS	HRSA-21-064	07-May-2021	250,000,000 USD
	Contact Name	Jaclyn Perlman				
	Contact Telephone	301-945-0836				
	Contact Email	JPerlman@hrsa.gov				
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL					
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	This notice announces The purpose of this co enhance capacity build centeredness, safety, a identified PEPFAR cour partners in country (su Ministries of Health to responsive approach to to be agile and current on HIV/AIDS (UNAIDS)	the opportunity to apply for fundin operative agreement, funded under ding in PEPFAR countries. Capacity accessibility, equity, and sustainabin ntries. HRSA is committed to sustain the as civil society, faith-based and build the capacity of health care wo the HIV epidemic in resource-lime in their response to the needs of p 95-95-95 targets, and sustain thes	ng under the Capacity Buildin er the U.S. President's Emerge building encompasses quality lity of all HIV clinical services nable control of the HIV/AIDS community-based organization vorkers and health systems to ited countries. The program a program beneficiaries, achiev e efforts over time.	g for Sustainable HIV Se ency Plan for AIDS Relie , effectiveness, efficien and related non-clinica S epidemic, by working ons, key populations gr produce a sustained, e aims to build the capaci re the Joint United Natio	ervices project. f (PEPFAR), is to cy, patient- l support in with local oups, etc.) and efficient, and ty of countries ons Programme



SPIN ID	Program Title		Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount		
102390	Sickle Cell Disease Treatment Der	monstration Progr	<u>am</u>	Maternal and Child Health Bureau/HRSA/DHHS	HRSA-21-032	03-May-202	1 5,000,000 USD		
	Contact Name	Alisha S. Keehn							
	Contact Telephone	301-945-4817							
	Contact Email	akeehn@hrsa.go	<u>v</u>						
	Sponsor Website	Link to sponsor w	<u>vebsite</u>						
	Program URL								
	Deadline Dates (ALL)	03-May-2021							
	Synopsis	The Health Resou Disease Treatmen comprehensive c knowledgeable a improving care co	irces an nt Demo are for i bout the pordinat	d Services Administration (HRS, onstration Program (TDP). The p individuals with sickle cell disea e care of SCD, 2) improving the tion with other providers.	A) is accepting applications for ourpose of the TDP is to increas se by: 1) increasing the numbe quality of care provided to ind	fiscal year (FY) 2021 se access to quality, r of clinicians or hea ividuals with sickle c	for the Sickle Cell coordinated, Ith professionals ell disease, and 3)		
102731	<u>Global Reach ?</u>			Health Resources and Services Administration/DHHS	s HRSA-21-066	10-May-202	1 Not Specified		
	Contact Name	George Tidwell							
	Contact Telephone	301-443-4688							
	Contact Email	gtidwell@hrsa.go	<u>v</u>						
	Sponsor Website	Link to sponsor w	<u>ebsite</u>						
	Program URL								
	Deadline Dates (ALL)	10-May-2021							
	Synopsis	This notice announces the opportunity to apply for funding under the Global Reach I Program. The purpose of this initiative is to collaboratively formulate and deliver high quality solutions across the range of programming required to achieve durable HIV epidemic control, emphasizing new and innovative approaches pursued jointly with HRSA and other stakeholders. An additional purpose is to assist with translating new science into programming and to mitigate the impact of forces such as global pandemics in the HIV response. Programs and activities are to span health services, structural interventions, and data use and tracking systems.							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
055305	Program to Accelerate Clinical	Trials (PACT)		Alzheimer's Dru Foundation	ug Discovery	16-Apr-202	3,000,000 USD	
	Contact Name							
	Contact Telephone	212-901-8019						
	Contact Email	grants@alzdisco	overy.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	16-Apr-2021 , 2	8-May-2021 [LOI/Pre-A	vpp], 30-Jul-2021	, 01-Oct-2021 [LOI/Pre-Ap	p], 03-Dec-2021		
	Synopsis	The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.						
055304	Drug Development Program			Alzheimer's Dru Foundation	ug Discovery	16-Apr-202	1 600,000 USD	
	Contact Name	Alessio Travagli	a, PhD, Scientific Progra	am Officer				
	Contact Telephone	212-901-7998						
	Contact Email	atravaglia@alzo	discovery.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	16-Apr-2021,2	8-May-2021 [LOI/Pre-A	vpp], 30-Jul-2021	, 01-Oct-2021 [LOI/Pre-Ap	p], 03-Dec-2021		
	Synopsis	The Drug Devel Alzheimer's dise deliver a compo	opment RFP seeks to su ease and related demen ound with strong poten	upport in vivo pr ntias to IND-enal tial for clinical ar	eclinical studies that advan bling studies. The proposec nd commercial application.	ice lead molecules of studies should be This funding oppor	leveloped for structured to tunity prioritizes	



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
		novel drug mechanisms and modes of	action related to	the hiology of aging and c	ther emerging ther	aneutic areas for			
		dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be const for this RFP.							
000570	Junior Investigator Research G	rant Program	American Academy of Clinical Toxicology		01-May-202	21 4,500 USD			
	Contact Name								
	Contact Telephone	703-556-9222							
	Contact Email	admin@clintox.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-May-2021							
	Synopsis	The AACT is offering a research grant program that supports clinical toxicology research and the development of new investigators' research skills.							
090208	Annual Meeting and Exposition	n Travelships	American Assoc Pharmaceutica	ciation of I Scientists	01-May-202	21 Not Specified			
	Contact Name								
	Contact Telephone	703-243-2800							
	Contact Email	abstracts@aaps.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-May-2021							
	Synopsis The American Association of Pharmaceutical Scientists (AAPS) awards travelships to support the participation of student and post-doc authors who have submitted abstracts for the AAPS PharmSci 360.								



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
015781	Presidential Gold Medal			American College of Rheumatology	17-May-202	1 5,000 USD		
	Contact Name							
	Contact Telephone	404-633-3777						
	Contact Email	ACRnomination	<u>s@rheumatology.org</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
Deadline Dates (ALL) 17-May-2021								
	Synopsis	The Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire is career. Candidates will have made important contributions in multiple areas such as clinical medicine, research, education or administration. The recipient will receive a \$5,000 cash award.						
010661	Ephraim P. Engleman Endowed	Resident Resear	rch Preceptorship	American College of Rheumatology	01-May-202	1 15,000 USD		
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	Foundation@rh	eumatology.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL) 01-May-2021							
	Synopsis The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience.							
049768	Investigator-Initiated Research	Grant Program		American Institute for Cancer Research	14-May-202	Not 1 Specified		
	Contact Name							



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Fundi	ing Amount	
	Contact Telephone	202-600-3004						
	Contact Email	research@aicr.o	org					
	Sponsor Website	nsor Website Link to sponsor website Program URL Link to program URL						
	Program URL							
	Deadline Dates (ALL) 14-May-2021							
	Synopsis	The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform our Investigator Initiated Research Grant Program so that we can prioritize issues of greatest scientific importance and with the highest potential for translation into effective strategi for cancer prevention and improved outcomes for people living with and beyond cancer.						
005022	nvestigator-Initiated Research	<u>Grants</u>	American In Research	stitute for Cancer	14-May-20)21 7	75,000 USD	
	Contact Name							
	Contact Telephone	703-237-0159						
	Contact Email	research@aicr.	org					
	Sponsor Website <u>Link to sponsor website</u> Program URL <u>Link to program URL</u>							
Deadline Dates (ALL) 14-May-2021								
	Synopsis	The Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes. The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition ar physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform the Investigator Initiated Research Grant Program so that the sponsor can prioritize issues of greatest scientif importance and with the highest potential for translation into effective strategies for cancer prevention and improve						


SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		outcomes for people living with and b	beyond cancer.		
002145	Eight and Forty Lung and Respi	ratory Nursing Scholarship Fund	American Legion	15-May-20	21 Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	lasecretaire@8and40.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021			
	Synopsis	The 8 & 40 is rooted in supporting the respiratory illnesses in children.	e medical community, specifically those pro	fessionals directly in	volved in
058266	Overseas Assistance Grants		American Medical Women's Association	05-May-20	21 1,000 USD
	Contact Name				
	Contact Telephone	847-517-2801			
	Contact Email	associatedirector@amwa-doc.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021 , 05-Sep-2021			
	Synopsis	The AWHS Overseas Assistance Grant pursuing medical studies in an off-car	provides assistance with transportation co pus setting where the medically neglected	sts up to \$1,000 con I will benefit.	nected with
021267	John F. Perkins, Jr. Research Ca	reer Enhancement Award	American Physiological Society	31-May-20	21 20,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name							
	Contact Telephone	301-634-7164						
	Contact Email	awards@the-ap	s.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	31-May-2021						
	Synopsis	John F. Perkins, Jr. Research Career Enhancement Award is designed to enhance the career potential of the awardee. The award of up to \$20,000 allows an individual in the early phases of his/her career to obtain special training or an individual in the later phases of his/her career to develop new skills or retrain in areas of developing interest.						
072012	David P. Rall Award for Advoca	cy in Public Healt	t <u>h</u>	American Publi	c Health Association	14-May-20	21 1,000 USD	
	Contact Name	Deborah Dillard						
	Contact Telephone	202-777-2742						
	Contact Email	deborah.dillard	@apha.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	14-May-2021						
	Synopsis	The David P. Ra contribution to	ll Award for Advocacy i public health through s	n Public Health i science-based ad	s awarded to an individual lvocacy.	who has made an c	outstanding	
021409	DeLano Award for Computation	nal Biosciences		American Socie and Molecular	ty for Biochemistry Biology	05-May-20	21 3,000 USD	
	Contact Name							
	Contact Telephone	240-283-6600						
	Contact Email	asbmb@asbmb	.org					



SPIN ID Program Title	Sponsor Name	9	Sponsor Number	Deadline Date	Funding Amount				
Sponsor Website	Link to sponsor website								
Program URL	Link to program URL								
Deadline Dates (ALL)	05-May-2021								
Synopsis	The DeLano Award for Computational development or application of compu	e DeLano Award for Computational Biosciences is given to a scientist for the most accessible and innovative velopment or application of computer technology to enhance research in the life sciences at the molecular level.							
039495 Bert and Natalie Vallee Award	in Biomedical Science	American Society and Molecular B	y for Biochemistry iology	05-May-202	21 10,000 USD				
Contact Name	2								
Contact Telephone	240-283-6600								
Contact Emai	asbmb@asbmb.org								
Sponsor Website	Link to sponsor website								
Program URL	Link to program URL								
Deadline Dates (ALL)	05-May-2021								
Synopsis	The Bert and Natalie Vallee Award in E accomplishments in basic biomedical	Biomedical Science research.	e is awarded to an establi	shed scientist for ou	tstanding				
021408 Earl and Thressa Stadtman Dist	tinguished Scientist Award	American Society and Molecular B	y for Biochemistry iology	05-May-202	21 10,000 USD				
Contact Name	3								
Contact Telephone	240-283-6600								
Contact Emai	asbmb@asbmb.org								
Sponsor Website	Link to sponsor website								
Program URL	Link to program URL								
Deadline Dates (ALL)	05-May-2021								



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Earl and Thressa Stadtman D their legacies as scientists and m achievement in basic research in cash award and travel expenses f	istinguished Scientis entors. It is awardec the fields encompas or the ASBMB annu	st Award was established by I to an established scientist ssed by the ASBMB. The awa al meeting to present a lect	friends and colleagu for his or her outstan ard consists of a plaq ure.	es to preserve ding ue, a \$10,000
019022	Department of Urology - Endou	rology Fellowship at Northwester	n American Urc	ological Association	28-May-202	Not Specified
	Contact Name	Debra Caridi, Fellowship Coordin	ator			
	Contact Telephone	516-520-1226				
	Contact Email	debra@endourologysociety.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-May-2021 , 21-Jun-2021				
	Synopsis	The endourology fellowship is a p on to successful careers in both a	program with clinica academic and specia	l, operative and research co lized private practice setting	mponents. Previous s.	fellows have gone
089255	General Grants - United States		Biogen, Inc.		15-May-202	Not Specified
	Contact Name					
	Contact Telephone	617-914-1299				
	Contact Email	grantsandgiving@biogen.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 , 15-Aug-2021 , 01-	Nov-2021 , 15-Feb-2	2022		
	Synopsis	Biogen provides funding to an eli	gible institution or c	organization to support a pro	gram or project that	does not fit any



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		of the other defined grant categories. Biogen is cur	rently accepting requests in A	lzheimer's Disease.	
089253	Professional & Scientific Develo	opment Grants Biogen, Inc.		15-May-202	Not Specified
	Contact Name				
	Contact Telephone	617-914-1299			
	Contact Email	grantsandgiving@biogen.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021 , 15-Aug-2021 , 01-Nov-2021			
	Synopsis	Biogen provides funding to an eligible institution or professionals or researchers within Biogen's therap	organization to support train reutic areas of interest.	ing and developmen	t for medical
074616	Research Grants	California W	/alnut Commission	17-May-202	21 500,000 USD
	Contact Name	Carol Sloan RDN, FAND, Health Research Director			
	Contact Telephone	916-932-7070			
	Contact Email	<u>csloan@walnuts.org</u>			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-May-2021			
	Synopsis	The California Walnut Commission (CWC) is current observational studies in the areas of human clinical and metaanalyses examining the association betwee impact the quality of life or health across the lifesp	tly soliciting Letters of Intent (trials, observational studies, een walnut consumption and l an. The total proposed budge	(LOI) for human clinic narrative reviews, sy health outcomes that t must be no more th	al and stematic reviews t significantly nan \$500,000.
085272	Syringe Access Program Grants	Comer Four	ndation	01-May-202	1 Not



SPIN ID Program Title	Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount				
					Specified				
Contact Name									
Contact Telephone									
Contact Emai	grants@comerfam	nilyfoundation.org							
Sponsor Website	Link to sponsor we	<u>ebsite</u>							
Program URI	Link to program U	<u>RL</u>							
Deadline Dates (ALL)	01-May-2021 , 01-	Nov-2021							
Synopsis	The Comer Founda health and wellnes community wrapa grants range from	The Comer Foundation provides support to harm reduction-centered syringe access programs (SAP) to improve the realth and wellness of people affected by drug use. These programs provide free sterile syringes, education, and ofter community wraparound services to reduce transmission of HIV, hepatitis C and opioid overdose. Average single-year grants range from \$2,500 to \$20,000.							
001440 Career Development Awards		Crohn's Americ	a & Colitis Foundation of	05-May-202 [LOI/Pre-Ap	1 Not p] Specified				
Contact Name									
Contact Telephone	646-943-7501								
Contact Emai	mmbesch@crohns	scolitisfoundation.org							
Sponsor Website	Link to sponsor we	<u>ebsite</u>							
Program URI	Link to program U	<u>RL</u>							
Deadline Dates (ALL)	05-May-2021 [LOI,	/Pre-App], 20-Jul-2021							
Synopsis	The goal of the Car investigation in the	reer Development Award (Cl e area of Crohn's disease and	DA) is to encourage a career of i dulcerative colitis research.	ndependent basic and/o	or clinical				
000055 Research Fellowship Awards		Crohn's Americ	a & Colitis Foundation of	05-May-202 [LOI/Pre-Ap	1 174,750 USD				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name	Orlando Green						
	Contact Telephone	646-943-7501						
	Contact Email	ogreen@crohns	scolitisfoundation.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
Program URL Link to program URL								
Deadline Dates (ALL) 05-May-2021 [LOI/Pre-App], 20-Jul-2021								
The Crohn's & Colitis Foundation's Research Fellowship Awards are intended to support individuals in the post- Synopsis doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.							n the post- ld of	
000628	Senior Research Awards			Crohn's & Colit America	is Foundation of	05-May-20 [LOI/Pre-Ap	21 Not pp] Specified	
	Contact Name	Orlando Green						
	Contact Telephone	646-943-7501						
	Contact Email	ogreen@crohns	ogreen@crohnscolitisfoundation.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	05-May-2021 [L	OI/Pre-App], 20-Jul-20	21				
	Synopsis	Senior Research competitive for Disease (IBD) or	n Awards provide estab funds from other sour r Chrohn's disease and,	lished researche ces. Support wil 'or ulcerative co	ers with funds to generate s I be provided for proposals litis.	sufficient preliminar relevant to Inflamn	y data to become natory Bowel	
063869	Litwin IBD Pioneers Initiative			Crohn's & Colit America	is Foundation of	05-May-20	Not 21 Specified	
	Contact Name							
Icahn Mount	School of Medicine at t Sinai		Non Federal Fundin	g Opportunities:	May 2021			

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	646-943-7505						
	Contact Email	grant@crohnsc	olitisfoundation.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>1 URL</u>					
	Deadline Dates (ALL)	05-May-2021,	20-Jul-2021					
	Synopsis	The Litwin IBD I impact the trea identification of innovative pilot	e Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to pact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, entification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds novative pilot research so that scientists can test their initial ideas and generate preliminary data.					
001887	<u>One-year Scholarship</u>		Euro	opean Assoc	iation of Urology	01-May-202	21 35,400 USD	
	Contact Name	Angela Terberg						
	Contact Telephone	+31(0)26 389 0	6 80					
	Contact Email	eusp@uroweb.	org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>1 URL</u>					
	Deadline Dates (ALL)	01-May-2021,	01-Sep-2021					
	Synopsis	The European Association of Urology offers support through their European Urology Scholarship Programme (EUSP) is Members may apply for a one-year scholarship of up to €30,000 to be completed at a leading European research institution.						
010950	General Request for Applicatio	ns (RFA)	Fou Rese	ndation for I earch	Prader-Willi	21-May-202	21 100,000 USD	
	Contact Name Contact Telephone	Jessica Bohono 888-322-5487	wych					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	jessica.bohonov	wych@fpwr.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	21-May-2021					
Synopsis The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS.							esearch to y of funds to I to new
073959	Research Grants			Gerber Founda	tion	15-May-202 [LOI/Pre-Ap	21 Not p] Specified
	Contact Name						
	Contact Telephone	231-924-3175					
	Contact Email	tgf@ncresa.org					
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	15-May-2021 [L	.OI/Pre-App], 15-Aug-2	021 , 15-Nov-202	21 [LOI/Pre-App], 15-Feb-2	022	
The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that imp Synopsis the nutrition, care and development of infants and young children from the first year before birth to three years of age.						ects that improve three years of	
066449	Gene-Targeting Strategies for N	Neurofibromatos	is Type 1	Gilbert Family F	oundation	31-May-202	1,200,000 USD
	Contact Name	Jim Goss					
	Contact Telephone	313-782-9500					



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	Deadline Date	Funding Amount			
	Contact Email								
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	31-May-2021							
	Synopsis	The Gilbert Family Foundation high-impact research on gene in neurofibromatosis type 1 (N collaborative research amongs	e Gilbert Family Foundation's (GFF) Gene Therapy Initiative is pleased to announce a Request for Proposal (RFP) for gh-impact research on gene therapy strategies aimed at addressing the loss of neurofibromin 1 (NF1) gene function neurofibromatosis type 1 (NF1) patients. Proposals will be accepted for Team Science Awards defined as llaborative research amongst investigators with experience in gene-targeting strategies in or outside the NF1 field.						
086725	Alpha-1 Antitrypsin Laurell's Tr	aining Award (ALTA)	Grifols		31-May-202	21 59,000 USD			
	Contact Name								
	Contact Telephone								
	Contact Email								
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	31-May-2021							
	Synopsis	A primary goal of the Alpha-1 Antitrypsin Laurell's Training Award (ALTA) is to identify and engage investigators (both physicians and scientists) who are early in their careers in a longstanding commitment to investigating alpha-1 antitrypsin deficiency (AATD). In awarding 2 grants, the goal/intention is to award one grant for a clinical proposal and a second for a basic research proposal. Another objective of the ALTA award is to strengthen the network between scientists and clinicians working in the field of AATD.							
022177	Young Investigators Groups		Helmholtz Asso	ciation	03-May-202	21 1,770,000 USD			

Contact Name Julia Eberhardt



SPIN ID	Program Title	Sr	oonsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	+49 30 206329-16				
	Contact Email	julia.eberhardt@h	<u>elmholtz.de</u>			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UI	<u> </u>			
	Deadline Dates (ALL)	03-May-2021 , 31-	Aug-2021			
The Helmholtz Young Investigator Groups offer early scientific independence to international top talents. The fu Synopsis generally amounts to at least € 300,000 p.a. for five years with an option of a permanent position in case of a po evaluation.						ents. The funding case of a positive
091630	pine and Sports Medicine Fello	<u>owship</u>	Hospital for	Special Surgery	01-May-20	21 95,755 USD
	Contact Name	Deja Pressley, Serv	rice Line Coordinator			
	Contact Telephone	212-774-7351				
	Contact Email	PressleyD@hss.ed	<u>u</u>			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UI	<u>RL</u>			
	Deadline Dates (ALL)	01-May-2021				
	Synopsis	The Department o Fellowship focusin musculoskeletal sy	f Physiatry at the Hospital for Spe g on a comprehensive, nonsurgic stem.	cial Surgery (HSS) offers a on al approach to conditions and	e year Spine and Spo I diseases that affec	orts Medicine t the
003498	Research Internships in Science	e and Engineering (F	RISE) Indo-US Scie Forum	ence & Technology	31-May-20	Not 21 Specified
	Contact Name					
	Contact Telephone					
	Contact Email	internship@indous	sstf.org			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	31-May-2021,3	30-Nov-2021				
	Synopsis	Indo-US Science to create unique undertake inter D laboratories i	e and Technology For e opportunities for s nships in national lal n India.	rum (IUSSTF) annou cience, technology, boratories, federal	unces the Research Interns , engineering and medical research centers, academi	ships in Science and students from the U ic research institutes	Engineering (RISE) nited States to and private R &
102853	adiation Health Protection Invo Radiation	olving Ionizing an	d Non-Ionizing	InfoEd Global	CD0 EH2	C-RFA- 21-2103 17-May-202	Not Specified
	Contact Name	Maryann Schler	nmer, Project Office	r			
	Contact Telephone	770-488-3752					
	Contact Email	AAQ8@cdc.gov					
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	17-May-2021					
	Synopsis	The purpose of public, workers occupational so radiation science and local public following perfor effects associate factors. Build ar	this solicitation is to and emergency resp urces as well as nucl be by the radiation pr health agencies. Me rmance goal(s) for the ed with environment and enhance effective	improve the under onders from expos- ear disasters. The r rotection communi- easurable outcomes the National Center f tal exposures. Prev partnerships to im	standing of radiation scier sure to radiation from natures results of this work will hel ty and will assist making p s of the program will be in for Environmental Health (ent or reduce illness, injur prove environmental heal	nce to better protect aral, environmental, p improve the unde ublic health decision alignment with one (NCEH): Determine y and death related th capacity.	the American medical, and rstanding of s by federal, state (or more) of the numan health to environmental
043953	Antonio M. Gotto, Jr. Prize in A	therosclerosis Re	esearch	International A	therosclerosis Society	31-May-202	21 20,000 USD



SPIN ID	Program Title	Spor	nsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	1-713-797-0401				
	Contact Email	GottoPrize@athero.c	org			
	Sponsor Website	Link to sponsor webs	<u>iite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-May-2021				
	Synopsis	The International Ath Atherosclerosis Resea prevention, and treat	nerosclerosis Society and Weill Cor arch to encourage basic, clinical, a tment of cardiovascular disease glo	nell Medical College offers nd translational research i obally.	s the Antonio M. Go n areas relating to tl	tto, Jr. Prize in ne causes,
075448	Prize for Achievement		International Sc and Adolescent	ociety for Pediatric Diabetes (ISPAD)	22-May-202	Not Specified
	Contact Name					
	Contact Telephone	+49 (0)30 24603-210				
	Contact Email	secretariat@ispad.or	'B			
	Sponsor Website	Link to sponsor webs	<u>iite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-May-2021				
	Synopsis	The ISPAD Prize for A outstanding contribu childhood and adoles	Achievement is the society's highes itions in the areas of science, educ scent diabetes. The prize winner w	it honor. It is awarded to a ation and advocacy which vill receive a free registration	n ISPAD Member wl have had a major in on to the virtual mee	no has made npact on eting.
095169	Educational Grants Infectious	Diseases (HIV/AIDS)	Janssen Biotech	ı, Inc.	15-May-202	Not Specified
	Contact Name					

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Na	ime	Sponsor Number	Deadline Date F	unding Amount
	Contact Telephone					
	Contact Email	jtgrantinfo@its.jnj.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021				
	Synopsis	Janssen provides grants to s patients. Priority is given for knowledge, practice and pe in the area of Infectious Disc Continuing Education (NCE)	upport educational activiti activities within Janssen's rformance for healthcare p eases. Grants are available ; Fellowships; and Patient E	es for healthcare providers areas of scientific interest roviders and improved hea for: Continuing Medical Ed Education.	s, allied healthcare pro that contribute to im alth outcomes for pat lucation (CE)/Non-Acc	oviders and proved ients, including credited
081727	Therapeutic Area Contributions	s - Neuroscience Program	Janssen Pharma	aceuticals, Inc.	31-May-2022	Not 1 Specified
	Contact Name					
	Contact Telephone	908-218-6095				
	Contact Email					
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-May-2021 , 30-Sep-2021	, 15-Oct-2021			
	Synopsis	Janssen Pharmaceuticals, In evaluated competitively wit disparities or unmet needs. disease; major depressive d	c. makes charitable contrib h emphasis given to innova The Neuroscience area of i isorder; schizophrenia; and	outions to support theraped ative programs with measu nterest supports the follow I schizoaffective disorder.	utic area initiatives. A rable outcomes that ving disease states: A	pplications are address Izheimer's
						Not

081724 Therapeutic Area Contributions - Infectious Diseases Program

Janssen Pharmaceuticals, Inc.

31-Mar-2021 Not Specified



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date F	unding Amount			
	Contact Name								
	Contact Telephone	908-218-6095							
	Contact Email								
	Sponsor Website	Link to sponsor website	3						
	Program URL	Link to program URL	-						
	Deadline Dates (ALL)	31-Mar-2021 , 31-May-	2021 , 31-Jul-2021 , 30-Sep-202	1,15-Nov-2021					
	Synopsis	Janssen Pharmaceutica evaluated competitivel disparities or unmet ne HIV / AIDS; Respiratory	Inssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are valuated competitively with emphasis given to innovative programs with measurable outcomes that address isparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; IV / AIDS; Respiratory Infections; and Vaccines.						
021422	Grant Programs - Medical Rese	arch Phase I Application	Keck (W. M.) Fo	oundation	03-May-2021	5,000,000 USD			
	Contact Name	Melissa Gage, Program	Coordinator						
	Contact Telephone	213-680-3833							
	Contact Email	Research_Med@wmke	<u>ck.org</u>						
	Sponsor Website	Link to sponsor website	2						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	03-May-2021 , 01-Nov-	2021						
	Synopsis	The Medical Research F risk/high-impact work o that will save lives, prov from \$500,000 to \$5 m	Program seeks to support pione of leading researchers, laying th vide innovative solutions, and a illion and are typically \$2 million	ering discoveries in medica e groundwork for new par dd to our understanding of n or less.	al research by funding adigms, technologies f the world. Historical	the high- and discoveries ly, grants range			
077000			Kim (D.) Found	ation for the History					

077322Conference/Workshop GrantKim (D.) Foundation for the History
of Science and Technology in East01-May-20212,500 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
				Asia			
	Contact Name						
	Contact Telephone						
	Contact Email	applications@d	kimfoundation.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	01-May-2021 ,	01-Dec-2021				
	Synopsis	The D. Kim Four each twice per present papers	ndation for the History year to scholars who a at international confer	of Science and T re working in the rences or worksh	Technology in East Asia awa history of science and tech lops.	ards several grants o hnology in East Asia	f up to \$2,500 who plan to
066491	Visiting Professorships			Leverhulme Tr	ust	06-May-202	21 207,000 USD
	Contact Name						
	Contact Telephone	020 7042 9863					
	Contact Email	grants@leverhu	<u>ulme.ac.uk</u>				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>n URL</u>				
	Deadline Dates (ALL)	06-May-2021					
	Synopsis	Visiting Profess knowledge of th of £150,000. A spread over 2 o	orships are for UK insti he academic staff and/ Visiting Professorship r r more visits.	tutions to invite or students. App nay last for betw	an eminent researcher from lications are invited for a m veen 3 and 12 months, and	m overseas to enhar ninimum of £10,000 tenures of 6 month	nce the skills and and a maximum s or more can be
082543	Request for Proposals: LCRF Re Cancer	esearch Grant on	Disparities in Lung	Lung Cancer Re	esearch Foundation	07-May-202	21 150,000 USD
			Non Federal Fundir	a Opportunities:	May 2021		



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name							
	Contact Telephone	212-588-1902						
	Contact Email	grants@lcrf.org						
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	07-May-2021						
	Synopsis	LCRF will fund t applications fro	LCRF will fund two research projects with a focus on overcoming disparities in lung cancer. The sponsor encourages applications from investigators of all career levels and on a wide variety of disparities-related topics.					
026029	Career Development Awards fo	or Translational R	Research	LUNGevity Four	ndation	10-May-202	1 300,000 USD	
	Contact Name	Margery Jacobs	on					
	Contact Telephone	312-407-6109						
	Contact Email	mjacobson@LU	NGevity.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	10-May-2021						
	Synopsis	LUNGevity's Car leaders who wil years of their fa the required sul	reer Development Awar I keep the field of lung culty appointment. The bmission.	rd in Lung Cance cancer research e Career Develop	r Translational Research p vibrant with new ideas. Ap ment Awards are mentore	rogram supports fut oplicants must be wit ed awards; a mentor	ure research hin the first five ng plan is part of	
068239	<u> Grants Program - Health & Mea</u>	dical Research		McGowan (Will Fund, Inc.	iam G.) Charitable	03-May-202	1 Not Specified	
	Contact Name							
	Contact Telephone	312-761-9503						



SPIN ID	Program Title	Sponsor Name	Spo	onsor Number	Deadline Date	Funding Amount
	Contact Email	info@williamgmcgowanfund.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021 , 15-Jul-2021 [LOI/Pre-Ap	p], 01-Sep-2021 , 15	-Nov-2021 [LOI/Pre-A	op], 03-Jan-2022	
	Synopsis	The McGowan Charitable Fund partner build healthy communities through inn	s with institutions th ovative heart diseas	nat advance cardiac-dis e prevention program	sease research and s.	organizations that
073452	Paul Marks Prize		Memorial Sloan-Ket Center	ttering Cancer	07-May-20	21 150,000 USD
	Contact Name					
	Contact Telephone	212-639-2000				
	Contact Email	marksprize@mskcc.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021				
	Synopsis	The Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or research. The winners will present their work at a scientific symposium at Memorial Sloan Kettering Cancer Cent share a cash award of \$150,000.				
038045	Research Grants		Ménière's Society		15-May-20	Not 21 Specified
	Contact Name	Natasha Harrington-Benton				
	Contact Telephone	+44 0 1306 876883				
	Contact Email	research@menieres.org.uk				



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 , 15-Aug-2021	, 15-Nov-2021			
	Synopsis	The Ménière's Society's Rese	earch Programme supports	vital research into vestibu	ılar disorders.	
061247 👖	Merck MISP Clostridium Difficil	<u>e Grant</u>	Merck		14-May-202	1 Not Specified
	Contact Name	Boski Patel				
	Contact Telephone	267-305-3173				
	Contact Email	<u>boski_patel@msd.com</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-May-2021				
	Synopsis	The Investigator Studies Proprovision of drug/vaccine an and sponsored by external in publications.	gram aims to advance scier nd/or total/partial funding, nvestigators. Results will be	nce and improve patient ca high-quality research that e generated and properly c	are by supporting, th is initiated, designed lisseminated in peer-	rough the l, implemented -reviewed
058805 <u> </u>	nvestigator Studies Program (N	MISP) Surgery Anesthesia	Merck		01-May-202	1 Not Specified
	Contact Name	Lisa Mount				
	Contact Telephone	267-305-1258				
	Contact Email	lisa_mount@merck.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-May-2021 , 1	18-Jun-2021 , 01-Sep-2021 , 19-Oct-20	21		
	Synopsis	The Investigator provision of dru and sponsored I publications.	r Studies Program aims to advance scie g/vaccine and/or total/partial funding by external investigators. Results will b	ence and improve patient ca , high-quality research that be generated and properly c	are by supporting, t is initiated, designe disseminated in pee	hrough the d, implemented r-reviewed
067593	Pilot Project Grants		Myositis Assoc	iation	01-May-20 [LOI/Pre-A	21 pp] 100,000 USD
	Contact Name	Chrissy Thornto	n			
	Contact Telephone	703-553-2631				
	Contact Email	<u>chrissy@myosit</u>	is.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-May-2021 [L	OI/Pre-App], 30-Jun-2021			
Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract fund other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existi research program. Any industry partnership must be clearly disclosed and a letter of support from the industri must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 annua subject to satisfactory progress.					ract funding from Il lead to future or's existing le industry partner 00 annually,	
067591	Mentored Research Fellowship	<u>s</u>	Myositis Assoc	iation	01-May-20	21 100,000 USD
	Contact Name	Chrissy Thornto	n			
	Contact Telephone	703-553-2631				
	Contact Email	Chrissy@myosit	is.org			
	Sponsor Website	Link to sponsor	website			



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-May-2021 , 30-Jun-2021				
	Synopsis	Mentored Research Fellowships two years, subject to satisfactor received annually of \$50,000. Ca PhD within the three years prior an established mentor. Recipier clinical experience in allied field	s are designed to help p ry progress, at the salar andidates should have r to commencing the Fe nts must devote at leas s. There should be limi	promising junior investigatory level approved by the pa completed residency or fe ellowship and be performin t 50% of their time to resea ted supplementation of sa	ors (MDs and PhDs) Inticipating institutio Ilowship training or I ng research under th arch, but may includ Iary from outside so	for a period of n, to a maximum nave received a le supervision of e some study and urces.
037398	Research Associateship Program	<u>m (RAP)</u>	National Acade	emies	01-May-202	Not 21 Specified
	Contact Name	Attn: NRC Research Associatesh	ip Programs			
	Contact Telephone	202-334-2760				
	Contact Email	<u>RAP@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-May-2021 , 01-Aug-2021 , 01	L-Nov-2021			
	Synopsis	The NRC Research Associateship conducted by the U.S. governme level research opportunities at s	o Programs (RAP) prom ent through the admin sponsoring federal labo	note excellence in scientific istration of programs offer pratories and affiliated insti	and technological re ing graduate, postdo itutions.	esearch octoral, and senior
078941	Research Grants - MPS II (Hunt	<u>er Syndrome)</u>	National MPS S	Society, Inc.	15-May-202	Not 21 Specified
	Contact Name					
	Contact Telephone	919-806-0101				
	Contact Email	grants@mpssociety.org				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2021 , 15-Jul-2021 [LOI/Pre-A	.pp], 15-Sep-2021	, 15-Nov-2021 [LOI/Pre-A	pp], 15-Jan-2022	
	Synopsis	The National MPS Society funds resea applications for innovative research p	rch that may lead rojects that invol	d to treatments for MPS an ve clinical research, basic r	nd ML diseases and s research and translat	olicits ional studies.
001639	Research Associateship Program Center/Naval Health Research	ms Naval Medical Research Center (NMRC/NHRC)	National Resea	rch Council	01-May-202	Not Specified
	Contact Name					
	Contact Telephone	202-334-2760				
	Contact Email	<u>rap@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-May-2021				
	Synopsis	The mission of the NRC Research Asso research conducted by the U. S. gover and senior level research opportunitie	ociateship Program rnment through t es at sponsoring f	ms (RAP) is to promote exc he administration of progr ederal laboratories and aff	ellence in scientific a ams offering gradua iliated institutions.	and technological te, postdoctoral,
058602	Research Associateship Program Materiel Command	ms U.S. Army Medical Research and	National Resea	rch Council	03-May-202	Not Specified
	Contact Name	Dr. Ray Gamble, Program Administrat	or			
	Contact Telephone	202-334-2787				
	Contact Email	rgamble@nas.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	unding Amount
	Deadline Dates (ALL) Synopsis	03-May-2021 The mission of the NRC Research research conducted by the U.S.g and senior level research opportu	Associateship Progra overnment through t nities at sponsoring f	ms (RAP) is to promote exc he administration of progr deral laboratories and aff	cellence in scientific a rams offering graduat filiated institutions.	nd technological e, postdoctoral,
001045	Research Associateship Program Research Institute	ns Armed Forces Radiobiology	National Resea	rch Council	01-May-202	1 57,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Dr. Ray Gamble 202-334-2787 <u>rgamble@nas.edu</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 01-May-2021 , 01-Aug-2021 The National Academies of Science research awards on behalf of U.S. locations throughout the U.S. and	es, Engineering, and federal research age l abroad. Awardees h	Medicine administers com encies and affiliated institut ave the opportunity to: co	petitive postdoctoral ions with facilities at nduct independent re	and senior over 100 esearch in an
	Зупоры	area compatible with the interest access the excellent and often un and engineers at the sponsoring I	s of the sponsoring la ique facilities of the f aboratories.	aboratory devote full-time ederal research enterprise	effort to research an collaborate with lead	d publication ding scientists
058572	Research Associateship Program	ns Naval Postgraduate School	National Resea	rch Council	03-May-202	1 Specified
	Contact Name	Dr. Ray Gamble, Program Adminis 202-334-2787	strator			
	Contact Email Sponsor Website	rgamble@nas.edu Link to sponsor website				



SPIN ID	Program Title	Sponsor Name	1	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				
	Synopsis	The mission of the NRC Researd research conducted by the U. S and senior level research oppor	ch Associateship Progra . government through t rtunities at sponsoring f	ms (RAP) is to promote exc the administration of progr federal laboratories and aff	ellence in scientific a ams offering gradua iliated institutions.	and technological te, postdoctoral,
058545	Research Associateship Program Atmospheric Administration (N	ms National Oceanic and OAA)	National Resea	rch Council	03-May-202	1 Not Specified
	Contact Name	Dr. Ray Gamble, Program Admi	nistrator			
	Contact Telephone	202-334-2787				
	Contact Email	<u>rgamble@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				
	Synopsis	The mission of the NRC Researce research conducted by the U. S and senior level research opport	ch Associateship Progra . government through t rtunities at sponsoring f	ms (RAP) is to promote exo the administration of progr federal laboratories and aff	ellence in scientific a ams offering gradua iliated institutions.	and technological te, postdoctoral,
058605	Research Associateship Program	ms U.S. Army Research Office	National Resea	rch Council	03-May-202	1 Not Specified
	Contact Name	Dr. Eric Basques, Program Adm	inistrator			
	Contact Telephone	202-334-2707				
	Contact Email	<u>ebasques@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	03-May-2021				
		The mission of the NRC Research Asso	ociateship Program	ms (RAP) is to promote exc	ellence in scientific a	and technological
	Synopsis	research conducted by the U.S. gover	nment through t	he administration of progra	ams offering graduat	e, postdoctoral,
058596	Research Associateship Program Development & Engineering Co	ms U.S. Army Research, ommand, NVESD (RDEC/NVESD)	National Resea	rch Council	03-May-202	1 Not Specified
	Contact Name	Dr. Eric Basques, Program Administra	tor			
	Contact Telephone	202-334-2707				
	Contact Email	<u>ebasques@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				
	Synopsis	The mission of the NRC Research Assored research conducted by the U.S. gover and senior level research opportunities and senio	ociateship Program nment through t es at sponsoring f	ms (RAP) is to promote exc he administration of progra ederal laboratories and aff	ellence in scientific a ams offering graduat iliated institutions.	ind technological e, postdoctoral,
058604	Research Associateship Program	ms U.S. Army Research Laboratory	National Resear	rch Council	03-May-202	1 Not Specified
	Contact Name	Dr. Eric Basques, Program Administra	tor			
	Contact Telephone	202-334-2707				
	Contact Email	<u>ebasques@nas.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The mission of t research conduc	he NRC Research Assoc cted by the U. S. govern research opportunities	ciateship Program Iment through t	ms (RAP) is to promote exc he administration of progr rederal laboratories and aff	ellence in scientific ams offering gradua	and technological ite, postdoctoral,
058542	Research Associateship Program	ns Air Force Re	esearch Laboratory	National Resea	rch Council	03-May-202	21 80,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Ms. Ellen M. Ro 703-588-8527 <u>ellen.robinson.1</u> <u>Link to sponsor</u> <u>Link to program</u> 03-May-2021 Competitive aw and affiliated in	binson .@us.af.mil website URL ards are available for so stitutions. Awards inclu	cientists and eng ide attractive sti	gineers to conduct indepen pends, health insurance, p	dent research in feo rofessional travel, a	deral laboratories nd relocation.
058592	Research Associateship Program Research, Development, and En	ns Army Aviati ngineering Cente	on and Missile r (AMRDEC)	National Resea	rch Council	03-May-202	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Dr. Eric Basques 202-334-2707 <u>ebasques@nas.</u> Link to sponsor Link to program 03-May-2021 The mission of t research conduc and senior level	, Program Administrato <u>edu</u> <u>website</u> <u>URL</u> he NRC Research Assoc cted by the U. S. govern research opportunities	ciateship Program nment through t s at sponsoring f	ms (RAP) is to promote exc he administration of progr ederal laboratories and aff	ellence in scientific ams offering gradua iliated institutions.	and technological ite, postdoctoral,



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
057794	Research Associateship Program Laboratory	ms National Energy Technology	National Resea	rch Council	01-May-20	21 Not Specified			
	Contact Name	Dr. Eric Basques							
	Contact Telephone	202-334-2707							
	Contact Email	<u>ebasques@nas.edu</u>							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021 , 01-Nov-2021								
	Synopsis The National Research Council provides opportunities to outstanding scientists and engineers at recent postdoctoral and experienced senior levels for tenure as guest researchers at the National Energy Technology Laboratory (NETL).								
001033	Research Associateship Program	<u>ms Naval Research Laboratory</u>	National Resear	rch Council	01-May-20	21 Not Specified			
	Contact Name	Ms. Erica Deschak							
	Contact Telephone	202-767-8323							
	Contact Email	erica.deschak@nrl.navy.mil							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-May-2021 , 01-Aug-2021 , 01-Nov-	2021 , 01-Feb-20	22					
	Synopsis	The Naval Research Laboratory conduction technological development, technique	cts a broad based es, systems, and r	d multidisciplinary program related operational proced	n of scientific resear ures	ch in advanced			
070292	Research Associateship Program Faculty Fellowship Program (EP	ms Environmental Protection Agency PA/FFP)	National Resear	rch Council	01-May-20	21 Not Specified			
	Contact Name	Dr. Eric Basques							



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	202-334-2707					
	Contact Email	ebasques@nas.	.edu				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>1 URL</u>				
	Deadline Dates (ALL)	01-May-2021 ,	01-Aug-2021 , 01-Nov-2021				
	Synopsis	The National Research Council provides support to promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senio level research opportunities at the Environmental Protection Agency.					
088605	Research Grants		North America	n Spine Society	10-May-20	21 100,000 USD	
	Contact Name	Karen James, N	lanager of Research				
	Contact Telephone	630-230-3691					
	Contact Email	KJames@spine.	org				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>1 URL</u>				
	Deadline Dates (ALL)	10-May-2021					
	Synopsis	NASS research grants provide funding for promising research projects by qualified investigators in the field of spine. Research grants should focus on basic science, clinical or translational research. Basic research may focus on projects that further our understanding of the mechanisms of disease and developing novel models for prevention and/ or treatment. Clinical research may focus on projects that investigate the epidemiology, prevention, and or treatment of spine disease. Translational research may focus on projects that move findings from the 'bench to bedside'					
088607	Nontraditional Nonsurgical Tre	atment Grants	North America	n Spine Society	10-May-20	21 100,000 USD	
	Contact Name	Karen James, M	lanager of Research				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone	630-230-3691						
	Contact Email	KJames@spine.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	10-May-2021						
	Synopsis	he Nontraditional, Nonsurgical Treatment Grant is the result of a donation to research as part of a settlement of a class action lawsuit unrelated to NASS. This grant supports research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such pack and neck pain and radiculopathy. If TNF-inhibitors other than etanercept are used in research and/or treatment funded, comparison studies using perispinal etanercept in at least as many research subjects or patients should be done. Funding amount and number of grants are at the discretion of the NASS Research Project Management Committee based upon merit of applications and amount of funding available each year. It is recommended that approved grant budgets range between \$20,000-\$40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$50,000 per year.						
088606	oung Investigator Grants	North A	nerica	n Spine Society	10-May-20	21 100,000 USD		
	Contact Name	Karen James, Manager of Research						
	Contact Telephone	630-230-3691						
	Contact Email	KJames@spine.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	10-May-2021						
	Synopsis	One to two Young Investigator Grants may be a applicants must be within five years of completi five years of their post-doc training. Applicants	wardec on of t nay no	d each year. Principal inves raining at the time of appli of have received previous g	tigators may be any ication; PhD applica ;rant funding from t	[,] age. MD nts must be within he NASS Research		



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
		Project Management Committee. It is recom per year. In rare cases and at the discretion of	mended that approved grant budget of the committee, each year may be u	s range between \$2 up to \$50,000 per ye	0,000-\$40,000 ear.				
078645	Research Traveling Fellowship	North	h American Spine Society	10-May-202	21 7,000 USD				
	Contact Name	Karen James, Manager of Research							
	Contact Telephone	630-230-3691							
	Contact Email	KJames@spine.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	10-May-2021							
	Synopsis	The Research Traveling Fellowship spans at least five months at one medical center (other than the facility at whe the applicant currently practices). The center selected by the applicant should have appropriate research facilities agree in writing to accept the applicant if he/she receives the Fellowship. The Fellowship primarily covers the contravel and housing and typically ranges from \$3,000-\$7,000.							
088608	Clinical Traveling Fellowship	North	h American Spine Society	10-May-202	21 7,000 USD				
	Contact Name	Karen James, Manager of Research							
	Contact Telephone	630-230-3691							
	Contact Email	KJames@spine.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	10-May-2021							
	Synopsis	The Clinical Traveling Fellowship spans at least one month to be spent in three to five different medical centers studying spine techniques. The centers selected by the applicant should agree in writing to accept the applicant if he/she receives the Fellowship. The Fellowship primarily covers the costs of travel and housing and typically ranges							



SPIN ID	Program Title	Sponsor Name	S	oonsor Number	Deadline Date	unding Amount	
		from \$3,000-\$7,000.					
026662	Research Grants		Ophthalmic Resea Australia	arch Institute of	25-May-202	1 38,500 USD	
	Contact Name						
	Contact Telephone	02 9690 1001					
	Contact Email	grants@oria.org.au					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	25-May-2021					
	Synopsis	ards grants to ophthalm alent) of Ophthalmology	ologists, trainee oph or Ophthalmic Rese	thalmologists or arch Institutes.			
038162	Pragmatic Clinical Studies to Ev	aluate Patient-Centered Outcomes	Patient-Centered Research Institute	Outcomes e (PCORI)	04-May-202	10,000,000 1 USD	
	Contact Name						
	Contact Telephone	202-827-7700					
	Contact Email	info@pcori.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	04-May-2021					
	Synopsis	he Patient-Centered Outcomes Research Institute (PCORI) seeks to fund pragmatic large pragmatic studies in patient- entered comparative effectiveness research (CER) that are designed to aid decision makers in choosing between two r more clinical care interventions through the comparison of their effectiveness, safety, and other characteristics that re important to stakeholders.					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
030477 Broad PCORI Funding		P R	atient-Centere esearch Institu	ed Outcomes ute (PCORI)	04-May-202	3,000,000 21 USD	
	Contact Name						
	Contact Telephone	202-827-7700					
	Contact Email	info@pcori.org					
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	04-May-2021					
_	Synopsis	The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA cover the following four priority areas outlined in PCORI's National Priorities for Research and Research Agenda: Address Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. These broad areas encompass the patient-centered comparative CEF support.					
056359	Pew Biomedical Scholars		Р	ew Charitable	Trusts	17-May-202 [LOI/Pre-Ap	21 300,000 USD
	Contact Name	Kara Coleman					
	Contact Telephone	215-575-9050					
	Contact Email	kcoleman@pew	<u>/trusts.org</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	17-May-2021 [L	OI/Pre-App], 01-Sep-202	1			
	Synopsis	The Pew Schola in science releva	rs Program in the Biomed ant to the advancement d	dical Sciences p of human healt	provides funding to young i th. The program makes gra	investigators of out ints to selected acad	standing promise demic institutions



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to support the independent research on the assistant professor level.	of outstanding individuals who are in the	ir first few years of the	ir appointment at
102065	Medical Education Grants: Loca Increase Awareness & Understa Cardiomyopathy (ATTR-CM)	al Level Educational Grants Program to anding of Transthyretin Amyloid	Pfizer Pharmaceuticals	30-Mar-202	1 20,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Amanda Stein, Grant Officer 212-733-2323 <u>amanda.j.stein@pfizer.com</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 30-Mar-2021, 27-May-2021, 29-Jul-20 Pfizer requests applications focused or Cardiomyopathy (ATTR-CM).	021 , 30-Sep-2021 , 28-Oct-2021 n improving the care of patients on the le	ocal level with Transthy	rretin
102813	Medical Education Grant: Topic Surgery	cal Hemostasis in Minimally Invasive	Pfizer Pharmaceuticals	12-May-202	1 200,000 USD
	Contact Name Contact Telephone	Jessica Romano, Grant Officer			
	Contact Email Sponsor Website Brogram UBL	jessica.romano@pfizer.com Link to sponsor website			
	Deadline Dates (ALL) Synopsis	12-May-2021 Pfizer is issuing this Request for Propositional beauthcare professionals on topical beauthcare	sals (RFP) to support projects that will fo	cus on educating surge	ons and other



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
		and practice gaps specific to periopera projects requesting up to \$200,000 wi	ative bleeding du Il be considered.	ring MIS including robotic	ally-assisted procedu	ires. Individual		
102433	Competitive Grant Program: Pr Multiple Myeloma	e-clinical & Translational Research in	Pfizer Pharmace	euticals	17-May-202	21 150,000 USD		
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Jacqueline Waldrop 212-733-2323 Jacqueline.Waldrop@pfizer.com Link to sponsor website Link to program URL 17-May-2021						
	Synopsis	Pfizer is issuing this Request for Propo Myeloma. Individual projects requesti	sals (RFP) to supp ng up to \$150,00	port pre-clinical and transl 0 will be considered.	ational research in N	Iultiple		
102627	<u>Competitive Grant Program: NS</u> <u>Outcomes</u>	SCLC Therapy Management for Optima	Pfizer Pharmace	euticals	05-May-202	21 150,000 USD		
	Contact Name Contact Telephone	Jacqueline Waldrop						
	Contact Email Sponsor Website	Jacqueline.Waldrop@Pfizer.com Link to sponsor website						
	Program URL Deadline Dates (ALL)	Link to program URL 05-May-2021						
	Pfizer is issuing this Request for Proposals (RFP) for projects that focus on development of an algorithm or tool to Synopsis guide the optimal treatment and support of patients with ALK or ROS1 re-arranged – Non-Small Cell Lung Cancer (NSCLC). Individual projects requesting up to a maximum of \$150,000 will be considered.							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
102679	Competitive Grant Program: Qu Endocrinology Fields	uality Improveme	ent in Pediatric	Pfizer Pharmace	euticals	31-May-20	21 0 USD		
	Contact Name	Akihiro Kamina,	Grant Officer						
	Contact Telephone								
	Contact Email	meg.japan@pfiz	<u>er.com</u>						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	31-May-2021							
	Synopsis	Pfizer is issuing fields in Japan. I	izer is issuing this Request for Proposals (RFP) for projects related to quality improvement in pediatric endocrinology Ids in Japan. Individual projects requesting up to 2,500,000 JPY will be considered.						
102678	Competitive Grant Program: Im Metastatic Breast Cancer	prove the Care o	of Patients Living with	Pfizer Pharmace	euticals	13-May-20	21 79,000 USD		
	Contact Name	Dewayne Bruml	ow, Grant Officer						
	Contact Telephone								
	Contact Email	Dewayne.Brum	ow@pfizer.com						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	13-May-2021							
	Synopsis	Pfizer, through a proposals for th cancer (mBC) pa cancer, where t cure. Individual	a partnership with Reth e implementation of st atients. Projects should reatment goals focus o projects requesting up	nink Breast Cance trategies that wil l use optimal mea n improving qua to \$100 000 (CA	er, is issuing this Request for I measurably improve the asures to improve care for lity and length of life as the D) will be considered.	or Proposals (RFP) t quality of care of m patients with meta ere is, to date, no ki	o encourage etastatic breast static breast nown		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
010211	010211 Franco-American Medical Exchanges Grants		Philippe Fo	Philippe Foundation, Inc.		21 Not Specified		
	Contact Name	Claire Waiss						
	Contact Telephone	212-687-3290						
	Contact Email	philippefoundat	tion@fourpointsam.com					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	31-May-2021,3	31-Aug-2021 , 30-Nov-2021					
	Synopsis	The purpose of the Philippe Foundation is to encourage, assist, aid and support scientific and medical activities and research by giving grants to doctors and scientists (post-graduates) interested in exchange programs between France and the United States, specifically in medical laboratories.						
008850	New Research Workers' Award	<u>s</u>	Quaternary	Research Foundation	15-May-20	21 2,070 USD		
	Contact Name	Dr Kathryn Adai	mson					
	Contact Telephone	+44 (0) 161 247	6251					
	Contact Email	k.adamson@mi	<u>mu.ac.uk</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>1 URL</u>					
	Deadline Dates (ALL)	15-May-2021, 2	15-Sep-2021					
	Synopsis	The Quaternary science. The Ne	Research Foundation provides fination Research Workers' Awards scher	ancial support for early career ne supports postgraduate rese	research workers in earch activities.	Quaternary		
008855	Quaternary Conference Fund		Quaternary	Research Foundation	15-May-20	21 1,035 USD		
	a . .							

Contact Name Dr. Kathryn Adamson


SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	+44 (0) 161 247	6251					
	Contact Email	k.adamson@mi	<u>mu.ac.uk</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-May-2021 , 1	15-Sep-2021					
	Synopsis	Synopsis The Quaternary Conference Fund is available to all members of the QRA of at least one year's standing to attendance at conferences and field meetings.						
008897	Quaternary Research Fund			Quaternary Res	earch Foundation	15-May-20	21 2,070 USD	
	Contact Name	Dr Kathryn Ada	mson					
	Contact Telephone	+44 (0) 161 247	6251					
	Contact Email	<u>k.adamson@mi</u>	<u>mu.ac.uk</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-May-2021, 2	15-Sep-2021					
The Quaternary Research Fund is available to all members of the QRA of at least one year's standing, in age and status, to foster research in any area of Quaternary studies.Grants are normally for sums up to be used for any purpose deemed suitable by the Awards Panel (typical claims might be to fund field ex equipment to clean sections, etc.).						irrespective of to £1500 and can expenses, hire		
093261	Amgen Fellowship Training Aw	ard_		Rheumatology	Research Foundation	03-May-20	21 50,000 USD	
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rh	eumatology.org					
	Sponsor Website	Link to sponsor	<u>website</u>					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				
	Synopsis	The purpose of this award is to help children and adults with rheumatic investigators to train future clinicia Awards may be used to support the program.	p ensure an adequat diseases in all areas ns and advance rese e salary of any fellov	te supply of (a) rheumatoles of the country and (b) rhe earch in rheumatic disease v in an ACGME-accredited	ogy providers meeti eumatology educato s. The Amgen Fellov rheumatology fellov	ng the needs of ors and vship Training wship training
061077	Fellowship Training Award - Wo	orkforce Expansion	Rheumatology	Research Foundation	03-May-202	21 150,000 USD
	Contact Name					
	Contact Telephone	404-365-1373				
	Contact Email	foundation@rheumatology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-May-2021				
	Synopsis	The Fellowship Training Award for rheumatology providers meeting the particularly those currently underse	Workforce Expansio ne needs of children erved.	n award is meant to help e and adults with rheumation	ensure an adequate c diseases in all area	supply of s of the country,
063215	Lawren H. Daltroy Preceptorsh	ip in Health Communciation	Rheumatology	Research Foundation	03-May-202	21 15,000 USD
	Contact Name					
	Contact Telephone	404-365-1373				
	Contact Email	foundation@rheumatology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	unding Amount	
	Deadline Dates (ALL)	03-May-2021 ,	01-Nov-2021					
	Synopsis	The Lawren H. Daltroy Preceptorship in Health Communication was established with the aim of improving patientclinician interactions and communications. This award provides resources to support the training, ca development, and/or enhancement of research skills of researchers and clinicians. The award is up to \$15,0 year.						
061076	Paula de Merieux Fellowship Tr	raining Award	RI	neumatology F	Research Foundation	03-May-202	1 50,000 USD	
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rh	eumatology.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>n URL</u>					
	Deadline Dates (ALL)	03-May-2021						
Annually, one Paula de Merieux grant is awarded to support a trainee who belongs to an underrepresented Synopsis within rheumatology, or is a woman. For the purposes of this program, "underrepresented minority within rheumatology" shall mean Black, Hispanic, or Native American.							ented minority ⁄ithin	
057304	Grants - Hansen's Disease/Lepr	osy	Sa Fo	sakawa Memo oundation	orial Health	05-May-202	Not 1 Specified	
	Contact Name							
	Contact Telephone							
	Contact Email							
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	05-May-2021						



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		1					
	Synopsis	Through its gran disease (leprosy disease can reco tackling disease	nt program, Sasakawa I ·) is not deemed an issu- eive the treatment and , fighting discriminatio	Health Foundation ue, discrimination services they ne n, and preserving	on is promoting projects to n and stigma do not exist, eed. In FY2021, we are supp g history.	build a society whe and persons affecter porting projects in th	re Hansen's d by Hansen's nree areas:
006463	New Investigator Grant			Scoliosis Resea	rch Society	15-May-202	21 30,000 USD
	Contact Name						
	Contact Telephone	414-289-9107					
	Contact Email	info@srs.org					
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	15-May-2021					
	Synopsis	New investigato deformity. Up to	or research grants are r o \$30,000 (\$15,000 per	neant to stimula [.] year) may be re	te younger members into a equested.	a career of investiga	tion in spinal
095418	Simons Foundation Autism Res	earch Initiative (SFARI) - Pilot Awards	Simons Founda	ition	06-May-202	21 300,000 USD
	Contact Name						
	Contact Telephone	646-654-0066					
	Contact Email	sfarigrants@sim	nonsfoundation.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	06-May-2021					
	Synopsis	The mission of t and treatment of relevance. To th	the Simons Foundation of autism spectrum disc his end, the Foundaitor	Autism Researc orders (ASD) by t solicits applicat	h Initiative (SFARI) is to imp funding innovative researcl ions for SFARI Pilot Awards	prove the understan n of the highest qua n from individuals wh	ding, diagnosis ity and no will conduct



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		bold, imaginative, rigorous and relevant these awards. The total budget of a Pilot of up to two (2) years.	research. Investigators new to the field o Award is \$300,000 or less, including 20	of autism are encour percent indirect cos	aged to apply for ts, over a period			
048725	Gita Patel Best Practice Recogn	iition Award P	ociety of Infectious Diseases harmacists	26-Apr-202	Not 1 Specified			
	Contact Name	Kate DeSear						
	Contact Telephone	331-248-7888						
	Contact Email	deseak@shands.ufl.edu						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	26-Apr-2021 , 24-May-2021						
	Synopsis	The Society of Infectious Diseases Pharm Recognition Award. The purpose of this a documented the impact of an innovative infectious diseases.	acists (SIDP) is pleased to solicit nominate award is to recognize an SIDP member we or collaborative "best practice" initiative	tions for the Gita Pa ho has implemented e to improve care in	tel Best Practice d and patients with			
091400	Early Career Awards	Т	hrasher Research Fund	07-May-202	21 25,000 USD			
	Contact Name							
	Contact Telephone	801-240-4753						
	Contact Email							
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-May-2021 , 14-Sep-2021 , 05-Nov-202	21					
	Synopsis	The Fund recognizes that young investigation	ators may find it difficult to remain in pe	diatric research beca	ause of a lack of			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		funding. Thereford by awarding sm applicants who cycles (15 award	ore, the purpose of th all grants to new resea will go on to be indepo ds each).	s program is to e archers, helping t endent investigat	ncourage the developmen hem gain a foothold in this ors. The Fund will make up	t of medical researc important area. The to 30 awards total	h in child health e goal is to fund with two funding
059714	Ara Parseghian Medical Resear Research Grants	ch Fund (APMRF	<u>) at Notre Dame (ND)</u>	University of No	otre Dame	01-May-202	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	574-631-4689 skassen@nd.ed Link to sponsor Link to program 01-May-2021 The mission of t Type C (NPC) dis information ples	<u>u</u> <u>website</u> <u>URL</u> he APMRF is to promo sease and targets deve ase read the rest of th	ote research that elopment of nove e RFP including th	furthers understanding of I strategies to treat and/or he General Information sec	the molecular basis cure the disease. Fo	of Niemann Pick or more
062085	Innovator Awards			Wellcome Trust	t	24-May-202	1,035,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	+44 0 20 7611 5 <u>Link to sponsor</u> Link to program 24-May-2021	757 <u>website</u> <u>URL</u>				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	These awards su significant impa apply.	upport researchers who are transformi ct on human health. Individuals and te	ng great ideas into healthca ams from not-for-profit and	are innovations tha d commercial organ	t could have a isations can
024768	Collaborative Research Grants		Zoos Victoria		21-May-20	Not 21 Specified
	Contact Name	Dr Michael Mag	rath, Senior Research Manager, Wildlin	fe Conservation & Science		
	Contact Telephone	+61-3 9340 275	2			
	Contact Email	research@zoo.c	org.au			
	Sponsor Website Link to sponsor website					
	Program URL Link to program URL Deadline Dates (ALL) 21-May-2021 , 23-Jul-2021 , 17-Sep-2021 , 12-Nov-2021 Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria r Synopsis active collaboration with Zoos Victoria staff or independent research at one of Zoos Victoria's three pro Melbourne Zoo, Werribee Open Range Zoo or Healesville Sanctuary.					

